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I. Introduction 
The present study deals with the influence of psychoactive drugs on self-
stimulation behaviour in the rat. The term «self-stimulation» denotes the 
particular behaviour performed by the rat, in order to obtain electrical 
stimulation through chronically implanted electrodes in the brain. The 
discovery of self-stimulation by Olds and Milner (1954) occurred 
accidentally, but it was the start of numerous studies (see survey in: Brain 
stimulation reward; Wauquier and Rolls, 1976). In 1953, Jim Olds worked 
as a postdoctoral fellow together with the graduate student Peter Milner, 
who was experienced in surgical and electronic techniques, at McGill 
University in Canada. Olds was interested in the neurophysiology of 
learning. For this purpose, he used the rather new and still crude 
technique of chronically indwelling brain electrodes. These electrodes 
were aimed at the reticular formation, which was stimulated during 
learning at chosen points in a simple maze. During one of these 
experiments Olds observed that a rat did not run into an arm of the maze, 
but, rather, returned to the place where it had previously received brain 
stimulation. In the light of the experiments of Delgado et al. (1954), who 
showed the brain stimulation could elicit eversive reactions, it occurred 
to Olds that the rat apparently «liked» the stimulation. The behaviour 
could be evoked repeatedly and Olds together with Milner aimed to 
quantify this behaviour. For this purpose, the rat was placed into a 
Skinner box equipped with a lever, on which pressing evoked brain 
stimulation. To their surprise, the rat rapidly started to press the lever. 
Moreover, the rat continued for many hours and Olds, being afraid that 
this would not be repeatable, collected many meters of paper with 
cumulative recordings of the rat's activity. Although not certain, because 
histology could not been studied, it is likely that the electrode they had 
implanted went deeper than originally planned and arrived in the 
hypothalamic region. During subsequent weeks, many rats were 
implanted and it was confirmed that rats could be trained to press a lever 
for direct brain stimulation in septal and other regions. 
Olds and Milner reported their original findings in 1954, and papers 
attractively entitled «Pleasure centres in the brain?» reached the public 
press. The phenomenon self-stimulation (term introduced by Brady, 
1955) gained a world-wide popularity. The experiments of Delgado et al. 
(1954) on the one hand, and Olds and Milner (1954) on the other hand, 
suggested that «hell and heaven» were detected in brain. 
During the years following the discovery, self-stimulation was shown in 
many species throughout the whole phylogenic scale, including Man. 
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Sem-Jacobsen and Torkildsen (1960) and Heath and Mickle (1960) (see 
survey by Sem-Jacobsen, 1976) demonstrated during stereotaxic surgery 
that electrical stimulation of particular brain areas in Man was experienced 
as pleasant. It is not without significance that a symposium dedicated 
to electrical brain-stimulation was entitled «The role of pleasure in 
behaviour» (Heath, 1964). This reflected the belief that pleasure could be 
caused directly in the brain by electrical current. Feibleman wrote: «The 
best interpretation seems to indicate that the stimulated animals are 
experiencing pleasure» (Feibleman, 1964). Together with the findings in 
humans by Delgado (see survey Delgado, 1976) the self-stimulation 
experiments contributed to the myth that control of human behaviour by 
stimulation through implanted electrodes was possible. Valenstein (1973) 
situated the experiments in their proper context by pointing out the 
limitations of evoked behaviour as opposed to the rich emotional variety 
of human behaviour and the restrictions imposed by ethical consider-
ations. 
Unfortunately, animals do not talk and describing self-stimulation by the 
rat in terms of pleasure sensations is an anthropomorphism. There are, 
however, many demonstrations of the fact that electrical stimulation of 
particular brain areas in the rat (and other species as well), is able to 
reinforce a variety of behaviours besides lever-pressing, such as maze 
learning and discrimination. Therefore, the electrical activation of certain 
neurons can be considered as rewarding. This means that reward and 
drive neurons are a special set of neurons, which contradicts, to a certain 
extent, the concept that reward is, rather, a property of certain 
unidentified systems, as formulated in the drive-reduction theory of 
Miller (1951, 1957) and Hull (1943) or the arousal theory of Hebb (1955) 
(see Olds, 1976). 
«In terms of dramatic impact and the amount of theoretical speculation 
and experimentation generated, no single discovery in the field of 
brain-behavior interactions can rival the finding that animals could be 
highly motivated to stimulate certain areas of their own brain.» 
(Valenstein, 1973, p. 38). The Olds-and-Milner experiments resulted in a 
new emphasis on hedonistic explanations of behaviour, i.e. behaviour 
must be controlled by pleasant or unpleasant consequences of behaviour 
(Berlyne, 1973). The hedonistic principle is formulated in a famous 
sentence by Bentham (1789): «Nature has placed mankind under the 
governance of two sovereign masters, pain and pleasure.» 
Whether a stimulus results in reward or aversion depends on the un-
conditioned reaction of the subject (Vossen, 1973), and manifests itself 
as respectively approach or withdrawal from the stimulus (see more 
details on this concept in publication by van der Staak, 1975). 
Brain stimulation directly elicits approach behaviour or withdrawal 
behaviour. Behaviour is steered by the reward (brain stimulation in 
«positive» areas) and the probability of the responses preceding reward 
is increased. Further, sensory signals become attached to the reward. A 
delicate functional balance between the two systems (mediating reward 
and aversion), must determine which behaviour is selected. 
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Whereas the arousal theory would maintain that drive-reduction is 
rewarding, i.e. source of reinforcement of responses closely following 
arousal reduction (e.g. Berlyne, 1960), important features of self-
stimulation behaviour appeared inconsistent with this view. For instance, 
the lack of satiation, independence of a causal relationship with drives 
and the fact that brain stimulation aroused rather than reduced «arousal» 
in such areas as the lateral hypothalamus, made a reconsideration of 
certain motivational theories necessary. Even Miller (1961, 1963) a strong 
defender of the drive-reduction theory modified his view. 
The neurophysiological bases of motivation became a major point of 
research. Mapping studies made it clear that lateral and far medial 
hypothalamic regions were rewarding areas whereas the areas in 
between were a mixture of rewarding and eversive. In the latter areas 
drive-effects could overlap and there is a certain relationship between 
self-stimulation and basic drives hunger, thirst, sex etc. (e.g. Hoebel, 
1969). Many other experiments demonstrated that drives were not 
necessarily causally related to the phenomenon self-stimulation. Drives 
could, however, act as gates and co-determine final output. 
A further question was whether self-stimulation could only be obtained 
in the hypothalamic areas. Anatomical mapping studies showed that the 
self-stimulation sustaining areas reached from olfactory-paleocortical 
areas of the telencephalon, through the ventral surface of the midbrain 
towards dorsal parts of the medulla (e.g. Olds and Olds, 1963). 
Neurochemical mapping studies demonstrated that the reward system 
was localized from cellbodies in the medulla (noradrenergic) and in the 
ventral midbrain (dopaminergic) and followed the fibres to their terminal 
regions in the forebrain and cortex. There appeared, therefore, a marked 
overlapping between the catecholaminergic systems and the anatomical 
placements of the electrodes sustaining self-stimulation (German and 
Bowden, 1974). This formed the basis of the so-called «catecholamin-
ergic theory» of self-stimulation (Dresse, 1966 and Crow, 1971). The 
study of the pharmacological influence on self-stimulation behaviour 
adopted a neurochemical approach. 
The important question arose as to whether pharmacological substances 
applied systemically or intracerebrally affected the reward system, or 
rather affected a system common to instrumental learning in general. It 
could further be argued that the self-stimulation substrate is involved in 
all kinds of operant behaviour. It is, however, difficult to imagine that a 
reward system could operate without integration with other brain 
systems which modulate and/or determine final output. 
The lesionino studies clearly demonstrated that behaviour does not 
reside at the tip of the electrode, but requires a coordinated functioning 
of various brain structures. A locus of self-stimulation as postulated by 
Olds and Olds (1965) could not be confirmed and Valenstein (1966) 
pointed out the interaction, plasticity and even redundancy of the brain 
structures. The experiments by Huston (1973) showed that rats 
extensively lesioned in forebrain structures continued to self-stimulate in 
the lateral hypothalamic region, provided that the behaviour was very 
simple and did not require spatial orientation. 
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These experiments emphasized the organization of reward at different 
levels of complexity of behaviour. 
Reward is involved at different levels of CNS-organization: i.e. learning of 
motor skills, learning of behavioural sequences, learning of maps and 
objects (Olds, 1976). The research on self-stimulation behaviour and its 
manipulation by pharmacological substances may contribute «to under-
standing those parts of the behavior repertoire that are modifiable by 
training. To me these are the most important features of human 
behavior.» (Olds, 1976, p. 25). 
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II. Aims of the study 
The present work deals with the influence of psychopharmacological 
substances on self-stimulation behaviour in rats with chronically im-
planted electrodes in the lateral hypothalamic region of the medial 
forebrain bundle. 
A large number of papers, all dealing with the influence of psychoactive 
drugs on self-stimulation in rats, has been published since 1956. Because 
of considerable differences between these studies with respect to 
methodology, drug-description and drug-analyses, a comparative 
analysis and review of the results is difficult to achieve (Chapter III). The 
general methods applied in our experiments, are described in chapter IV. 
Most studies on self-stimulation have been done on rats lever-pressing 
for brain-stimulation. From these studies, it is clear that the characteristics 
of the electrical stimulation parameters are very important factors in 
determining the rate of lever-pressing. However, studies in which the 
question as to how stimulus parameter combinations influence response 
rates is investigated systematically are rare. 
Therefore, we examined the relationship between different combinations 
of stimulus parameters and lever-pressing rate. One of the hypotheses 
tested, was whether the quantity of charge contained in a stimulation, 
determined the number of lever-pressings. Further, because the 
assessment of drug-effects is partly dependent upon base-line respond-
ing, it was of interest to know whether systematic relationships exist 
between specific stimulus parameter combinations and rates of lever-
pressing (Chapter V). 
In a quantitative approach to a particular behaviour, drug-effects are 
defined as facilitatory or inhibitory, according to whether they increase or 
decrease base-line behaviour. In view of the fact that drugs can produce 
increase, decrease or both, we had to develop a standardized method 
which would make it possible to study the influence of a variety of 
psychoactive drugs. Different base-lines of responding were achieved by 
introducing different stimulus parameter combinations to the same rats, 
during the same session. The response rates obtained during control 
sessions, are determined by various factors, such as the stimulus 
parameter combinations, subjects, time of experiment, etc. An adequate 
analysis of the control data required a factorial approach. We therefore 
applied an analysis of variance to the control results obtained with a 
group of rats (Chapter VI.2.). 
Next, the effects of various psychoactive drugs on rates of lever-
pressing under adequate stimulus parameter combinations were studied. 
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The aim of the study was to construct profiles of lever-pressing, based 
upon these stimulus parameter combinations, which would enable us to 
differentiate groups of psychoactive drugs. 
Special attention was paid to the problem of distinguishing between the 
effects of the drugs on the reinforcing properties of electrical stimulation 
(specific effects) and the effects of drugs on behavioural variables, such 
as- general activity, which may affect rate of lever-pressing (unspecific 
effects). The effects of the drugs on lever-pressing behaviour were 
compared with the effects of the drugs on a number of other behavioural 
variables (Chapter VI.3.). 
A large number of neuroleptics with well established clinical efficacy in 
the treatment of various psychiatric disorders, has been developed over 
the past 20 years. One of the characteristics of the neuroleptics is, that 
they cause a «specific» inhibition of operant behaviour. The inhibition of 
self-stimulation by neuroleptics has been used as evidence for a 
catecholaminergic involvement in self-stimulation. The particular 
problem studied in the present work, was to reveal the characteristics 
and nature of the neuroleptic-induced inhibition of self-stimulation, with 
particular emphasis on the rôle of the dopaminergic nigro-striatal system 
(Chapter VII). 
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III. The influence of psychoactive 
drugs on brain self-stimulation 
behaviour: a literature survey 
127 papers, published between 1956 and 1974 and all dealing with the 
influence of psycho-active drugs on brain self-stimulation in rats, are 
reviewed here. The methods and results of these papers are summarized 
in tables and followed by critical remarks on methodology and 
description of the results. The interpretation of the effects of psycho-
active drugs on self-stimulation is incorporated in the discussion of the 
experimental results (Chapters VI and VII). 
1. MATERIAL COLLECTION 
The classification of drugs used here is a compilation of different 
classifications made on pharmacological or chemical bases (e.g. Ehrart 
and Ruschig, 1972; Janssen, 1970; Janssen et al., 1965a) and should only 
be used as a guide-line. 
1.1. Classification 
I. Psycholeptics 
1. Hypnotics or hypnosedatives 
- pentobarbital 
- phénobarbital 
2. Neuroleptics 
2.1. rauwolfia alkaloids 
- reserpine 
2.2. benzoquinolizines 
- tetrabenazine 
2.3. dimethylpropylphenothiazines 
- chlorpromazine 
- other phenothiazines 
2.4. butyrophenones 
- Haloperidol 
- other butyrophenones (spiroperidol, etc.) 
2.5. diphenylbutylamines 
- pimozide 
- chlopimozide 
3. Minor tranquillizers 
- chlordiazepoxide 
- diazepam 
- nitrazepam 
- meprobamate 
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II. Psychoanaleptics (psychic stimulants) 
1. Vigilance stimulators 
- amphetamine (1) 
2. Antidepressants 
2.1. Tricyclic antidepressants 
- Imipramine 
- desipramine 
- amitriptyline 
- nortriptyline 
2.2. Mao-inhibitors 
2.2.1. hydrazides 
- iproniazid 
2.2.2. indolalkylamines 
- etryptamine 
2.2.3. cyclopropylamines 
- pargyline 
2.2.4. propargylamines 
- tranylcypromine 
3. Other psychic stimulants 
- cocaine 
III. Psychodysleptics 
1. Related to indolalkylamines 
- LSD 
2. Phenylethylamines 
- mescaline 
3. Tetrahydrocannabinols 
- 9-tetrahydrocannabinol 
IV. Cholinergics and anticholinergics 
1. Cholinomimetics 
1.1. Cholinergic agonist 
- a recoline 
1.2. Acetylcholine-analogue 
- pilocarpine 
1.3. Anticholinesterase 
- neostigmine 
- physostigmine 
1.4. Ganglion stimulating agent 
- nicotine 
2. Anticholinergics 
2.1. Muscarinic anti-cholinergics 
- atropine 
- scopolamine 
- dexetimide 
2.2. Tropine-derivative 
- benztropine 
(1) dl-, d-, l-amphetamine and methamphetamine. 
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V. Narcotic analgesics 
- fentanyl 
- morphine 
- piritramidfi 
VI. Anticonvulsants 
- diphenylhydantoin 
- azetazolamide 
VII. Drugs interfering with catecholamines 
1. Blockade of NA-synthesis 
- a -methylparatyrosine 
2. Dopamine-ß-hydroxylase inhibitors 
- diethyldithiocarbamate 
- disulfiram 
- Fla-63 
3. Precursor 
- L-dopa 
4. Direct receptor stimulation 
- apomorphine 
5. NA-receptor blocking (1) 
5.1. OÍ-blockers 
- phentolamine 
- phenoxybenzamine 
5.2. ß-blockers 
- propanolol 
VIII. Drugs interfering with indolamines 
1. Tryptamine and analogues 
- N,N-dimethyltryptamine 
2. 5.-Hydroxytryptamine 
3. Synthesis inhibitor 
- parachlorophenylalanine 
12. Key to the tables 
Compounds: references in chronological order 
dose expressed in mg/kg body weight 
Rte : route of ad min istration 
s.c: subcutaneous; ¡.p.: intraperitoneal; or.: oral 
Ti: time of drug-administration 
(1 ) Most of the neuroleptics described are considered to block DA-receptors 
(see Chapter V I I section 6). 
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Brain structure: 
Rats: 
Stimulus 
Session: 
Procedure: 
Results: 
refers to the structure in which the electrode was im-
planted (all-or-none as demonstrated by histological 
examination); 
abbreviations: 
MFB: medial forebrain bundle 
VMH: ventromedial hypothalamus 
accumb.: accumbens 
amygd.: amygdala 
hypoth.: hypothalamus 
forebr.: forebrain 
midbr.: midbrain 
ant.: anterior 
dors.: dorsal 
dorsomed.: dorso-medial 
lat.: lateral 
post.: posterior 
ventr.: ventral 
number and sex 
Ç female, cf male 
E electrode, monopolar (M) or bipolar (B) 
I intensity, in volts (V) or ampères (A) 
F frequency, number of cycles per second (^) or 
pulses per second (pps) 
pulse width 
train duration = duration of the stimulation 
PW 
TD 
duration of the session, eventual subdivisions indicated 
refers to the schedule used 
CRF continuous reinforcement 
FR fixed ratio (ratio responses/stimulations) 
VI variable interval 
Fl fixed interval 
the description is short, but as complete as possible 
/ denotes increase 
4 denotes decrease 
special procedures are indicated when relevant to the 
data 
1.3. Tables 
The following tables are ranked according to the classification described 
in 1.1. 
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Scopolamine: aema a · with amphetamine 
.t at 1 5 , 4 5 and M mg/kg hlgheat at 
4 h r · (reepectlvely 122. 137 and 134 
mean preaaing« of 3 aubjecta com­
pared «1th control r a t e · : at 30 mg/kg 
highoet at 5 hr · (127 pretainga) 
. average t : 50 * at 4 h r · . 30 % at 
28 h r . 
. three intenaity l e v e l · · l o« (threehold: 
26-44 <iA). medium (45-84 uA). high 
(110-160 μΑ) 
t at all I n t m i l t l e · 
REMARKS 
Only data of the 30 μΛ-period 
No •peciflcauona 
% ratloa of pressing rate under 
the drug to placebo rats 
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1 RESERPINE 
REFE31ENCE 
Old · , J. «t . 1 . 
1ЧЫ 
O l d · . J . at · ! . 
1957 
Stem, L. 
1962 Ь 
Stela. L. 
1 9 6 4 a 
(and Stein L . . 1 967) 
D r e · · · . A. 
1967 
H . l . r . T . J . « » ι . 
196« 
Cibion et a l . 
1970 
Do·« 
mg/k, 
о.ъ 
1.0 
0 . 6 
1.0 
1.0 
(S.O) 
0 . 1 6 
0.31 
0 . 6 3 
1.29 
3 . 0 
0 . 3 
o.s 
R I . 
' . p . 
l . p . 
1. P. 
a .c 
l . p . 
i .p 
T i . 
min. 
-to 
3 h r · 
-2 h r · 
èRAIN STHUCTUKE 
a. »«ρΙΑΐ area 
b. medial hypothaU 
m a · 
c. amyg. 
•epul region 
ventral region poat. 
bypothalamu· 
•nter. tegmentum 
U t . part rhlnencepfa, 
bypothalamu· 
ml dbr.tegmentum 
hypothalamu· 
anter. midbr. teg­
mentum 
MFB 
(Ut.bypothaUmue) 
If dorsomed.hypo-
thalamue 
6 9 . Ut.hypotbalanua 
2 9- doraomed. bypo­
thalamu« 
MTB 
poat. bypothalamu· 
RATS 
N 
S M 
it 
it 
it 
6t 
• t 
'»» 
25 І 
STIMULUS PARAMETERS | 
E 
В 
В 
В 
В 
В 
В 
В 
I 
1 - 1 . 5 V 
1 V 
( ± 3 S | l A ) 
0 . 2 5 - 0 . 5 0 
mA 
< 160 
Τ: 5-14 V 
Г 
6 0 % 
6 0 % 
100 
ΡΡ· 
100 
ΡΡ· 
5 0 % 
"«к 
P.W. 
m««c. 
" 
0.2 
0 . 2 
T . D 
т в « с 
600 
500 
150 
150 
500 
150 
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1 SESSION 
Dur. 
mia. 
ВО 
60 
5 Ь г · 
T««t *t 
ι. 2. Z4 
tu·· 
8 
to 
d . , 7 
P r o c . 
CUF 
CRF 
CRF 
thr..h 
t«»tiA| 
CRF 
CRF 
RESULTS 
· . Ъ ω 75 * оГ norm»! ( r u f o Ы-tS « ) 
b. \ to 7-4S % o l D o m u l 
c. V to 1-22 % oí αοπΠΑΐ 
* І п с г м в е in oatMUvlty OB ouccotv ive »dm 
-S«pul ro f los 0 «ffect (79-110 % of conlrol) 
гЫпввсорЬ. pronouncod k 
-Pootarlor part Ьгаіл 0-30 % of control, 
anterior !«•· \ (шаж. 68 % of control) 
Τ · ο lever eituatiai one SS etepwiee de-
c r e a e e in mteneity, one (reeet lever) roeete 
current to the top eet (6 4 mA) 
1.0 mf/kg elevation threebold after 45 
min. , paui ln i 2 lire, f l u l l y t V , 
3 dar · later atmonnal ly b l ih 
0 . 6 e ü n i U r eUect 
Revereal by dl-amplietamilie (0 2 9 - 1 . 0) 
Reeerplne + at 0, 1, 3 or 24 bre d-amphet-
amin« 1 ing/)t | .erfecte of amphoumuic di-
mlniehedor abortened at all intervale . Sharp! 
• 1 1 2 , 3 hra, . l i g h t f at 24 hra 
5 mg/kg diamiehed effect amphetamine 
1 eaample of eight « e e U y in). 1 .0 mg/kg 
Reaerpine inhibition more rapid 
Ы е а Л г - а hra. 
With 0 . 1 6 ' 0 effect at i h r · 
1.25 eign. to 32-48 hr · 
5 .0 . 3 rata inhlb. up to 72 hra 
E D J Q : 2 bra. 0.27 ( .IB-,41) 
5 hra· 0.31 ( .19- .49 ) 
В hra. 0 .33 ( . 2 2 - 49) 
24 hra 0 60 ( . 3 5 - 1 . 0 ) 
32 hra 0.B7 ( 62-1.2) 
48 h r a > 1 . 2 5 
Dally aeaaicne for approa, 40 daye 
5 0 mg/kg (3 0 mg/kg effect e l m l U r ) 
high redation at 24 hre, not fully recovered 
for 3 daye 30 % of control (mean for 3-10 
daya) 
Recovery only to 78 % of control (10-28 daye) 
Voltage difference betw thre ahohk folio-
wing admlniatratlon of a drug and the control' 
threahold taken aa the effect of the drug. 
^ t h r e a h o l d (n rata) 
• 1 1 V + 2 . 2 V + 3 . 3 V 
0 .3mg/kg 12 В 2 
O.Smg/kg 0 0 J 
REMARKS 
% of control 
NA 5 HT 
95 ВО 
70 70 
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f TETRABENAZINE 
REFERENCE 
poechel , B P H . . 
Nintenuo, F W 
1963 
Slcln. L. 
1967 
пгевае A 
1967 
Haley Τ J et a l . 
1968 
( l d · . Μ E 
1972 » 
Old · . Μ E . . 
11». M 
197Э 
Do·« 
•»•Αι 
2 
0 31 
1.25 
5.00 
40 
• 2 . 0 
Ь 2 0 
4 
Rie 
i P. 
• с 
1 Ρ 
1 Ρ 
» Ρ 
1 Ρ 
τι 
min 
-120 
+77 
•62-77 
+ 30 
BRAIN STRUCTURE 
lat hypoüialanuia 
MFB (lat hypotbal· 
m u . ) 
2
 S MFB 
1 y doraomed hypo-
thaUmua 
1 o U t hypothalami· 
MFB 
MFB 
poat lat hypothala 
•nut 
RATS 
N 
S a 
Э 4 
β ί 
и 
7І 
it 
44 о» 
STIMULUS PARAMETERS 1 
E 
M 
В 
в 
в 
в 
I 
20-30 
« 160 
30-50 % 
above Τ 
5 V 
F 
бог 
5 0 % 
6 0 % 
80 
рра 
Ρ W 
ina ее 
* 
0 3 
Τ D 
•naec 
400 
500 
500 
250 
24 
I SESSION 
Dur. 
min. 
7-β br i 
β 
periods 
2, 5, θ 
h r . 
60 
1. 45 
ϊ. 32 
i. 80 
. 30-45 
ì . 32 
) . 80 
30+ 
30+ 
4% 
PFOC 
CRF 
CR F 
CRF 
CRF 
CRF 
RESULTS 
- Complete к íor 3 .5 h r · . 
- Pretr«Atment paniate (1 mg/kg) SS Л. 
Brief lUnmUtioQ with 
2 . 0 mf/kg tetra ben я ein e, 17 h r · »iter 
pargyline 5 0 . 0 mg/kg 
0.31 m g A g almoat me fíe с Uve 
V.25· complete *t 2 Ьт . іесо ету to 5 0 % 
At S bra 
5.00 complete At 2 and 5 h r · , recovery 
50 % at β hr · 
ED50 »t 2 hr- 0 .63 ( .32-1.23) 
5 h r · 1.48 ( .94-2.34) 
Sedation for 24 h r · , withm control range 
2 day· post-admlniatration 
1 SS - no drug 
2 SS - injection » l i n e 
3, SS - injection tetrabenagine 
Effect \ at β mm. 32 %. at 16 min. : ВЗ %. 
at 24 min. 94 % - 1 0 0 % 
1. SS - no drug 
2. SS - injection amphetamine ( 2 . 0 mg/kg), 
•copolamine (0. 5 mg/kg) or chlordiaae-
poaide ( 5 . 0 mg/kg) 
3 SS - injection letrabenazlne 
Amphet protection**tetrab., throughout 
80 min 
Scopol delay depression »tβ, 16and 24 min. 
Chlordiax delay (16-24 min) - did not 
potentiate. 
Г period (30 mm) SS 
2" period (10 mm) SS after Injection te t ra · 
b*na«ine 
4 at 1 5-30 min after injection 
У period (4 5 mm) injection amphetamine 
(2 m g A g ) . 
SS reinstated, 5-15 mm after injection 
REMARKS 
One example . 
Dally s e s s i o n for > 33 days. 
SS correlated with neuronal act i­
vity. 
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1 CHLOHPROMAZINE 
REFERENCE 
Old· . J. « t a l . 
1956 
Millar. N . E . 
1957 
Old · . J. at »1. 
1957 
Old· . J. 
195« 
Old · . J. 
1959 
Нй.л....і. 
Old·. J . . Travia, Я . 
V. 
1959 and 1960 
Stein. L . . Ray. O . S . 
1960 
я. Stein. L. and 
Sel l ter, J . 
1961 
b. Stain. L. 
1962 a.b. 1967 
Old·, M . E . and 
Old · . J. 
1964 
D o · · 
miAf 
2 . 5 
4 
a. î . s 
ь.г 
2 . 0 
а.г.о 
Ь. 0 .5 
1.0 
1.5 
2 .0 
1.5 
3 . 0 
1.0 
1.5 
2 . 0 
Uta 
I. p. 
ι. Ρ-
l . p . 
i. p. 
i . p . 
i .p . 
i .p . 
1 Ρ 
Tl. 
min. 
-10 
+1 -
1.5 h r · 
+32 
BRAIN STRUCTURE 
Mlddla hrpotbalaniiu 
Septal area 
Amrid . area 
Hrpothalamui 
Vautrai poater.hyp. 
Lat. part · rhlnencaph 
Poetar.mlddla anter 
hypotbalamua 
Anterior preoptic 
Septal ragion 
Anterior aeptal 
DiH. parta hypoth. 
Poet, to enter, hyp. 
area 
Septal area 
MFB 
Poater .hyp. 
Mldbr. tegmentum 
Poeter.bypotbabmn« 
Mldbr. tegmentum 
lat. hypoth» lamua 
tegmentum 
RATS 
N 
Sen 
7 
6 
2 
7 
17 
31 
6/β 
par 
group 
4 ·β-9 
it 
IÎ 
STIMULUS PARAMETERS j 
E 
В 
В 
В 
В 
В 
В 
В 
ІжЪ 
Г* 
1 to 
1.5 V 
1 V 
( ± 6 5 μ Α ) 
0-55 
0-10 
20-30 
40-50 
0-10 
20-30 
40-50 
0 to 7. 5 
mA 
100-250 
40-60 
Г 
«ч 
60
 % 
«ч 
6 0 % 
50 
рра 
100 
рр· 
60 4, 
P.W 
т * е с . 
-
50 раас. 
Interval 
200 uaac. 
0 . 2 
T . D . 
m e e c 
600 
300 
500 
500 
250 
150 
250 
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SESSION 
Dur. 
min. 
ВО 
105 
60 
6ж 
6κβ 
1Ьж8 
Ρ гос. 
CRF 
CRP 
CRF 
CRF 
CRF 
CRF 
RESULTS 
H r p . . t B - l l % of normal 
Sept. · | 0-38 % oí normal (0-7Τ % range) 
A m r | d . - H - 1 7 % oí normal 
On one lever preaalng: W o ± ÎS % after l/Z 
hour 
a. Mapping effect: 
- medial area- 12 — 83 % oí control 
- lateral area 0 — 9 2 % of control 
- septal area β — β β % of control 
Cr eat cet effect poaterlor part 
b. Strong ¿ventra l pot te n o r hypothalamus, 
mild i m septal and sgb-septa l region». 
к almost complete 
5 consecutive days of Injection \ (0-40 %) oí 
control In all points tested 
a. Mapping effect varied according to 
SS rate; higher 
rate SS most inhibited 
b. Dose -response 
2 0 almost complete V . lower doses 
slight \ (SO % between 1. Ъ and 2 . 0 
пц/кі) 
Threshold ra ised. 
Onset. 15 і.-ш. 
a. At threshold current' antagonism of f by 
d-methamphetamin« ( 0 . 2 5 mg/kg) 
b. Same resul ts - mention that 1. S mg/kg of 
chlorpromazlne produas a substantial 
prolongation of methamph. ( l . Z S m g / k g ) 
1. One electrode tn LH, one In tegmentum 
(escape) 
Each period of β min consisted of. 
1. 2 min SS on LH 
2 2 min SS on Τ 
3. 2 mm escape LH 
4. 2 min escape Τ 
Analysis of I 6 ж Ζ mui periods SS In LH 
(and comparison escape) 
¿S. Eft* Pf 
1 . 0 mg/kg 0 0 
1 .5 mg/kg +• 0 
Ζ. 0 mg/kg +++ ++(•) 
Effects U s t e d the total 96 min poat-lnjec-
tion. 
REMARKS 
Two levers placed diagonally-
one to turn the stimulation on, 
one lever to turn the stimulation 
off. Eaperlment by Kirschner. 
No further d e u i l s . 
Refers to «»périment» 1956. 
Increase jiA in s t eps of 5 to 10 
each 8 min period. Mapping ef-
fect in 6 cross sections with 
2-9 points tested in rectangle 
1 . 5 mm above the base of the 
brain, 1. 5 mm later e l . 
A lmost no effect on escape 
See Olds. J. et a l . , 1957 
Two lever situation one lever 
(stimulation lever) SS and s tep-
WIB« decrease In intensity, s e -
cond lever ( r e s e t l e v e r ) r e s e t s 
current to top value (7. 5 mA). 
Cumul, record of one rat 
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1 CHLORPROMAZINE 
REFERENCE 
Drefve, A. 
1 lit шпЛ 1967 
¡Urk. P . et *l. 
969 
Old· , M . E . 
1972« 
Rltter.S. SDd 
ate in. L. 
1973 
Do»e 
mg/kg 
i. O.ÍI 
1.25 
5 .00 
b. 6 .4 
0 . 5 
2 . 0 
5 . 0 
>. 2 . 0 
b . 2 . 0 
1 .5 
3 .0 
6 . 0 
Rte 
e . c . 
• • p . 
i . p . 
• •p . 
> Ρ 
Ti. 
mut. 
-2 bra 
Ohr 
-15 
+77 
+62 -77 
0 
BRAIN STRUCTURE 
МГВ ( U t . h y p . ) 
MFB 
Septal « re* 
Anter. mid. h^potb. 
g o i t e r , hyp. 
MFB 
MFB 
locua coeruleue 
RATS 
N 
Sex 
ві 
6 « 
» з а 
:ij 
> 3 < 
7 / 
w 
S T I M U L U S P A R A M E T E R S ] 
E 
в 
в 
В 
В 
I 
-τ 
τ 
tT 
τ+ 
T=1S 
Τ=15 
Τ . 2 0 
Τ=20 
30-50 * 
«bove Τ 
β-40 
F 
"4, 
60 ч, 
60 t 
100 
PP« 
ποηο-
ph««ic 
Ρ W. 
ma ее . 
0 . 2 
Τ D. 
ma ее 
500 
250 
500 
120 
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I SESSION 
Dur. 
mio. 
24 
(з»в) 
8 
per iod · 
each 
hour 
1-8 hr i 
1 0 + 4 E 1 0 
1. 45 
I. 32 
3. 80 
1. 30-4» 
2. 32 
3. 80 
120 
P r o c . 
CHF 
CR F 
CRF 
CRF 
RESULTS 
». R/B mm 
•olvenf 361 1.25 mg/kg- 318 
0.31 mg/kg 331 5.0 mg/kg- IB 
Ε Ο ς 0 Inhibition.2.0 ( 1 . 2 7 - 3 . lb) mg/kg 
b. Complete Inhibition reached at 2-5-6 
hra. 
Recovery at 7 h r · 50 %. ± 80 % at 
8 h r · . 
Total effect gradual Inhibition at in­
creasing d o a e · . 
Poet .hypoth*Umu· a n i m a l · l e a · affected 
by low dose ( 0 . 5 mg/kg). 
1. SS - no drug 
Z. SS - injection «aline 
3. SS - injection tetrabenaxlne 
1' В min 49 %¿ 2* 8 min: 96 % 
No recovery for 80 min 
1. SS - no drug 
2 SS - injection amphetamine (2. 0 m g / 
kg), acopolamine (0 .5 mg/kg) or 
с Mordía ζ epoxide ( 5 . 0 m g Д g ) 
i. SS - injeciiwn tetrabenaxlne 
- amphetamine ( 2 . 0 mg/kg) p r o t e c t · 
fully 60 % at 24 min, 100 % а і 4 в т 1 п 
- «copoUmine (0.5 mg/kg) p r o t e c t · 
fully throughout B0 min 
- chlordtazepoxide ( 5 . 0 mg/kg) s i g n . 
protection only at 24 min 
Ь % oí aaline. 
1.5 mg/kg . i 75 % 
3 .0 mg/kg i 30 ft 
6 .0 mg/kg + 1 0 % 
REMARKS 
Ten minute per iod · at Τ (thre-
•hold intenBity) T - l , T + l . T+2 
(±1 = 5pA). 
Fig. representat ion 
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I HALOPERIDOL Ι 
REFERENCES 
D r e n e , Α . 
1966 »nd 19(7 
№ i l e i e U w · . К. 
1973 end 1974 
U P F · . A . S . e t · ! . 
1973 
D o . . 
mi A i 
0,01 
0.04 
0 .16 
O.OS 
0 . H 
0 .29 
0.01 
Rie 
e . e . 
I m 
Ir. 
TI 
hr 
-2 
I SPIROPERIDOL 
D r e e e e , A . 
1966 «ли 1967 
B o U · . E . T . e i e ! . 
1 9 7 4 « , Ь 
O.OOS 
0,02 
O.M 
0.02 
0 .09 
0 .1 
0 .29 
e . c 
' . p . 
• 2 
МГВ 
[lat.hrpotbaUmui) 
poet.Ut.hypotbAU-
poet, hypotbaUmu· 
MFB 
(Imt.hypothftUaiue) 
• r e e 
-hippocampus 
-enter. hjrpDÜiaU-
mue 
- • c p u l erea 
-nuc l . eccumb. 
RATS 
N 
Sem 
erf 
per 
doee 
J 
4 Í 
per 
d o . . 
7 Í 
STIMULUS PARAMETER 1 
E 
B 
В 
В 
В 
SM 
I 
3 ν 
3.9 V 
4 V 
19-70 
3 V 
3 .5 V 
4 V 
1 . 9 . Τ 
Γ 
50 V 
5 0 * 
200 
PI» 
50 4 
200 
pp. 
P.W. 
m e e c 
0.2 
0.1 
T . D . 
meec 
500 
400 
300 
500 
300 
30 
I SESSION 
D m . 
milt 
( 3 . 0 
S ) « 
,Í2400R 
1) )»β 
5 « S 
P r o c . 
CRF 
CRF 
CRF 
CRF 
RESULTS 
S 47» ± 3» E D } 0 . 0 0S2 
0.01 4 1 0 ± 4 1
 U | n l u 0 „ « . о 0«0 
0.04 3 3 1 1 5 3 Ы , П И * * · " * ° ° " 0 
0 . 1 4 3 0 1 1 5 
Oaa«t and darsdoa of 0 .16 m g A g : 
< l / 2 h < 7 h 
РлшЫ d«p*«taloii at 1 h. 
1) 0 .05 m i A i i 25 * 
0 I S m i / k i 1 
0 .25 mg/kg compiate blockada for 
3-4 h. 
2) bacraaaa after Dopo, attanuatod or 
pravaotad br 0.05 т | Д | of haloporl-
dol. 
% of maao SS rata for 3 pro-drug daya 
4 6 * . 
S 431 1 2 2 E D . . 0.01 
0 005 426 1 34 5 
0.02 8 3 1 1 5 
0.0« 1 1 0 . Τ 
Onaat Duration Peak dopreaeloo 
< I / 2 h > 0 h 3 k 
- 3 min SS m enter. b r p o t h a U n i e -
thereefter 5 min on eacb e lectrode. 
with 1 m m time-out. 
- Doee-related decrenee at dtffereol 
e ltee 
SS rate % of placebo d чаіиое) 
, Р 1 Г
Г Л Г 0 . M 0 0 5 „ , 0 „ 
nucl.ftccumb. U 40 IS 
• « p U U r · · 70 IS Ъ 
hippockmpua SS 5 IS 
in ter hypo- 95 60 IS 
tbtUfflu· 
l*t.hrp<Hh»- 70 »0 - 5 
l*mu· 
v « n t r « l l a | - 100 70 
ro«ntum»r«a 
REMARKS 
1) 1 ' period i n f r k l u n l u r int«a*i · 
ty (SOR/» min). 
2* *nd 3 ' period i n c r e a · · 
0 5 V. 
2) Duration activity S-mtn peri­
ode l /г h and at each hr up 
to Ь hr. 
No motor unpalrment · . 
1) 1* period inlraliminar шіепеі-
ty (SO R/e mm). 
2* and J* period, in с r e a · e 0. SV 
2) Duration activity β-min 
perioda 1/2 Kr and at each 
hr up to В hr. 
F i l . 
- SS decreaaed relative to the 
haee- l lne . 
- Attenuation SS > feedin« > drin-
k U i . 
- S i m l U r V when bar-preeelng 
la the required r e e p o n a · . 
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ACEPEHONE 
REFERENCES 
D r e · · « A 
1 966 »nd 1967 
Dove 
п ч Л | 
S 0 
20 
80 
RI« 
• с 
TI 
hr 
-2 
BENPEHIDOL 
D r e s t e A 
1966 and 1967 
0 005 
0 02 
0 С« 
• с. 2 
DROPERIDOL 
D r í i i e A 
1966 and 1967 
0 01 
0 04 
0 16 
• с. -2 
TRIPERIDOL 
Зге · ·« A 
l966>Qd 1967 
0 01 
0 04 
а и 
• с -2 
BRAIN STRUCTURE 
MFB 
(UI ЬгрогЪЫшвшш) 
MFB 
(Ut hirpotbiUnui·) 
MFB 
(Ut hypoüuUiTuii) 
MFB 
(Ut hypotbaUmua) 
RATS 
Ν 
S o i 
β ƒ 
Ρ " 
d o . , 
»J 
Ρ" 
doae 
Ρ " 
do·« 
· < / 
Ρ · ' 
doa« 
STIMULUS PARAMETER Ι 
E 
В 
В 
В 
В 
I 
3 V 
3 5 V 
4 V 
3 V 
J i ν 
4 V 
3 ν 
3 S ν 
4 V 
3 V 
3 4 V 
4 V 
Γ 
5 0 * 
5 0 « 
5 0 * 
40 4 
P W 
швее 
Τ D 
meec 
500 
500 
500 
500 
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I SESSION 
Dar. 
mio 
1) Іжв 
!) 9 ι β 
) j . e 
Ϊ) Ч ж В 
1) З ж в 
2) 9 ж В 
1) Зжв 
г) де 
Р г о с . 
CRP 
CRF 
CRF 
RESULTS 
S 408 1 27 ED 42 
20 121 i 56 
Peak depreeeuin 
S 515 * 25 ED 0 03 
l.TiïÎW U^U 0 020.0.045 
О.Ов 13 ± 1 3 
Onset Dur*hOD Peak d e p r e t i u m 
< l / 2 h > в h 2-3 h 
CRF S 47Ì * it ED 0 .051 
IZXiZ u—a.-. .-
О.Ов 9 0 і 2 в 
Omet Duration P*«k d e p r e s s i « 
< 1 / 2 1і < 6 h 1/2 h 
CRF 
CRF 
CRF 
5 510 + 37 E D 5 0 0 .035 
0 01 461 + 38 Llmlt*0 0 2 2 Ό . 0 5 6 
0,04 280 1 5 6 
0 16 61 ± 2 8 
Oniet Duration Peak depreai ion 
< l / 2 h > e h 2 h 
HEUARKS 
1 ) 1 " period mirali m in* г inlenal-
ty (50 R/8 tnln). 
2* and 3" period u i c r e a i e 0 5 V 
2) Duration acüvi ty в-min peri­
odi 1/2 h and at each hr up to 
8 hr 
1) 1" period miral i mi nar intent i ' 
ty (50 R/β min). 
2* and 3 ' period increate 0 5V 
2) Duration activity В-min peri­
oda 1/2 hr and at each hr up 
to 8 hr. 
1) 1' period mir ali minar intenei-
ty (50 R/8 min) 
2 ' and 3 ' period increate 0 5 V 
2) Duration activity 8-mm 
perioda 1/2 hr and at each hr 
up to 8 hr 
L) 1' period infraliminar uitenei-
ty ( 5 0 R / 8 m . n ) . 
2* and 3* period Increate 0 . 5 V 
2) Duration activity 8-min peri­
oda 1/2 h and at each hr up to 
8 hr. 
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1 PIMOZIDE 
REFERENCE 
Ш в * в « «t · ! . 
| 4 U 
Liebm.n. J . M . » d 
Butcher. L L. 
H 7 3 
Ritter. S end 
Stein, L 
1973 
Liebman. J . M . and 
Butcher. L L. 
1974 
D o . . 
O . U 
0.11 
0 . 6 3 
1.2S 
0 . 3 5 
0 . 5 0 
0 S 
1.0 
0 . 3 5 
0 . 5 0 
Me 
• с. 
l p . 
• e 
1 Ρ 
Tl. 
houre 
-2 
- 3 
- 4 
- 3 
U U I N STRUCTURE 
MFB 
1 m e e . n c e p h . f r a y 
l o c u · 
coen j leu · шлА 
MFB 
1 U t hypotlukUnui· 
1 eubfUBtlA Bigr« 
RATS 
N 
Sez 
5 « 
1 6 * 
1 0 « 
3 Í 
ut 
STIMULUS PARAMETER 
E. 
В 
2>B 
гжв 
2MB 
I. 
PA 
•0 
64 
4β 
зг 
15-40 
»-40 
" 
F. 
s<4 
« 4 
100 
PP· 
mono 
pbe.ic 
M » 
P.W. 
m i e e . 
0.2 
T .D 
meec 
50« 
100 
150 
200 
every 
2 вес 
34 
1 SESIÓN 
Dur 
m i o 
4 ж · 
It 2 i » 
12 uut 
It Ьг 
.fUr fa«) 
lOtlO 15 
гжьо 
гжч 
P r o t 
CUF 
CHF 
CRF 
RESULTS 
Control maan intarval botweeo two n i e 
coaaiv« reapon ·« · for the S rata 0 β, 
1 S 1 7 2 1 and 2 2 
Plmoaide 
- \ SO * and Н О Я 
0 I t D i / k f 0 63 m i / k f (rat 2 and 3) 
0 31 1 25 (rat 1 and 5) 
0 i l 0 63 (rat 4) 
Eatlmatad а с doa« which givea 30 % V 
0 2 mf Α ϊ ΊΟ % \ 0 6 m i A l 
Du ratio» hlihaat I at 5 and β hr a 
aftar Injactton 
Ftrat poi iod of aoaaton Intoaalty ylaUtng 
SO 75 Я of maximal r a t · a . c t e d partod 
doubl« currflBt 
Markad Ъ 
Effect of 0 35 mg/kf le«a acvara and 
fr«at«r Individual variability 
Doublinf current 
no a l taraüon of \ with 0 5 mf A t 
at 0 35 π ι ι Λ ι ' "° baacllne 
U F B 
0 img/i, 100 4 * t 5 4 
1 0 m f / k l 69 β % i 3 2 
Locua coeruleua 
0 5 m i / k l 92 S К « 6 В 
1 0 mf/kj β9 7 * » 6 1 
0 35 mf A l Ь SN 
0 S O m f A f ISN VHL 
ISN > χ HL 
REMARKS 
Analyal · of the effect« at the two 
moat atable of the four β min 
period« 
No «edatlon or obvtoue motor 
dlaabl l i t ia · 
Pimoctde Injected а с aa an 
aqueoua аиірепыоп 
- 1 hr on MFB 1 hr on locua 
coeruleue 
Rate free teat of SS every 2 вес 
1 S in one of the a ide · of the 
cage every 2 3 min aldea 
awitched 
35 
1 CHLORDIAEEPOXÏDE 
REFERENCE 
Old· Μ E 
1966 
Gandelnun, R 
Trowill, J 
1968 
St»rk Ρ d a l 
1969 
Pi i ik icpp, J et »1. 
1970 
Old· Μ E 
1970 
Domino E F . Old· 
Μ E 
1972 
Old· Μ E 
1972 b 
D o · · 
5 0 
15. 
0 S 
2 . 0 
Б 0 
IS 
5 0 
2 ; 
5 0 
10 
20 
40 
Rt« TI 
min 
-5 
20 
-IS 
- I S 
+ 30 
+J0-4S 
BRAIN STRUCTURE 
ρο·ι hrpotbsUmu· 
»otar hypothaUmu· 
• eptol « r e · 
intero mldd hypo-
th l lamu· 
post hypothmUmua 
midtar tegmentum 
bypoth «ree 
po«t U t hypothaU-
tnu· 
mu· 
RATS 
N 
S M 
to I 
ti 
t . i l 
. 15« 
ь i s t 
e IS< 
ni 
ni 
STIMULUS PARAMETER 
E 
M 
2 . M 
В 
В 
в 
в 
I 
РА 
S0(rm. ) 
35-120(rm·] 
Τ - 15 
Τ = IS 
Τ - 20 
Τ * 20 
2S 70 μΑ 
T í S - l O p A 
T « _ i S | i A 
40-60 
F 
60 Ц, 
60 , , 
6 0 % 
6 0 , , 
6 0 , , 
6 0 % 
Ρ w 
ms«c 
Τ D 
m«ec 
2S0 
soo 
2S0 
SOO 
2 SO 
2S0 
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I SESSION 
Dur. 
D U D , 
6 ж 8 
JO 
10+4мIO 
it T. 
Г-1, 
Г+1. 
т+г 
60 
io 4 го 
5+ТмЬ 
30+ЙО 
30+80 
Ргос. 
CRF 
CRF 
CRF 
CR F 
CRF 
CRF 
RESULTS 
Meso c h u g e : 153 % (f) 
(range- 125-276) 
UemnchMBga 30.2 % (\ ) 
(range. 19.0-62.4 ) 
U u . effect 24 min after injection. 
LaaAng the total •«••ion 
No difference to reach criterion between 
treated and non-treated animala (551 
min. va 575 min.) 
Rei iataace to cjctinction in group 
treated during а с qui ai ι ion and e s t l n e U « 
mean 124 R compared with 3 0 . 5 to 5 5 . 2 
extinction rcapon·« · in other group· 
Τ = threahold current + or - 5 μΑ 
( T - l . T. T+l, Т+г) at random in аеаакж 
Lowering threahold in poat. hypoth. 
and midbr tegmentum 
D e c r e a s e high rate · of responding at 
aupra -threahold mteneibea 
a. Croup drug-high f in 10 rata 
Croup rot drug-high-1 in 6 rata 
b On threshold testing (decreasing 
s t e p · of 2 μΑ) high current l e v e l · i 
lower (4 s tep · ) t in group « * drug 
high 
Croup drug high t at all supra-
threshold current levels 
e Rate-intensity (current increase 
5 μΑ every 5 min.) 
Control rate 16 min. 479 (range < 150 
> 1 0 5 0 ) . 
f a l l r a t · , in many instances lasting 
the βΟ mm. sess ion, sign, at β, 16, 24 
and 32 mm. 
No aign. effect <m eatinction 
Various groups responses < 100/6 mm 
(п=3), 100-350/вт іп . (n=6). 350-750/ 
8 min. (n=5), 750-1200/6 min (n=3) 
D o s e · 2 5, 5 0- f 80 %. 24 min after 
injection. 
10 and 20 mg/kg some faci l i tât . , 
40 mg/kg 4 . 24 min. after injection 
Low responderá- sUght / , ratea at 
32 and 56 m m . equal to control, 
Moderate responder · · / , peak effect 
at 24 m m . , laating 46 min. 
High responder · tf , peak at 24 m m . 
and laating the 60 minute seaauai. 
REMARKS 
6 e lectrode» in same region 
each tested for 8 m m . 
Before acquisition test 3 c o n s e -
cutive days of injection, 
Criterion time in min . to reach 
1800 reepons ее 
Groupa treated (D) during 
acquisition and extinction 
D-D ND-D 
D-ND ND-ND 
CDP increased sel f-st imulation 
ratea primarily from e lectrodes 
that a l s o yielded rel iable eacape 
CDP facilitated SS especia l ly in 
high rate se l f-st imulators 
Marked individual variation 
Effect only with 5. 0 mg/kg 
non-eel i-eti imilators or in naive 
a n i m a l · 
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1 CHLORDIAZEPOXIDE 
REFERENCES 
3 l d · . Μ E. 
1 9 7 2 · 
Old·, Μ. E. 
1972b 
DIAZ 
Old·, Μ. E. 
1966 
D o · . 
m i / k , 
5.0 
EPA M 
5 
Rt . 
i .p 
Ti. 
min 
+ 30 -45 
Lp- -5 
1 MEPROBAMATE 
Old · . J. 
I9S9 
Old·, J. «nd Travia. 
R P. 
1959 
Old·. J. and Travia, 
R P. 
1960 
Olda. M . E . . 
Old., 3. 
I9M 
tfelnrcich, D, and 
Clark, C D . 
1970 
во 
a 60 
t>. в о 
100 
120 
160 
а. «О 
ι. ВО 
100 
120 
160 
40 
60 
во 
60 
во 
too 
50 
^ P-
». P. 
*.p. 
i .p . 
I .D. 
» P . 
' . p . 
0 » 
0 *» 
о ·> 
+32 
+ S2 
BRAIN STRUCTURE 
MFB 
poit.hypothMBinuB 
»at. hypotbaUmu· 
*nt«r.ior«br«u) 
MFB. 
post, middle bypo-
». c e p u l region. 
hypoth. tegmen t»l 
region 
b. MFB 
ft. leptAl region 
anter. MFB 
poet. MFB 
tegmentum 
». MFB 
U t , hypotheUma· 
(LH) 
tegmcnlum (T) 
•ntar and p » t . 
hypothalami· 
MFB 
RATS 
N 
Sea 
ni 
tS 
21 i 
Л1 
6/в 
por 
rO|ÌOD 
> 6 
P«r 
d o · · 
7 ί 
4 - 1 0 
STIMULUS PARAMETERS | 
E. 
В 
M 
(6) 
M 
(6) 
в 
в 
в 
в 
2жВ 
2жВ 
в 
μ> 
Г. 
Т + 3 0 - 5 0 % 60CJ, 
50 
10 
20 
30 
40 
50 
10 
20 
30 
40 
50 
10 
20 
30 
40 
50 
40-60 
50-100 
60 ъ 
6 0 % 
604, 
6 0 % 
60 S 
175-
230 
PP· 
P.W 
mace 
-
0.1 
T . D . 
•niet 
500 
250 
500 
?*n 
500 
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1 SESSION 
Dur. 
min. 
1 ) 3 0 · « S 
г)зг 
3)βα 
« ι а 
1 + 5 . « 
6 . 8 
бжв 
Ι ί , , β 
U m · 
10 7 
Proc 
CRF 
CUF 
СНГ 
CRF 
CRF 
CRF 
RESULTS 
1) Control SS 
2) 1BJ. CDP «od SS 
3) loj deprellABI d r u | 
CDP' t . рык at 24 min., Intting 48 min 
No protection agalnt l tclrnbcnnrine 
(2. 0 mg/kg) delmylng «ebon U i t i n g 
16-24 min. 
Only l l ight protection ngnlnat ch lor · 
promnnio« (2 S mg/kg), eign. at 24 min 
No effect a g a i n · ! phyaoatlgmine (0 1 
m g A g ) 
Potentiat.or the depreaaant effecta of 
pentobarblul (10 mg/kg) 
Uean % change: ІІЭ (± 47) 
Mean % change- 107 (± І6) 
a. t In ambivalent region: 0 or Blight k 
la MFB 
h. pointe teeted In hypothalamua and 
adjacent геціип·. 
У In reg 'o- of ambivalence (17 pointa) 
a. Mapping 
χ» In ambivalent region 
Mild Ъ in other region· 
b. No general I ( t and U 
Median va lue · ÍO-90 % of control 
with 80-120 mg/kg, • 50 * at 1Ь0 
mg/kg 
a. Mapping' 
- algn f lo И % of the c a i e · and 
32 ТЛ 
- tegmental area- all (-1) f 
• aeptal region all (-1) V 
- hypothalamua moat of the r a t · 0 
effect 
b. Doao-reaponae (median va lue · ) 
•light f with 80 mg/kg 
•light 4 with 100 and 120 mg/kg 
\ SO * with 160 m g A g 
1. One electrode in LH. one m Τ ( e · . 
cape). 
Each period of 6 mm conaiated of: 
1. 2 min. SS on LH 
2 . " SS on Τ 
3. " ' e .cape LH 
4 . . eacape Τ 
Analyaia on 2 min perioda: 
- no pronounced doar-relationahlp 
- effect of 100 mg/kg 
% of control (median-range) 
-SS. fifí·« 
0-48' 84 47 
(2B-11() (0-57) 
48-96' IOS 28 
(91-274) (11-49) 
2 min SS - 2 mm time out \ whole 
• eaaion with high dosce 
¿ I B % / (teated at peak effect 30, 60 
or 120 min, but not defined) 
REMARKS 
Each rat had 6 e lvc lrodee m each 
• truclure, teated for 8 min. 
2 eaamplea 
t>. Data at 30 |iA 
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I AMPHETAMINE 
REFERENCE 
Old · . J. 
1959 
m e t h a m p h e u m l n e 
ajnphcUrolne 
Stein. L. ftnd Rav 
O.S. 
1940 
dl- amphetamine 
«e in . L. . Seifter. J. 
961 
Stein, L. 
196Z a 
d-methamphrt«nlne 
d-ampheumlna 
Sleln, L. 
1962 Ь 
methamphetamioe 
Old· , M . E . and 
Old · . J . 
1964 
amphetamine 
D o · · 
miAg 
3.0 
3.0 
0 .75 
0 .25 
0 .25 
0 . 5 0 
0 . 5 0 
1.5 
0 . 5 
0 .75 
1.0 
2 . 0 
2 
3 
Rte 
i .p . 
l .p . 
i .p . 
i .p . 
I.p. 
i .p . 
i .p . 
i .p . 
Tl . 
m m . 
•60 -90 
• ± 1 5 
• 32 
i n t e r , f o r e b n l n ; 
MFB; poat.middle 
pott.hypcthAlamui 
poi t . hypoihAlAinuB 
•nidbr. tegmentum 
poi t . hypothalamui 
midbr. tegmentum 
po»t.bypoth*l*mu· 
mldbr. tegmentum 
lat. hrpotbalunua 
U t . hypotbaUmu· 
tegmentum 
RATS 
N 
S M 
и 
¿ 
In 
tOtAl 
i 
sS 
STIMULUS PARAMETERS | 
E 
В 
В 
В 
В 
в 
2aB 
I. 
1 0 . 2 0 . 3 0 , 
4 0 . 5 0 
0-7. 5 т Л 
100-250 
100-250 
0 - 6 . 4 т Л 
40-60 
Г. 
601), 
50 pp. 
100 pp. 
100 pp. 
100 pp. 
60 V 
Ρ W. 
maec. 
50 paec 
(ZOOp.ec 
interval) 
0.2 
0.2 
0.2 
Τ D 
maec 
250 
150 
150 
150 
250 
40 
1 SESSION 
Dur. 
min. 
1-5жв 
210 
» 1 2 0 
> U 0 
300 
itae 
Р г о с . 
CRF 
tbr«.h. 
test ing 
C R F ' 
thrc ih. 
curren 
C R F ? 
Ihreth. 
current 
C R F ? 
threeh. 
te lt lng 
RESULTS 
f middle hypoth. ('ambivalent' region) 
f MFB (on 10, 40 and SO |iA) 
Amphet. lover/threahold, o m e t : 5 min. 
Relett ing at + 1.4 mA (< than preferred 
int. > 25-50 mA) 
t oneet, IS min. 
Potentiation by Imipramine ( 5 . 1 5 mg/ 
AnugODlim by c M o r p r o m u t n e (3 mg/ 
4) 
Sharp f ; current off: no effect 
Potentiation by Imipramine ( < 20 mg/ 
kg), a m i m p t y l m e (<«30 mg/kg), 
Lpronlaeld (100 mg/kg), etryptamlne 
(2. 5 mg/kg), с Mor prom as ine ( 1 . Ъ mg/ 
kg), cocaine ( 5 . 0 mg/kg) .ant ih l i taminее 
diphenhydramine (3. 5, 10 mg/kg), 
chloroten (Э.5, 10 mg/kg) 
Antagonltm by chlorpromaslne ( > 1. 5 
mg/kg) 
L*t,hypothalami!·: Lowering threehold 
and l e e · pausing. 
One e lectrode in LH and on« in tegmen-
Mm (eacape). 
Each period of 8 min c o n i U t e d of: 
1. 2 m m SS on LH 
2. 2 min SS on Τ 
3. 2 min «»cape LH 
4. 2 min eacape Τ 
Analyal · of 1 6 χ ? min perioda SS In LH 
"Uncertain e f fect · on the v e r y rapid 
approach b e h a v i o r · " . 
REMARKS 
Map of SS In different hypothalami« 
region· Createat e f fect · in area 
of overlap of sympathetic .ind p a · 
rasympathetlc pointa {- dorsal 
poet, hypothalamue, ventral middle 
hypothalamua and the dorsa l a n t e r . ) 
Two lever aituatlon. one SS with 
atepwiae d e c r e a s e in intensity, 
one {ree*t lever) reaeta current 
to the top eet . 
1 cumul, record of representat ive 
rat 
Е ж а т р і е · of cumulative r e c o r d · 
Two lever aituatlon (aee Stein and 
Ray. 1460). 
Same reaul t · aa Stem 1 9 6 2 a . 
Augm.ef fect · on the «lower e s ­
capo behaviour«. 
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1 AMPHETAMINE 
REFERENCE 
SteLn, L 
1ЧЫ· 1967 
methKmphetamiDe 
d-Amphcumln· 
1- к d-ampheumlnc 
Wamui, H.U , 
Batt le, KF 
1966 
Mogenaon. С J 
196« 
ampheUmtDC 
•Mark. Ρ at al 
1969 
d-ampfactainlne 
Crew T . J . 
1969 
metbamphaumlne 
}lda. Μ E. 
970 
d-amphatainína 
Oída, Μ E. 
1972 a 
Old!. U . E . 
1972 Ь 
D o · . 
ш і Л , 
O.S 
0.2S 
0.50 
1.00 
0 .25 
0 . M 
1.00 
1 
2 
1.0 
0 1 
1 0 
J.O 
0 25 
0.4 
2 0 
2 .0 
Rt« 
i . P . 
i-P-
I.P-
i .p . 
ι Ρ 
' p. 
1 Ρ 
1 p. 
Tl 
min. 
• IS 
«IS 
• 15 
- I 
-10 
-IS 
-
+32 
+ 3 0 1 4S 
к г · » · of hypotbftU-
m u · ttnd tot · !- , mid-
bram tegmcotum 
Ikt hypotbaUmiu 
(MFB) 
») leptAl · Γ · » 
b) •oUr.mid.hypo-
thAlamus 
d) midbr. tegmentum 
v«ntr»l mldbr. | · | -
mentum 
poat.Ut hrpothaU-
mu· 
MFB 
RATS 
N 
Sex 
• · / 
в 
a S 
ь. IS 
> 3 
> 3 
> 3 
> 3 
7 * 
» 1 3 І 
8І 
CT 
STIMULUS PARAMETER 1 
E. 
В 
M 
в 
в 
в 
в 
в 
с* 
Τ I B I . 
40-120 
2e-S(Krma) 
Τ « IS 
Τ = IS 
Τ . 20 
Τ = 20 
Τ 
30-S0 % 
above Τ 
Γ. 
100 
ΡΡ· 
200 
ΡΡ· 
60 % 
60Ц 
loo ι, 
боц, 
60Ц 
Ρ W 
ma«c 
0.2 
2 
0 S 
-
-
Т . О . 
m · ее 
190 
SOO 
a. 200 
Ь.1200 
290 
400 
250 
SOO 
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D O T . 
min. 
ZmZ.i 
30 
10«4ж10 
1 ht 
periodi 
ao 
>) 30-49 
>)32 
: ) β 0 
Proc 
CRF 
•id 
VI 
CRF 
CRF 
CRF 
CRF 
CRF 
CRF 
RESULTS 
Effect of Uueractioa d-»mphet. . ( 1 . 0 
mg/ltl) end reierpln« ( 1 . 0 mg/kg). 
6 r a u higheal V »t 3 hr», r e c o v e r r 
20-40 % of control kt 24 h n . 
Eight weekly Injectlooe reduce effect 
of empheumine (> thlrdweekly Injection). 
Teit lng on hldb (H) «nd low (L) current. 
Number of S per min 
% № С 1 Amph.( l ) Amph. (2j 
Η: · 2 . 2 9 1 . 4 8 2 . 1 
L. 44.« » 2 . 4 72.7 
. . f (cnitrol 1 2S00 R - dru!. ± 3W0 R) 
wAler louku In 12/15 rate 
b. Concurr. drl-iklng end SS 660 R/ 
30 m i n - « 8 5 6 R/30 nan 
ƒ lo» ratee. \ high » t e e (T+l end 1 4 2 ) . 
Poet.hypothnlnmue rnt· lenet •enchive 
to emphetnmlne. 
Sign, f et reduced current l e v e l · 
No dunlnuuon when
 r
r e t r e l t e d with 
0.61 mg/kg of ι iethyeerf.lde bimnleete 
(1 hr or J hr) 
o-methyl-peret froeine + emphetamine 
[0 4 tngAe) at 1 hr and at 12 hr interval. 
Up to 6 hr · aubatantial \ in the 2 h r · 
after each do»e Thereafter gradual 
recovery (till 60 h). 
Variable t dependent en r**p. rate 
a largeat 1 for low reap (R 150-300/ 
8 mm ), 
Ь no SS (< 150 R/β mio) 
f laeting 80 min , 
с moder SS 1 > 3 5 0 . < 750 R/8 min. ) 
• Ign t but indiv variability high SS 
к , other . / . 
d reaUtance to extinction 
a) SS - no drug 
b) Injection amphetamine 
c) injection eallne. tetrabenaalne (2 0 
m g A g ) . сМотртотаеІпе (2 5 mg/kg), 
barbital (10 mg/kg) 
AmpbeUmlne InjecUon alight f . ahort 
duration 
REMARKS 
Review of reaul t · of prev lou· 
t a p e r · . 
Eaamplee arc given of 10 rate 
(2 out of prev lou· paper · ) . 
Sequence · of 2. 5 min on high. 
followed by 2 . 5 min on low cur­
rent. 
P e r i o d · of 10 m m at Τ (« thre-
• bold current). T-l (1 =5(iA), 
T + l , T+2 
Τ not defined 
Repeated injeiUun ol 0.4 mg/kg 
methamphetamme 
High SS 
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I AMPHETAMINE 
REFERENCE 
Domino.E F. »nd 
Old· . M . E . 
1 9 ' 2 
Old«, M. 
1972 Ь 
d .ampl ieu in lne 
'h l l ip · , A G and 
Flbig.r. H С 
973 
Utter, S . , Stelo, L. 
973 
d-amphetaimne 
. lebnun, J . M . , 
lutcher, L . L . 
974 
d-amphetamlne 
l-ampbetamlne 
Atreni, D . M . et »1. 
1974 
AMPHETA1 
Atren*. D . M . et »1. . 
1974 
Dote 
m l / k g 
0 .29 
O.SO 
1 0 
2 . 0 
4 0 
8 . 0 
· . 0 10 
0 . 2 S 
O.SO 
1 00 
b. 0. SO 
1.00 
2 . 5 0 
0.1 
O.S 
1.0 
0.1 
0 .25 
1.0 
0 . 2 5 
1.0 
2 . 5 
0 . 5 
1.0 
2 . 0 
6 . 0 
ΛΙΝΕ 
Rte 
Ι. Ρ 
i .p . 
i .p . 
• ? 
i . p . 
Tl . 
min. 
»30 à 40 
+ 15 
« 30 
or 
t 60 
- 15 
- 30 
k. U t e n l hypeth*l»J 
mu« 
b. lateral bypotbaU 
шпат 
c. lateral bypothala 
m u · 
Л. MFB 
MFB 
Subit, nigra (SN) 
locua coeru leu · 
1 tat. hypotbalamai 
(LH) 
1 l u b a u n ü « о1 |га 
(SN) 
- paraventricular 
hypo Iba la mua 
(»-6) 
- medial brpothala-
m u · (n=17) 
- lat. hypethalamua 
(«=9) 
- thaUmui (n:6) 
RATS 
N 
Sea 
1 0 ¿ 
tÍ 
. - •6 
ƒ 
38 / 
J STIMULUS PARAMETERS | 
E 
В 
В 
В 
2жВ 
В 
I. 
I 1 * 
40-60 
Т > 5 
< 1 0 0 
в-40 
60 
5-60 
F. 
60Ц 
6 0 % 
ООрра 
mono-
)haaic 
60 V 
5 0 % 
P.W. 
maee 
-
0 . 2 
-
T.D 
maec 
250 
200 
1 
200 
every 
2 t e c 
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I SESSION 
Dur 
min. 
30-45 
+ Θ0 
2 x 1 5 
:o - зо 
ntcrval 
IZO 
2 ж M 
P r o c 
CR F 
CRF 
CR F 
-
RESULTS 
Pkrtial protection 4-» tetr»ben»clne ( βΟ' 
Full protection«-» сЫогрготкг іпе (ВО1). 
Petì»l protec t ion** phY«o· tig mine (60*). 
No protection«-»pentob«rbitt l during 
d e p r · · · . , after incapacintton / . 
a. high SS (750-1200 R/S min): Inelgn. 
change* by 0 .25 m g ^ g , 4 . 0 »ndB. 0 m g / 
kg \ i l g n . at 16 and 24 min 
b. 2. O m g / k g f o n l o « SS (100-350 R/β 
mi») 
с · l ight t u d eabaequtnt \ in moderMc 
SS (350-750 R/β min) 
d non -SS: 2 mg/kg / on· et 32 min. , 
duration > ВО min. 
MFB: - d-amphetamlne. moderate t at 
0. 1 mg/kg; «harp t hom 0 . 2 5 
to 1. 0 mg/kg 
- l-amphetamlne l e · · effective: 
•Ign difference at 0. 5 and 1. 0 
mg/kg 
Ratio d/1· 7-10/1 
SN Effect« d- к l-amphetamlne aiml lar 
t % oí pre-drug 
0. 10 mg/kg: + 1 ВО % 
0 25 mg/kg: ¿ М О * 
0 . 5 0 mg/kg: + 390 % 
1.00 mg/kg. ¿ 270 % 
1. SS 
- period 2 (not period 1)' d- and 1-
amphetamine / i n HL 
- period 1 + 2 (0 25, 1 . 0 m g / k g ) : d-
amphetamme J SS (not e ign. with 
1-amphetamine) 
2 . Number of c r o i i i n g · (one t ide to the 
other), oon-eign ^ emcept 2 . 5 m g / k g 
of l -amphetamlne In HL-group 
- Rate- free index of reward (moving 
from one t ide to the other in a ahuttle 
box) (2. S-m m per iod · ) . 
- IB r a t · run at three different current 
level ·(M) during 15 min (5 min w a r m -
up). 
1) In- No D e -
c r e e · · change c r e a s e 
PaH (nc6) 6 0 0 
MH ( m l 7 ) 17 0 0 
LH (n-9) 6 2 1 
Th. (a=6) J . JL _1_ 
Total ίβ 31 2 5 
2) 4 medial «ubject« only ahowlng e s ­
cape behaviour: under the influence of 
amphetamine, revereal to SS (In 3/4 
r a t · permanent). 
3) D o · « reaponte (n«12). a i y m p t o b c . 
0 5 - 1 . 0 mg/kg. decreaee to initiate SS 
2 . 0 mg/kg. no further decreaee 
4 . 0 - 6 . 0 mg/kg: deletertoue effect 
REMARKS 
Fig . and cumulative r e c o r d · 
Rate-free index of SS* every 2 e e c . 
1 5 in one of the s idee of the cage 
S i d e · where 5 i · on •witching at 
interval» oí 1, 2 or 3 m m . 
Total seaaion- 2 per iod · of 14 mm 
Eacape behaviour a U o i c c o r d e d . 
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1 IMIPRAMINE 
REFERENCE 
Stain, L . . Setíter, J. 
1961 
Stein. L. 
1962 » 
Stem. L. 
1962 Ь 
ìUrk. P . et «I 
969 
Deneflov·, О. 
1969 
AMITRIP 
Stein, L. 
1962 · 
Stein, L 
1962 Ь 
B e n e i o v i . O. 
1969 
D o . . 
m i / k i 
5.0 
15.0 
3.5 
5 .0 
10 
15 
40 
90 
5 0 
10 
15 
3 .0 
10 
20 
5.0 
T Y U N E 
3.5 
10 
30 
20 
2 . 5 
Rt< 
. P . 
i . p . 
i .p. 
'•p. 
' . ρ -
ι p. 
i p. 
i .p 
Ti. 
- 1 5 m i n . 
-15 nun. 
- 1 5 
- 1 5 0 
min. 
+30 min 
BRAIN STRUCTURE 
- poat. brpetbalaima 
- mldbr tefmantum 
- anter. mldbr. 
tegmentum 
- poat. hrpotbalamue 
-anter.roidbr. 
tegmentum 
aeptal area 
anteromld hypoth 
midbr. tegmentum 
lat. hypetbaUmua 
(MFB) 
1 
- I S m l n . 
+30 min 
| NORTRIPTYLINE 
Stark, P . et »1. 
1969 
1.0 
3 .0 
10.0 
i . p 15 and 
150 min. 
poat. hypothalamua 
ant.bypotbalamua 
lat.bypotbalamua 
(MFB) 
aeptal area 
anteromid. hypo­
thalamua 
poat. hypothnlamu· 
mldbr tegmentum 
RATS 
Ν 
Sea 
? i 
Ыі 
i t 
» 3 < 
*'! 
> з 4 
. 3 « 
1 <f 
i 
t 
> 3 Í 
> , ƒ 
> 3<f 
STIMULUS PARAMETERS | 
E . 
В 
в 
в 
в 
в 
в 
в 
в 
I. 
100-250 
100-250 
0-450 
Τ = 15 
Τ » 15 
Τ = 20 
Τ = 20 
40-100 
100 
250 
40-100 
Τ • 15 
Τ = 15 
Τ « 20 
Τ = 20 
F. 
100 
ρρι 
100 
ΡΡ· 
100 
ΡΡ· 
6 0 « 
50 
100 
pp. 
50 t 
60 4 
P.W. 
maec . 
0 . 2 
0 . 2 
0 . 2 
0.2 
-
T.D 
maec 
150 
150 
150 
250 
500 
150 
500 
250 
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I SESSION 
Dur. 
min. 
»ВО-ІЮ 
»ISO 
1 2 0 - M 
10 + 
4 к 10 
240 
» UO 
240 
10 + 
4 ж 10 
Р г о с . 
CR F 
СНГ 
CRF 
CRF 
CRF 
CRF 
CRF 
CRF 
RESULTS 
- Poteatlatton of 0.2» m | A | 
d-in«thampb«Umla· (preti-Mtmoit 
10 mio. ) 
mg/kf) and Imipramin* bafore *m-
ph«tAinLn· ·α(* |οα1· ιη 
- barg« d o · · · depraaa SS 
miAlï 
D o · · · » 20 m « / k | : reduction lo Ut· 
mmgnitud· of potcnliaUoa 
V«ry high d o · · · dlmànwh reapon·« to 
•mphetamln« 
• No polen ÜttiOD of cocaine 
- 10 mg/kg ra i l ed Шт..h о Id 
- modera i · d o · · · poMadat· and 
proloog ampbetamlne eff. Effect > 
than Increa·« by doubling amphetamine 
Ten m i a u l · per iod· at Τ (= threabold 
iotenai iy )T- l . T+l, T42 (+ 1 = 5 μΑ) 
- Effect on lhre«held: 0 от r a l · · · 
- Ъ m o i l pronounced with 2 0 . 0 mg/kg In 
antcronuddl« hypothalamua 
1. Ь m g A g 1. p. : no «ffect or alight 4 
Potentiation of effect cocaine ( 5 . 0 mg/ 
kg l .p . ) 
Potentiation of 0 .23 m g A g d-meth-
amphcumlne b/ 3. S and 10 m g A g -
Diminution of d-methamphetaminc 
effect by 30 mg/kg. 
Two lever «Ituatlon ( a a · Imipramin·) 
Augmentation of d-amphetamine ( 1 . 5 ) . 
2 5- 5 .0 mg A t 1· P. ' »0 affect 
Potentiation of affect cocaine ( 5 . 0 mg/ 
kg L P . ) 
Poat. hypothalamua and venlro-tegmen-
tal animal · lowering threahold and 
REMARKS 
On« emample of repreaentatlve 
animal 
Example · of cumulative r e c o r d · 
Two lever aituaUon: one lever 
(atlmulauon lever) 55 and atep-
wiae decreaae in intenaity, 
aecond lever (reaet lever) reaeta 
current to top value 
No data 
On« example 
On« cumulative record 
One o a m p l c 
One esample of 2. Ъ mg/kg effect 
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I IPRONIAZID 
HEFEBENCE 
SKln L 
1962 · 
Stem L 
19M . 1967 
P o i c h e l Β Ρ 
N m t í m . n F W 
IIb* 
Haley Τ J c l «1 
1968 
Do«e 
•nt/k« 
100 
· . 100 
Ь 25 
с 100 
100 
40 
Rie 
i Ρ 
τι 
min 
0 
0 
-22 5 
Ьг· 
+60 
о 
ETRYPTAMINE 
iteiD L 
1962 · 
Po iche l Β Ρ 
Niiilcin«n F W 
19M 
2 S 
t 0 
1 Ρ 
Ρ 
0 
4 1 S hra 
, . 
PARCYLINE 
' o . c h c l Β Ρ 
Ninteman F W 
SO » Ρ ti ¡Ьгш 
»RAIN STRUCTURE 
midbr tegmsntuoi 
hypothaUmua 
rmdbr tegmentum 
poet let bypotheU-
mue 
doreomed nucleue 
MFB 
let hypothelemue 
ventromed 
hypothelemue 
mldbrein 
tegmentum 
poet let hypothale 
mue 
poet, let hypotbele 
mue 
RATS 
N 
Sem 
l à 
1 « 
2 
II 
1 « 
I 
I 
STIMULUS PARAMETER 
E 
В 
В 
M 
В 
В 
M 
M 
I 
Ι Α 
100 
250 
Τ 
40 
100 
250 
40 
40 
F 
loo 
ppe 
100 
ppe 
6 0 % 
100 
ppe 
6 0 , 
6 0 » 
Ρ w 
m e e c 
0 2 
0 2 
0 2 
" 
-
Τ D 
m e e c . 
150 
150 
400 
150 
400 
400 
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1 SESSION 
Dur. 
h i 
>3 
»2 
6 
ISO 
360 
360 
P r o c . 
CRP 
CR Γ 
li 
VI 
1 шііь 
π 
CR F 
ι 
VI 
CRF 
CR F 
CRF 
CRF 
CRF 
RESULTS 
1 e n m p l · of potentiation methnmphet-
•muie (0 .25 mg/kg) long pretrontment 
Interval n e c a l t a r y . Й0 nun. 24 hra later 
•Uli potent 
a. » SS 
b. Dallr (β a) Injection, i m a l l errat ic t 
c. Stün. e l íect oí phenethrlamine (1 .0 , 
2 5 or 10 mg/bg) 2. 5 bra after ipro -
nla i ld 
t SS after two daily inj IpronUald 
1-2 bra delay 
10 dally injectione 
З/β r a t e r during drug 
^ 8th day poet-admrnletratlai 
- No •timulatlng effect 
• Before d.methamphetamlne (0 25 mg/ 
kg) aimilar potentiation aa with 
ipromexid 
immediate / 
t SS. delay of 1 to 2 hre 
REMARKS 
1 enample 
1 eaample 
1 example 
(amphetamine-like propertiee) 
1 example 
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1 TRANYLCYPROMINE 
REFERENCE 
Stem L 
1 9 M . 
P o t c h « ! Б Ρ 
Ninteman 
I 9 M 
Poachel Β Ρ 
1969 
Stinul L et al 
1971 
Dote 
п ч Л і 
г о 
г о 
г о 
S 0 
Rie 
ι ρ 
' Ρ 
1 Ρ 
Τι 
min 
* 1 5 
hr 
30 
20 
1 COCAINE 
Strln L 
1962 > 
B m e l o v « О 
1 9 » 
Cro» Τ J 
1970 
·< 0 
i 0 
i 0 
s o 
1 Ρ 
1 Ρ 
1 Ρ 
*\п 
*60 
or 
•ιβο 
460 
BRAIN STRUCTURE 
poft U t hypothaU 
π ι υ · 
m.pplng 
tclencepb hypothaU' 
mua 
meacncepbalon 
ventral tegmentum 
lat hypothalamua 
mlilbr tegmentum 
poet hypothatamu^ 
U I hrpothaUfnue 
(MFB) 
ventral midbr 
tegmentum 
RATS 
N 
Sea 
i 
a i 
1 3 < 
1 1 < 
ïi 
t 
t 
7І 
STIMULUS PARAMETER 1 
E 
M 
M 
В 
в 
в 
I 
Ρ* 
20 30 
l O t o M 
τ ( ' ) 
100 7V1 
40 100 
F 
«"к 
60,, 
100 ц, 
100 
PP· 
5 0 % 
юоч, 
Ρ w 
maec 
0 2 
0 Ъ 
T D 
maec 
400 
400 
200 
140 
500 
200 
50 
1 SESSION 
Dur. 
hr 
6 
5 .5 
5 
I ft η 
240 
120 
P r o c . 
CRF 
CRF 
CRF 
CRF 
CRF 
CRF 
RESULTS 
Uodart te і в с г в м е , for · short t ime 
kflar injection 
f . 1-2 hr delay 
Flret pott-hour InjecUon not counted 
L^rgeat f : 
MFB, 
ventral tegroent&l area of Teai, 
tieaue directly over interp*<hincuUr 
nuel. 
No correlation between SS-rate and t 
20 nuitutea after Injection and during 
5 hra a l g n . t 
f e f fect · greater In ventral tegmentum 
area 
Pretreatment with P C P A (parachloro-
phenylalanine). 350 mg/kg. 24 h r · 
DO change in f e f fect · . 
Intrmaic action wea> / 
5 0 mg/kg clear t of d-methampheta-
mlne (0 25 mg/kg) given 10 min after 
cocaine, but not In l e · · re ipoaalve 
animal 
No potentiation of 10 mg/hg Imipramine 
Intrinaic action f 
Potentiation oí effect of atropine ( 5 . 0 тщ/ 
kg). Imipramine (5 0 mg/kg) and 
amitrlptyllne (2 5 mg/kg) 
Reduced current (control r a t e · 50-ЭООО 
R/hour) Л CRR 9 « , cocaine 1943. 
difference 994 (+ 196) 
REMARKS 
No data 
1 ежашріе 
3 rcpreeoitatWe cumulative 
r e c o r d · 
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1 MESCALINE 
REFERENCES 
B . l l e y . P. T . , 
Pradhin . S . N . 
197Z 
S . N . , 1174) 
Do· e 
t . ì 
12 .5 
18 
25 
25 
Rte Ti 
min 
| 
Old· . J. «1 »I. 
19*7 
Olde. J. 
1959 
РтяаЫп, S . N . 
1974 
0 . 2 
200 
1 
1. P. 0 
I A ' - T E T R A H Y D R O C A N N A B I N O L ( Д ' - Т Н С ) 
nai ley. P . T . , 
Pradtan, S . N . , 
197Z 
(•ci Pradtun.1974 = 
enrne) 
1 
5 
10 
15 
20 
1 
5 
10 
15 
20 
10 
15 
20 
i . p . 
'•p. 
0 
BRAIN STRUCTURE 
poat. lat. hypothaU -
mua 
aeptal, preoptic 
poat.ventr.hypotha-
lamua 
• ub-aeptal middle 
hypolhalamua 
poat.lat.hypothala-
mua 
poat. lat.hypothala-
mua 
RATS 
N 
Sea 
10 / 
4 J1 
г 
uS 
1 3 / 
2 Í 
l i 
1<Г 
STIMULUS PARAMETERS 1 
E 
В 
В 
в 
в 
I 
Р* 
г т а 
30-55 
Τ 
г т а 
> Т 
F 
60 V 
«оъ 
60-к 
4 0 » 
P.W. 
maec 
. 
. 
T . D . 
maec 
400 
500 
400 
400 
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D U T . 
min 
- % ch&Dge from control (mean + S . E . ) 
6. 3 mg/kg. - 1 1 + 8 η u l i u U V 7/10 
12S mg/kg -44 + 9 n a n i m a U i 9/10 
18 mg/kg. - 5 4 ± 8 n a n i m a l a l 10/10 
25 mg/kg: - 7 0 ± 7 П А П І І П Л І * ^ . IO/IO 
- Onset. 10 min, peak effect. 30-40 min, 
- 3/5 r a u b lphit ic r e · p o n t e 
uutt&l Ь t there»fter )* over normal . 
Daily injecüon for II days 
- lat injection marked V 
- Development of іоіяталсс. return to 
control or alight f within 7 daya. 
НБ MARKS 
Lack of c ro ia- to lerance to ¿J -
ТЛС in me аса l ine-tolerant r a t · 
. Pronounced Ь , largeat during aecond 
B-imn period (at 35 μΑ). 
. Serotonin (0.9 mg/kg) 1/2 hr before 
LSD 
- antagomam of ^ in aeptum, preop­
tic and poat.ventr hypothalamua 
- no antagonism other г eg ton· 
. Brom-LSD i in aub-aeptaL and middle 
hypolhalamui. 
Each 8-min period, increate 
current by S μΑ. 
Inhibition from 7-94 % In 80 % of 
catea 
No clear doae-reaponae 
Threahold atudy only periodic c e t · * -
tion. 
No detaila, 
1 example. 
% change from control (mean + S E ) 
1 mg/kg -16 i 9 η animala « 6/1 3 
5 m g A g -17 ¿ 7 η animala * 8/1 3 
10 mg/Vg - 3 6 + 9 η ammala »10/13 
15 mg/kg - 3 5 + 8 η animale i lZ/13 
20 mg/kg -32 ± 9 η animala t i 1/1 3 
Decrease starla 10-20 min 
P e r a i a t e n t l , peak al 10-20 m g A g , 
duration at 10 m g A g (n=7) 4-8 hra 
Daily injection: 
- max V after 1-3 day· 
- tolerance within 7 days (return to baae 
line or above) 
Lack of croas-to lerance to 
meacal ine m A 9 -THC-tolerant 
rata. 
Lack of croas-tolerance to 
Д 9 - Х Н С in meacaline-tolerant 
ra ts . 
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1 ARECOUNE 
REFERENCE 
ЗИЛ, M E. u d 
Domino. E F 
1 9 6 9 · 
Oidi M E ш ! 
Domino. E F 
1 9 И Ь 
Frftdbne. S . N . And 
Kam·). К А 
P I L O U 
N.wmnn L M. 
1972 
m^/kl 
0.1 
0 4 
o.a 
1.6 
2 . 0 
3 .0 
0. 
1.6 
2 . 0 
I . » 
0 . 9 
1.0 
1 .0 
Ut PINE 
0 . 5 
1.0 
2 . 0 
4 . 0 
RM 
• . с . 
• с . 
» Ρ 
1 Ρ 
τι 
» Μ min 
* 30 min 
0 
- ] 
1 NEOSTICUroE 
Jim|. О H. and Bord. 
E S 
1966 
Domino, E F. u d 
Old·, Μ E 
1968 
Old· M E . . Domino, 
E.F 
1969 b 
N e w m u L U 
1972 
Prndluu. S N. «nd 
K u u t К А 
1972 
O.OS 
Ы.І 
ai 
162 
2 0 2 . 5 
243 
• 0 5 
161 
Ff/k» 
0 025 
0 .05 
0.1 
0 . 2 
0 . 0 6 
0.1 
i Ρ 
• . с . 
• с 
ι Ρ 
ι.ρ 
-15 
+ J0 
t í o 
- 1 
0 
BRAIN STRUCTURE 
Ui pon brpotbal*-
nrni 
р п н U t hypothnU-
m a · 
m a · 
»rea Trom mlddl« 
antar cominlaaura 
U t . bypotbalamu· 
poet. U t . hrpothala-
ania 
poat.bypothaUinua 
U t . bypothaUmiu 
Ut.poat .brpotbaU-
σηι· 
poit.hrpotbaUinna 
RATS 
N 
Sea 
6-14 
i par 
d o · · 
7-14 
' p a r 
doaa 
-
it 
з4 
9 * 
4 - 6 « 
Ρ · ' 
d o · · 
12 i 
: t 
4 
STIMULUS PARAMETER 
E 
В 
В 
В 
В 
В 
В 
В 
В 
В 
А 
40-60 
40-60 
7» та.· 
о . > 
Т» 15-25 
40-60 
40-60 
75 i m · 
or » 
-
Г 
м* 
"» 
«Ч 
6 0 * 
юц 
6 0 % 
60% 
«* 
6 0 * 
Ρ W 
maae. 
-
* 
-
-
-
" 
" 
Τ D. 
maac 
250 
250 
400 
200 
ISO 
ISO 
EOO 
200 
( M 
54 
S E S I Ó N 
Ä : 
3 0 + » 0 
эомо 
60 
( Ж І О 
s 
nr loda 
0+12 
ο+βο 
im 10 
(О 
Ржос. 
СНГ 
СИГ 
CRF 
VI 
J0 
••с. 
СНГ 
СНГ 
СНГ 
VI 
-и 
••с. 
СНГ 
RESULTS 
- к SS, «bort Ut«ncr. ршк V »t β-16 
olia.. quick recovery. Ыеш rate of 
SS: 15 M l . t m s A i ) - » « ( 0 . 1 ~l/ 
U). 
- A B U i o n l t m ( a a U | a n l i t , i . e . . -30 
mlA.)' тяшя r a u altar p r a t r e a t m u t : 
• copoUmlne ( 0 . 5 mg/kj). IZ5 % 
ni«th .copoUmin. ¡t.img/kt): il % 
m e c a m y l a m ü i · \}.0 mg/kg): 11 % 
tTlnuUüdlallua ( 5 . 0 > П | / к | ) : 4 2 % 
- Al 16 m i a . : У Ш * : 15 % ( 1.6 п ц / к , ) -
M » ( J . O m i / k , ) 
- At 64 mia. : racovary lo Z/Э o í CODtrol 
r a t · · (63-78 %) 
\ S 3 
20-30 m i a . , l o l l a · « ! by r a c o v a r / 
Poat. bypothalainu·: mora • •aa l t iv« 
% of control (6 r a t · togalbar) at 2 0 / 3 0 ima 
0 . 5 m j / k f : » 0 5 - 7 5 * 
1.0 i n g A r i 65-75 * 
2.0 m i A | ± 60.60 * 
4.0 n i l A r ± 35-35 » 
No ckaag· from control rang a 
«0. 5 | i | A · : 0 effact 
• 1 | i f / k | imaU V (72 % control r a u · ) , 
•коп duration: 16-24 mia. 
> d o a o · . graatarV 
Paak al iaci · m i a . . 5 5 . 5 Hg/kg: 73 % of 
coatrol, 161|ig/kg. 63 % of coatrol 
0 .025 mi/kg: alga, t at 20-60 mia. In 
3/4 poat. hypothalamic ra t · aad 1/2 lat, 
Othar d o · · · : 0 affact 
0. OS mg/kg: * : % chaag« from coatrol: for 
th · laiUrl<kial aa l ina l · : -09, -95. -20, -30 
0.1 mg/kg: marked к 
HEUARXS 
Alao chollnergic-lnduced crlai 
(2/6 .ubj. •) 
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1 PHVS05TIGMINE 
REFERENCE 
Juni Ο H Mid 
Воув E J 
1966 
Domino E F *nd 
Old · Μ E 
1968 
Olds M E and 
Domino E F 
1969 • 
nldB M E and 
Domino E F 
1969 Ь 
Mahck J В and 
Goldberg Μ E 
1970 
N. »mar. L M 
1972 
1 radhan 5 N and 
Kamat К A 
1972 
Old· M Ito M 
1973 
D o · · 
•"•Αι 
0 1 
о г 
12 s 
25 
so 
100 
200 
Mi/k« 
SO 
to 
эоо 
ρ«Λ· 
so 
100 
200 
эоо 
(••А· 
0 4 
0 β 
0 05 
0 1 
0 2 
0 4 
0 OS 
0 I 
о г 
0 2 
RU 
ι Ρ 
• с 
• с 
• с 
i Ρ 
1 Ρ 
ι Ρ 
• Ρ 
τι 
min 
IS 
430 
+30 
• 30 
IS 
3 
0 
• 30 
BRAIN STRUCTURE 
arca Trom midbr 
hypoltialamu· to 
anter сопишаяиге 
lat hypothalamu· 
post lat hypothala 
m u · 
post lat hypothala 
m u · 
post lat hypothala 
poat lat hypothala 
m u · 
lat po*t hypothala 
mu« 
post hypothalamua 
po«t lal hypothala­
m u · 
RATS 
N 
S u 
l i 
4 t i 
P«r 
d o · · 
22 t 
32 t 
:i 
υ 
s i 
28 J 
STIMULUS PARAMETER 
E 
В 
В 
В 
В 
В 
в 
в 
в 
I 
Τ IS 25 
40 60 
40 60 
40-60 
7S rma 
or » 
a 25-4« 
Ь « 45 
S V 
F 
6 0 , , 
6 0 % 
6 0 Ц 
ь°<Ь 
100 
с у А « 
6 0 % 
6 0 , , 
»0 pp. 
Ρ w 
maac 
о г 
0 3 
Τ D 
mace. 
4S0 
2S0 
2S0 
2S0 
300 
200 
400 
250 
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1 SESSION 
Dur 
mio 
Ъжі 
зоог 
unto 
) 0 И 0 
60 
6ж10 
ЬжІО 
10 30 ti 
Pro« 
СНГ 
CUF 
CRF 
CRF 
CRF 
VI 
30 
• ec 
CRF 
CRF 
RESULTS 
Effect cm Τ Τ+5 Τ* 10 Τ+20 Τ+25 μΑ 
- i r a i l 0 1 mg/pg monte f at Τ (not algn ) 
0 2 mg/kg к at Τ and Τ 410 
- S r a t · 0 1 mg/kg algn ( 
- 1 rat no affect 
•12 9 and 25 Ui/kg 0 effect 
- 5 0 pi/kg к in 25 % (indlv variabi l i ty) 
-100 | l g A a all aiibj ;>50 % 
- » d o a e a prolonged ef fect · 
% of control rate t at 32 min after Injection 
50 Mg/kg 76 9 ( P < 2) 
I 0 0 u g / k g rt 1 
гооп/kt 17 0 
Î00 Mg/kg 4 4 (all P < 001) 
Onaet 8 16 min peak effect 24 to 40 m m 
D o · · dependent \ 20 % (50 p g A g ) 95 Я 
(100 p |/kg) Peak effect 32 m m 
0 4 m g A g alight \ (not algn ) 
0 β mg/kg V ( " i n ) control/drug 
5561 • 598/2769» 95β 
Doae and t ime related Ь at 20 nun with 
0 4 mg/kg 
0 1 mg/kg moderate i peak at 20 30 or 
40 min 
a Conatant current throughout aeaa i tn 
(2 auhj ) 
b Stepping up current (each etep + 6 μ Α υ ρ 
to 48 μΑ each 10 min ) 
0 05 m g A g 
1 % change from control Ín Indiv anlm 
-17 45 35 36 23 
1 ' period (30 min ) SS 
2 ' period (30 min ) injection phyeoatigmlne 
W t 15 a 30 mm 
3* period (45 min ) injection ΒοοροίΛηιΙηβ 
(0 5 mg/k«) 
remétate SS 
REMARKS 
Ineffective in e scape behaviour 
Mean + S E 8 ra t · 
Correlated with neuronal Activity 
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1 NICOTINE 
REFE!« ENGE 
W.no.r. H.U.. 
ext ia 
19М 
nowllna, С. UMI 
Pradhin. S . N . 
19é7 
l'r>dltui, S . N . · Ι · 1 . 
1967 
l i d · . M . E . «ad 
nomino. E . F . 
1969 a 
Did· . M . E . «ed 
Domino. E . F . 
1969 Ь 
l>r»dh»o. S . N . u u l 
nowl in i . С 
1971 
N c w m « . U . M . 
1972 
Р і ч Л » « · . S . N . »od 
IUm»l. K.A. 
1972 
Coolloued 
D o · · 
•»l/hl 
0 .29 
0 . 5 0 
0.1 
0 .4 
0 .025 
0 . 2 
25 
50 
100 
200 
400 
600 
0.4 
0 . 6 
0 .0125 
0 .4 
0.1 
0 . 2 
0 .4 
0 . · 
0.05 
0.10 
R U 
i .p . 
i-p. 
ίρ. 
• . с . 
• . с . 
à. p. 
l . p . 
ι. p. 
Τέ. 
m i o . 
•IS 
«10 
t í o 
0 
- 1 
0 
JRAIN STRUCTURE 
U t . bypothtlomu· 
(MFB) 
bypot taUmu· 
hypotboUmus 
U t . bypotbAUnro· 
p o s t . l o t . b y p o t b i U -
m u · 
pos t . l o t .brpotboU-
m u · 
U t . b r p o I b o U m o · 
U t . p M t . b y p o t h a U -
m u · 
poet .hypotboUmo· 
RATS 
N 
Sos 
5 
'.r 
poi 
d o · · 
7-< 
P · ' 
d o · · 
· . 24 
b . 15 
¡i 
lit 
STIMULUS PARAMETER | 
E 
В 
В 
рА 
40-120 
40-60 
40-60 
· . Т . 2 5 - 1 0 0 
Ь. < 46 
TS r m · 
or» 
F 
200 
PP« 
6 0 * 
6 0 % 
6 0 % 
6 0 % 
6 0 % 
p.w. 
ina«c. 
2 
T . D . 
т о о с 
500 
250 
250 
400 
200 
400 
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[SESSION 
Dur. 
nün . 
2ж2.* 
30+ÍO 
)0+»0 
ta 
or 
-«•IO 
6ж10 
Ы 
Р г о с . 
CUF 
CRF 
CR F 
CRF 
VI 
-JO 
• •с. 
CRF 
RESULTS 
T««ted on h ^ h (H) ··* lo» (L) c o r r a l i 
% »tlmolotiOB per minute 
H вг.г βτ г во.г 
L 44. θ 7 5 . 4 7 ] . в 
Alter prntonted period of SS « h a i SS ' l o ^ e d 
down nicotine t SS 
— pbenoberbiUl (10-15 m t / k , ) 
L e · · · * r e e c r p l n · (0 . 5-1.0 mg/kg) 
Reduced by pre-ndm. mecnmlrtninlne (1-2 
•ni/k!) 
SS f 
\ , but trnaal«nt end ver l tb le 
№ control rate at Increanng d o e e · 106.7 . 
в і . в . 4І.Ъ. Si.4. 32 S, 69 1 % 
After transient Ъ , •ome facilitation at 200 
ugAi. 
\ completely, though tranalently 
m Я change 400 Hg/kg 32. S Я . ( 0 0 | ig/k( 
¿9 % at peak effect (S min ) 
At »4 min . t 4 0 0 | i g / h g 1 1 7 % . ЫЮ pg/kg 
110 % of control 
1. 100 or 200 pg/kg 1 in ra t · « i t h alow SS 
(»00-1500 R/hr). Ind. variabil ity aome-
t i m e · initial Ъ . 
2 . a) Constant c u r r e t at 1 12 5 pg/kg -
200 pg/kg.overall e f l tct gradual t I r a 
3 % to 41 %. duration 50 min at 37. 5 
and 50 pg/kg and > 60 min. at higher 
d o · · · . 
Second group M s * at 50-400 pg/kg 
b) Stepping-up current: 6 μΑ period up to 
48 μΛ 
7 d o · · · (20-400 |ig/kg) 
Rata with high SS f at l o · current 
L e v e l · ( l t - 2 4 μΑ), \ at higher current 
R a u with lower SS t . шаж at 30 μΑ. 
higher current I 
No defln do*e-rcapai«e c u r v e · . Duration 
at 100 pg/kg 30-50 min. 
At baaellne rate « 3 0 0 R/10 min · d o a e · 
5 0 | i g A g a n d > «ign. r n t e - d o · · interaction 
100 pg/kg f. Injected after 9-10 bra SS 
(SS reduced by 24-03 % of Initial rate) 
No effect on unrelnforced reepondlng 
SS f d irect ly related to t ime and doae 
No algn difference between p lacement · 
No initial d e c r e a · · . Sign, f (onset 10) 
Pretreatment with mecamylamtno ( 1 . 0 mg/fcg 
In 9 r a t · (3 poat , 4 lat . ) b locked, of Іпсгшя 
CoMtant curront throughoitf ••••Ion (5 rata), 
or atepplng current ( i n c r e a · · each 10 min. 
by i μΑ) ( · ra t · ) « change (rom c o i t r o l · 
5 r a t · ' 0 or «Ughi к . • m u f (range 10-54 
REUARKS 
Sequence of 2 5 min high cui 
rent followed by 2 . 5 min low 
current (comparable e f f e c t · 
with a m p h e u m i n e ) . 
N o d a u 
0 .50, 1 00 mg/kg) enhanced f a c l l i u t o r y 
e f fect · nicotine in в rate In 5 r e t · with 
high reap, rat« further k or unaffected 
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1 SCOPOLAMIIŒ 
REFERENCE 
Old· M E «od 
Toimno Ε Γ 
9 6 9 · 
Э о т ш о E F and 
Did.. Μ E 
1972 
31 da M E 
1912 Ь 
l ewman L M 
1972 
Oída Μ E 
1972 a 
Oída Μ E 
1972 b 
Pradhan S N and 
Kamat К А 
1972 
D o a · 
m i / k i 
0 S 
0 2» 
0 S 
0 4 
0 β 
1 6 
0 5 
0 оъ 
0 1 
0 25 
0 5 
Rie 
а с 
в с 
в с 
а с 
' ρ 
Tl 
mia 
*10 
«30-45 
- 3 
«30-45 
-IO 
BRAIN STRUCTURE 
poBt.lat.bypothaU-
muB 
post.hypathalamuB 
MFB 
lat ров! hypothala-
mua 
poat hypothaUmuB 
RATS 
N 
SBK 
tt 
o r » 
p . t 
(roup 
li 
e« 
par 
doae 
5 Í 
STIMULUS PARAMETER 
E 
В 
В 
В 
В 
В 
Р * 
40-60 
40-60 
75(гіпв) 
or > 
40-60 
F 
6 0 , , 
6 0 % 
6 0 % 
' ° Ч. 
60
 % 
Ρ W 
т а а с 
" 
Τ D 
т а в с 
250 
250 
250 
250 
400 
60 
SESSION 
Dur. 
min. 
эо+ео 
120 
Ьш 10 
1.30-45 
2 .32 
3.80 
ЬхЮ 
Ртос. 
CRF 
CR Г 
VI­
SO e c c . 
CRF 
CRF 
RESULTS 
SS Tftt« after pretreatmott «copoUtnln« 
I l/2 hr before the agoni · t ) : 
•cop. -f pÉiyeoeÜjmlne (100 μ | Α ι ) : 105 % 
•cop. + arecoUne (1600 μ ί Λ « ) ' 125 % 
•cop. f nicotine ((Л0 pg/kg: 91 % 
Methacopolamlne. no effect 
a. Croup· with control ratei 100-1200R/ 
β min. 
0.25 mg/kg: 114-27 %. 14-24 man. 
after Injection 
Higher dove · : mean effeet \ , т а н 
16 min. 
2 m g A g - 1 · · · Ind. varUblltty, mean 
\ l e · · than 50 % 
b. 2 mg/kg 
No effect on lo« (100-Э50 R/β min) 
or moderate SS (150-750 R/B min). 
High SS (750-1200 R/B min) \ 50 %. 
8 min after injection, ralee to β0 % 
of control, U· t ing BO min ·Ε· · ιοη 
c. Slight facilitation in non-responder· 
and naive rat · , with peak at 16 min. 
No *ign. di f ference· 
Individual data: 2 •ubjects f at 1.6 and 
O.Bmg/kg 
1. On 80 min. ••••ion. minor change· 
2 . 30-45 min. no drug 
32 min. inj. •copolamlne 
80 min. In) telrabenasine ( 2 . 0 mg/ 
kg), chlorpromaaine ( 2 . 5 mg/kg), 
phyaoetigmiae (0 1 mg/kg) or 
pentobarbital (10 mg/kg) 
Antag. depreeaion tetrabenasme: elgn. 
a t S , 16 and 24 mm. 
Anlag. depre«ston chlorpromaxine. 
protection throughout 80 min. сеааюп 
(•ign. 16, 24. 32 min.), 
Antag. depression phycostigimne full 
protection 
Antag. depre**ion pentobarbital' 
potentiation Initially, facilitation later 
(after 32 min. ) 
a. Stepping-vi ρ current, increaae each 10 
min. with 6 μΛ (таж. 48 μΑ), 6 ж 10 
min. 
b. Con·tant current throughout аееяіоп 
a. 5tepping-up current 
0.1 mg/kg aign.f (10/12 rat · ) 
higher doac · \ , l eas •timulating 
except at low SS ratea 
b. Constant current. 
0 . 0 5 - 5 . 5 mg/kg: s ign, f, no doae-
r e a p o n · · , onaet 10-20 m m . , peak 
4 0 . 5 0 min. 
c . 0 .25 mg/kg 0.50 m g A g 
acopolamln· •copolamlne' 
29 % * 32 % f 
3 % V 22 +\ 
REMARKS 
A n a l y i i · of variance 
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1 SCOPOLAMINE 
R E F E R E N C E 
(could ) 
Prodhan, S N »od 
Κ · π · | . Κ Α. 
1971 
D o · « 
m i / k , 
0 OS 
0.1 
0 25 
0 . 5 
RI« 
ι Ρ 
τι 
mia 
-10 
1 ATROPINE 
Jun, Ο Η olid 
Boyd, E S 
\4bk 
Newmui. L M 
! 9 7 î 
P r . d h . n S N »od 
K a m · ! . К А 
1973 
0 .1 
0 . 2 
г.о 
4 0 
>.o 
l b 
0 . 5 
1.0 
г.о 
5 0 
Ρ 
1 Ρ 
ι ρ 
-го 
-J 
-10 
3RAIN STRUCTURE 
U t . p o e t . h r p o i h · ! · -
m u · 
poat hypothktamu· 
• rea from midbr. 
hypothalamus to 
•nt. commtseure 
post . hypothaUmua 
1 · ! hypothalamua 
poat. hypothaUma· 
Lat poat.bypothala-
nui · 
RATS 
N 
S · · 
s i 
рот 
d o · · 
it 
M 
ti 
to 
i s « 
P " 
d o · · 
STIMULUS PARAMETERS 
E 
В 
В 
В 
В 
I 
Τ« 15-25 
7 S ( ™ . ) 
o r » 
Г 
ω,, 
«>% 
6 0 Ц 
ω,, 
Ρ W 
mace 
Τ D 
ю««с 
400 
«50 
200 
400 
62 
1 SESSION 
Dur. 
min. 
M 
5 
І ж І О 
6 0 
>r tmlO 
F r a c . 
CUF 
CRF 
VI 
-30 » с 
CRF 
RESULTS 
d. Complete u i U g o m i m of the к of 
phy*o*ti( inme ( 0 . 0 S mg/kg) by 
• copoUmiDe ( 0 . 1 -1 .Ъ mg/kg), no 
aaUgODiem of Aeoftjgmuie { 0 . 0 5 
h i g A g ) · DiathylscoiioUiOiae U 
m g A g ) »-omplet* OF і а н і я і 
aotsg . of ncoet igminc . 
Stopping-up current end c e a e u m curren 
(•e· H 7 2 ) 
Groufdng Ы r o t s in low. medium, 
high SS 
» in low reop. with 0 . 1 - 0 . S mg/kg 
« i n med. reep. with 0. 1-0. 2S mg/kg 
rmrinble e f f e c t · in high reepondere 
Ef lect at Τ (thre.bold), Τ +5 to 10, 
τ+го № 25 
No e ign. change (nor by tncthylntrop.) 
Pretroatment : complete blockade of 
no effect with methylatropino 
between doeea. 
Sign, offecte (% of control) 
2 , 0 m g / k g . ^ t 115 % (60 min) 
4 . 0 m g / k g · * + 120 * 130.40, 50 min) 
β.Ο i n g A g i ' h + 90-85 % (20. 30 min) 
1 i . 0 mg/kg: ·^ • β 0 - 9 0 * (30, 40, 50, 
60 min) 
2 . 0 mg/kg. / 1 0 0 - 1 0 5 * (50. 60 min) 
4 . 0 mg/kg' M 80 % (20-60 min) 
B. 0 mg/kg idem 
1 6 . 0 m g / k g . Ъ . » > 0 - 5 5 Я ( 1 0 - 6 0 min) 
Conetant c u r r m t through 60 m i o . 
e e e e l o n or increaee in atepe of 6 uA 
e v e r y 10 min. 
% f from control: 
- etepping -up c u r r o t : 
1.0 mg/kg: 10 * (4/4 rata f ) 
Î . O m g A g : 30 « ( 5 / 6 ) 
5 . 0 m g / k g - 2 6 * (4 /4) 
- conetant current 
0 . 5 m g / k g : 5 » ( 6 / 1 2 ) 
1 .0 m g / k g : 6 * (11/15) 
2 . 0 m g / k g : 14 %(9/«2> 
REMARKS 
^ O u e lo low aal ine b a e e - l i n e 
Drug effecte apprec iable a t low 
baeel ine ratee leee marked at 
higher r a t e · ( > 7 0 0 R / l 0 m m ) 
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MORPHINE 
REFERENCE 
Old · J. 
I9S9 
Old · . J . T r . v l . . · 
R P. 
I960 
b 
A d a m · , W J .1 »1 
1972 
Click. S . D «t a l . 
1975 
L o r e n · , S A , 
Mstcbell С С 
197Э 
L o r e n · S A 
197J 
B U h e 
•nd Help»™ 
1971 
M a r c u · R , 
K o r a e u k y С 
1974 
D o · · 
•niAi 
7 0 
7 . 0 
5 .25 
7 00 
ê . 7 5 
>0 « 
10. 
0 . 5 ml 
of 
50m,Aol 
5 .0 
10 . 
20. 
7 5 
10 
15 
4 
β 
12 
R I · 
i Ρ 
1 Ρ 
ι.ρ 
• с . 
• . с 
• с . 
• с 
' Ρ 
• с . 
Ti. 
-
* 10 
m i s 
• 5 h r · 
* 10 
m i s . 
-1 
-10 
bRAIN STRUCTURE 
•nt«r forebraln 
MTB 
poat mldd.hypothel». 
mua 
•eptnl r e g i « 
•ut U F B 
poal. U F B 
U F B 
(MTB) 
U F B 
U t . b r p o t b a U m u · 
U t hypotbalnon· 
( U F I » 
RATS 
N 
S « 
W 
6/0 
6/e 
6 / · 
± 4 0 
2 . 7 Í 
6>4-6 
ê 
4 , a« 
4 r f 
j / 
| STIMULUS PARAMETERS 
E 
В 
В 
В 
В 
В 
В 
В 
В 
I 
1 0 . 2 0 . 3 0 . 
4 0 . 5 0 
0 . 1 0 . 2 0 . 
Ж 40. S0 
120-000 
зо-βο 
240 - »ВО 
25-150 
F 
M » 
« 4 
100 pp, 
"Ч. 
100 pp. 
100 pp. 
200 pp· 
p w . 
ma«c. 
-
0 1 
0.1 
0 .1 
0 2 
T . D 
m e e c 
500 
200 
500 
200 
200 
500 
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1 SESSION 
Dur. 
mia. 
ft 4 te» 
6 . 8 
6ш10 
kt hrIn­
ter v*l 
SO 
ш 10 
kt brio-
U m i 
2 • 10 
kt 1.) 
LixMtn 
50 
Pro«. 
CRF 
CRT 
СНГ 
CRF 
CRF 
RESULTS 
Sligbft / IA »mbivalent region (middle 
brpothnUmu·), 
\ln*Ql«r. iorebrkln. po«. hypothnU-
rnue 
». ижрра
Ч
. Tot&l effect 66 % \ of the 
time. 20 %/. 
Hypoth. réglant. 
Sign, difference between яерШ region 
[\ ) and tegmentkl eree (/ ) 
*t 7.0 to 10.25 mg/kg compered 
«1th meprohemnte 
S delly injection·. 
lei day at 2Ьтш\ . at 5th and 6lh hr f ! 
3rd day tolerance to enppreeaivc effect. 
5th day emcltatory f and apparent 
earlier. 
Repeated Injection for Э daye. 
- Airing SS 
- during withdrawal 
InltiaUy \ 
SS during depmdmce minim, wfcbdiml 
no effect tm withdrawal 
SS during withdrawal SS f 
4 daUy lnjectl<me 
- ^ and t , develop, tolerance — 
escitatory effect appeared earlier and 
tended to rlae 
- * " « A i H br. Ζ hre 0. î hr. / 
complete tolerance 3rd day 
- lOmgAg \ 1 hr. / 3rdand4thhr 
- 20 mg/kg \ for 3 hre. f 5th and 
6th hr 
• land* 
- Tolerance to euppreaalvc effect· 
3rd day 
- No difference between S leelon and 
control aide 
Two phaee· 
1. 90-150 min after Inj«сttor. time 
period· with no re«pondlng. when 
rat re •ponde, reepon·· rate *m or/ 
2. Rate eaceed· control rate· 
- Threehold determination- '•talrcase' 
procedure 
Procedure. 1 non-contingent S. R with­
in Τ S ««с period followed by 1 con­
tingent S 
mg/kg Ь threshold. > doae no effect 
REUARKS 
2 ежат plea 
Only data at 30 μΑ level 
Implantation of reservoir 
No correlation with wheel turning 
activity 
- Bilateral implantation 
- Rat· leaioned unilaterally in 
locus coeruleue 
- Current adjusted upiol SO R/10 
min 
Long period· of SS 
Comparison with threshold. 
Increasing effect on escape for 
negative S 
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DIPHENYLHYDANTOIN 
REFERENCES 
O U · . U . E . 
1970 
Weinrieb. 0 . . CUrk, 
L . D . 
1970 
D o · · 
•»•Αι 
75 
25 
50 
ACETAZOLAMIDE 
Welnrtch. D . . CUrk, 
L . D . 
1970 
A L P H A - M E T H Ï L -
BUck, W C . 
Cooper, B . R . 
1970 
:ibsoii. S . 
. l iGcer , E . G . , 
.IcGeer. Ρ L. 
970 
L - o - M P T 
D L - o - M P I 
'oûper. B . R . . 
Hack, W . C . , 
Col ino . R M. 
971 
Itinu·. L . . 
л Moki. M.. 
Заrdo, В. 
972 
10 
PA RA-Τ 
200 
400 
«00 
1. 75 
2. 100 
3. 200 
200 
600 
150 
R t . 
ι.». 
i.p. 
Ti 
min 
M 
ι. p. 
mos 
or 
' . p . 
or 
i .p . 
W 
INE 
• 4 h r . 
+300 
•Ы> 
3RAIN STRUCTURE 
p o s t . U l . h y p o t h a U -
m i · 
MTB 
MTB 
IM. hrpolbkUniu· 
(MFB) 
mediftl lorebr. re­
gion of tke poet. 
hypotbkUmu· 
6 # · »eiKkliorebr. 
region (5-F) 
6 # · M . h y p M I u l · -
πκι · (LH) 
10 # . «rek venir. 
tegmemi (A VT) 
12 il· U t . b r p o t h . U . 
m u . (LH) 
RATS 
Ν 
See 
12 / 
1 2 / 
. < / ' 
23 J" 
1 2 / 
2 2 / 
STIMULUS P A R A U E T E U | 
E 
В 
В 
В 
В 
В 
В 
В 
I 
μΑ 
50-100 
50-500 
300 
Τ 5-14 V 
300 and 
500 
7 1 . 5 ± 2 . 0 
(A VT) 
7 1 . 2 1 1 . 0 
(LH) 
F 
M * 
175 
200 
И » 
175 
200 
PP· 
200 
PP« 
60 V 
200 
PP· 
200 
P.W. 
Duac 
" 
0.1 
0.1 
0 . 2 
(interval 
0.2) 
0.2 ( * 0 . 2 
interval) 
T . D . 
•пае« 
250 
500 
500 
250 
•very 
1.5 
150 
250 
200 
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»ESSION 
Dur. 
mia 
W t M 
10-mlD 
per lad · 
ia-min 
p»tt»· · 
1 0 . m i » 
1 0 - m l · 
pftuse, 
-R»le-
Freetett . 
) 0 m l n 
l«v«r. 
a r c i n g , 
• IIb IO 
nlnionr-
» 1 . 
• D o s 
l i v . n l o 
З ж і / J . l 
0, 2 »od 
< h i · . 
D A » 
11/2-10 
br, »iter 
Injection. 
D r u | c s -
pe riment 
throAigh 
toy 
V o l u t e 
dllCeren-
c e b e n « 
control 
Ihreihold 
ind lo l lo-
»Inidrua 
tdmlni-
• tretlon, 
l e k e n e , 
drug-ef-
[ect 
2M20 min 
• IthlO 
mlnm-
lervel, 
Г р е г ю і 
100 μΑ 
1'period 
500 ||Λ 
Relc-free 
inshultle 
»ж30 min 
»IIb 10 
mlntn-
[ervele 
В control 
toy.. 
»•dn, 
N e d 
10* toy 
e - M P T 
u.u.ij· 
•toy con­
trol. 
pecor­
umi per 
5 min. 
P r o t . 
CRP 
CRP 
CRP 
RESULTS 
- Control rete 1» » min J t S - 1 1 9 0 . 
- i to W %. 40 min »Пег Injectloo. 
eti l i SO % 80 min erter InJecUon. 
- No »Ignlflcnnl c b e o g e , in e n t l n c t i « . 
Bllght к . Î0 min efter Injection, l 10 Я 
with M m j A i 
31І|Ы V . M min »(ter injection. ±10 % 
with 10 mg A l 
- Rete free teet every 2 nun 
S on о м elde of the cegó, rendomly 
•witched. 
- i In rete free end lever-pre*»tng e l -
tuetlon. 
- I n v e r , · r e U ü o n et lmuUtlon rete end 
doee . 
- Wide renge of Individu·! d i f f e r e n c e , . 
- 18 /23 r e t , > In threihold 
3 no effect, 1 decreeec 
- Меж effect 5-9 hr , efter Injection. 
- Recovery complete vithln 24-48 hr , 
- Increeee v o l u g e (n ret, ) 
1) 1 1 0 
2) 3 2 6 
3) 1 0 5 
Mein effect i , differed from eech p ie. 
cement eccordlng to current inteo, i-
ty. 
Significent difference from control 
LH -300 μΑ between doeee end control. 
-500 μΑ hlgheel doee. 
S - r - 3 0 0 p A d o s e , from control, not 
between doee*. 
-500 μΑ d o e e , differ from eech 
other end control 
1 Immedlete I 
2 . Pnrtlel recovery et » t e n eech period 
(eepectel ly l , t m l n ) . 
3. Credul i decreeee during ee»»lon. 
4 24 h r , l e ler etili к 
AVT ellghlly higher 
5 48 hre complete recovery AVT, 
pert le l ly for LH 
REMARIB 
Teel et poeh effect. 
% of control 
25 15 
49 100 
Effect on locomotor ecl iv i ly 
1, Immedlete i (50 % of contr. ) 
2. 4 hr, leter k(19 % of contr ) 
(S5 et thel time 73 % of c m -
trol). 
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1 ALPHA-METHYL-PARA-TYROSINE 
REFERENCE 
Reiugrand, J . , 
St .-Laurent. J. 
1973 
Rilter, 5 . . 
S u m . L. 
1973 
St inu · . L. . 
Thierry, A 
1973 
Stinua. L. . 
Thierry. Α., 
Blanc. С 
Clowinaki. J . , 
Cardo, В. 
1973 
Yunger. L. XI. 
et a l . 
197J 
D o · · 
mg/k» 
100 a 3 
200 
150 
130 
2 SO 
Rie 
l . p . 
1. p. 
l . p . 
1 Ρ 
l .p . 
TI 
min 
0 
15 
and 
3 hr 15' 
-4 hr 
»60 
» 1 hr 
-4 hr 
1 ALPHA-METHYL-PARA-TYROSINE 1 
Yuwtler, Α . . 
Oída, Μ. E. 
И 7 3 
Stinua, L., 
Thierry, Α . 
Cardo. В. 
1974 
400 
50 
75 
l .p-
l . P . +1 hr 
RATS 
N 
S e i 
poet. MTB 
or 
AVT 
locua coeruleua 
22 φ area venir. 
tegmenti (AVT) 
19 # lat hypothala-
m u . (LA) 
area ventr. tegfnen-
tl (AVT) 
lat bypotbalamu· 
area ventr. tegmen-
li (AVT) 
»S 
b¿ 
41 ƒ 
24 i 
¿ 
г, i 
STIMULUS PARAMETERS 
E 
В 
В 
в 
В (2) 
В 
в и 
I 
и* 
60 
к» t i 
(AVT) 
73 • 2 
(LH) 
7 1 ± 2 
356 ± 4 9 
and 
»>7 • 82 
F 
60 V 
100 
ρρ· 
100 
су 
100 
'Y 
200 
ppa 
P.W. 
maec 
0 . 2 
0.1 
Τ D 
m s e c 
250 
150 
200 
200 
200 
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SESSION 
Dur. 
-10 mm 
readiM 
f . c h l / 2 
ÌT ШІІ9Ж 
Ine ш 
l / 2 h r 
•eaaion· 
1 perdky 
- ¿ r e a -
ding! fob 
lowing 
1 »t li 2nd 
injection 
tiler 12 
h r · reet , 
5 additi-
onal rea -
dings . 
- T h e r e -
i f ter L · 
dopa 
ІЗк 30 
min. 
with 30 
mm in­
t e r v a l · 
β rat i 
• ubmit-
tedto 
Impoied 
bi lateral 
S for 1 hr 
-2x125 
ng/kg 
о - M P T 
(4 hr in­
terval). 
-ThreAoU 
ÏS 356 
μΑ 
ТЬтшЛЬІа 
tnalgeila 
(pawTici) 
887 
Non-con-i 
ting ent 
or forced 
5 (no SS) 
1 0 * 30 
min with 
30 min 
intervaU 
F r o c . RESULTS 
- Valter l i t injection within l e t 1/2 hr 
- After ? h n SS completely abo luhed . 
- ZA h r · later recovery to l e a · than 
half of controls 
- L-dopa reduction and fubsequent r e ­
covery). 
- V of 42 5 % ± 9 . 5 %. 
- 2 rats with intraventricular cannula 
reversal suppressive effects by 
L -norepinephrine (10 pg) and not by 
dopamine. 
1. о - M P T + Ro04-4602(SOingAg) .gra­
dua I decline. 
2 . α - M P T + Ro 04-4602 + L-dopa (200 
ingAg) * h r a !*** ' reinstatement 
t i l l end e»p«rLmettt in LH and AVT. 
3. a -MPT + Ro 04-4602 + DOPS (400 
mg/kg) 4 hr« later reinit&tcmcnt 
Uli end experiment only In AVT, not 
in LA. 
No SS 
Lever-press ing per 10 rain 
356 uA I S t n A 887 oA 
15(5 365 109Й 
¿131 ±225 +285 
No se l f - s t lmulat loo . 
Rats lesioned by 6-OHDA in AVT, pe-
dunculus cerebral ! · (PCS) others «ham 
injected. 
о - M P T (50) 
6-OHDA les ions enhance· depress ing 
effect ID AVT (no significant diffe­
rence in PCS). 
α - M P T (75) 
controls i 52 % 
AVT and 
PCS « 8 6 % (6th . e · . i o n ) . 
REMARKS 
Spontaneous behaviour 
decrease of movements and hy­
potonia, drowsy. 
After 150 mm slightly more a c ­
tive 
Back to normal a l ter 12 hre rest 
% control valu*« ^
 D A 
1. α - M P T 1 hr HA * 79 * 
4 hr 56 * IB * 
8 hr 39 * 26 * 
2. α - М Р Т 4 . 5 h r 98 * 160 « 
+ 5 hr 92 * 290 * 
L-dopa 8 hr I 05 * 402 * 
3. a-MPT 5 hr 46 Ъ4 
+ β hr IS 31 
DOPS 
(Each analysis 8 rats, * s ignif i­
cant difrermcc) 
- After о-MPT NE end DA sigm-
cant ly\ 
• Imposed stimulation a t c e l e -
ration NE uli l i iation m Ьгащ 
stem, hypothalamus hippocam 
pus and cortex 
- NE sign, reduced in rats not 
submitted to S 
- DA In striatum not a c c e l e r a t e d . 
Change in NE and DA in non-im­
planted. implanted (but not rewar­
ding) and implanted (rewarding) 
with e lectrodes after forced S. 
Reduction in NE and DA in al l 
groups 
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I ALPHA-METHYL-META-TYROSINE 
REFERENCES 
Potchel, B.P H.. 
NintemKn, F.W. 
196) 
Poichtl. B . P . H . . 
Ninteman, F.W., 
Stanai, S.C 
I96S 
Doae 
m« A i 
» 0 
10 
25 
И 
KU 
ι.ρ. 
2 
1 
l.p. 
Τ ι 
min 
» 6 0 
«180 
1 DIETHYLDITHIOCARBAMATE 
Wi.c, C . D . . 
Stein. L. 
U M 
2 n i | In 
2 9 ) i l 
1. 
v « . 
t í o 
1 
1 DISULFIRAU 
WU«. C D . . 
51чп. L. 
19M 
Roll. S.K 
1970 
Lirbman. J . M . . 
riul<-h?r. L. L. 
1 9 U 
2 0 0 
1 0 0 
1 9 0 
• P. 
ι ρ 
i. p. 
• 6 0 
« 6 0 
•160 
FLA-бЭ 
/biafl -methyl-4-homoolperaEinvl-thloc«rbo-
ny\ dltullid«/ 
Stlnu· et a l . 
197J 
Lippa. A.S. « t a l . 
1971 
4 0 
Zi 
, Ρ . 
i .p. •T.Sbra 
lat hypothBtamua 
poat lat.hypothala. 
mua 
(MFB) 
medial forebr. 
bundle 
medial forebr. 
bundle 
medial forebr. 
bundle 
meaenccpfa. central 
( r a y 
lat.hypMhalrmua 
17 Implanted area 
ventralla te|inenU 
(AVT) 
poat. hypothalamue 
RATS 
N 
Se* 
I r f " 
IS 
iJ 
11 / 
24 ƒ 
4 / 
STIMULUS PARAMETERS 1 
E 
M 
M 
1 1 
в 
M 
2жВ 
В 
В 
1 
20-10 
29-10 
100-400 
100-400 
И - 4 0 
71 i 2 
F 
0 1 
60 4. 
100 
РРе 
100 
РРе 
6 0 % 
100 
СУ 
200 
РРе 
Ρ W. 
meec 
0 . 2 
0 . 2 
0 . 2 
T . D . 
meec 
4 0 0 
4 0 0 
I S O 
M O 
190 
or 
eoo 
1 0 0 
2 0 0 
1 0 0 
70 
I SESSION 
Dur. 
min 
Т+вЬг 
• e · · Ion 
+1 hr .2# 
trnnyU 
cypro-
m i n . (I 
m g A i ) 
1 i P. 
ιφ. 
pkrgy-
line (20 
mg/kg) 
в С 
SS for 
s e v e r a l 
hreatAQ 
Intensity 
maintai­
ning sta­
ble r e s -
ponding 
SS íor 
s evera l 
h r s a t a n 
Intensity 
maintai-
ning s ta -
ble r e s -
ponding 
rímente) 
Ь hr sea-
• ion on 
HOmeec 
( D o r 800 
meec (2) 
duration 
I ' p e n o d 
Int.y ie l-
d.ng70-
M H o f 
SS. 
2*period 
doubling 
current. 
β rata 
submit­
ted to 
imposed 
b i U i . S 
for 1 hr 
P r o c . 
RESULTS 
- α - M U T no effect. 
- 1 hr before parnate (1 mg/kg) / tor > 
3 h r · 
• 3. Shrs before t e a t a - Ы М Т . parnate 
(1 mg/kg) * tetrabenaxine (2 mg/kg)* 
SS к . 
I a period (3 hr IS 1 ) : control, DO v is ib le 
effects of UAO-inhlbitora. 
2* period (1 hr IS') ем с itati σο on in­
creasing d o s e s . 
IO mg/kg leas than control 
25 mg/kg ± 2 5 % 
50 mgAg- + 3 я control 
k . off in 30-4S m i o . 
V between 7 . 0 % and 2 0 . β % of control. 
Neurohormones administered 1 -3 h r · 
after dlBulÛram. 
i bar-press ing result from increase in 
frequency and duration of p a u s e s . Re-
placement on the bar sofflclent to induce 
resumption of SS. Pooled data (mean· 
3 rats) m ratea of responding (5 m m ) . 
control disulftram duu l f i ram 
(1) 171 102 152 
(2) 3S9 263 347 
И period * S S . 
2 ' period doubling current res tored 
lever-press ing to an average 
rate емсceding control rates . 
No SS 
Fla-63 vehic le: 96 % of mean SS rata 
O d a y . ) 
F U - 6 3 M % (no aign. difference) 
REUARKS 
L о ж а т р і е . 
ntraventncular injection oí 
-norepinephrine (5 pg) reversed 
• uppresaion, not with d-norepine-
phrine (S
 M ) , dopamine (S S |ig) 
or aerotonm (4 .8 pg) . 
% of control SS rate 
diethyld. 9 .7 + 4 . 2 
diethyld. + l - N E 66 .1 ± IS β 
Intraventricular (10 jig) oí l - ( f ug) 
or d l -norepinephnne reversed to 
respect ive ly 62 5 + 1 1 . 0 and 61 . 9 
± β.8 % of control 
No reversa l with α - N E . DA. SUT 
l-NE (injected ι .p . ) . 
After F l»-63 
- NE l e v e l · \ 1 hr after admini­
stration. 
- Imposed S marked acce lerat ion 
of NE utlliaation in brain stem, 
hypothalamus, hippocampus, 
corten. 
- NE i ( Î0 -45 %) of when c o m -
pared with rats not s t imul . 
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1 L-DOPA 
REFERENCES 
Kadsiel iwB, К. 
1971. 1974 
Liebman, J. M.. 
Butcher, L . L . 
1973 
nt'augrxnd, J . , 
St -Laurent, J. 
1971 
Doae 
n i i A g 
100 
75 
1Í0 
50 
and 
200 
Rie 
' . P . 
1 P. 
' . p . 
TI 
-30 
BRAIN STRUCTURE 
poat . lat , hypothala-
mua 
meaencepfa. central 
gray 
iBt.hypotbalamua 
po i t . MFB or AVT 
RATS 
N 
Sea 
• 
12 
IS 
80 J 
STIMULUS PARAMETERS 
E 
В 
!aB 
В 
I 
и* 
10-70 
15-40 
60 
F 
5 0 » 
ЬО« 
60 V 
P.W. 
maec 
T . D . 
maec 
400 
100 
250 
72 
SESSION 
Dur. 
mio 
4 c y c l e · 
oí 2400 R 
L-dopa 
together 
with (-30 
mm) 
R0 4 -44S 
(50 m g / 
kg). 
1 ' period 
SSat SO-
TS % oí 
т а м 
2'period. 
SSatdou-
Ые cur­
rent of 
per iodi 
• 10 min 
reading· 
after la t 
injection 
4 after 
t h e a e . 
cond(] 
hr later) 
•Rata 
were 
treated 
(ЭжЮО 
mg/kg) 
with α -
MPT, 
гоьіс' 
before 
P r o c . RESULTS 
L-dopa after SO mg/Vg 
RO4-4Ä02 i . p 
- I n t e n t e / during 45 nun teated in 12 
еж pér iment · 1 50 % . 
• Lasted 60-90 min. 
- In moat experimenta preceded by 30 
min alowing or blockade 
- 1 · period ЬSS 
- 2* period doubling current r e e t o n n g 
SS to l e v e l · not different from baae-
line r a t e · . 
- In each group- 3 rata failed to initiate 
lever-preae ing. Alt*г impoaedS (30S) 
restoration SS. 
- »-MPT decreased SS, after 12 hr res t 
5 reading· of 10 mm at 30 m m inter­
vals SS at + 1/2 control values. 
- L-dopa VwTthin U t 1/2 hr, following 
I/Z hr value before injection. 2nd 
injection same pattern V and subsequent 
recovery, but completely abolished 2 
hr after 2nd injection 2 days later 
complete restoration 
REMARKS 
- No potentiation with des Imi­
pramine 2 mg/kg 
- No antagonism with 3-5 mg/kg 
phenoicybenzaminc 
- Attenuation or prevented by 
0.05 mg/kg haloperldul 
- L-a methyl-dopa (300 mg/kg 
i .p . ) irnld * 2-3 hr after in­
jection, for 2 hra 
Spontaneous behaviour 
1 , 5 mg/kg leen spontan e ou s πιυ-
vementa. no hypotonia 
2 200 mg/kg 20 nun later po-
lypnoea, 2 rate Ьур гваіі апап 
1 gnawing - h>poactivity 
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1 ЛРОМОЯ RHINE | 
REFERENCE 
^iebinui, J . M . ллА 
lu lchcr. L . L . 
чіг 
ït -Laurent.J et al 
l?7 î 
Wotkkamp. C L E 
>nd Van Roaaum, 
1 M 
(adcie law*. К 
97J 
і г Ы і а о . 1 M.. 
Îulcbar L L· 
97< 
Ooae 
0 .75 
1.50 
0 25 
0 H 
0 1 
0 .2 
0 .4 -1 0 
0 25 
0 50 
0 75 
1 5 
Rte 
Ι Ρ 
> Ρ 
a с 
ι Ρ 
i Ρ 
ΤΙ. 
m i s . 
-15 
+240 
• 3 0 - 4 5 
-15 
| PHENTOLAMINE 
HaatiDga, L. Stuta. 
R M. 
1»7J 
Lippa et al 
197Э 
i 
50 
100 
1 Ρ 
[VL 
1 PHENOXYBENZAMINE 
n a ï U y . Ρ T. et al 
1972 
Kadzulawa K. 
1975 
1-4 
J-5 
| PROPANOLOL 
1\,Пг> et al . 
1972 
Haatlnfa. L . S t u u 
R M 
197) 
0 5 
2 . 0 
10 
> Ρ 
1
 Ρ 
ι.ρ 
-15 
-15 
-15 
lat. hypothalamue 
meaanceph contrei 
«roup 
poat lat hypothala-
mua 
- nucl accumb 
- lat kypotkaUmua 
- cel l-group 
A , - A m 
- locua cocruleua 
mua 
(MFB) 
(LH) 
aubatantla nigra 
(SN) 
tMjeci MFB 
po*t hypotbAUmu· 
m u · 
poat Ut hypothaU-
mut 
post Ut hypothaU· 
m u · 
traject MFB 
RATS 
N 
3-х 
' 5 1 
e< 
2 9 / 
35 г 
t 
1 4 / 
• • 
/ 
• 4 / 
STIMULUS PARAMETER 1 
E 
2 B 
В 
В 
в 
2аВ 
В 
В 
В 
В 
в 
в 
I 
15 - 40 
100 
(37. 5RMS) 
100 300 
15-70 
β-40 
Τ • 5-10 
15-70 
Τ * 5-10 
F 
" * 
60
 % 
100 
СУ 
5 0 % 
»* 
60 t 
200 
PI» 
5 0 * 
t o * 
Ρ W. 
m a e c . 
0 2 
-
-
0 2 
-
T . D . 
maac 
100 
250 
350 
400 
overr 
2 aec 
200 
maec 
300 
300 
40O 
300 
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SESSION 
Dur. 
min. 
10-15 
ВщЗО 
2 . 1 4 
C O . 
D-30 
30 
C=30 
D = » 
P r o c . 
CR F 
CRP 
CR F 
LH: 
F R 4 
CR F 
CR F 
CR F 
CRF 
CRF 
RESULTS 
Current umtá: 10 min »t current which 
yiekU+ M - 7 5 %oi n u x i m a l - 1 0 - 1 5 m i n . : 
at t * l c * Ьжіе-ІІле currant 
Apomorphine: ^ , m o r e variable with 
0 . 7 5 m i / k t 
DoubUd current: - no F at 1. 5 m g / k | 
- Sesceeding Ьаве-Іше 
at 0 . 7 5 m g / k g 
- o -metbylparatyroalne (a -MPT) 100 
mg/kg v ss 
- Apomorpbine (A), r e g a r d l e · · pra-
treatment: 
О.г тщ/кв \ 1/2 br 
0. W mg/kg i 1 br 
After 1 hour-
V-A 0 .25 or V - A 0 . 5 0 > η - M P T -
A 0 .25 or α - M P T - A 0. 50 
- 14/29 r a t e / . 13 V 
-At lODugAg- V,69. 1 ± 2 Z % 
- Rata « a h f (n=6): paraiatant re ·pendini 
(25-30 min) 
- A 9 - A 1 0 rata (n - 5)· O-current: 
pereiatent responding (22-10 mm) 
- Threebold effect 0.4 mg/kg 
- 1 i n g A g - / 4 5 %. 5-60 min 
- 0. 5 mg/kg·- · haloper idol 0. 1 mg/kg 
1. SS 
0 .25 mg A g · SS in HL ^ , period 1 
(no difference period 2) 
> SS In SN 
0 . 5 0 mg/kg (period 1 + 2) 
SS m HL > SS In SN 
во eign dWГ«renr* from 
ba»eline 
0 .75 and 1.5 mg/kg 
SSV in SN and HL. 
no diffirance SN-HL 
2. Number of c r e a t i n g · (ona aide to the 
other). 
Sign, differ enea from baael lnc. 
HL SN 
0 .25 X 0 
0 . 5 0 4 V 
0 .75 4 i 
1.50 4 ъ 
• Mean reeponae* ( ¿ S . E . ) 
- bate day 1622 ± 174 
- drug 1271 1 2 4 0 (p < .05) 
- On normal ra t · no e f fec t · . 
• to pretreated r a t · , «light t 
range 0-31 %. 
50 pg mean 11 % 
100 Mg maan 13 % 
- Decreaeed reepanding. 
- Prevented or reduced amphetamine- or 
cocaine facilitation ir ± 50 % of the 
•ubjecta. 
Increase m the rate after Dopa not anta. 
g wi iced . 
- Decreased responding. 
- Prevented or reduced amphetamine- or 
cocaine-induced facilitation in 50 % of 
the subject · 
Me*n re sponse · ( l S . E . ) 
- base day 1 ДО ± 1 33 
• drug 1431 ± 164 (p < .05) 
REMARKS 
Seaaion-
1 30 mm free SS 
2 . inj. α - M P T or vehicle (V) 
3. 30 min SS 
4. 2 J/2 hr rest 
5. 30 min SS 
6. at 4 hr inj »pomo r phi η ι- or 
vehicle 
7. readings 4 hr 10. 4 hr 4П, 
5 hr 10. 5 hr 40. 6 hr 10, 
6 hr 40, 7 hr 10 
- Monophaaic positive current 
- Submavimal reaponsv rate 
- No differente ac iording to 
implantation »itr 
Session 4-6 c y t l e s of 2400 r< »-
ftonsea 
Rate-free lest of SS cv« ry ¿ β«, 
1 S in one of the sidi в of tht сдщ , 
•witching at intervals of 1, Ζ or 
3 min 
Two perioda of И min in total 
С = control 
D = drug 
15 min pause 
Rats pretreated *lth 2 и 200 Mg 
6-OHDA. 
Tested after recovery. 
No data. 
No data. 
С = control 
D = drug 
15 min pause 
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SESSION 
Dur. 
min 
60 
Z65 
90 
45 
2*30 
¡-min 
Mгtoda 
2ж20 
4« 5 
P r o c . 
CRF 
CRF 
CRF 
CRF 
CRF 
CRF 
F . I . 
1 5.«C 
CRF 
RESULTS 
- No effect at , 0625 -1,0 ι η | Α | . 
- S l ight^ at 1.5 mg/kg. 
- Severe * at 2.0 mg/kg. 
- Pr ior treatment with 25 m g A g with 
pargyllne 1 day before teat required. 
- / , tmaet 45 min »iter Injection. 
- At 20 п і
в
Д
а
 umic. 
- In 5/7 rata mild V »iter Ro 4-4602 for 
± 4 0 %. 
- k, on ·e t 10 min after injection 
- % chang· with 28 mg/kg 32 %. with 
57 mg/kg. ¿ 57 %. with 115 m g A g 
± 6 6 %. 
- Peak depreealon 64 % between 20 and 
30 min after adminiatrauon. 
• With higher doeei 50 % V, 90 m m 
after injection. 
/ p e r a i · t e d > 3 day· 
- Ъ from 528 mean control reeponae 
ratea/e mln.lo 472 <p< .05) . 
- Recovered at 24 h r · . 
16 h r · after laat Injectloa no effect on 
cither of thi- 2 meaaure · 
Drug-effect me* tur ed in changea of con­
trol tbreahold ( increase + 1.1 V. 
+2.2 V, +3.3 V). 
9 r a t a / . 3 no effect. Э \ threshold, 
2-3 day· after injection. 
- At 6 hr · 50 І, \ at threshold current. 
• At 24 hr · 19 % h (not aigoificanl). 
- No •igniiicam effect· of auprathre-
•hold self-atlmuUtion. 
- No • igniiicant main drug effect or 
drug inieraction· 
Teat 3. 7 and 14 daya after drug treat­
ment % change. 
3 day· after injection: 
- / I n MFB and ventral tegmental area 
of Taai, 
- smal l / o r no effect in subaUntia nigra 
and MFB (anlerior). 
- no effect in doraomedial hypothaUmua 
- bin reticular formation 
• Threshold / = responding i 
- Міжітшп effect at 6 h r · . 
- No effect on Buprathreihold intensit ies 
REMARKS 
1 m g A g * n <* > hind l imb paralyaia, 
2 . 0 mg/kg convulsions. 
Cumulative records of representa­
tive r a t · . 
Cumulative record. 
Biochemical déterminations of i o n -
tent of biogenic a mint, β. 
No d e u i l s . 
30-min lever pressing, 
30-min rate-free, 
10-min interval. 
5-HT 
\ Au % and 30 % of control. 
Serotonin s t i l l a t o 79 %. 
Rate-free situation. 
lO-mm interval. 
Τ = threshold +1 - +5 μΑ, 
no c o r n l a t i o n with 5-HT 
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2. DISCUSSION 
2.1. Methodology 
Most authors used the intraperitoneal route of drug administration, 
by which solutions as well as suspensions can reliably be applied. Drug-
effects can differ according to the injection route, as regards local 
effects, uptake in blood, distribution, etc. For example cocaine injected 
i.p. causes stereotype behaviour at dose levels much lower than when 
given s.c. (Simon et al., 1972). Consequently, cocaine might elicit a 
different effect on operant behaviour according to the administration 
route. In several studies only a single dose is used. This way of studying 
drug-effects is not justified because the shape of the dose-response 
curves may differ from drug to drug. Moreover, the shape of the 
response curves may depend upon the particular test used (see effects of 
narcotic analgesics, Wauquier and Niemegeers, 1976a). The period of 
measurement after drug-injection can be an important variable, as 
shown, for instance, in the study of Adams et al. (1972). Morphine 
causes response depression when self-stimulation is measured for 2 
hours following injection; however, responding is significantly increased 
5 to 6 hrs after injection. We showed that the response depression or 
facilitation found with CNS-stimulants depends to a large extent on the 
period of measurement (Wauquier and Niemegeers, 1974b). 
In all the studies, regardless of whether sine-wave current or square 
wave pulses were used, the variations of the base-line were produced by 
changing the intensity of the current. Low base-line rates are mostly ob-
tained by applying «threshold» currents. The definition of threshold is 
often very arbitrary and vague. Furthermore, as will be shown in our 
experiments, the use of low frequency stimulation results in poor 
responding which is very sensitive to drugs. Drug-effects can differ 
according to the base-line rates of responding (see for example the 
effects of CNS-stimulants, Wauquier and Niemegeers, 1974b). Practically 
all authors studied drug-effects using a continuous reinforcement (CRF) 
schedule. Interpretation of data has to take into account the particular 
schedule used. For example: neuroleptics effectively decrease the 
response rate on a high fixed ratio schedule (i.e. with little reinforce-
ment), whereas their inhibitory effect is less pronounced on a CRF-
schedule. 
Most of the studies have been carried out on rats lever-pressing for 
hypothalamic stimulation. Drug-effects may also depend on the site of 
stimulation (see for example: Phillipsand Fibiger, 1973). 
From a methodological point of view the following points should there-
fore be considered: the injection route; the dose; the stimulation para-
meters; the base-line; the schedule; the injection time; the implantation 
site. These and other situational or experimental variables make a 
comparative study on drug-effects extremely difficult. 
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22. Drug-analyses 
Different publications provide descriptive analyses and contain state-
ments which lack quantitative accuracy. A frequent failure is the 
description of results by showing the results of a «representative 
animal». This way of presenting data is illustrative but facilitates 
erroneous generalization about drug-effects. Otherwise there is a lack of 
qualitative observations relevant to the interpretation or description of 
the results obtained. A drug-effect might be essentially unrelated to the 
behaviour studied (e.g. barbiturates depress self-stimulation because 
barbiturate-treated rats are drowsy or sleep; they are, therefore, unable 
to press a lever). 
For comparative purposes it would be worthwhile relating the drug-
effects obtained on self-stimulation to those obtained on other operant 
behaviours and/or to the results obtained in other pharmacological or 
biochemical tests. Such comparisons might indicate whether the 
modification of self-stimulation behaviour would permit generalized 
conclusions. It therefore should be emphasized that the effects obtained 
on self-stimulation behaviour should be analyzed quantitatively and 
should be related to qualitative observations as well as to effects 
obtained in other tests. Such an analysis may enable one to differentiate 
specific from unspecific drug effects. 
2.3. Theoretical aspects 
Some theories of psychic diseases are derived from theoretical concepts 
related to self-stimulation behaviour. Yet the heuristic value of these 
theories has not been subjected to experimental verification. For 
example, Stein (1967) proposed that depression could be caused by a 
hypoactive reward system or by an overactive punishment system. A 
valid model of depression using self-stimulation behaviour, would be one 
in which mood-elevating drugs, such as the tricyclic antidepressants, 
induce behavioural facilitation. Such a model has not yet been 
developed. It is interesting, however, that in a situation in which a 
progressive fixed-ratio schedule was used, i.e. in which reinforcement 
required progressively more and more effort, antidepressants enhanced 
responding which normally dropped gradually to zero (unpublished 
observations). There are few studies dealing with the interaction of drugs 
which might elucidate or confirm suspected interactions between brain 
systems (e.g. Wauquier and Niemegeers, 1975; Wauquier et al., 1975). 
It is obvious that drugs may affect self-stimulation behaviour by an 
action on a large number of systems, amongst others: the motor system, 
the sensory system, the integrative sensory-motor system and the 
reinforcement system. Drugs may also interfere with stimulation-induced 
or situation-dependent behavioural patterns. It will therefore be 
extremely difficult to affect differentially the various systems involved in 
behaviour. 
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IV. General methods 
1. SUBJECTS 
Adult male Wistar rats from the Janssen breeding laboratory, weighing 
250 ± 10 g at the time of surgery were used. They were transferred to 
the laboratory in which environmental conditions were kept constant, i.e. 
temperature of 21 ± 10C, relative humidity of 65 ± 5 %. A normal light 
(12 hrs) - dark (12 hrs) cycle was used and rats were tested during day-
time (light-period). The rats were kept in individual cages and provided 
with food and water ad libitum, except during the experimental sessions. 
When the oral route of drug administration was used, rats were deprived 
of food for a period of 24 hours prior to the experimental session. 
2. SURGERY 
Rats were anaesthetized with Thalamonal (1) (0.5 ml/kg s.c.) and 
positioned in a David Kopf Stereotaxic instrument with rat adaptor. The 
tooth bar was placed 5 mm above the ear bars. A sagittal incision was 
made on the skin of the skull, the membranes covering the skull were cut 
away and the skull surface was made clean, so that the external 
landmarks became clearly visible. The bregma was taken as reference 
point and with the use of coordinates adapted from the stereotaxic atlas 
of König and Klippel (1963) the site at which the electrode had to be 
placed was marked. Four holes were then drilled in the skull using a 
dental drill: one where the electrode entered the brain and three others 
into which jeweller's screws were driven. One of the screws served as an 
indifferent electrode and was placed anterior to the bregma, the other 
two served as anchor points for the dental cement covering the contact 
points after the electrode has been put into position. Coordinates for 
electrode placement in the lateral hypothalamus of the MFB were: 
anterior 4.0 mm, lateral 1.4 mm and 3.0 mm above the zero stereotaxic 
point, according to the atlas; and actual coordinates: 1.2 mm posterior to 
the Ь г е д т а Л ^ т т lateral and 8.8 mm beneath the surface of the skull. 
All studies involved stimulation via a monopolar electrode. However, a 
bipolar electrode was implanted in such a way that two monopolar 
electrodes could be used in the same rat. The electrodes consisted of 
0.254 mm nichrome wires twisted together, insulated at all points except 
for the cross section of the tip. 
(1 ) Thalamonal . droperidol 2.5 mg and fentanyl citrate 0.0785 mg per ml. 
80 
After implantation, rats were given 3 mg of nalorphine HCl i.v. in order to 
accelerate recovery from anaesthesia. Thereafter they were transferred 
to their home cage. The experiments started at least one week after 
surgery. 
3. MATERIALS 
Fig. 1 is a schematic diagram of the general set-up. 
Fig. 1 : General set-up. 
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3.1. Cage 
The experimental compartment was a 20 cm wide, 25 cm long and 33 cm 
deep PVC (polivinylchloride) cage with a 6 χ 3 cm stainless steel lever 
mounted in the back wall of the cage, 6 cm above the floor, which was 
made of stainless steel grid. Underneath was a funnel collecting faeces 
and urine separately. The front wall of the cage was made of transparent 
perspex, allowing direct observation of the rat. To prevent twisting of the 
electrode leads, a modification of Berkley and Kling's mercury contact 
swivel device with vertical movement compensation (Berkley and Kling, 
1967) was constructed. 
32. Electrode 
32.1. Metal 
In most studies stainless steel or platinum electrodes were used. 
Nichrome electrodes are generally used less as there is a lack of 
information about histological changes after chronic stimulation. 
There are impedance changes related to the type of electrode used, 
particularly with stainless steel electrodes. Moreover, mental deposits 
can be detected. Bollinger and Cerali (1971) and Wetzel et al. (1969) 
concluded in their comparative study that platinum electrodes resulted in 
a more stable self-stimulation rate together with a constant impedance. 
In our studies nichrome electrodes were used. Impedance was measured 
over periods of up to several months. As with other electrodes transient 
impedance changes could be detected, but there was no evidence of 
progressive changes (gradually increasing) during chronic experiments. 
Histological verification showed gliosis of tissue but no evidence of metal 
deposits was found. 
322. Monopolar vs. bipolar stimulation 
Bipolar stimulation is current given between the points of 2 electrodes 
inserted into the brain. With monopolar stimulation one electrode is 
implanted in the brain, while the second one is placed on the skull or in 
the skin (usually of the neck). The latter electrode is an «indifferent», i.e. 
this electrode does not determine the direction of the current (Fig. 2). 
Theoretically this electrode should be placed at infinity. 
Fig. 2: Monopolar and bipolar electrode. 
monopolir 
c u r r m t 
spread 
bipolar 
deep 
electrodes 
current 
spread 
СЮ 
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The position of the (deep) electrode in relation to the stimulated 
structurels) is of primary importance. It is, however, experimentally 
difficult to measure and compare the distribution of the current (and 
density in the field), when monopolar or bipolar electrode stimulation is 
used. Theoretically it is possible to make some statements but these are 
based on a number of assumptions which are not borne out in 
brain-stimulation (Stark et al., 1962). Only indirect evidence can be ob-
tained and the stimulated structure is often very heterogenous. 
Most of the authors used bipolar stimulation on the logical assumption 
that monopolar stimulation involves a greater neuronal field. It is, 
however, important to consider the many different stimulation para-
meters used. Current distribution will be pronounced if high intensities 
are used, even with bipolar electrodes. General statements must await 
comparative studies on current distribution using a large number of 
different stimulus parameter combinations. Of importance is the fact that 
manipulation of these combinations is found to activate a particular set 
of fibres responsible for the behaviour observed. Even with monopolar 
electrodes these fibres are very close to the point of the electrode (within 
a range of 1/4 to 1/2 mm, for stimulation-induced eating behaviour, 
Wise, 1972). 
3.3. Stimulator and electrical parameters 
3.3.1. Considerations on wave-form and current-characteristics 
In the study of behaviour induced by electrical current, 2 wave-forms are . 
mainly used: sinusoidal and square wave or rectangular pulses (mono-
phasic and biphasic). They are illustrated in Fig. 3. The different 
stimulation parameters are also indicated. 
In a short review on self-stimulation data, Wetzel (1968) mentioned that 
approximately fifty percent of the authors (150 publications surveyed) 
used sine-wave current (50 or 60 Hz). Very few authors compared the 
effectiveness of sine-wave current with square wave or rectangular pulse 
wave (Su et al., 1966). No conclusive reasons can be found for the 
selection of one or the other wave-form (such as showing, for example, , 
that one of the wave-forms used is more physiological than the other). 
Preference for square wave pulse current is mainly based on practical 
advantages: more individual parameters can be manipulated. Because of 
the possibility of varying the interpulse-interval (or frequency) it is 
possible to study refractory periods of a population of neurons involved 
in the stimulation (e.g. Deutsch, 1964; Smith and Coons, 1970; Wetzel, 
1972). 
Monophasic cathodal stimulation (one side rectangular pulses with 
negative pulse polarity) is quite common in neurophysiolpgical (^search. 
Lilly started a series of studies using a wave-form wîiich «did not destroy 
brain tissue» (biphasic triangle wave-form) (i,illy pt al.; 1955). However, 
according to different authors even the jjse otVnonÖph^ic stimulation 
does not result in brain lesions (e.g.-Wqtzel eta", 1969). *
 i 
A progressive distortion о{ the signal 4as seen on the oscilloscope) and a 
decrease in pulse amplitude constitute electrical evidence of tissue 
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Fig. 3: Electrical wave-forms: left side: sinus wave, right side: biphasic 
rectangular pulses or square wave. 
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changes. A distortion of rectangular pulses given by a constant current 
source is, however, observed immediately. This is due to impedance 
changes (vide infra). Tissue injury is found by histological examination, 
showing gliosis, debris of pigmented particles and, depending on the 
electrode used, metallic deposits. 
It seems safer to use biphasic square wave pulses in order to reduce the 
possibility of injury to brain tissue, especially in chronic experiments. 
The effects of the stimulation depend to a large extent on the current 
used. The effective intensity of the current applied to the brain depends 
on the resistance of the rat (connected in series with the circuit), on the 
resistance of the electrode and on the mechanical connections. The total 
of the different resistances or impedance (Z) is expressed by the formula 
Ζ = E (voltage)/! (intensity). 
Polarization impedance of the contact surface between the electrode and 
the brain tissue, and the impedance of the brain tissue itself are 
components which change the total impedance. 
The impedance can change during the experiment. The increase of 
impedance during the very first minutes of the experiment is a 
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phenomenon observed regularly. This increase can be due to certain 
changes of the electrolytes at the tip of the electrode or to glia cell 
accumulation (Bollinger and Cerali, 1971). Impedance increase associat-
ed with a decrease of self-stimulation rate can be found during long-term 
experiments. An increase of impedance and a decrease of current was 
associated with a decrease in lever-pressing when a constant voltage 
source was used (Bollinger and Cerali, 1971). The long-term change is 
ascribed to lesions produced by prolonged stimulation, or is due to the 
displacement by ionic current of charged particles. Therefore it is 
advisable to use a constant current source which delivers a stabilized 
current intensity in the stimulated tissue. 
In our experiments it was found that with a constant current source 
brain-stimulation could be maintained over long periods, without the 
necessity of adjusting the current. Impedance changes were not 
detected except shortly before rats completely stopped self-stimulation 
behaviour. These, however, occurred only after extended periods (up to 
many months of experiment) and could be due to lesions. 
3.3.2. Stimulator and recording 
Electrical stimulation was given by a stimulator of our own construction 
(Geivers et al., 1973, 1975) with constant current output from an integrat-
ed circuit. The rats could obtain electrical stimulation by pressing on a 
lever. The trains of biphasic rectangular pulses elicited were adjustable 
for constant current intensity, pulse frequency, pulse width and train 
duration. Fixed ratio schedules (ratio of the number of stimulations to the 
number of responses) could be programmed; an inhibition circuit 
prevented the responses given during the stimulation train from being 
rewarded. The output of the stimulators was monitored on an 
oscilloscope and the amplitude of the constant current measured across 
1 CI. The voltage from oscilloscope readings over the current input 
provided the impedance. The number of responses (number of lever-
pressings) and the number of stimulations received were visualized by 
seven segment displays. The numeric indicators were driven via Binary 
Decimal Code (BCD) and converted in the interface unit to American 
Standard Code for Information Interchange (ASCII-code). The in-
formation from the stimulators was changed in interface units from 
parallel to serial. The interface unit drove the teletype, which collected 
every minute the number of lever-pressings given and the number of 
stimuli applied. The numbers of responses and stimuli from each 
stimulator were converted via a digital to an analogue voltage which 
controlled a pen recorder. The responses and stimuli were recorded 
separately. 
4. ESTABLISHMENT OF SELF-STIMULATION 
Rats put in a self-stimulation cage show the characteristic behavioural 
pattern common to all rats in a new environmental situation. With 
priming stimuli (i.e. brain-stimulation delivered by the investigator), rats 
either approach, escape or act neutrally. When approach behaviour is 
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observed, which consists of a detailed exploration of the nearby sur­
roundings, the investigator usually gives priming stimuli when the rat 
approaches the lever. Very soon the rat discovers that pressing the lever 
elicits brain-stimulation and in turn, brain-stimulation reinforces the lever-
pressing. Self-stimulation behaviour is therefore quickly established, but 
not in all implanted rats and with various degrees of response. 
A total of 500 rats implanted with electrodes in the medial forebrain 
bundle region (MFB) of the lateral hypothalamus, were sampled. They 
were all trained in half-hour sessions for at least 4 days. In 46.4 % of the 
rats brain-stimulation applied by the investigator elicited escape 
behaviour (9.4 %) or induced motor effects (circling, tremor, shivering 
etc., 37.0 %); in 53.6 % self-stimulation behaviour could be established: 
in 17.4 % low lever-pressing (100-300 responses), in 21.2 % intermediate 
response rates (300-800) and in 15.0 % high self-stimulation response 
rates ( > 800) were found. 
The fact that in 46.4 percent of the rats, it was not possible to induce 
self-stimulation behaviour, may be due to a variety of reasons. Obviously 
some electrodes failed to reach the target structure. This may be due to 
anatomical differences from rat to rat, to incorrect positioning of the rat 
in the stereotaxic instrument, etc. 
Histological monitoring enables us to pick out the rats which have 
incorrectly implanted electrodes. In the nearby surroundings of the 
lateral hypothalamus, however, self-stimulation may be found, for 
example, in the zona incerta, Forel's Field 2, medial to the lateral hypo­
thalamus, dorsal to the fornix and in the capsula interna. On the other 
hand there are some unidentified reasons why rats failed to show self-
stimulating reactions to electrical stimulation via electrodes which 
histological examination revealed to have been correctly implanted. 
Within the group of correctly implanted rats, the number of self-
stimulation responses can differ greatly. Histological monitoring does not 
always distinguish between groups which differ in their total response 
output. 
An obvious reason responsible for the inter-individual variability in rate of 
lever-pressings is the fact that self-stimulation is elicited through 
stimulation of a field of neurons. Furthermore, relatively large electrodes 
are necessary (seemingly a minimum of 80 μιτιπι in diameter). The 
stimulated structure, particularly the lateral hypothalamic region, is very 
heterogeneous, containing fibres of different sizes, ascending and 
descending axons and cell bodies. 
It is conceivable that, within a particular region, different fibres are 
involved in the stimulation fields of different rats. This will be dependent, 
for example, on the relative position of the 2 electrodes of a bipolar set 
(Szabó and Milner, 1972) or on the position of the insulate-free tip of the 
electrode in relation to the stimulated structurels) (orientation of the 
electrode) (Szabó et al., 1972). 
A final word concerns intra-individual variability of self-stimulation. As 
will be described further (see Chapter VI. 2.) self-stimulation could be 
maintained over long periods of time. There was a general tendency to a 
progressively decreasing responding overtime, which was, however, not 
observed in all rats. 
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V. The influence of various stimulus 
parameter combinations 
Although the literature on lever-pressing for intracranial stimulation is 
extensive, only a few studies deal systematically with the influence of 
parameters of electrical stimulation on response rate. 
Stimulation with a single pulse cannot induce self-stimulation behaviour. 
This fact recalls the results of experiments of Brookhart (1952) who 
found that stimulation of the bulbar pyramidal tract with few pulses also 
fails to induce muscle contraction. Most of the earlier studies on 
electrical self-stimulation used sine-wave current with a frequency of 50 
Hz. The self-stimulation rate was therefore mainly varied by changing the 
intensity. In the various studies intensities ranged from a few micro 
Ampères (e.g. Uyeda and Genegerelli, 1959) up to 50 milli Ampères 
(e.g. Stein and Ray, 1960). 
Using rectangular pulses, different authors studied the effects of varying 
the frequency, pulse width and train duration of electrical stimulation on 
the rate of lever-pressing. Frequencies ranged from 20 pulses per second 
(pps) (Gengerelli et al., 1963; Keesey, 1962) to 480 pps (Beyra and Voisin, 
1971; Elder and Work, 1965), pulse widths from 50 usee (Stein and Ray, 
1960) to 5 msec (Ward, 1959) and train durations from 0.03 sec (Beyra et 
al., 1969a, b) to 10 sec (Hodos, 1965). / ín the case of sine-wave current, 
frequencies ranged from 10 to 3000 cycles per second (Ridgway et al., 
1965; Uyeda and Gengerelli, 1959J/. 
These studies clearly show that a large variety of stimulus parameters is 
able to elicit self-stimulation behaviour. Several authors hypothesize that 
a common variable underlies the influence of the different stimulus para-
meters: the quantity of charge (i.e. the total quantity of electricity 
provided by the combination of the different stimulus parameters). In our 
investigation, we tried to find an answer to the following questions: 
1. Is response rate dependent upon quantity of charge? 
2. What is the relationship between the variation of different stimulus 
parameters and the amount of lever-pressing? 
3. Is it possible to predict the response rate elicited by different stimulus 
parameter combinations? 
1. EXCITABILITY OFTHE NEURONAL TISSUE WITH RESPECT TO 
SELF-STIMULATION 
The excitability of peripheral nerves has been documented by many 
authors (e.g. Katz, 1939). The classical strength-duration curve demon-
strates the limits of neuronal excitability: a stimulus has to exceed an 
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intensity-threshold in order to induce a nerve-impulse (rheobase); a 
certain pulse duration is necessary. 
Therefore a certain quantity of charge (Q) is necessary to induce a nerve 
impulse. The threshold was found to be between 0.2 and 0.5 μ С for 
cortical electrodes and 0.05μΟ for deeper placements (Lilly, 1961). There 
are several reasons why classical strength-duration curves can hardly be 
applied directly to self-stimulation experiments where behaviour is the 
dependent variable. 
a. A single nerve responds to an all-or-none law, in that an axon is 
stimulated when the intensity of the pulse exceeds a threshold intensity. 
Behavioural effects in general require the firing of many neurons close to 
the electrode tip. Stimulation with pulse pairs, in which the interval 
between each pair of pulses is varied, can be used to characterize the 
refractory period of a population of neurons. These neurons may have 
different diameters and hence different refractory periods (e.g. Rolls, 
1973). 
Single pulse stimulation is, however, insufficient to induce self-stimula­
tion behaviour. This clearly demonstrates that temporal summation is 
required and that reinforcement of behaviour, to some extent, depends 
upon the degree of transsynaptic activation (Gengerelli et al., 1963). 
b. A definition of «threshold» in self-stimulation requires a behavioural 
criterion, for example, the amount of lever-pressing. Threshold detection 
requires complicated procedures (Huston and Mills, 1971). 
с The stimulation occurs in a neuron pole, i.e. transmission in a volume 
conductor. Recording in the neuron pole stimulated reveals a complex 
process of neuronal excitatory and inhibitory activity (Ito, 1972). 
Self-stimulation behaviour is induced by the stimulation of a set of 
neurons, producing organized patterns of cellular excitation (Mickle, 
1961). First, there is spatial summation in the stimulation field, which is 
very heterogeneous in the lateral hypothalamus, because this neuro-
anatomical structure contains fibres which have different threshold 
values (Szabo and Lénard, 1974). Second, temporal summation of 
neurons around the tip of the electrode and at points further away 
occurs. Increasing the intensity of the stimulation will increase the 
stimulation field and increasing the pulse width will not enlarge the distri-
bution because of volume conduction, but will depolarize neurons at the 
periphery above the threshold («fringe cells», Abeles, 1967a, b). It is 
important to note that an increase of train duration will increase trans-
synaptic activity remote from the stimulation point (Gengerelli et al., 
1963). 
Studies on the refractory period in self-stimulation have been conducted 
by different authors using behavioural criteria (Kestenbaum et al., 1973; 
Wetzel, 1971). An interpulse-interval of 1 msec was found necessary to 
sustain self-stimulation behaviour. 
The neuronal activity recorded close to the stimulating electrode is, how-
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ever, not always excitatory. Ito (1972), for instance, showed that 
rewarding brain-stimulation inhibited neurons in the lateral hypothala­
mus at a distance of 1 to 2 mm from the stimulating electrode in the same 
area. When the pulse trains were repeated these inhibitions decreased 
and excitatory responses became apparent. Further, Olds (1973) showed 
that lateral hypothalamic neurons showed either pure inhibition or an 
activation-inhibition sequence in response to medial forebrain bundle 
stimulation. These findings pose the question of whether the suppression 
of neuronal firing is related to brain-reward (as hypothesized by Olds, 
1973). 
The above considerations demonstrate the importance of studying self-
stimulation behaviour induced by various combinations of stimulus para­
meters. In analogy with peripheral nerve activity it could be argued that 
the interaction of the different stimulus parameters expressed by the 
total electrical activity contained in one stimulation was the determinative 
factor. 
2. EXPERIMENTAL STUDY (1) 
2.1. Experimental procedures 
Training 
Rats were implanted with a monopolar electrode in the lateral hypo­
thalamic area of the medial forebrain bundle. 
One week after the operation, the rats were trained to press the lever on 
a continuous reinforcement schedule 1:1, ten minutes a day for three to 
six days. Then the rats were given a fixed ratio reinforcement schedule 
2:1 with T-inhibition (2 responses were needed in order to obtain one 
stimulus and responses occurring during the stimulus-train were not 
rewarded) and further trained in sessions of 4 χ 10 minutes, each 10 
minute period being separated by 1 minute extinction during which no 
stimulation was delivered. The stimulus parameters during training were 
kept constant and the training was continued until the rats had adapted 
to the procedure (usually 2 weeks). 
Testing 
Five separate experiments were performed. Each experiment started with 
4 rats, lasted 4 weeks, and included 4 sessions a week. Each session 
consisted of 4 ten-minute periods of a fixed ratio schedule 2:1 with 
T-inhibition, followed by 1 minute extinction. Table 1 shows the detailed 
sequence of the different stimulus parameters in each experiment and 
within the sessions. At the end of the experiments, the brains were 
successively perfused with saline and with 10 % formalin. The electrodes 
were then localized in serial 4 μ sections stained with luxol fast blue. 
(1) This study was published earlier. Wauquier, Α., Niemegeers, C.J E , Geivers, Η Α.: 
Intracranial self-stimulation in rats as a function of various stimulus parameters 
I. An empirical study with monopolar electrodes in the medial forebrain bundle Psy-
chopharmacologia 23, 238-260 (1972). 
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Table 1: Sequence of the various stimulus parameters for the individual rats in the 16 experimental sessions. 
Exp. No. 
Rat No 
Week« 
1+4« 
2 
3 
Different 
Exp. 1,2 
Exp 3 
Exp 4 
Exp S 
Seeaion 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
eyatemat 
1 
1,5 
1 2 3 4 
AAAA 
BBBB 
ecce 
DDDD 
ABCD 
BDAC 
CADB 
DCBA 
DCBA 
CADB 
BDAC 
ABCD 
2.6 3,7 
Perioda 
1 2 3 4 
BBBB 
DDDD 
AAAA 
CCCC 
ABCD 
BDAC 
CADB 
DCBA 
DCBA 
CADB 
BDAC 
ABCD 
1 2 3 4 
CCCC 
AAAA 
DDDD 
BBBB 
ABCD 
BDAC 
CADB 
DCBA 
DCBA 
CADB 
BDAC 
ABCD 
4 . 8 
1 2 3 4 
DDDD 
CCCC 
BBBB 
ΛΑΛΑ 
ABCD 
BDAC 
CADB 
DCBA 
DCBA 
CADB 
BDAC 
ABCD 
3 
9 
1234 
D
. m 
D 2 2 2 2 
D 3 3 3 3 
D 4444 
D
, 2 3 4 
D 2 4 . 3 
D 3 1 4 2 
D 4 321 
D 4 32, 
D 3 1 4 2 
D 2 4 . 3 
D
. 2 3 4 
10 11 
Perioda 
1234 
D 2 2 2 2 
D 4444 
D
, m 
D 3 3 3 3 
D
. 2 3 4 
D 2 4 . 3 
D 3 I 4 2 
D 4 3 2 . 
D 4 321 
D 3 . 4 2 
D 2 4 . 3 
D
, 2 3 4 
cally varied parameter«. In bracket« aymbola uaed. 
,4, S pulae intenntiea in mA 0 100(A), 0 1S0(B) . 0 200(C), 0. 
pulie width in m» 2 ( l ) , 4 (2), 6 (3), 8 (4). 
pulse frequency in pps 20 (1), 40 (2), 60 (3), 80 (4). 
: train duration in ma 200 ( l ) , 400 (2), 600 (3), 800 (4). 
a •, с ana j only 
1234 
D 3 3 3 3 
D l l l l 
D 2 2 2 2 
D 2 2 2 2 
D
1 2 3 4 
D 2 4 . 3 
D 3 1 4 2 
D 4 32. 
D 4 32. 
D 3 1 4 2 
D 2 4 . 3 
D
, 2 3 4 
250 (D) 
12 
1234 
D 4444 
D 3 3 3 3 
D 2 2 2 2 
D 4 1 . 
D
, 2 3 4 
D 2 4 , 3 
D 3 . 4 2 
D 4 32, 
D 4 32, 
D 3 , 4 2 
D 2 4 . 3 
D
, 2 3 4 
Week 
13,17 
• 234 
A I 2 3 4 
A 2 4 I 3 
A 3 4 2 
A 4 32l 
B
, 2 3 4 
B 2 4 , 3 
B 3 I 4 2 
B 4 32. 
C | 2 3 4 
C 2 4 1 3 
C 3 1 4 2 
C 4 32l 
D
. 2 3 4 
D 2 4 1 3 
D 3 . 4 2 
D 4 32, 
4-
• 4,18 
5 
15, 19 
Perioda 
'234 
B 1234 
B 2 4 1 3 
B 3 , 4 2 
B 4 3 2 . 
D
, 2 3 4 
D 2 4 1 3 
D 3 , 4 2 
D 4 321 
A I 2 1 4 
A 2 4 i 3 
A 3 1 4 2 
A 4 32, 
C I 2 3 4 
C 2 4 I 3 
C 3 1 4 2 
C 4 3 2 1 
1234 
C 1 2 3 4 
C 2 4 , 3 
C 3 . 4 2 
C 4 i 2 1 
A
, 2 3 4 
A 2 4 1 3 
A 3 1 4 2 
A 4 32. 
D
. 2 3 4 
D 2 4 . 3 
D 3 . 4 2 
D 4 32, 
B 1 2 34 
B 2 4 , 3 
B 3 I 4 2 
B 4 32l 
16,20 
1234 
D
. 2 3 4 
D 2 4 , 3 
D 3 . 4 2 
D 4 321 
C
. 2 3 4 
C 2 4 1 3 
C 3 . 4 2 
C 4 32, 
B 1 2 34 
B 2 4 I 3 
B 3 , 4 2 
B 4 321 
A
, 2 3 4 
A 2 4 1 3 
A 2 1 « 
A 4 32l 
22. Results 
Experiment 1. (1) The detailed individual response rates obtained with 
various pulse intensities at a constant charge of 50 μΟ per stimulation 
and the corresponding pulse frequency, pulse width, and train duration 
are indicated in Table 2. As the electrode broke off, rat 1 did not perform 
the complete experiment, and was not considered for evaluation. 
The total number of responses given by the three rats was 73518, the 
total number of stimuli received 33253, i.e. a mean of 2.21 responses per 
stimulus. The individual differences in response rate varied from 9006 to 
45193 (Fig. 3). 
The response rate was lowest during the last week, i.e. 4060 (rat 2), 1369 
(rat 3) and 9418 (rat 4), although the response rate did not gradually 
decrease from the first to the last week. 
The total and individual response rates increased with increasing pulse 
intensities (Fig. 1). 
The response rate gradually decreased during the four periods within 
each session at .100 m A, .150 mA and .200 m A intensities but remained 
approximately constant at the intensity of 250 mA (Fig. 2). 
Experiment 2. (1) The detailed individual response rates obtained with 
various pulse intensities at a constant charge of 25 uC per stimulation 
and corresponding pulse frequency, pulse width, and train duration are 
indicated in Table 3. Rat 7 was not considered for evaluation, as from the 
second week its responses dropped to zero. 
The total number of responses given by the three rats was 75832, the 
total number of stimuli received 34678, i.e. a mean of 2.19 responses per 
stimulus. The individual differences in response rate varied from 17987 to 
36556 (Fig. 3). 
The response rate was highest the second week for rat 6 (9955) and the 
third week for rats 5 (5379) and 8 (6551). The response rate was lowest 
the first week for rats 5 (3119) and 8 (3448), the last week for rat 6 (7654). 
The total and individual response rates became higher as intensities 
increased from .100 m A to .200 m A but sharply decreased at the intensity 
of .250 mA (Fig. 1). 
The response rate decreased during the four periods within each session 
at .100 m A, .150 m A and .250 m A intensities, and remained approxim­
ately constant at the intensity of .200 mA (Fig. 2). 
Experiment 3. (2) The detailed individual response rates obtained with 
various pulse widths at a constant intensity, frequency and train duration 
and corresponding quantities of charge are indicated in Table 4. Rat 9 
was not considered for evaluation as, from the third week, the responses 
dropped to zero. 
The total number of responses given by the three rats was 139895, the 
(1) Stimulus parameters during training: pulse intensity: .200 mA, pulse frequency: 
50 pps; pulse width: 10 ms; tram duration 500 ms. 
<2)Stimulus parameters during training, pulse intensity: .200 to .250 mA; pulse fre­
quency. 50 pps; pulse width. 10 ms; train duration: 5 0 0 ms. 
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Table 2: Experiment 1. Variation ofpulse intensity at a constant charge of50 μΟ per stimulation. Number of responses for3 
S trained rats in 16 experimental sessions (4 per week for 4 consecutive weeks). Eachsession (SES) was divided into 4 periods 
(PER) of 10 minutes stimulation followed by 1 minute extinction. 
r— 
Stimulue parameiers 
INT. 
mA0 
. 100 
. 1 5 0 
. 2 0 0 
. 2 5 0 
FREQ. 
PP»C 
80 
P.W. 
m»·
1 
10 
(Q 4 8 . 0 μ Ο 
66 10 
(Q = 49. 5 uC) 
50 10 
( 0 = 50. Ο μ Ο 
ВО 5 
(Q - 5 0 . 0 μΟ) 
т о 
ms 
600 
500 
500 
500 
SES 
1 
2 
3 
4 
PER 
. 100 mA 
. 150 mA 
. 2 0 0 mA 
. 2 5 0 mA 
Per week 
Total responaei 
Rat No. 2 
1 
84 
40 
5 
6 
341 
149 
31 
5Э 
630 
301 
30 
16 
843 
922 
810 
814 
135 
573 
977 
3389 
5074 
a I N T . puU" intensity, FREQ. . pul ie frequency 
mA mill i Ampere 
c p p · pulsea per lecond 
d
m · m i l l i s e c o n d · 
Wecks 
2 
29 
27 
11 
Ь 
224 
74 
7 
19 
628 
263 
628 
260 
737 
921 
880 
912 
73 
324 
1779 
3452 
5628 
3 
26 
12 
6 
7 
60 
12 
15 
7 
684 
440 
30 
4 
678 
876 
918 
782 
51 
94 
1158 
3254 
4557 
19319 
, P.W. pulse 
4 
21 
4 
3 
1 
41 
9 
12 
0 
667 
51 
21 
32 
668 
865 
892 
769 
29 
64 
773 
3194 
4060 
width, 
Rat No. 3 
1 
67 
79 
42 
12 
65 
675 
560 
25 
37 
724 
147 
86 
137 
79 
198 
1297 
1094 
2668 
T . D . 
Weeks 
2 
38 
28 
26 
» 
SS 
10 
9 
0 
469 
145 
16 
11 
593 
418 
571 
467 
96 
77 
641 
2071 
2885 
1 
44 
15 
2 
3 
100 
22 
5 
4 
495 
48 
82 
2f 
303 
169 
227 
3 38 
64 
331 
652 
1017 
2084 
9006 
rain duration 
4 
40 
3 
39 
3 
109 
37 
69 
6 
196 
81 
57 
28 
395 
198 
90 
18 
85 
221 
362 
701 
1369 
Q. -
Rat No. 4 
1 
524 
164 
59 
53 
1046 
946 
356 
483 
1083 
768 
258 
159 
1062 
1152 
1168 
1153 
800 
2831 
2268 
4535 
10434 
Weeks 
2 
781 
80 
80 
49 
1105 
1129 
158 
257 
1144 
1105 
838 
602 
1075 
1209 
1282 
1217 
990 
2649 
3689 
4783 
12111 
3 
169 
97 
24 
57 
1115 
1168 
893 
457 
1092 
958 
1026 
1068 
1081 
1294 
1246 
1275 
547 
1641 
4144 
4898 
11210 
45193 
4 
119 
91 
51 
16 
11*4 
126 
200 
114 
1160 
539 
291 
422 
1113 
1210 
1257 
1181 
477 
1768 
2412 
4761 
9418 
quantity oí charge per atimulu 
2 
Í 
160 
83 
25 
20 
Ш 
Ш 
244 
65 
76 
i P 5 ç im 1057 
709 
112 
-шг-
1586 
3500 
Я ? 7 І 
1І2ЯІ 
β 
Rat No. 
4 
of 4 periods 
189 
51 
74 
10 
3?4 5U 
111 
95 
75 
fl?7 1815 
834 
180 
103 
1
 Ш 
95¿ 
976 
ΙΛΟ 
4 484 
1991 
4 12 
214 
175 
tÎH 
1569 
1597 
1 3 4 
1)70 
241 3 
2251 
'ли 4865 
4953 
ШЬ 
mrt 
ÍS Table 3: Experiment 2. Variation of pulse intensity ata constant charge of 25
 u
 С per stimulation. Number of responses for 3 
trained rats in 16 experimental sessions (4 per week for 4 consecutive weeks). Each session (SES) was divided into 4 periods 
(PER) of 10 minutes stimulation followed by 1 minute extinction. 
S t i m u l u s p a r a m e t e r » 
I N T , , 
m A 
. 100 
. 1 5 0 
. 2 0 0 
Льі 
К R E O . 
p p i c 
8 0 
Ρ W 
m . d 
5 
Τ g 
ma 
6 0 0 
( Q = 2 4 . 0 0 μ Ο ) 
6 6 5 5 0 0 
( Q = 2 4 . 75 MC) 
5 0 5 5 0 0 
( Q = 2 5 . 0 0 u C ) 
li ІА 506 
(Q - 2 5 . 0 0 p C ) 
S E S 
1 
2 
3 
4 
P E R 
. 100 m A 
. 150 m A 
. 2 0 0 m A 
. 2 5 0 m A 
P e r w e e k 
T o t a l r e e p o n e e s 
R a l N o . 5 
1 
15» 
50 
6 
9 
948 
135 
141 
111 
4 8 1 
4 5 6 
2 5 8 
461 
217 
84 
54 
132 
2 1 9 
7 3 5 
1656 
5Э9 
3 1 1 9 
b l N T . pulse i n t e n s U y , F R E U , p u l s r f r e q u e n c y 
ілЛ m i l h A m p e r e 
ppe p u l s e s p e r SfLOnd 
m e m i l h e e c o n d e 
W e e k . 
2 
134 
2» 
38 
14 
5Э5 
389 
31 
152 
7 52 
7 9 0 
6 0 7 
792 
Ш 
348 
145 
329 
2 0 9 
1077 
2 9 4 1 
9o6 
5 1 9 1 
3 
81 
30 
23 
2 0 
56 3 
6 1 3 
32 
359 
714 
8 1 4 
8 4 2 
8 2 7 
U 4 
162 
115 
40 
154 
1567 
3197 
461 
5 3 7 9 
1 7 9 8 7 
, P. W . pul»i-
4 
86 
66 
12 
27 
4 2 9 
72 
185 
2 3 1 
7 2 0 
786 
6 9 2 
7 0 2 
m 80 
36 
33 
191 
9 1 7 
2 9 0 0 
2 8 8 
4 2 9 6 
w i d t h 
Rat No. 6 
1 
522 
2 8 2 
157 
129 
1296 
1 1 16 
1 187 
2 0 8 
1197 
1269 
6 0 ) 
1 1 ) 7 
241 
150 
85 
80 
1090 
1807 
4 2 0 6 
558 
9 6 6 1 
T . D . 
W i i k a 
2 
4 0 2 
9 
70 
6 5 
1225 
1 ) 0 7 
2 0 5 
8 1 6 
1 115 
1 ) 8 2 
1415 
1 ) ) 7 
116 
77 
48 
146 
54<> 
) 5 5 1 
5 4 4 9 
407 
4 9 5 5 
) 
2 6 1 
16 
52 
44 
1 )5B 
1455 
57 
5 0 ) 
Ι 2 Θ 0 
1276 
1 ) 6 5 
1407 
«? 
46 
28 
5 ) 
) 7 ) 
) ) 7 ) 
5 ) 2 8 
2 1 2 
9 2 8 6 
3 6 5 5 6 
t r a i n d u r a t i o n 
4 
5 8 8 
131 
9 6 
9 1 
1116 
184 
97 
1 12 
1 2 ) 0 
1415 
1 ) 5 5 
9 1 ) 
Ш 
77 
52 
Я) 
90o 
1509 
4 9 1 ) 
326 
7 6 5 4 
0 . - 4 
Rat N o . 8 
1 
88 
19 
15 
22 
8 1 8 
164 
42 
47 
6 ) 0 
2 2 8 
6 7 4 
627 
28 
26 
5 
15 
144 
1071 
2 1 5 9 
74 
3 4 4 8 
u a n t i t y 
W e e k » 
2 
120 
30 
9 
8 
« 1 3 
8 1 5 
56 
367 
861 
8 4 5 
8 0 3 
9 6 2 
52 
2 4 
4 
10 
167 
2 0 5 1 
3 4 7 1 
9 0 
5 7 7 9 
3 
79 
31 
13 
6 
8¿1 
752 
67 
846 
940 
1009 
866 
925 
40 
27 
30 
9 
129 
2526 
3740 
156 
6551 
21289 
of c h a r g e per 
4 
51 
20 
25 
26 
á44 
614 
401 
94 
877 
775 
725 
837 
127 
49 
22 
10 
122 
1967 
3214 
208 
5511 
Bt imul 
5 
1 
455 
169 
79 
70 
7 1 1 
1 8 ' 5 
1219 
314 
SÍJ i W 6 
2 Í Í 7 
2 8 ' 6 
23С9 
2 7 1 2 
І О І Ы 
EH 6 7 6 
350 
ì 1 
ІІ'Л 
J B 
R a t N o 
• 
of 4 p e r i o d · 
1 7 7 ) 
4 38 
) 7 5 
129 
? 1 1 ί 
4 9 9 5 
4 0 6 2 
1 5 4 6 
1 6 ) 9 
1>74Í 
5022 
5 ) 4 2 
4 7 ) 8 
4 794 
l4Mfl 
"Sie 
350 
21 ) 
Ж l ini 
) ) 8 
100 
62 
62 
i/,? 
USÓ 
2 ) 4 5 
566 
)54 
615 
1Ò8 
2857 
)06H 
И 5 І 
'MlH 
126 
61 
l i 
« Ä 
Fig. 1: Changes in response rate with different pulse intensities, pulse 
widths, pulse frequencies and tram durations; changes expressed as the 
ratios between the indicated (X) and the lowest parameter values. 
Broken lines are the means per group. 
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Fig. 2: Changes in response rate during 4 consecutive periods with different intensities texp. 1: o—o and exp. 2: m—·) or 
different pulse widths (exp. 3. x—x). Mean response rates per group of 3 rats expressed as percentages of the responses 
given during the first period (= 700 %). 
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Table 4: Experiment 3. Variation of pulse width at a constant intensity. Number of responses for 3 trained rats in 16 
S experimental sessions (4 per week for 4 consecutive weeks). Each session (SES) is divided into 4 periods (PER) of 10 
minutes stimulation followed by 1 minute extinction. 
S u m u l u e p a r a m r l t r e 
Ρ W. 
г.о 
4 . 0 
6 . 0 
8 . 0 
I N T 
inA' 
. 2 5 0 
(Q - I 
. 2 5 0 
( Q - 2 
. 2 5 0 
( О - 1 
. 2 5 0 
( Q 5 
ΚΗΕ,Ο 
ppe 
50 
i. 5 μ Ο 
SO 
>. O p C ) 
50 
' . 5 μ Ο ) 
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). O p C ) 
I 
T. g. 
m s 
5 0 0 
ьбй 
5 0 0 
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SES 
' 
2 
s 
4 
P E R 
2 . 0 me 
4 . 0 m · 
6 . 0 m " 
8 . 0 m« 
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j m A n u l l i Л т р і т с 
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1 
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22 
1262 
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1 6 2 ) 
1122 
1274 
1157 
1279 
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1289 
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1179 
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Rat No. U 
1 
П О 
79 
6 4 
44 
316 
64 
167 
ìli 
300 
178 
235 
678 
435 
481 
80 
297 
1056 
1428 
1674 
4455 
Q. = quant i ty 
Wi 1 
2 
255 
148 
118 
65 
481 
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274 
220 
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Ι. ίΰΊ 8)4 
3850 
) 5 9 9 
}ЧІ 
И і « 
8 6 0 
4 09 
I l 1 
2 0 6 
I'48 
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14
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2 5 5 0 
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I 191 
вт 
' 
total number of stimuli received was 62370, i.e. a mean of 2.24 responses 
per stimuli. The individual differences in response rate varied from 21277 
to 70262 (Fig. 3). 
The response rate was highest in the third week for rat 12 (7052) and in 
the last week for rat 10 (19688) and 11 (13804). The response rate was 
lowest in the first week for rat 12 (4455), the second week for rat 11 
(10304) and the third week for rat 10 (16431). 
The total response rate increased with increasing pulse width from 2 to 
8 ms. For rats 10 and 11 responses became more frequent as the pulse 
width was increased, up to 6 ms. For rat 12 the response rate increased 
up to a pulse width of 8 ms (Fig. 1 ). 
The response rate decreased during the 4 periods within one session at a 
pulse width of 2 ms, but remained approximately constant at the pulse 
widths of 4, 6 and 8 ms, except for rat 12 whose responses decreased 
even at the highest pulse width of 8 ms (Fig. 2). 
Experiment 4. (1) The detailed individual response rates obtained with 
various pulse frequencies at various intensities and corresponding pulse 
width, train duration and quantities of charge per stimulation are 
indicated in Table 5. 
The total number of responses given by the 4 rats was 83179, the total 
number of stimuli being 39539, i.e. a mean of 2.10 responses per 
stimulus. The individual differences in response rate varied from 7817 to 
34510 (Fig. 3). 
Response rate increased gradually with increasing intensities regardless 
of the frequencies, and with increasing frequencies regardless of the 
intensities (Fig. 1). 
The total response rate for the 4 rats gradually increased in direct 
proportions to the quantity of charge per stimulus from 8 дС onwards, 
reaching a number of responses up to 50 times the response rate 
obtained at 4 μ 0 (Table 6). This pattern was mainly determined by rat 16, 
the response rate of the three other rats being somewhat erratic. A 
predictably high response rate ( >1000), however, was obtained at and 
above 16 juC for rat 16, 20 дС for rat 13, 30 дС for rat 15 and 40 uC for 
rat. 14. 
Experiment 5. (2) The detailed individual response rates obtained with 
various train durations at various intensities and corresponding 
frequencies, pulse widths and quantities of charge per stimulus are 
indicated in Table 7. 
The total number of responses given by the 4 rats was 135941, the total 
number of stimuli received 62217, i.e. 2.18 responses per stimulus. The 
individual differences in response rate varied from 10218 to 67983 (Fig. 3). 
(1) Stimulus parameters during training: pulse intensity: .200 to .250 mA; pulse fre­
quency: 50 pps; pulse width: 4 ms; tram duration: 500 ms. 
12) Stimulus parameters during training: pulse intensity: .200 to .250 mA; pulse fre­
quency: 80 pps; pulse width: 4 ms; train duration: 500 ms. 
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s Table 5: Experiment 4. Variation of pulse frequency at various intensities. Number of responses for 4 trained rats in 16 ex­perimental sessions (4 per week for 4 consecutive weeks). Each session (SES) was divided into 4 periods (PER) of 10 
minutes stimulation followed by 1 minute extinction. 
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Table 6: Experiment 4 Response rate for 4 rats in relation to the quantity of charge per stimulation. 
Quantity ( ц С ) а 
Intensity ( m A ) b 
Frequency (pp»)c 
Rat No 13 
14 
15 
16 
S of rats 
Means 
Ratio 
4 
100 
20 
66 
84 
44 
77 
271 
1 0 
6 
150 
20 
35 
61 
60 
49 
205 
0 8 
8 
100 
40 
62 
73 
36 
90 
266 
8 
200 
20 
84 
120 
156 
164 
524 
393 
1 5 
10 
250 
20 
68 
124 
106 
454 
752 
2 8 
12 
150 
40 
74 
123 
56 
540 
793 
2 9 
16 
1O0 
80 
770 
48 
19 
1845 
2682 
16 
200 
40 
427 
133 
292 
2200 
3052 
2867 
11 
20 
100 
100 
1905 
35 
50 
2695 
4685 
20 
250 
40 
2441 
410 
948 
2473 
6272 
5479 
20 
24 
150 
80 
1994 
435 
259 
3268 
5956 
22 
30 
150 
100 
1829 
712 
1201 
3777 
7519 
28 
32 
200 
80 
3526 
878 
3348 
4235 
11987 
44 
40 
200 
100 
3781 
1184 
3525 
44 09 
12849 
40 
250 
80 
3198 
1556 
3534 
4022 
12310 
• 
12580 
46 
50 
250 
100 
3285 
1886 
3861 
4212 
13244 
49 
pC micro Coulomb 
mA milli Ampere 
pp» pulses per second 
Response at 4 μ€ - 1 0 
Table 7: Experiment 5. Variation of train duration at various intensities. Number of responses for 4 trained rats in 16 
experimental sessions (4 per week for 4 consecutive weeks). Each session (SES) was divided into 4 periods (PER) of 70 
minutes stimulation followed by 1 minute extinction. 
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Table 8: Experimento Total and individua/ response rate in relation to the quantity of charge 
Quantity (μΟ) 
Intensity (niA) 
Train duration$nsif" 
Rat No 17 
18 
19 
20 
Σ of 4 rat· 
Means 
Ratio 
6 4 
100 
200 
1058 
11 
48 
33 
1150 
1 0 
9 6 
150 
200 
1796 
894 
18 
288 
2996 
2 6 
12 8 
100 
400 
3800 
13 
46 
44 
3903 
12 8 
200 
200 
5515 
1439 
574 
732 
8260 
6081 
3 4 7 2 
16 
250 
200 
4847 
3767 
436 
1498 
10548 
9 2 
19 2 
100 
600 
494 3 
49 
43 
19 
5054 
19 2 
150 
400 
5304 
2354 
15 
961 
8634 
6844 
4 4 7 5 
25 6 
100 
800 
4503 
23 
46 
20 
4 592 
25 6 
200 
400 
5687 
3521 
1348 
1635 
12191 
8391 
4 0 11 
28 8 
150 
600 
4 583 
3307 
6 
521 
8417 
7 3 
32 0 
250 
400 
4650 
3193 
1117 
3501 
12461 
11 
38 4 
150 
800 
3932 
3033 
22 
481 
7468 
6 5 
38 4 
200 
600 
4813 
3 392 
2014 
3467 
13686 
48 
250 
600 
4735 
2792 
1130 
4027 
12684 
13175 
12 11 
51 2 
200 
800 
3880 
2605 
2382 
3358 
12225 
11 
64 0 
250 
800 
3937 
2266 
973 
4495 
11671 
10 
μΟ micro Coulomb 
mA milli Ampere 
.me nulli seconds 
Response at 6 4 μ€ = 1.0 
The total response rate for the four rats and for rats 18 and 20 increased 
with increasing pulse intensity regardless of train duration up to .250 mA 
for rat 17 up to .200 mA. The response rate was much less regular for rat 
19 (Fig. 1). 
For the four rats, the lowest response rate occurred with a train duration 
of 200 ms regardless of pulse intensity and the highest response rate at a 
train duration of 400 ms for rat 17, at 600 ms for rat 18 and of 800 ms for 
rat 19 and 20. The total highest response rate was obtained with 600 ms 
(Fig.1). 
Although higher quantities of charge produced the highest response 
rates (Table 8), the total response rate was poorly correlated with the 
quantity of charge, since it was determined by pulse intensity, train 
duration and the high response rate of rat 17. 
A predictably high response rate ( ) 1000) was obtained at and above 6.4 
μΟ for rat 17,28.8 μ0 for rat 18 and 48.0 μΟ for rat 19 and rat 20. 
2.3. Discussion 
Implantation sites. Fig. 3 shows that the implantation sites for the 17 
rats covered a relatively small area in and around the fasciculus medialis 
prosencephali. Nevertheless the marked individual differences in overall 
responsiveness and in sensitiveness to selective stimulus parameter 
combinations indicate the importance of correct implantation, and may 
reflect the heterogeneity of the stimulated structure (Wetzel, 1970). 
Experimental schedule. Although in the fixed ratio reinforcement 
schedule 2: 1 with T-inhibition, the responses exceeded the stimuli more 
than twice, the correlation between R and S was >/.98 for each individual 
rat in all 64 sessions. 
Pulse intensity. Response rates increased with increasing intensities 
from .100 to .250 mA (Fig. 1 and Tables 2, 5, 7). At .100 mA the lever 
pressing frequency was very low in all rats except rat 17, .150 mA elicited 
a low response rate in about half the rats, whereas the highest response 
rate was achieved with .200 mA in rats 17 and 19, and with .250 mA in all 
other rats. However, when the optimal intensities were combined with 
the low frequency of 20 pps the response rate dropped dramatically 
(Fig. 1 and 3). Conversely, subthreshold intensities combined with high 
frequencies enhanced the response rate (Table 5). 
Thus the response rate is not exclusively determined by pulse intensity, 
which indicates that the important factor is not the number but the type 
of neuronal fibers reached. 
Pulse frequency. Response rates increased with increasing frequencies 
from 20 to 100 pps (Fig. 1 and Table 5). At 20 pps the lever pressing 
frequency was always very low and could not be improved by high 
intensities; 40 pps usually produced poor responsiveness which however 
improved with high intensities; 50 pps usually produced adequate 
response rates. 
Thus individual thresholds of pulse frequency should be reached. More-
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over, since in the stimulus combination of 20 pps χ .250 mA frequency 
outweighs intensity, pulse frequency seems determinative for trans­
mitting the neuroimpulses needed to induce lever pressings, perhaps 
because a certain amount of neurotransmitter substance has to be 
deposited in the synaptic cleft. 
Pulse width and train duration. At a constant intensity, frequency and 
train duration, the response rate increased as the pulse width rose from 2 
to 6 ms, levelled off at a pulse width of 6 to 8 ms and dropped slightly at a 
pulse width of 10 ms (Table 4 and compare Table 2 with Table 3). 
Optimal response rates occurred with train durations between 400 and 
600 ms (Fig. 1 and Table 7); lever pressing frequency was always lower 
with short train durations (200 ms) and sometimes lower with long train 
durations (800 ms). In the selected ranges, pulse width and train duration 
are less critical than pulse frequency and intensity. 
Quantity of charge. As reported by Beyra et al. (1969a, b), Keesey 
(1962, 1964), Mclntire and Wright (1965), Reynolds (1958), Smith and 
Cox (1967) and Ward (1959) response rate generally increased with 
increasing quantities of charge. However, the response rate was not 
simply a reflection of the quantity of charge (Fig. 4). In experiments 1 and 
2 (Tables 2 and 3) although the quantity of charge was kept constant, the 
response rate varied from low to high. In the five experiments, the 
quantity of charge varied between 4 μΟ and 64 μΟ. Although significant 
(p <0.001 ), the correlation between quantity of charge and response rate 
was rather poor (r = 0.468). In addition, low response rates could be 
obtained with high quantities of charge (24.0 to 49.5 μΟ provided the 
intensities or frequencies were low. Conversely relatively high response 
rates could be obtained with relatively low quantities of charge (12.5, 
12.8 and 16.0 μΟ, when pulse intensity and frequency were optimal 
(Tables 4,6,7 and 8). 
Duration of the experimental sessions and contrast effects 
Stimulus parameter combinations were considered optimal if response 
rates remained at a constant level throughout the four-period sessions 
(Fig. 2). These stimulus parameter combinations constitute an adequate 
basis for further investigations. 
Although contrast effects, mentioned earlier by Panksepp and Trowill 
(1969,1970), occurred when the parameter combination sequence within 
one session was assigned by a latin square design (Table 1), these 
contrast effects did not markedly after the response pattern. 
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Fig. 3: Implantation sites for the 17 rats. Total number of responses, 
stimuli and ratio responses stimuli. Coordinates according to König and 
Klippel. 
F.M.P. = Fasciculus media/is prosencephali; hi = nucleus lateralis 
hypothalami. 
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Fig. 4: Scattergram of methods and results. Each point represents, for 
each individual rat, the percent response of the highest response (100 %). 
The crosses indicate the corresponding parameter combinations in 16 
sessions χ 17 rats. 
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VI. The influence of various psycho-
active drugs on brain self-stimulation 
behaviour: an experimental study 
1. TEST PROCEDURES 
In a quantitative approach to a particular type of behaviour, drug-effects 
are defined as facilitatory or inhibitory according to whether they 
increase or decrease base-line behaviour. It may be clear that the 
assessment of drug-effects is partly dependent upon base-line respond-
ing. Because of physical limits to frequency of responding, high levels of 
base-line responding, for instance, are not suitable for the investigation 
of facilitatory effects of drugs on responding. As we have demonstrated 
before, electrical stimulation parameters play an essential role in 
base-line responding. 
Accordingly, different base-lines resulting from different stimulus para-
meter combinations (SPC's) given during the same session, within the 
same rats, have been studied. 
After self-stimulation had been established during pre-training, rats were 
selected and further trained on the schedule used for the drug 
experiments. Criterion for selection was: at least 300 responses per half 
hour during pre-training. 
The schedule used in training and during drug-experiments was as 
follows: daily one-hour sessions were held, 5 days a week. Each session 
consisted of six 10-min periods during which rats could obtain brain 
stimulation by pressing on a lever. The periods were separated by a 1-min 
«reset-period» during which no brain-stimulation was available. During 
each period, a different SPC was selected {based on the study of 
Wauquier et al., 1972, Chapter V.2). Of the six SPC's chosen two elicited 
low response rates, two high response rates and two intermediate 
response rates. A fixed ratio-schedule 2:1 was used, i.e. 2 lever-pressings 
were needed to obtain 1 stimulation (1). Lever-pressings during the 
stimulation were not rewarded. 
Table 1 depicts the different SPC's used. Two stimulators, differring 
slightly with respect to the SPC's were used (2). 
The SPC's were given to groups of 3 rats in a partially randomized 
sequential order. The sequence of the SPC's is also given in Table 1. The 
particular sequence given to a rat remained constant during the whole 
experiment. 
(1) This schedule was used in order to minimize the occurrence of seizures occurring 
when rats get contin JOUS brain-stimulation. 
(2) The use of 2 different types of stimulators is purely incidental: the second type 
of stimulator was developed at a later stage of the research. 
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Table 1: Six selected stimulus parameter combinations (SPC) usedinpre-
drug training and experimental sessions, and the sequence in which they 
were given. 
S P C s t i m u l a t o r 1 
Quantity of charge (uC) 
Intensity (uA) 
F r e q u e n c y (pps) 
P u l s e width ( m s e c . ) 
Tra in durat ion ( m s e c . ) 
S e q u e n c e С 1 
С 2 
С 3 
S P C s t i m u l a t o r 2 
Quantity of charge (uC) 
Intensity (uA) 
F r e q u e n c y (pps) 
P u l s e width ( m s e c . ) 
Tra in duration ( m s e c . ) 
Sequence С 1 
С 2 
С 3 
1 
Li 
12. 5 
250 
20 
5 
500 
4 
6 
5 
7 
Li 
10 
250 
20 
4 
500 
4 
6 
5 
2 
4 
1 6 . 5 
100 
66 
5 
500 
1 
3 
2 
6 
L2 
12 
100 
60 
4 
500 
1 
3 
2 
3 
Ml 
2 0 . 0 
2 50 
32 
5 
500 
5 
4 
6 
ál 
18 
150 
60 
4 
500 
Ζ 
1 
3 
4 
M2 
2 4 . 8 
150 
66 
5 
500 
2 
3 
10 
M 2 
20 
250 
40 
4 
500 
5 
4 
6 
5 
Hl 
3 1 . 8 
2 5 0 
50 
5 
500 
6 
5 
4 
11 
Hl 
30 
250 
60 
4 
500 
6 
5 
4 
6 
H2 
4 0 . 0 
200 
80 
5 
500 
3 
2 
1 
l i 
H2 
32 
200 
80 
4 
500 
3 
2 
1 
цС : m i c r o Coulombs L' low 
iiA : m i c r o A m p è r e s M in termedia te 
pps : pu l s e s per second H. high 
m s e c . : m i l l i s e c o n d s 
Training was continued until the rats had adapted to the schedule. 
Criteria for adaptation were: indications of differential responding on the 
S PC's and a total of approximately 900 or more responses on the highest 
SPC's. After training, which required 2 to 3 weeks, drug-experiments 
were started. Each rat received a solvent on the second day (control-
session) and a drug on the fourth day (drug-session); on the first, the 
third, and the fifth day rats received neither a solvent nor a drug. Starting 
with the lowest dose in the first week progressively higher doses were 
given in subsequent weeks. 
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2. CONTROL RESULTS: ANALYSIS OF VARIANCE 
The response rates obtained during the control session are determined 
by various factors. Because different factors, such as stimulus parameter 
combinations, subjects, time of experiment and so forth, were manipulat­
ed, an adequate analysis of the control data required a factorial 
approach. An analysis of variance was used to evaluate the data. 
2.1. Definition of the variables 
Table 2 depicts schematically the different factors involved. A first 
variable is the stimulator, further symbolized as treatment A. This treat­
ment has 2 levels (A-| and A2), i.e. two different stimulators have been 
used. 
A second variable is the various stimulus parameter combinations 
(SPC's) (Table 1), and is further symbolized as treatment B. The effects 
of this treatment are restricted to a single level of A, i.e. B. is nested 
within Α (Β Π A). The reason for this is that the two stimulators slightly 
differed, as regards the possibilities for selecting SPC's. (see Table 1). In 
Table 2, stimulator 1 corresponds to Αι and the SPC's 1 to 6 to Bi ... Be; 
stimulator 2 corresponds to A2 and the corresponding SPC's to By ... 
Bi2· For both stimulators, two low SPC's (Li and L2), two intermediate 
SPC's (Mi and M2) and two high SPC's (Hi and H2) can be 
distinguished (see Table 1 ). 
A third variable is the sequence of the SPC's further symbolized as 
treatment С (Table 1 ) (С П A). 
The fourth variable is the time factor, further symbolized as treatment D. 
D has 5 levels, i.e. the first and the second week (Di and D2) after 
termination of the training period, one week in the middle of the 
experimental period (D3), and the two last weeks of the experimental 
period (D4 and D5). Thus, the selected rats were tested for at least 5 
weeks. 
The fifth variable is the subjects, and is further symbolized by S. The 
subjects are nested within a treatment combination of A and С (S Π AC). 
For each AC combination 14 subjects were used, i.e. a total of 84 rats. 
22. Design 
This is a description of the structural model of the design, the expected 
values of mean squares and the choice of an adequate error term. The 
treatments А, В, С and D have fixed effects, i.e. all treatment levels about 
which inferences had to be drawn, were included in the experiment. The 
subjects (S) were randomly selected from the same population and after 
implantation randomly assigned to the different treatments (C). It follows 
that the factorial design used is a mixed model (Model III) (see Kirk, 1968; 
Huitson, 1966) with both crossed and nested treatments. The following 
notation rules will be used: 
- fixed effects are designated by Greek letters 
- random effects are designated by Roman letters 
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Table 2: Schematic representation of the different treatments and the repartition of the subjects within the treatment 
combinations. 
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Pq(¡ 
Tr(¡] 
«t 
Ч(ік 
- nested effects are indicated by adding the subscripts between brackets 
the symbols referring to the particular level of the treatment(s) within 
which they are nested. 
The effects of the levels of the different treatments are designated as 
follows: 
(p = 2) (fixed crossed effects) 
(q = 6) (fixed nested effects) 
(r = 3) (fixed nested effects) 
(t = 5) (fixed crossed effects) 
(s = 14) (random nested effects) 
Let Xjjkuma be a measure for a randomly selected observation «a», in a 
treatment population ABCDS¡jkum . Under the mixed-effects model, it is 
assumed that measurement Xjjkuma ¡s equal to the following terms: 
Xijkuma = 
μ + a-, + β; + 7k(i) + 5 U + s m ( i k ) 
+ a 6 i u + 0 7 j k ( i ) + 0 6 j u { i ) + / J s j m ( j k ) + 75ku( i) + S s u m ( i k ) 
+
 075jku(i) + ^ s j u m f i k ) 
+ e a ( i j k u m ) 
where μ: grand mean for treatment populations 
a i ' 0 j ' "УкО). a n d s m < i k ) : 
- effects of the different treatments; 
a 5 i u ' РУіШ· 0ô ju( i ) · 0 s jm( ik) ' 75ku( i ) · 6 s um( ik ) a n d 
/ ^ j M O ' / t ô s j u m U k ) 
- effects that represent non-additivity of the stated effects (respectively 
first and second order interactions); 
ea(ijkum) 
- experimental error, which is normally and independently distributed 
with mean = 0 and variance = a ^ (within cell error term). 
The expected values of the mean squares/E (MS)/, are determined 
according to the general rules described by Kirk (1968) and given in 
Table 3. 
However, in this design only one observation is available for each 
treatment combination (1 ... a ... η: N = 1). For such an experiment a 
mean square within cell ( ea (jjkum)) term cannot be computed. There­
fore, the pooled highest-order interaction(s), instead of the within-cell 
error term, is used as an estimate of the experimental error. 
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Table 3: The expected values of mean squares [E(MS)], determined 
according to the general rules described by Kirk (1968). 
E f f e c t . 
(1) a , 
(2) P, 
<»> Щ і ) 
(4) 6 U 
<5> » m l . k l 
(6) a B l u 
(7) Ρϊ,Μ.) 
(β) Ρ » ) « ! , ) 
(9) p s , m ( ¡ k ) 
do) в
к и Ы 
f1 1' 6«ит(ік) 
( l z ) P v 6 j k u ( , ) 
0 3) PesjumOk) 
« » « » " l . j k u m ) ' 
t ( M S ) 
4? 
*/ 
«^ ε 
«1 
•г 
•г 
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4 
«г 
«г 
^ 
"ε
2 
4 
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• 4«ησ2$ + ς ι ΐ η σ 2 γ 
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t q ln0 2 s 
• qna26í + qrinff a 6 
+ γ η σ 2 ρ ι » » i n ^ P v 
•f n a 2 p 6 s + rsna z P6 
* γ η σ
2
Ρ ι 
4- q n a 2 6 j •qsnU2Ye 
f q n a 2 6 i 
•- η σ
2
ρ β ι » ι η σ
2
Ρ γ 6 
+ na 2 P6s 
Degrees oí 
freedom 
P-l 
P(q- l ) 
P ( r - l ) 
t -1 
p r ( . - l ) 
( p - l ) ( t - l ) 
p ( q - l ) ( r - l ) 
p ( q - l K t - l ) 
p r ( q - l ) ( » - l ) 
P ( r - l ) ( t - l ) 
p r ( t - l ) ( . - l ) 
p ( 4 - ! ) ( r - l ) ( t - l ) 
p r ( q - l ) ( t - l ) ( B - l ) 
pqr ta (n - l ) 
E r r o r 
t e r m 
η > 1 
E r r o r 
t e r m 
η = 1 
5 
9 
5 
M 
( U + 13) 
η 
9 
(іг + із) 
( I Z t 13) 
11 
( I Z + 13) 
ι I 
2.3. Some remarks concerning the fundamental assumptions in 
the analysis of variance 
Cochran and Cox (1957) stated that failure to meet the fundamental 
assumptions affects both the significance level (in both directions) and 
the sensitivity of the test. However, the F-distribution is very robust with 
respect to violation of these assumptions. Cochran (1947) stated that it is 
impossible to be certain that all required assumptions are satisfied. 
Analysis of variance must therefore be regarded as approximate rather 
than exact (Kirk, 1968). One of the requirements for a ratio of variances in 
order to obey the F-distribution is that the numerator and denominator of 
the ratio are independent. If scores are randomly sampled from a normal 
population, this requirement is satisfied. The errors also have to be 
normally distributed for each treatment population. Because the only 
source of variation within a treatment population are the errors, thé 
above mentioned assumption is equivalent to the assumption of normally 
distributed scores. Fortunately, the F-distribution is relatively unaffected 
by lack of symmetry or by kurtosis, provided the populations are homo-
geneous in form (Lindquist, 1953). 
I l l 
The F-distribution is robust with respect to violation of the assumptions 
of homogenity of population-error variances, provided the number of 
observations in the samples is equal (Cochran, 1947; Lindquist, 1953). 
A further basis assumption of the particular statistical model used to 
analyze the present data, is that a score is the sum of the effects of the 
linear model. A particular situation occurs when the number of 
within-cell observations is 1, as is the case in the present model. As 
pointed out, the higher order interactions are considered to be zero. Thus 
the corresponding E (MS) of these terms yields an estimate of 
experimental error. This means that o2£fys and σ2βγδ are supposed to be 
0. If this is true, the E (MS) for effects (12) and (13) (see Table 3) are both 
estimates of σ The mean square for the experimental error term is 
calculated by pooling the SS of (12) and (13), i.e. MS (12 + 13) = 
^
S 1 2 + S S 1 3 = MS residual. 
6fl2 + fifl3 
The basic question to be answered is: are the higher-order interactions 
equal to zero? Some a posteriori remarks concerning this assumption 
will be discussed in the next section. 
2.4. Results 
The results of the analysis of variance are shown in Table 4. The 
following factors were significant: stimulus parameter combinations (B) 
(p < .01), time (D) (p ( .01) and subjects (S) (p < .01). The following inter­
actions were significant: stimulus parameter combinations χ sequence (B 
χ C) (p < .05), stimulus parameter combinations χ subjects (Β χ S) 
(ρ ( .01 ), and time χ subjects (D χ S) (ρ < .01 ). 
in the present table of variance, the MS residual was found by pooling 
the variance of the second order interactions В χ С χ D (within A) and Β χ 
D χ S (within AC) (respectively effects 12 and 13 in Table 3). If the MS's 
are calculated for these interactions, then we find: 
27 382.6488 for BCD (within A) (effect 12) and, 
29 413.4742 for BDS (within AC) (effect 13). 
The E (MS) for these effects are respectively: 
(12) σ* + na2ßss + sna2ßys 
U3)a^ + na2ß8s 
If the interaction term σ ß6s is equal to zero, the F-ratio of effect 12 to 
effect 13, should be significant. By contrast, the F-ratio is even slightly 
smaller than 1, proving that the assumption should not be rejected. 
From the present design, no such exact test can be derived for the 
assumption that σ2βδ$ is equal to zero. 
If σ ßbs is not equal to zero, the error variance will be overestimated and 
an F-test involving σ (35s in the denominator will be negatively biased. 
On the contrary, if a significant F-ratio is obtained, one can be confident 
that there are real treatment differences. This is exactly the case in the 
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Table 4: Analysis of variance table. 
S o u r c e of var ia t ion 
( D A 
(2) В (within A) 
(3) С (within A) 
( 4 ) D 
(5) S (within AC) 
(6) A χ D 
(7) Β χ С (within A) 
(8) Β χ D (within A) 
(9) Β χ S (within AC) 
(10) С χ D (within A) 
(11) D x S (within AC) 
(12) Re»idual 
Total 
S u m of equa ree 
632 9 2 2 . 2 1 0 
310 OU 5 0 1 . 3 9 1 
8 191 1 0 5 . 0 2 7 
2 038 7 2 5 . 1 4 0 
68 246 1 1 1 . 3 5 5 
254 7 0 4 . 8 4 4 
8 538 5 5 6 . 9 2 5 
1 444 2 8 7 . 2 6 3 
92 707 5 4 4 . 3 1 7 
1 051 8 5 0 . 9 0 2 
29 808 0 1 7 . 8 4 6 
48 075 6 3 1 . 6 0 5 
571 000 9 5 8 . 8 2 5 
df 
1 
10 
4 
4 
78 
4 
20 
4 0 
390 
16 
312 
1640 
2519 
Mean s q u a r e s 
632 9 2 2 . 2 1 0 
31 001 1 5 0 . 1 3 9 
2 047 7 7 6 . 2 5 7 
509 6 8 1 . 2 8 5 
874 9 5 0 . 1 4 6 
63 676.211 
426 9 2 7 . 8 4 6 
36 1 0 7 . 1 8 2 
237 7 1 1 . 6 5 2 
65 7 4 0 . 6 8 1 
95 5 3 8 . 5 1 9 
29 3 1 4 . 4 1 0 
-
F 
(1/5) 0 . 7 2 3 
(2/9) 1 3 0 . 4 1 5 * * 
(3/5) 2 . 3 4 0 
(4/11) 5 . 3 3 5 * * 
(5/12) 2 9 . 8 4 7 * * 
(6/11) 0 . 6 6 7 
(7/9) 1 . 7 9 6 * 
(8/12) 1 . 2 3 2 
(9/12) 8 . 1 0 9 * * 
(10/11) 0 . 6 8 8 
(11/12) 3 . 2 5 9 * * 
» p^o.os 
* · Pi. 0.01 
present analysis of variance. All effects tested against MS residual are 
significant at ρ ( .01. There is only one exception, i.e. the Β χ D (within A) 
interaction. However, in this test, no negative bias can occur, as σ^βδβ 
appears both in the numerator and in the denominator of the F-ratio /see 
Table 3: E (MS)/. 
2.5. Discussion 
The factor B, effects of the SPC's, was found significant (p < .01). Fig. 1 
shows the mean response rates per SPC for stimulator 1 and 2. 
In general, the higher the quantity of charge of the SPC, the higher the 
response rates (see also Wauquier et al., 1972, Chapter V). The response 
rates obtained on stimulator 1 are slightly higher than those obtained on 
stimulator 2. Although not significant (see factor A), this difference could 
depend on the higher quantity of charge of the SPC's of the first 
stimulator (see Table 1). There is a tendency to obtain higher total 
response rates with sequences starting with a low SPC (Ci and C4) and 
the lowest total response rate with those starting with high SPC's (C3 and 
Co) (see Fig. 2). However, the difference is not significant. The 
interaction В χ С was significant (ρ ( .05) and is illustrated in Fig. 3. This 
clearly shows that the effects of factor В (SPC's) will differ according to 
the sequence in which they are tested. The most marked differences 
occurring for both stimulators, are the higher response rates for B2 and 
Be with sequence Ci and C4 respectively, and for B5 and В ц with 
sequence C3 and Cß respectively. 
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Fig. 1: Mean response rates per SPC (L: low. M: intermediate; H: high; see 
details Table 1) for stimulator 1 and 2. 
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Fig. 2: Total response rates (sum 6 SPC's) in function of the sequence of 
the SPC's: sequence 1: low SPC (Cj, C4); sequence 2: intermediate SPC 
(C2, Cß); sequence 3: high SPC (C3, Cgi, given at the start of the 
session. 
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fíg. 3: Interaction В (SPC) χ С (sequence). 
Mean response rate in function of stimulator (A j, A2). SPC's (Bj... Bgand 
Βγ... В12) and sequence (Cj... Ορ). 
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Higher or lower responding caused by reward shifts are described in the 
literature (Panksepp and Trowill, 1969). The reinforcing value of the 
different S PC's may be dependent on the sequence in which they are 
tested and actually produce higher or lower responding. However, the 
present shifts cannot clearly be interpreted because all possible 
sequences of the SPC's were not tested. 
The factor time (D) was significant (p < .01). As seen in Fig. 4 the further 
response rates increased slightly from the first to the second week of 
testing, and subsequently decreased over the following weeks. It is of 
interest to note that the analysis was done on rats which had been tested 
for 5 weeks, as well as on rats which had been tested for longer periods. 
The latter increases the possibility of response decline, so that the actual 
results may underestimate the response decrease as a function of time. 
For the progressive decrease in responding as a function of time two 
explanations are possible. The first explanation refers to the fact, that the 
rats received drug-treatment between control sessions. Drug-treatment 
can cause shifts in control values, which outlast direct drug-effects. For 
example, chlordiazepoxide markedly enhanced responding during the 
days following drug-injection (Wauquier, 1974). A second explanation 
for the decline in responding as a function of time may be found in the 
possibility, that prolonged electrical stimulation induces lesions in the 
brain structures stimulated. 
The factor subjects (S) was found significant (p < .01 ). The total response 
rates emitted by the subjects, varied over a large scale. The variability in 
sensitivity to brain-stimulation was described previously (see, for 
example, Wauquier et al., 1972, Chapter V.2) and various reasons for this 
were described above see Chapter IV-4). 
The significant interaction Β χ S (SPC's χ subjects) (ρ ( .01) pointed to the 
fact that, for individual rats, there are qualitatively different relationships 
between the quantities of charge (SPC's) and response rates. For 
instance, some rats exhibit no further increase, or even a decrease of 
responding at the highest SPC's because the limits of performance are 
reached, or because the stimulation becomes eversive. 
Further, large differences with respect to the evolution of responsiveness 
asa function of time, are observed for individual rats. Consequently, the 
interaction D χ S (time χ subjects) was found significant (p < .01 ). 
In conclusion: Because of the significant effects of the factors В (SPC's), 
D (time) and S (subjects) and the significant interactions in which these 
factors are involved, it is absolutely necessary to relate data 
possibly involving drug effects to control data obtained (a) in the 
same rats, (b) for the same SPC's and (c) during the same week. 
3. DRUG EFFECTS* 
3.1. Introduction 
In total, 38 compounds were investigated; each compound was given in 
3 to 6 doses and each dose was tested on 3 to 6 rats. The effects 
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Fiq. 4: Total response rates as a function ottime (Dj... Dg). 
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obtained with the 20 neuroleptics are extensively described in Chapter 
VII. 
As was mentioned before, each rat in our investigation received a drug 
on the fourth day of each week. For each rat, for each dose of the various 
drugs used and for each SPC, the response rates obtained during the 
drug session (the fourth day of the week) were expressed as percentages 
of the response rates obtained during the control session (the second 
day) of the same week. As a test for significance of differences between 
drug- and control-response rates obtained with the different rats on each 
SPC-dosis combination, the Wilcoxon matched-pairs signed-ranks test, 
one-tailed probability (Siegel, into consideration 1956, pp. 75-83) was 
applied. It is of interest to note that the test takes the direction as well as 
the magnitude of the differences between control- and drug-treatment. 
The material in the following sections is organized as follows: each 
section, which pertains to a class of drugs, is introduced briefly; the 
results of the drug-experiment are represented in a figure and followed 
by a description of the results; finally, the results are discussed with 
respect to the findings reported in the literature. 
The figures are constructed as follows: 
the generic name of the drug, the chemical formula, the injection route, 
the injection time (in min before the session) and the number of rats (n) 
are indicated at the top of the figure; the response rates obtained with all 
rats on each SPC and after each dose of a drug during the drug session 
(fourth day of the week) are expressed in percentages of the control 
response rates obtained during the control session (second day of the 
week). Significant (p \(.05) differences are indicated by an asterisk. Note 
that the statistical test could not be applied where only 3 rats were used. 
The reasons for analysing the data separately for each dose and for each 
SPC are the following: a) some doses of a particular drug may cause 
response enhancement (RE), other doses of the same drug may cause 
response decrease (RD); b) RE and RD are base-line dependent; as we 
have seen before, different SPC's induce different levels of base-line 
responding. So, on each of the parameters described, RE as well as RD 
may be found. Finally, significant RE and RD may be partly determined 
by the sensitivity of the individual rats to drug effects. 
32. CNS-stimulantsd) 
Amphetamine, cocaine and apomorphine are central stimulants inducing 
stereotype behavior and agitation in various animal species. Animals 
tend to self-administer these drugs if they are offered the opportunity to 
do so; cocaine and amphetamine possess abuse liability in humans. 
• This chapter is based on Wauquier (1976a). 
(1) The results of this investigation have already been published (Wauquier and Nieme-
geers, 1973, 1974a,b). 
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32.1. Cocaine (Fig. 5) 
Cocaine induces a dose-related facilitation of self-stimulation. Thus, the 
higher the dose, the higher the RE. The RE is predominantly observed on 
the SPC's inducing low control response rates and approximately the 
same on SPC 1 and 2. Cocaine does not cause any significant RD. 
There are individual differences between the rats with respect to the 
sensitivity to cocaine-induced RE. Some low responders are more 
sensitive to RE. However, there is no direct relationship between RE and/ 
or RD and the individual control response rates. 
In contrast to the effects of amphetamine and apomorphine (see 3.2.2., 
3.2.3.), no difference is found between the effects of cocaine on the first 
and second half hour of the session. 
322. Amphetamine (Fig. 5) 
All doses of amphetamine preferentially induce RE. The highest RE is 
observed with 0.63 mg/kg, higher doses causing a somewhat lower RE. 
Low control response rates are more susceptible to RE. On increasing the 
dose of amphetamine one also observes a gradually increasing RD. This 
effect is most pronounced on the SPC's inducing high response rates. 
There is no direct relationship between the response rates obtained in 
each individual rat and RE or RD. 
With the doses 0.16 and 0.31 mg/kg of amphetamine no apparent 
behavioural changes are seen; 0.63 mg/kg produces a slight increase in 
sniffing, rearing and ambulation. Increasing the dose of amphetamine 
results in a gradually and more pronounced stereotype locomotor 
activation, but chewing movements are not observed. The peak intensity 
is reached between 50 and 90 minutes after injection. 
Concomitant with these observations, RE is most pronounced during the 
second half hour of the session, while RD found with 1.25 and 2.50 
mg/kg of amphetamine also increased during the second half hour of the 
session. With the two highest doses, rats pressed the lever at nearly 
equal rates regardless of the particular SPC given. 
32.3. Apomorphine (Fig. 5) 
With apomorphine RE and RD are dose-related. The highest RE is 
obtained with 0.63 mg/kg and the highest RD with 1.25 mg/kg. RE is 
most pronounced at the SPC's inducing low control response rates, 
while RD is most pronounced at the SPC's inducing high control 
response rates. Whereas RD is not related to the individual control 
response rates, RE is directly related. The higher the control response 
rates, the higher the RE. Apparently, rats sensitive to brain-stimulation 
(low threshold, high responders) are more susceptible to the facilitating 
effects of apomorphine. This was confirmed in additional experiments 
using high and low responders at low frequency stimulation. 
RD is most pronounced during the first half hour of the session, and RE 
during the second half hour of the session. The time-course of these 
effects corresponds with the stereotype behaviour induced with 0.31,0.63 
and 1.25 mg/kg of apomorphine, lasting for 40, 50 and 60 min 
respectively. 
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Fig- 5: Response rates (all rats combined) in percentages of the respective 
control response rates, obtained with different doses (mg/kg) and for each 
stimulus parameter combination (SPC) with cocaine, dl-amphetamme 
and apomorphme. Chemical structure, injection raute, time of injection 
and number of rats tested are indicated at the top of the figure 
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32.4. Discussion 
The effects of the CNS-stimulants cocaine, amphetamine and apo-
morphine are dependent on the dose, the time of measurement after 
injection and the base-line rate. These drugs facilitate and/or depress 
leverpressing for brain-stimulation. There are, however, marked differen-
ces between the 3 compounds. Facilitation is most pronounced with 
cocaine and lowest with apomorphine. Depression is not found with 
cocaine, but with amphetamine and most pronounced with apomorphine. 
As far as neurotransmission is concerned, it can be stated that cocaine, 
amphetamine and apomorphine all have a common denominator: they 
influence dopaminergic systems. This does not exclude the involvement 
of other neurotransmitters such as NA and SHT. Cocaine was reported 
to block the uptake of DA (Hamberger and Masuoko, 1965; Ross and 
Renyi, 1967), amphetamine, to release DA (Stein, 1964a) and apo-
morphine to stimulate DA receptors directly (Ernst, 1965). The com-
pounds having synergistic action with cocaine or amphetamine could 
either enhance the available DA (MAO-inhibitors, tricyclic antidepressants 
and some antihistamines) (Beneáová, 1969), or antagonize the inhibitory 
cholinergic system (anticholinergics) interacting with the nigrostriatal 
dopaminergic system. NA-antagonists (phenoxybenzamine and propra-
nolol) only moderately antagonize the amphetamine-induced facilitation 
(Pradhan, 1976), whereas DA-receptor blockers (specific neuroleptics) are 
potent inhibitors of amphetamine- or apomorphine-induced stereotype 
behaviour (e.g. Janssen et al., 1967; see also further 4 and Chapter VII). 
32.5. Discussion 
The doses of amphetamine and apomorphine which cause depression of 
high rates of self-stimulation induce stereotype behaviour. The time 
course of the depression coincides with the time course of stereotypy. 
At high doses of apomorphine, self-stimulation is severely interrupted. At 
high doses of amphetamine, self-stimulation is not completely inhibited. 
The rats press the lever at lower rates for high SPC's and at higher rates 
for low SPC's; the self-stimulation rate is rather independent of the 
particular SPC used. In addition, amphetamine-treated rats show a 
strong resistance to extinction (Olds, 1970). Broekkamp (1976) also 
observed that apomorphine-treated rats continue to press the lever, even 
when brain-stimulation is no longer supplied. 
Apparently, the rats lost their adaptation to the situation, and this loss 
resulted in facilitation, depression and persévérant lever-pressing. This 
may, to some extent, be due to a competition between lever-pressing 
and stereotype behaviour. Further, direct receptor activation (apo-
morphine) is more disrupting for adapted behaviour than the non-
stimulation contingent release of catecholamines (amphetamine). 
Stereotype behaviour is characterized by the reduction of a behavioural 
pattern to fragmentary behaviour during which restricted particular 
movements predominate. By means of the continuous drug-action other 
behavioural elements not related to lever-pressing behaviour may be 
reinforced. The CNS-stimulants, in addition, may change response-
related cues, which tend to enhance the disruption of lever-pressing. 
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The persévérant responding when the stimulation is switched off, can 
hardly be explained in terms of a competition between lever-pressing and 
stereotype behaviour. Lever-pressing, when there is no reinforcing brain-
stimulation is, in a certain sense, itself, a stereotype act, the only source 
of reinforcement being the drug. The CNS-stimulants used here have 
apparently reinforcing properties of their own. This is demonstrated by 
the fact that rats and other species self-administer these drugs. Further, 
except for apomorphine, these drugs possess abuse liability. 
An alternative, and maybe more likely interpretation for the persévérant 
responding when the stimulation is switched off, is that rats fail to 
habituate. The performance of such rats is like the performance of rats 
extensively lesioned in forebrain structures (Huston and Ornstein, 1976). 
It appears that CNS-stimulants cause a «functional lesion». 
The facilitation of responding is independent of the type of the response. 
The stimulants increase the frequency of many differently reinforced res-
ponses (see e.g. the noise-escape situation in which lever-pressing and 
jumping were alternated during the same session, Niemegeersetal., 1972). 
Liebman and Butcher (1973) described how apomorphine caused depres-
sion of self-stimulation, which was restored to control levels on doubling 
the current. According to these authors, their data suggest a deficit in 
reward. However, the facilitation of lever-pressing is not specifically 
related to the positive motivation involved in brain self-stimulation. The 
CNS-stimulants also facilitate negatively motivated behaviour, such as 
Sidman shock-avoidance behaviour (Niemegeers et al., 1970a). Further, 
as shown for apomorphine (Broekkamp and van Rossum, 1974) 
facilitation or depression of self-stimulation occurs independently of the 
brain-site stimulated (see also Liebman and Butcher, 1973,1974). 
The above date suggest that CNS-stimulants activate a brain-system 
involved in both reward and avoidance. It was argued, quite justifiably 
(Stein, 1962a, 1964b), that amphetamine augments self-stimulation and 
avoidance, by virtue of lowering the thresholds in the hypothalamic 
incentive system. In this conception, reward and punishment interact 
reciprocally, both feeding into the motor system (Stein, 1964b). The 
self-stimulation substrate is then a reinforcement system involved in all 
kinds of operant behaviour. 
Because drug-effects are independent of the electrode localization, the 
effects cannot be explained by an action of these drugs on the neurones 
activated by the stimulation. Further, the mainly noradrenergic hypo-
thalamo-limbic system is hardly likely to be the only substrate for the 
observed effects. It is emphasized that the dopaminergic nigrostriatal 
system is a more likely candidate. 
It has been established that striatal systems not only control motor 
functions (e.g. Cools, 1973). Overactivation of this system (for example 
by amphetamine) or nonphysiological receptor stimulation (for example 
by apomorphine) is disturbing. This confirms the concept that an intact 
DA nigrostriatal system, functioning within limits, is required for the 
expression of learned behaviour (Ungerstedt, 1971b). Finally, many of 
the features of the effects of CNS-stimulants fit into the hypothesis that 
the nigrostriatal system is a drive-induction system (Crow, 1976). 
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3.3. Cholinergics and anticholinergics 
The role of acetylcholine (ACh) at the vertebrate neuromuscular junction 
(e.g. Eccles, 1964) is one of the best studied examples of chemical trans-
mission. At the periphery, a distinction has been made between a 
«muscarinic» and a «nicotinic» type of receptor. The presence of 
cholinergic neurons in the brain is demonstrated by histochemical 
staining of the enzyme acetylcholinesterase. These neurons are widely 
diffused (Lewis and Shute, 1967 and Shute and Lewis, 1967). A central 
representation of both cholinergic systems, muscarinic and nicotinic, has 
been described by Bradley (1968). It is generally assumed that cholinergic 
systems play a modulatory role in various types of behaviour (Pradhan 
and Dutta, 1971), including self-stimulation (Olds and Domino, 1969a, b). 
3.3.1. Cholinergics 
Cholinergic muscarinic agonists exert response depressant effects on 
self-stimulation behaviour. With pilocarpine, the ACh analogue, RD was 
dose-related, peaking 20-30 min after injection (Newman, 1972). The 
Cholinesterase inhibitor physostigmine induced a time- and dose-related 
RD (Newman, 1972; Olds and Domino, 1969a, b). Arecoline, a more 
peripherally acting Cholinesterase inhibitor, also induced RD (Olds and 
Domino, 1969a, b; Pradhan and Kamat, 1972). The onset was short and 
recovery was quick. The quaternary ammonium neostigmine, acting 
mainly peripherally, was virtually without effect. (Jung and Boyd, 1966; 
Domino and Olds, 1968; Newman, 1972). 
With nicotine, a ganglion stimulating agent. Olds and Domino (1969a, b) 
found a transient and variable RD, while other authors were able to 
demonstrate facilitation (Bowling and Pradhan, 1967), which was most 
prominent in low self-stimulators and which was related to time and dose 
(Newman, 1972). 
3.32. Anticholinergics (Fig. 6) 
3.3.2.1. Dexetimide 
Dexetimide induces a dose-related facilitation of self-stimulation. The RE 
is observed on the SPC's inducing low control response rates (SPC 1 and 
2) and almost exclusively significant on SPC1. The lack of significant 
effects on other SPC's is mainly due to inter-individual variability. In 4 out 
of 6 rats RE is more pronounced than RD, but in 2 other rats RD 
predominates. 
3.322. Benztropine 
A rather irregular dose-response curve is obtained: RE is highest at SPC1 
with 10 mg/kg of benztropine and at SPC2 with 40 mg/kg of 
benztropine. The RE is most pronounced at the low intensity SPC2, 
which contrasts with the observation that dexetimide causes a more 
pronounced RE at the low frequency SPC1. As with dexetimide, a slight 
RD is found at the other SPC's, but statistical significance is not reached. 
This, again is mainly due to inter-individual variability because RD 
predominates in 2 out of 6 rats. 
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Fig. 6: Response rates (all rats combined) in percentages of the respective 
control response rates, obtained with different doses (mg/kg) andforeach 
stimulus parameter combination (SPC) with dexetimide, benztropine and 
scopolamine. Chemical structure, injection route, time of injection and 
number of rats tested are indicated at the top of the figure. 
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3.32.3. Scopolamine 
The number of animals tested is small but the results indicate that 
scopolamine induces effects comparable to those found with dexetimide 
and benztropine. The dose-response curve is irregular. RE is highest with 
10 mg/kg and lowest with 2.5 mg/kg of scopolamine. In 1 out of 3 rats, 
RD outweighs RE. 
3.3.3. Conclusion 
Muscarinic cholinergic agents mainly exert RD. The peripheral acting 
cholinergics do not change the self-stimulation rate. Nicotine, on the 
other hand, facilitates self-stimulation. Muscarinic anticholinergics in-
duce peripheral and central effects (Janssen and Niemegeers, 1967). 
Relatively high doses of the anticholinergics are required to induce 
changes of self-stimulation rate. A central action is required since 
peripherally-acting anticholinergics, such as isopropamide, do not affect 
self-stimulation. The RE is not clearly dose-related, only observed during 
low base-line responding and the inter-individual variability is pronounc-
ed. The latter is responsible for lack of significance. 
3.3.4. Discussion 
Muscarinic agonists cause depression of self-stimulation. This is due to a 
central action, because cholinergics which do not cross the blood-brain 
barrier fail to change self-stimulation performance. Domino and Olds 
(1968) have shown that the depression of self-stimulation is associated 
with rise in the ACh-level. It could be expected that lowering the 
ACh-level, for instance by means of anticholinergics, would facilitate 
self-stimulation. It was subsequently confirmed that muscarinic anta-
gonists chiefly produce response enhancement. 
The effects on self-stimulation are probably not only due to an 
anticholinergic activity, since muscarinic anticholinergics also affect 
catecholamines. Scopolamine and benztropine increase the turnover of 
noradrenaline (NA) and decrease the turnover of dopamine (DA) 
(Corrodi et al., 1972). Benztropine and dexetimide also block the uptake 
of DA (Coyle and Snyder, 1969; Leysen, pers. comm.). The effects of 
anticholinergics on DA and NA are indirect and can be demonstrated 
most easily in those structures in which cholinergic neurones are 
supposed to interact with aminergic neurones, such as in the striatal 
structures. Such an interaction between dopaminergic and cholinergic 
neurones can be demonstrated behaviourally in experiments in which 
anticholinergics are shown to reverse the inhibition of self-stimulation 
produced by neuroleptics. The latter effect is assumed to be due to a 
blockade of DA-receptors (van Rossum, 1966,1967; see further Chapter 
VII, section 7). The action of nicotine might also depend on NA, since 
depletion of NA, for instance by reserpine, prevents nicotine from 
facilitating self-stimulation. In order to obtain measurable effects on 
self-stimulation, high doses of the anticholinergics are required. As 
measured in the anti-pilocarpine test in rats (Janssen and Niemegeers, 
1967), the EDtß-dose of central anticholinergic activity (e.g. tremor, 
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chewing) is obtained with 0.016 mg/kg of scopolamine, 0.080 mg/kg of 
benzetimide and 0.24 mg/kg of benztropine. The doses used in the self-
stimulation experiments largely exceed the centrally active doses of the 
anticholinergics. So, the effects of the anticholinergics might not be due 
to an effect on ACh but on DA (or NA) via cholinergic neurons. This led 
to the question of whether a central muscarinic cholinergic system is 
functional during self-stimulation. The absence of significant changes on 
neuronal responses measured in various parts of the brain (hypothala-
mus, preoptic, cingulate and midbrain) after administration of anti-
cholinergics, suggests that cholinergic systems modulate diffusely (Olds 
and Ito, 1973). 
The type of modulation would be inhibitory. The concept inhibition plays 
an important rôle in the description of behaviour. Loss of inhibitory 
control has been shown in experiments in which various limbic structures 
were lesioned (e.g. McCleary, 1966). 
Stein (1964b, 1967) assigned the inhibitory role in self-stimulation to the 
periventricular cholinergic system (which he termed «no-go system»). 
The ventromedial nucleus of the hypothalamus would be an important 
link in a cholinergic system mediating behavioural suppression (Margules 
and Stein, 1969). This system would interact with a facilitatory 
noradrenergic system (termed a «go-system»). Both systems would be 
mutually inhibitory and determine behavioural output. Such an inter-
action was shown in, for instance, experiments by Olds and Olds (1964) 
in which they described how stimulation in «eversive» brain areas, such 
as the tegmentum, significantly depressed self-stimulation. 
Although the idea of a dual system feeding a final common pathway is 
interesting, there is little evidence for the cholinergic mediation of a 
suppressive system. It is not known whether «eversive» stimulation 
depressed self-stimulation merely by stimulation of cholinergic neurones 
or by some other means. The behavioural deficits occurring after 
lesioning limbic structures can be interpreted in terms of a loss of 
inhibitory control. However, lesions do not only affect cholinergic 
systems and it is hard to accept that a general cholinergic blockade 
interferes with all inhibition-related mechanisms (Grossman, 1972). 
Further, limbic structures do no serve identical behavioural purposes. 
Finally, findings on lesioning or locally administered cholinergics and 
anticholinergics cannot unequivocally be interpreted in terms of response 
modulation, Colpaert (1975) proposed that lesions of the ventromedial 
hypothalamus and of other limbic structures as well, caused a failure in 
the acquisition of fear as secondary drive. 
On a hypothetical basis, one could assume that cholinergic systems are 
one source of inhibitory control, whereas other systems subserve 
adaptation to the environment by way of fear acquisition. These systems 
could modulate behavioural output and function in balance with 
aminergic transmitter systems sustaining self-stimulation. 
3.4. Minor tranquillizers 
Drugs which belong to the chemical group of the benzodiazepines, share 
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a variety of properties (Schallek et al., 1972; Zbinden and Randall, 1967). 
At lower doses hyperactivity can be observed, while at higher doses they 
cause sedation and EEG-deceleration. Chlordiazepoxide (Librium) and 
diazepam (Valium) are used as anti-anxiety agents whereas nitrazepam 
has sedative-hypnotic properties and is used as a «sleeping-pill». 
3.4.1. Chlordiazepoxide (Fig. 7) 
Chlordiazepoxide mainly facilitates self-stimulation, but no linear dose-
relationship is found. RE is also pronounced at dose-levels (10 and 20 
mg/kg) causing a pronounced disturbance of locomotor activity (named 
«ataxia»). RE is statistically significant at SPC1 and SPC2 (except with 
5 mg/kg at SPC1 ). The very high RE obtained at SPC2 might particularly 
be due to a very low control response level. In addition, less sensitive 
self-stimulators (rats responding at low rates) are more susceptible to RE 
than rats which have higher control response levels. In all rats, however, 
RE exceeds RD. 
In additional experiments (Wauquier, 1974), chlordiazepoxide was given 
to rats which could freely and continuously lever-press for brain-
stimulation (SPC1). These rats lived in cages where the environmental 
conditions were kept constant. The rats self-stimulated at low rates but 
the self-stimulation activity showed a circadian rhythmicity. Chlordiaze-
poxide (10 mg/kg given orally) markedly enhanced self-stimulation in 3 
out of 6 rats. Moreover, prolonged RE was found, exceeding direct drug 
effects. 
3A2. Diazepam (Fig. 7) 
RE as well as RD increase as the dose of diazepam increases. 
Simultaneously, a gradual, more pronounced disturbance of locomotor 
activity is observed. RE, however largely exceeds RD. The RE is most 
easily observed at low control base-line levels. The facilitation of 
self-stimulation is clearly dose-related, but the results fail to reach 
statistical significance at all dose-levels. This is especially due to the large 
variability with respect to drug-effects and especially because RD 
exceeds RE in one rat. 
3.4.3. Nitrazepam (Fig. 7) 
Nitrazepam causes a dose-related RD. With some doses RE is also 
observed. RE is far less pronounced than the RE induced by chlordiaze-
poxide and diazepam. Again, there is a large inter-individual variability. 
There is further no relation between RE and base-line responding 
obtained with each individual rat. 
3.4.4. Conclusion 
Chlordiazepoxide and diazepam preferentially induce a dose-related 
facilitation of self-stimulation, whereas nitrazepam causes more in-
hibition. The highest RE is found with chlordiazepoxide. All three 
compounds induce facilitation of low base-line responding. The inter-
individual variability is pronounced. The doses ) 5 mg/kg of chlordiazep-
oxide, > 2.5 mg/kg of diazepam and > 2.5 mg/kg of nitrazepam cause a 
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Fig. 7: Response rates (all rats combined) in percentages of the respective 
control response rates, obtained with different doses (mg/kg) and for each 
stimulus parameter combination (SPC! with chlordiazepoxide, diazepam 
and nitrazepam Chemical structure, injection route, time of injection and 
number of rats tested are indicated at the top of the figure. 
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pronounced muscle relaxation (Desmedt et al., 1976) and induce 
disturbance of locomotor activity (ataxia). 
3.4.5. Discussion 
The slight depression of self-stimulation found with chlordiazepoxide 
and diazepam and the more pronounced inhibition induced by nitraze-
pam, might be related to the uncoordinated motor activity and sedation 
caused by these drugs. Corrodi et al. (1971) reported that benzodiazepines 
decrease the nervous activity in noradrenergic neurones, which could be 
related to the sedation and EEG-deceleration. At the dose-levels causing 
ataxia, the benzodiazepines protect against tonic and clonic seizures 
induced by pentylenetetrazol in rats (Desmedt et al., 1976). This 
characteristic explains their clinical usefulness in convulsive seizures in 
humans (e.g. Gastaut et al., 1965; Millichap and Ortiz, 1966). The muscle 
relaxation might, to a certain extent, contribute to the anti-anxiety 
effects, assuming that there is a reciprocal interaction between the 
vegetative peripheral nerve system and brain. 
It is very unlikely that the anticonvulsant properties of the benzo-
diazepines explain the facilitation of self-stimulation. Convulsions are not 
very often associated with self-stimulation in the lateral hypothalamic 
area and anticonvulsant drugs such as baclophen, diphenylhydantoin, 
ethoxsuccimide and trimethadione do not enhance self-stimulation 
(unpublished observations). Olds (1966) suggested that chlordiazepoxide 
«primarily affected the reward system». If this is true, one might, for 
instance, wonder why the interindividual variability is so large. Panksepp 
et al. (1970), on the other hand, favoured the hypothesis that chlordiaze-
poxide facilitated self-stimulation indirectly, i.e. by counteracting an 
«eversive» system. These authors showed that chlordiazepoxide mainly 
increased self-stimulation from electrodes which also yielded reliable 
escape behaviour. Self-stimulation through such electrodes would be 
rewarding but also fear-inducing. Chlordiazepoxide might reduce this 
fear and consequently enhance self-stimulation. 
Further, when stimulation is shifted to sub-threshold level, chlordiaze-
poxide prolongs responding in the extinction period (Gandelman and 
Trowill, 1968). The latter effect could be explained in terms of a 
counteraction of the aversion produced by non-reinforcement. It is not 
known whether chlordiazepoxide reduces the threshold for self-
stimulation, which would also explain the facilitation. 
Chlordiazepoxide did not facilitate the escape behaviour induced by 
aversive stimulation in the dorsal tegmental area (Olds, 1966) but 
facilitated escape from stimulation in hypothalamic areas (Panksepp et 
al., 1970). These contrasting findings might indicate that the inhibitory 
system on which benzodiazepines impinge is not cholinergic-mediated 
(dorsal tegmental reticular formation). It is more likely that facilitation of 
self-stimulation results from the inhibition of a serotonergic system 
running through the medial forebrain bundle. Moreover, Stein et al. (1973) 
presented evidence that the antianxiety action of benzodiazepines is due 
to a decreased activity in serotonergic neurones. It is likely that the 
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effects of minor tranquillizers on DA (and NA) are related to their 
sedative properties at high dose levels (Corrodi et al. 1971 ). 
There is experimental evidence for the rôle of serotonin in self-
stimulation. Stein (1971) showed that serotonin, given intraventricularly, 
suppressed self-stimulation. Poschel and Ninteman (1971) also postulat-
ed an inhibitory role of the serotonergic system in self-stimulation 
behaviour. Their interpretation is mainly based upon the facilitatory 
effects obtained with parachlorophenylalamine (PCPA), an inhibitor of 
the synthesis of serotonin. Results of PCPA-effects described by Stark et 
al. (1970), however, cast some doubt on the specificity of PCPA. 
Beyond doubt is the fact that the inhibitory role of a serotonergic system 
is not related only to self-stimulation. PCPA for instance, also induced 
hyperphagia and obesity when given intraventricularly (Breisch et al., 
1976). It is further known that stimulation in the raphe nuclei, from which 
serotonergic fibres originate, produces electroencephalographic sleep 
(e.g. Kostowski et al., 1969), whereas lesioning these structures 
produces extreme activation and sleepiness (Jouvet, 1974). Low 
frequency stimulation in the raphe nuclei (and in the lateral hypothalamic 
area as well) was shown to release serotonin in terminal forebrain 
structures (Kostowski et al., 1969). It could be argued that serotonin has 
not a suppressive influence on self-stimulation in the lateral hypothalamic 
area, since self-stimulation can also be obtained from electrode 
placements in raphe nuclei (e.g. Margules, 1969). It is, however, still a 
matter of debate whether raphe-self-stimulation is not due via activation 
of the locus coerulens, origin of the dorsal noradrenergic pathway. 
One might tentatively suggest that a serotonergic system originating in 
the raphe nuclei and running through the medial forebrain bundle, might 
have a suppressive influence on behaviour, including self-stimulation. 
Suppressing this system would for one thing, result in fear-reduction 
(Stein et al., 1973) and consequently facilitate behaviour. This is, most 
convincingly demonstrated in situations in which fear is probably 
causally involved in inhibition. Reward behaviour might be governed by 
two inhibitory systems: one which is cholinergic and not active during 
self-stimulation, another which is serotonergic, active during self-
stimulation and mainly related to fear acquisition. 
3.5. Narcotic analgesics (1) 
Narcotic analgesics cause depression or facilitation which is species-, 
time- and dose-related. Some of these, such as morphine, are self-
administered by animals, cause dependence and are abused in humans. 
The effects of fentanyl, piritramide and morphine were tested on self-
stimulation. In additional experiments analgesic activity and catatonia 
were measured. 
Analgesic activity was measured in the tail withdrawal test in rats 
(Janssen et al., 1963). Failure to withdraw the tail from water at 55°С 
(1) The results of this investigation have already been published (Wauquier and Nieme-
geers, 1976a). 
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within 10 sec was used as the criterion for calculating ED50 values. 
Catatonia (muscular rigidity and loss of righting reflex) was assessed 
according to a scoring system described previously (Wauquier et al., 
1974). Muscular rigidity was felt by hand grip and scored from о (no 
rigidity) to 3 (lead-pipe rigidity). For calculating ED50 values (mg/kg) 
score)/2 (obvious rigidity) was adapted as criterion. 
3.5.1. Morphine (Fig. 8) 
With morphine a dose-related RD is found. The estimated EDjjQ-value of 
RD is 16.4 mg/kg. RD is most pronounced at the highest dose tested 
(20 mg/kg) and significant at the SPC's 3, 4, 5 and 6. At lower doses 
morphine slightly enhanced self-stimulation. The results fail, however, to 
reach statistical significance. There is no apparent relationship between 
RD and individual sensitivity of the rats to brain-stimulation. 
At dose-levels inhibiting self-stimulation, morphine causes catatonia. 
The calculated EDso-value of morphine-induced catatonia is 11.8 mg/kg 
(limits: 9.20-15.21 ). Analgesia is obtained at even lower doses, the ED50 -
value being 7.86 mg/kg (limits: 6.82-9.06). 
In another study (Wauquier et al., 1974 and see Chapter VII, section 7), it 
was shown that naloxone at a dose (5 mg/kg) which was ineffective on 
its own, reversed the morphine-induced inhibition (40 mg/kg) of self-
stimulation, as well as the associated catatonia. 
3.52. Fentanyl (Fig. 8) 
Fentanyl, a potent analgesic (Janssen et al., 1963), causes a dose-
dependent RD. The estimated EDsQ-value of RD is 0.099 mg/kg. At the 
highest dose tested (0.16 mg/kg) RD is significant at all SPC's. At low 
doses RE exceeds RD, but this is only statistically significant at SPC 6 
with 0.02 mg/kg of fentanyl. There is no direct relationship between 
drug-effect and individual sensitivity to brain-stimulation. At dose-levels 
inhibiting self-stimulation 0/0.08 mg/kg) fentanyl causes catatonia, the 
EDgQ-value of catatonia being 0.068 mg/kg (limits 0.053-0.088). Analgesia 
is obtained at 0.036 mg/kg (0.028-0.046) of fentanyl. In additional 
experiments it was found that with chronic administration of fentanyl 
(1 injection of 0.16 mg/kg of fentanyl per day, half an hour before the 
session), tolerance to the suppressive effects developed. However, it 
took several days or, in some rats, even weeks to obtain these effects. 
Furthermore, excitation and depression alternated in a seemingly random 
fashion. 
3.5.3. Piritramide (Fig. 8) 
Piritramide is a potent analgesic with unusual chemical features 
(Janssen, 1961). Piritramide causes a dose-related RD, the ED^-value 
being 11.4 mg/kg. The RD is significant at all SPC's with the highest 
dose tested (40 mg/kg). RE exceeds RD at low dose levels, but statistical 
significance is only reached at SPC3 with 2.5 mg/kg. Catatonia is 
induced with 11.3 mg/kg (6.21-20.56) and the ED^-value of analgesia is 
5.67 mg/kg (4.42-7.28). 
131 
Fig. 8: Response rates (all rats combined) in percentages of the respective 
control response rates, obtained with different doses (mg/kg) andforeach 
stimulus parameter combination (SPC) with morphine, fentanyl and 
pintramide. Chemical structure, injection route, time of injection and 
numberofrats tested are indicated at the top of the figure. 
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3.5.4. Conclusion 
The three narcotic analgesics described here induce a dose-related RD, 
which is most pronounced at the highest dose tested. At low doses or 
after chronic administration, RE is also observed. There is no direct 
relationship between the sensitivity to brain-stimulation in each individual 
rat and drug-induced RD or RE. 
The doses effectively inhibiting self-stimulation are higher than those 
inducing catatonia (muscle rigidity and loss of righting reflex) and those 
causing analgesia (as measured in the tail-withdrawal test). 
3.5.5. Discussion 
The inhibition of self-stimulation produced by the three narcotic 
analgesics fentanyl, morphine and piritramide is not necessarily related to 
the rewarding value of brain stimulation, since the doses effectively 
inhibiting self-stimulation are much higher than those required for 
profound analgesia, obvious rigidity and loss of righting reflex. These 
observations indicate that inhibition of self-stimulation might be due to a 
non-specific catatonia-inducing effect and, thus, that it results from 
motor incapacitation. Further, response depression obtained after i.p. or 
s.c. injection of morphine (doses ranging from 5 to 20 mg/kg) appears 
equally well with electrode placement in the medial forebrain bundle, 
septal region and posterior and lateral hypothalamus. (Olds, 1959; Olds 
and Travis, 1960; Adams et al., 1972; Lorens and Mitchell, 1973). 
The facilitation observed after narcotic analgesics depends on the dose 
and time of measurement after injection. 
Tolerance to the suppressive effects of narcotic analgesics has been 
described (Adams et al., 1972; Lorens and Mitchell, 1973). The excitatory 
effects appeared earlier on the 5th day of administration. In the study 
reported here, facilitatory effects were also found after the acute 
administration of narcotic analgesics, although statistical significance 
was rather weak. 
Click et al. (1973) reported that morphine affected the «reward 
structures» involved in self-stimulation, which in turn altered the degree 
of dependence. Further, Marcus and Kornetsky (1974) reported that 
morphine reduced the threshold for self-stimulation. These findings 
might indicate that the facilitation obtained after administration of 
narcotic analgesics is due to a specific effect on structures underlying 
reinforcement of brain-stimulation. Moreover, it is well known that 
morphine is self-administered by different animals and abused by 
humans. We also showed that rats preferred to drink a solution of 
fentanyl + saccharine than to drink water + saccharine alone (Colpaert et 
al., 1976b). 
The drug-induced increase of the excitability of reward pathways might 
be experienced as more rewarding, just as human beings experience 
these drugs as pleasurable. The increased activity of reward pathways 
might be responsible for drug-seeking behaviour (Collier, 1968; Marcus 
and Kornetsky, 1974). One might wonder, however, whether drug-seek-
ing in addicts is not also avoidance behaviour for the anticipated 
unpleasurable withdrawal effects. 
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The sensitizing of the reinforcing substrate could be due to some altered 
biochemistry, but interpretation of this would be highly speculative. 
Some hypothesis related the effects of narcotic analgesics to their 
interaction with dopamine-receptors (Sasame et al., 1972, Broekkamp 
and van Rossum, 1975). 
Finally, the most convincing effect of acute administration of narcotic 
analgesics on self-stimulation described here, is inhibition which was 
related to a non-specific catatonia-inducing effect. 
3.6. Antidepressants 
Nowadays three groups of antidepressants are used in medical practice: 
tricyclic antidepressants, some CNS-stimulants and MAO-inhibitors. 
This does not mean that chemically different compounds cannot possess 
antidepressant activity, for example, some antihistamines such as 
diphenhydramine and the anthelmintic tetramisole and its isomers. The 
antidepressants of the tricyclic type do not cause observable behavioural 
effects except at high doses and/or in combination with other drugs. 
3.6.1. Desipramine (Fig. 9) 
This compound was only studied in 3 rats. The main effect in RD, 
reaching -12.1 %, -15.9 % and -14.6 % in total (sum of the 6 SPC's) with 
respectively 2.5, 10 and 40 mg/kg. A small RE not exceeding control 
variability is observed. The inhibition is highest on the SPC's inducing 
low control response rates and vice versa. The highest RD is obtained 
with rat 3, for which the lowest control response rates were recorded. 
3.62. Amitriptyline (Fig. 9) 
This compound was only studied in 3 rats. The doses 2.5 and 10 mg/kg 
cause only minor effects. Some RE is observed at SPC1 and RD on the 
other SPC's with 40 mg/kg, mainly due to the effects in one rat. 
3.6.3. Dexamisole (Fig.9) 
Dexamisole is the d-isomer of tetramisole, a broad-spectrum anthelmintic 
(Thienpont et al., 1966). It was found that tetramisole (Brugmans et al., 
1972) and both isomers levamisole (Deberdt, 1973) and dexamisole 
(Bobon et al., 1974) are of benefit in certain forms of depression. Bobon 
et al. (1974) reported that dexamisole was effective in 40 % of the tested 
patients with retarded depression. Side-effects, probably related to the 
doses and not reliably found in all patients, were tension, anxiety, tremor 
and some insomnia. 
On self-stimulation, dexamisole induces RE at all doses tested. The dose-
response curve is rather irregular. RE is most pronounced on SPC1 and 2, 
being significant only at SPC1 with 20 mg/kg. RD is rather small. In 5 out 
of 6 rats a preferential RE is observed, whereas RD is more pronounced 
than RE in one rat. 
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Fig. 9: Response rates (all rats combined) in percentages of the respective 
control response rates, obtained with different doses (mg/kg) and for each 
stimulus parameter combination (SPC) with desipramme, amitnptyline 
and dexamisole Chemical structure, injection toute, time of injection and 
number of rats tested are indicated at the top of the figure. 
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3.6.4. Conclusion 
Desipramine preferentially causes RD, amitriptyline induces a slight RE 
and dexamisole causes a clear but not dose-related RE. It appears that 
the effects obtained with dexamisole are different from the tricyclic anti-
depressants. There are, however, individual differences between the rats 
with respect to drug-response, which are responsible for the lack of 
significance. 
3.6.5. Discussion 
Antidepressants only slightly affect spontaneous or conditioned 
behaviour. Their activity is mainly shown in situations where base-line 
activity is lowered or, by the potentiation of enhanced activity. An 
example of the former is the antagonism of reserpi ne (or analogues)-
induced behavioural and peripheral phenomena in rats and mice, i.e. 
locomotor activity inhibition, hypothermia, miosis and ptosis (e.g. Col-
paert et al., 1975a). An example of the latter is the potentiation of the 
effects of CNS-stimulants such as amphetamine-induced stereotypes in 
rats (e.g. Lew et al., 1971). Antidepressants would be expected to 
facilitate behaviour maintained by low reinforcement, such as the low 
control response rates induced by SPC1 and 2. In our experiments, 
tricyclic antidepressants cause minor effects or are depressing at high 
dose levels. This was also found in other experiments on conditioned 
behaviour (Cook and Kelleher, 1962). Only one report available in the 
literature describes facilitation of self-stimulation in cats obtained with 
Imipramine (2-3 mg/kg) (Horovitz, 1962). No further experimental work 
has been done on this, possibly species-related, effect. 
Tricyclic antidepressants potentiate the excitatory effects of ampheta-
mine and cocaine on self-stimulation (Bénesová, 1969; Stein, 1967). This 
effect might be due to a retardation of the inactivation of released 
amines. The amphetamine-interaction is a metabolic interaction 
(Lewander, 1969) resulting in higher amphetamine levels in the brain. The 
pharmacological interaction consists, rather, of a prolongation of 
stereotypes and agitation induced with amphetamine. 
Self-stimulation which according to Stein (1968), is mediated by NA is 
not, however, enhanced by tricyclic antidepressants, as would be 
expected on the grounds of potentiation of released NA during 
stimulation. This might be due to the a-adrenolytic activity obtained with 
some anti-depressants, usually at relatively high doses (Van Nueten, 
pers. communications). Dexamisole, on the other hand, facilitated 
self-stimulation. Recently, it was found that dexamisole potentiates the 
response to sympathetic stimulation, probably by stimulating sympathe-
tic ganglia, and NA effects as well. The latter may be explained by 
inhibition of reuptake of NA (Vanhoutte and Van Nueten, 1975) and 
could be responsible for the observed effects. 
Hypotheses on depression have been based on biochemical or pharma-
cobiological data. Janowsky et al. (1972) proposed a cholinergic-
adrenergic hypothesis of mania-depression. This «balance-theory» was 
particularly based on the finding that some compounds, such as 
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¡prindole, did not affect amines (Fann et al., 1972). Another type of 
theory was advanced by Stein (Stein 1962 a,b). He stated that 
depression is due to either a «hypoactive» reward system (passive or 
primary depression) or an overactive punishment system (active or 
secondary depression). The main point in this concept is that depression 
is due to a disordered functioning of the reward system. The idea that 
behaviour should be governed by two antagonistic systems: one 
responsible for aversion, withdrawal, punishment, and one responsible 
for approach and reward is far from being new (see for example Van der 
Staak, 1975). Undoubtedly, other systems may also modulate the reward 
system (see previous sections). Both mechanisms would be active when 
an organism is presented with a stimulus. The hedonic value would then 
be determined by the stimulus intensity. 
Berlyne (1960) extended this concept by relating hedonic value to arousal 
potential, the latter being determined by specific stimulus properties. 
This differs from Hebb's concepts (Hebb, 1955) in which hedonic value 
depends on the level of arousal. Berlyne (1973) further stated that 
hedonic value can result from either reducing or enhancing arousal 
(termed respectively «arousal reduction» and «arousal boost»). 
These ideas correlate with Olds' and Olds' (1965) scheme of interacting 
brain systems governing hedonic processes, except that these authors 
postulate a third positive reinforcement focus, located in the lateral 
hypothalamic region. 
Stein's hypothesis is, although interesting, an over-simplification. The 
advantage is that it might be a starting point for advancing experimental 
models. One which we developed consisted of using a progressive (each 
2 min) increasing fixed ratio (FR) schedule (up to 9 responses for 1 
stimulation) of brain-stimulation reinforcement, during sessions of 3 
consecutive 20 min periods. Such a schedule resulted in a progressive 
increase of self-stimulation (up to FR 3:1), followed by decreased 
responding (up to FR 5:1) and a still further decrease to operant level. 
During the last 2 min of each period a continuous reinforcement 
schedule (CRF, 1:1) was applied. The rats were automatically given 1 
stimulation at the start of the CRF. This resulted in an immediate revival 
of self-stimulation. This type of schedule might be a «model» of 
depression, since increasing the effort to obtain stimulation (increased 
FR) resulted in a drop of responding. Anthropomorphically stated, the 
effort became too much for the little reward achieved, rats became 
«depressed». Preliminary experiments with antidepressants indicated 
that responding was maintained for longer periods (or higher FR) than 
during control sessions. 
The drawback of this type of experiment is that variability in control 
sessions is rather large (maybe reflecting «internal state») such that 
enhancement after drug-treatment as compared to control is not 
extremely pronounced. Changes in procedure might result in a better 
stability of control responding. The creation of a model of a human 
disease in rats, however, is still very much a matter of speculation, but 
a valid approach consists of translating fundamental symptoms into 
experimental terms. 
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37. Hypnosedatives 
Hypnosedatives cause minor behavioral effects at low dose levels; at 
higher doses they produce ataxia (uncoordinated locomotor activity); at 
still higher doses they induce hypnosis (sleep). At the dose-levels 
producing hypnosis they protect against convulsions induced by 
pentylenetetrazol. The effects of a non-barbiturate, etomidate, metho-
hexital and pentobarbital are described. 
3.7.1. Etomidate (Fig. 10) 
Etomidate is a novel, non-barbiturate and fast-acting compound (Janssen 
et al., 1971,1975b). It produces EEG-effects quite similar to those of the 
barbiturates such as methohexital, but has no undesirable cardiovascular 
side-effects (Wauquier et al., 1976b). On self-stimulation one observes 
very slight RE and KD with the 3 lowest doses tested (0.16, 0.63 and 
2.5 mg/kg). At the highest dose tested (10 mg/kg, s.c), RD is virtually 
complete and significant at SPC3,4,5 and 6. The RD is nearly equal at all 
SPC's except SPC1. In all rats RD is more pronounced than RE. 
3.72. Methohexital (Fig. 10) 
Methohexital is a barbiturate inducing hypnosis at doses approximately 
7 times higher than obtained with etomidate. EEG-effects are similar to 
those obtained with etomidate, but the drug causes tachycardia and 
frequently apnea (Wauquier et al., 1976b). Methohexital was only tested 
on three rats for self-stimulation. At the dose-range tested RD is only 
small, RE is also observed at low control response rates. 
3.7.3. Pentobarbital (Fig. 10) 
Pentobarbital was only tested in three rats. Mainly RD is found and with 
one dose (10 mg/kg) RE on SPC1. The highest dose tested (20 mg/kg) 
causes a pronounced RD but the effects are quite variable on the 
different SPC's. In the three rats RD outweighs RE. 
3.7.4. Conclusion 
Hypnosedatives cause unspecific effects on self-stimulation, inhibit 
self-stimulation at dose levels inducing hypnosis. The unspecificity of the 
effects is best illustrated with etomidate, which at the highest dose 
tested produced almost the same RD at all SPC's. 
3.7.5. Discussion 
It is quite clear that hypnosedatives only affect the performance level, 
since they only moderately change self-stimulation, whereas high doses 
completely inhibit self-stimulation performance. The inhibition is un-
specific, because, at these high doses, rats are under hypnosis and are 
therefore unable to press a lever. The drugs can therefore be discussed 
in terms of their interference with performance ability. They might be 
explained by their interference with the ascending reticular formation, 
this system determing consciousness and organization of motor patterns 
(Routtenberg, 1971a). 
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Fig. 10: Response rates (all rats combined) in percentages of the 
respective control response rates, obtained with different doses (mg/kg) 
and for each stimulus parameter combination (SPC) with etomidate, 
methohexltal and pentobarbital. Chemical structure, injection route, time 
of injection and number of rats tested are indicated at the top of the figure. 
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They may also affect the cortex, as postulated by Doenicke et al. (1973) 
for etomidate, thus causing a disinhibition of subcortical structures. 
Some hypnotics cause excitatory effects and induce an EEG-picture 
resembling an epileptic seizure. The excitatory effects might be a reason 
why certain barbiturates are abused. It appears, however, that barbitur-
ates are abused not because they facilitate reward, but as a flight into 
unconsciousness. 
3.8. General discussion 
Self-stimulation is a particular kind of behaviour, i.e. caused by 
pathologically induced neuronal processes (Olds, 1973), through stimu-
lation of implanted brain electrodes. Self-stimulation is sustained by 
positive reinforcement. Reinforcement is «In essence, this system 
involved in bridging the gap between behaviour and its physiological 
consequences.» (Valenstein, 1966, p. 158). The description of the self-
stimulation phenomenon and its anatomical distribution suggested that 
the substrate of «immediate reinforcement» was detected. The concept 
«immediate reinforcement» was introduced by Valenstein (1966,1970) to 
stress the independence of feedback from the physiological con-
sequences of the behaviour and referred to the direct elicitation of the 
reinforcement process whether triggered by exteroceptors or inter-
oceptors. This means that drive-reduction is only one source of 
reinforcement, which cannot account for reinforcement of direct brain 
stimulation. This does not exclude drives to action, such as gating 
behaviour. The hedonic value of the stimulation could, according to 
Berlyne (1973), be determined by increments or decrements of arousal 
potential, which covers all stimulus properties. Reinforcement could be 
activated by some complex changes in the activity of the underlying 
substrate. In self-stimulation then, situational factors, experimental 
paradigms and gating mechanisms (cues depending on internal states) 
codetermine the final output. Further, brain-stimulation, especially in 
certain structures such as the lateral hypothalamus, activates not only 
neuronal fibres mediating reward. Other modulating (inhibitory, fear-
inducing) systems may be activated simultaneously. 
The study of the influence of psychoactive drugs on brain self-stimulation 
is not only indicative for central drug-effects (Grossman, 1967, p. 284) 
but could help to elucidate which brain systems are involved and how 
they interact in the mediation of observed behaviour. Undoubtedly, 
drugs injected systemically have multiple actions. The following list is not 
even exhaustive. Drugs could change self-stimulation by affecting 
performance, reward, reinforcement, sensorimotor integration, retrieval; 
drugs may induce state-dependent effects or act as cues (see Colpaert et 
al., 1976a), etc. The main point discussed here, is that drugs influence 
self-stimulation through an action on performance or reinforcement, 
regardless of the particular motivation involved and further, through an 
action on modulating systems functioning in balance with transmitter 
systems underlying brain self-stimulation. 
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Some of the drug-effects can be discussed in terms of drug-interference 
with the performance ability, such as those obtained with hypnose-
datives, high doses of minor tranquillizers or narcotic analgesics. The 
effects of these drugs are unspecifically related to reinforcement or 
reward. Obviously, hypnosedatives completely inhibit self-stimulation at 
dose-levels inducing hypnosis. Narcotic analgesics, at least when they 
are acutely administered at sufficiently large doses, inhibit self-
stimulation by causing motor incapacitation (catatonia: muscle rigidity 
and loss of righting reflex). High doses of minor tranquillizers (and to a 
certain extent also tricyclic antidepressants) cause sedation and/or un-
coordinated locomotor activity. These drugs, therefore, might inhibit 
self-stimulation by an action on motor systems and interfere with the 
ability to perform. High doses of CNS-stimulants which cause stereotype 
behaviour, also decrease performance. However, in this case, rats are 
able to perform since they even press the lever when brain-stimulation is 
no longer supplied (during «extinction»). The inhibition caused by these 
drugs is for a large degree due to a competition between goal-directed 
movements and stereotype behaviour, not related to lever-pressing. Self-
stimulation at equal rates for different SPC's and the failure to extinguish 
after stimulation has been cut off, cannot be explained "by the same 
mechanism. The performance of such rats is more like the performance 
of rats extensively lesioned in forebrain structures (Huston and Ornstein, 
1976), which show a failure to habituate. It appears, therefore, that the 
high doses of CNS-stimulants cause a «functional lesion» interfering 
with the physiological activity of self-stimulation substrate systems. 
CNS-stimulants are self-administered by animals and some are abused in 
humans. They appear to have reinforcing properties of their own, the 
physiological consequences being experienced as rewarding. 
The mechanism accounting for the facilitation of self-stimulation might 
consist of a sensitizing or threshold-reduction of the reinforcement sub-
strate. The failure to extinguish, however, might be due to a shaping of 
stereotype lever-pressing and to a lack of habituation non-relevant 
stimuli since brain-stimulation reward is lacking. Alternatively, one could 
assume that the interaction with the environment itself becomes 
rewarding (see for example Nuttin, 1973) or reflects a sustained 
anticipation. 
The facilitation of self-stimulation seen after CNS-stimulants and acute 
or chronic administration of narcotic analgesics, might be due to a 
sensitization of the reinforcement substrate or to threshold-reduction. 
Sensitization is a difficult concept to handle, since there is no evidence 
that the biochemistry of the system has been chronically affected. In 
addition, when administering drugs chronically, one probably has to take 
state-dependent effects into consideration, i.e. where making or not 
making a response is conditional upon a given drug (Colpaert et al., 
1976a). Effects conditional upon the chronic administration of a drug can 
be shown, but these depend on stimuli associated with drug-administra-
tion rather than the drug itself. State-dependent effects associated with 
a given drug could play a rôle in drug-induced performance changes of 
self-stimulation. In order to demonstrate the involvement of these 
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effects, specific experiments are required to show that there is a lack of 
transfer to the no-drug condition and experiments in which similar or 
different drugs are substituted for the training drug. 
It is conceivable that the effects obtained with lower doses of CNS-
stimulants and narcotic analgesics are due to a specific effect on 
reinforcement. Reward could increase by threshold-reduction. This 
implies that stimulation which is not rewarding gains rewarding 
properties. Further, self-stimulation performance could increase for 
stimulation which is moderately rewarding. It might be questioned, that 
these drugs specifically affect reward, since similar enhancement of 
responses, aimed at escaping or avoiding eversive stimulation, such as 
electrical shock, is observed after the administration of these drugs (see 
Niemegeers et al., 1969a, b 1972). 
Common to both reward and aversion in an operant behavioural 
situation, is the occurence of a reinforcing process. Both mechanisms 
interact with each other (Stein, 1964b) and feed into motor mechanisms, 
determing final output. These considerations imply that the «reward 
system» plays an important rôle in avoidance behaviour. Olds (1962) 
suggested, for instance, that chlorpromazine inhibited self-stimulation by 
virtue of an increase of the hypothalamic incentive system (see further 
Chapter VII). CNS-stimulants and narcotic analgesics may act by the 
opposite mechanism, i.e. decrease the threshold of the reinforcing 
system involved in both reward and aversion. 
These considerations also imply that it is impossible to discuss «reward» 
without taking into consideration other mechanisms which modulate the 
former. From a pharmacological point of view, it is difficult to explain the 
effects obtained with cholinergics, anticholinergics and minor tranquil-
lizers only on the basis of an impact on DA- or NA-systems, substrates of 
self-stimulation. Cholinergic and serotonergic systems probably function 
as systems involved in behavioural suppression on the one hand, and as 
systems involved in fear-induction on the other hand. The interaction is 
demonstrated by the fact that cholinergics at high doses, suppress self-
stimulation, which is normalized by anticholinergics, which themselves, 
also at high doses enhance self-stimulation. Further, the action of 
nicotine might depend on the NA-system. 
The inhibition seen after cholinergics suggests that the cholinergic 
network mediates behavioural suppression. This is further extensively 
described by Pradhan and Dutta (1971). It is unlikely, however, that the 
«eversive» system is only cholinergic-mediated and that all inhibition-
related mechanisms are cholinergic. 
The interaction between reward and aversion is also demonstrated by 
the fact that chlordiazepoxide facilitated self-stimulation primarily in 
those rats also showing escape behaviour. Since the activity of minor 
tranquillizers is regarded as being due to their influence on a serotonergic 
system, one could assume that escape is mediated through such a 
system. In view of the anti-anxiety effects of these drugs, one could 
argue that fear-reduction is causally related to the facilitation found and 
further, that the system mediating this [s serotonergic. Again, one cannot 
state that all serotonergic systems are involved in mediating fear. 
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In conclusion: Psychoactive drugs change the self-stimulation activity by 
affecting the performance ability or by interfering with reinforcement. 
The latter is independent of the particular motivational state involved. 
Similar changes can be found on behaviour sustained by positive or 
negative motivation. 
It is not clear whether certain drugs specifically alter reward, but one 
should not exclude such a possibility. 
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Chapter VII. Neuroleptics and brain 
self-stimulation m 
INTRODUCTION 
The question of which neuronal pathways are involved in self-stimulation 
behaviour and what rôle they play in the different aspects of this 
behaviour, has been the subject of a large number of studies (Wauquier 
and Rolls, 1976). The reinforcing properties of electrical stimulation of 
particular neuronal pathways must in some way be related to the 
activation of these pathways, caused by the electrical stimulation. 
Pharmacological studies on self-stimulation and neurochemical identifi-
cation of the pathways involved gave rise to the so-called catecholamine-
hypothesis of self-stimulation behaviour (Crow, 1972; Dresse, 1966; 
Stein, 1968). According to this hypothesis the effects of electrical self-
stimulation are mediated by noradrenergic and dopaminergic neuronal 
pathways. It has been shown, however, that self-stimulation behaviour 
can also be induced by applying electrical stimulation to non-aminergic 
structures (e.g. Liebman and Butcher, 1974). Moreover, there are con-
troversies with regard to the functional rôle of the different aminergic 
structures in self-stimulation behaviour. 
There are a variety of neuroleptics belonging to different chemical 
classes: the rauwolfia alkaloids (reserpine-like), the phenothiazines 
(chlorpromazine-like), the butyrophenones (haloperidol-like) and the 
diphenylbutylamines (pimozide-like). Particular attention has been direct-
ed towards neuroleptics which effectively control psychotic symptoms, 
reduce relapse and which enable patients to be reintegrated into society. 
Some neuroleptics are of benefit in neurotic or psychosomatic disorders; 
most of the neuroleptics, however, lack any beneficial effect on affective 
disorders. 
Because neuroleptic drugs are specific and potent dopamine-receptor 
blocking agents (van Rossum, 1966), their inhibitory effect on self-
strmulation appears consistent with a dopamine-hypothesis of self-
stimulation. It could be argued that the inhibition is not specific for self-
stimulation behaviour, and that the self-stimulation inhibition may be a 
simple consequence of impaired motor activity or may be due to a 
motivational deficit. The alternative hypothesis is that neuroleptics cause 
self-stimulation inhibition by interfering with sensorimotor integration. 
The latter is mediated partly via the dopaminergic nigrostriatal system. 
(1) This chapter is based on Wauquier (1976b). 
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2. THE INVOLVEMENT OF DOPAMINE IN BRAIN SELF-STIMUL-
ATION 
The evidence for an involvement of catecholaminergic (CA)-systems was 
extensively reviewed by German and Bowden (1974). They studied the 
degree of overlap between CA-systems (Ungerstedt, 1971a) and the 
distribution of anatomical sites supporting self-stimulation (e.g. Olds and 
Olds, 1963; Routtenberg and Malsbury, 1969). (1) 
The following systems are now considered as substrates for self-
stimulation: the dorsal noradrenergic system, originating in the locus 
coeruleus and running through the medial forebrain bundle (MFB) at the 
posterior hypothalamic level, through the basal forebrain and terminating 
in the amygdala, hippocampus and cortex; the nigrostriatal dopaminergic 
pathway and the mesolimbic dopaminergic pathway. 
There have been discussions as to whether the ventral noradrenergic 
system originating in medullar nuclei A l , A2 and A5 and joining the MFB 
with the other CA-systems, was implicated or not (Arbuthnott et al., 
1970; Clavier and Routtenberg. 1973,1974). 
Briefly, the involvement of dopaminergic systems in self-stimulation has 
been substantiated by anatomical studies, utilizing implanted electrodes, 
the brain lesion technique and pharmacological tests. Firstly, self-
stimulation can be elicited when electrodes are placed in the cell bodies 
of the nigrostriatal pathway (Anlezark et al., 1973a, b; Crow, 1971, 1972; 
Routtenberg and Malsbury, 1969). Self-stimulation can also be obtained 
from the substantia nigra in dogs (see further: 5.2). In such dogs self-
stimulation was associated with pronounced contralateral turning of the 
head and the trunk (which might indicate unilateral dopaminergic 
activation, Ungerstedt, 1971a). 
Dresse (1966,1967) described self-stimulation obtained from placements 
dorsal to the interpeduncular nucleus, where the cell bodies of the 
mesolimbic pathway are localized. Lesioning of these structures resulted 
in a diminution of noradrenergic (neocortex, gyrus dendatus, septum and 
preoptic area) and dopaminergic (olfactory tubercle and nucleus 
accumbenssepti) terminals. Belluzi et al. (1975) explained self-stimulation 
resulting from the substantia nigra placements as being due to activation 
of a noradrenergic system passing in the vicinity of the electrodes. 
However, these experiments do not exclude an involvement of 
dopaminergic structures. 
It has been shown that the cell bodies, the neuronal pathway, as well as 
the terminal sites of the DA nigrostriatal system, are able to support 
self-stimulation (German and Bowden, 1974; Routtenberg and Malsbury, 
1969). Prado-Alcalá et al. (1975) obtained self-stimulation from the 
substantia nigra to the entopeduncular nucleus, but not further. It could 
be argued that the lack of self-stimulation beyond the 
entopeduncular nucleus was due to stimulation of an insufficient number 
of fibres. However, in spite of these negative results there are other 
(1) Anatomical and biochemical mapping studies are extensively described in Wauquier 
and Rolls (1976). 
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reports of self-stimulation in the caudate nucleus (Phillips et al., 1976; 
Routtenberg, 1971b and unpublished observations in dogs), and species-
dependent effects could be involved (Justesen et al., 1963; Porter et al., 
1959). 
Secondly, lesion studies revealed the importance of the DA-systems as 
substrates for self-stimulation. Lesioning the substantia nigra or caudate 
nucleus produced drastic effects on behaviour in general (Mitcham and 
Thomas, 1972). Lesioning of the CA-pathways brought about by the 
intracerebral administration of 6-hydroxydopamine (6-OHDA) suppressed 
self-stimulation in addition to other behavioural responses (Bréese et al., 
1971; Stein and Wise, 1971). The local administration of 6-OHDA poses 
some methodological problems since, at the doses used, this agent lacks 
specificity and may effectively reduce concentrations of NA as well as of 
DA (E.g. Bréese and Taylor, 1970). 
Thirdly, the role of the DA-systems has been substantiated by the 
administration of drugs interfering with synthesis and release of DA. 
a methyl-paratyrosine (α-МРТ), which causes a functional depletion of 
CA, depressed self-stimulation (Black and Cooper, 1970; Cooper et al., 
1971; Liebman and Butcher, 1973) in the lateral hypothalamic area and in 
the ventral tegmental area. This was reinstated by L-dopa, which repletes 
cerebral DA (Stinus and Thierry, 1973) but also by NA (Ritter and Stein, 
1973). 
L-dopa itself increased self-stimulation when given together with a 
peripheral dopa-decarboxylase inhibitor. This is not antagonized by 
phenoxybenzamine but is by haloperidol (Kadzielawa, 1973). Liebman 
and Butcher (1973) found that L-dopa actually depressed self-stimulation 
behaviour, but that this was reinstated by doubling the current. 
These experiments implicate an involvement of both amines, DA and 
NA. 
Fla-63, an inhibitor of the synthesis of NA, caused a complete 
suppression of self-stimulation which was associated with a decrease in 
NA (Stinus et al., 1973). Wise and Stein (1969) found that this induced 
suppression could only be reversed by the application of I- or dl-NA and 
not by DA. Lippa et al. (1973), however, did not find that Fla-63 caused 
any significant effect on self-stimulation. 
These discrepancies could be a consequence of the doses used, the 
administration schedule, the time of measurement and so forth. More 
important is the question of whether one is dealing with specific or 
unspecific behavioural effects. Rolls et al. (1974a) showed that disulfiram 
caused a moderate reduction in self-stimulation which was associated 
with drowsiness and Roll (1970) described that replacement of the 
sedated rats on the lever resulted in an immediate revival of self-
stimulation. Similarly, Liebman and Butcher (1973) demonstrated that 
doubling the current resulted in active self-stimulation in a similar 
situation. 
It can be concluded that there is evidence that self-stimulation is also 
induced from DA-structures, particularly those of the nigrostriatal 
146 
system. The pharmacological studies are less conclusive, but do 
emphasize problems in interpretation of the functional rôle of the DA 
nigrostriatal system in self-stimulation. The neuroleptic-induced effects 
on self-stimulation may be an additional means of defining this functional 
rôle in view of the fact that these drugs are potent dopamine-receptor 
blockers (van Rossum, 1966, 1970). In addition, selective NA-blockers 
and NA-agonists may be of importance in the further elucidation of the 
rôle of NA in self-stimulation behaviour. This is of importance since, 
according to recent experiments, DA- and NA-systems may mutually 
interact (Stephens et al.,1976). 
3. THE INFLUENCE OF NEUROLEPTICS ON SELF-STIMULATION 
Shortly after the discovery of self-stimulation, Olds and co-workers 
tested the influence of chlorpromazine and reserpine (e.g. Olds et al., 
1957). These drugs were found to be powerful inhibitors of self-
stimulation behaviour. However, site-dependent effects were apparent 
and self-stimulation in the posterior hypothalamic area was more 
susceptible to the disruptive effects of these agents than the other sites 
tested. 
Dresse (1966,1967) described the effects of larger groups of phenothiazi-
nes and butyrophenones and related the effects obtained on self-
stimulation to a biochemical substrate. 
In recent years some butyrophenones (haloperidol, spiroperidol) and the 
diphenylbutylamine pimozide have been tested more extensively, but the 
number of neuroleptics tested still remains limited. In addition, no 
comprehensive data on the characteristics of the inhibition obtained with 
neuroleptics and consequently, the nature of the inhibition, has been 
formulated. The aim of this section is to describe the influence of a large 
group of neuroleptics on self-stimulation. 
3.1. Methods 
A detailed description of the experimental animals, their housing 
conditions, surgery, electrical stimulation and the general set-up of the 
experiment has already been given in chapter IV. The procedure, 
followed in this investigation, is identical to that described in chapter VI. 
In all, 20 neuroleptics belonging to different chemical groups (Fig. 1) 
were investigated with respect to their effects on self-stimulation 
behaviour. 19 neuroleptics were tested on groups of 6 rats and one 
neuroleptic (droperidol) on a group of 3 rats. Four doses of each 
compound were given, the lowest during the first week and progressively 
higher doses on subsequent weeks. The neuroleptics were administered 
either subcutaneously or orally with one exception: pimozide. This 
compound was administered orally to a group of 6 rats and sub-
cutaneously to another group of 6 rats. As was the case in the 
investigation described in chapter VI, saline was given on Tuesdays and 
drugs on Thursdays. The long-acting neuroleptics clopimozide, penfluri-
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dol and pimozide (orally), however, were given on Monday sessions. 
Saline sessions preceded drug-treatment and recovery to control level 
occurred within one or two weeks after each dose. 
The figures showing the drug-effects are presented in the same way as in 
Chapter VI: they represent the response rates obtained with all rats at 
each SPC and after each dose of a neuroleptic during the drug session 
(fourth day of the week, except for the long-acting neuroleptics 
clopimozide, penfluridol and pimozide - given orally - for which the first 
day was taken). They are expressed as percentages of the control 
response rates obtained during the control session (second day of the 
week, and fifth day for clopimozide, penfluridol and pimozide). Significant 
(p\< .05) differences are indicated by an asterisk (Wilcoxon matched-pairs 
signed-ranks test, one-tailed probability). 
Additional statistical tests are described in subsequent sections. 
32. Results 
The effects of the neuroleptics described have been reported very briefly 
by Wauquier (1976a) and some of the neuroleptics more extensively by 
Janssen et al. (1975), Wauquier and Niemegeers (1972, 1975, 1976b, c). 
Because the profiles of the neuroleptics tested are quite similar, it was 
not considered necessary to discuss each one separately. 
32.1. General description 
Fig. la-f shows the percentage of lever-pressing as compared with the 
control response rates, obtained with each of 4 doses of the 20 
neuroleptics and at each of the 6 SPC's. 
All neuroleptics caused pronounced response inhibition and only slightly 
enhanced the response rates. The total response inhibition (effects on 
the one hour session, i.e. sum of the 6 SPC's) ranges from 24 % 
(thioridazine) to 65 % (pimozide, orally given). The inhibition is 
dose-related, ranging from a dose which is almost ineffective, to a dose 
causing almost complete suppression of self-stimulation. It appears that 
the response inhibition is inversely related to the base-line responding. 
322. Dose-effect relationship 
Fig. la-f shows dose-effect relationship. The Wilcoxon matched-pairs 
signed ranks-test, one-tailed probability, was used as a test for the 
significance of differences between drug- and control response rates. 
Significant effects (p\( .05) are indicated by an asterisk. 
All neuroleptics tested inhibited self-stimulation in a dose-dependent 
way. The dose-dependent decrease of self-stimulation obtained after 
some of the neuroleptics described here, has been observed in different 
situations and with different electrode localizations (Dresse, 1967; 
Kadzielawa, 1973, 1974; Liebman and Butcher, 1973, 1974; Olds and 
Olds, 1964; Olds and Travis, 1959, 1960; Phillips et al., 1975; Rolls et al., 
1974b; Stark et al., 1969) (See Chapter III). The inhibition, however, is 
clearly base-line dependent. 
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Fig. 1a-f: Self-stimulation response rates in relation to control response 
rates, obtained with each of the 4 doses of 20 neuroleptics on each of the 
6 SPC's. Asterisks indicate significant difference (pi .05) as compared to 
control (for details see Methods). 
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32.3. Potency 
Although there are great differences between the neuroleptics with 
respect to chemical structure, biochemical and behavioural as well as 
clinical effects, they all decrease self-stimulation in a dose-dependent 
way. There are, however, considerable differences with respect to 
potency. In order to estimate quantitative differences between neuro-
leptics, ED50 values with confidence limits and potency ratios were 
calculated, as described in the following paragraphs. 
The median effective dose, often referred to as ED50, is a term used to 
characterize the potency of a treatment by reference to the amount 
(dose of a drug) which produces a response in 50 % of the cases. In 
practice: after defining a criterion (for our data: \( 79 %, which 
corresponds to the .05 probability level of distribution of the control 
values), one obtains data of the all-or-none type. Therefore it is possible 
to solve a dose-percent curve, by which doses are converted to 
logarithms and percent effect to probits (Logarithmic-probability paper 
enables one to plot the data in original units, but leaves one with the 
problem of converting log-probit equations to their arithmic equivalent). 
After the data have been plotted, a straight line is fitted through these 
points (for instance percentage lever-pressing rate as compared with 
control versus doses of the neuroleptic). A goodness-of-fit test is applied 
by performing a chi-square test (expected against observed values). If 
the test is acceptable, the ED50 value can be read off directly on the 
intersection of the plotted line and the 50 % line on the ordinate. 
The confidence limits represent the values in between which the ED50 is 
supposed to lie. The width of these limits is influenced by the 
heterogeneity of the data besides the slope of the curves. If this 
heterogeneity proves to be significant, a correction for significant 
heterogeneous data is performed. 
Additional tests can be carried out if it proves necessary to compare two 
or more drugs, i.e. a test for parallelism (slopes) and the estimate of the 
relative potency. If no significant deviation of parallelism can be found, 
tests to detect significant differences in potency can be carried out and 
potency ratios with confidence limits may be calculated. 
For a detailed description of the procedures just described, see Litchfield 
and Wilcoxon (1949). The results of the tests are given in Table 1. 
This Table gives the ED50 values of the neuroleptics, slopes, slope 
function, potencies and potency ratios of the neuroleptics as compared 
with those of the most potent compound, fluspiperone. The ED50 of 
pimozide (orally given) could not be calculated, since 3 out of 6 rats were 
already found positive at the lowest dose tested. Comparison with 
fluspiperone was made since no significant differences of parallelism was 
found with the most potent neuroleptic. As seen, thioridazine, the 
weakest neuroleptic is 659 times less potent than fluspiperone. The 
inhibition obtained with fluspiperone, spiperone, benperidol, bromperi-
dol, haloperidol and droperidol does not differ significantly from one 
substance to another. 
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Table 1: EOcg-values with confidence limits, slopes, slope ratios and 
potency ratios obtained with 20 neuroleptics tested on brain self-
stimulation. Fordetailssee text. 
Compound 
Fluipi perone 
Spiperone 
Benperidol 
Brompendol 
Haloperidol 
Droperidol 
Moperone 
Oxiperomlde 
Clothiftpine 
Fluftmlone 
PimoBide or. 
Pimotlde i . e . 
Buisclamol 
Clopi moeide 
Chlor promAcine 
Metoclopramide 
A zape rone 
Penfluridol 
Pipamperone 
Clocapine 
Thioridazine 
* Significantly 
E D 5 0 (limit·) 
Ο.ΟΙβΐ (O.0111-O.02»9) 
0.0185 (0.0106-0.0323) 
о.огоо (O.OUe-0.0270) 
0.0200 (0.0124-0.0322) 
0.0218 (0.0125-0.0380) 
0.0285 (0.0193-0.0422) 
0.0330 (0.023B-0.0457) 
0.0569 (0.0374-0.0867) 
0.0970 (0.066-0.143) 
0.133 (0.073-0.243) 
10.160 ( ) 
0.160 (0.101-0.253) 
0.270 (0.144-0.505) 
0.340 (0.207-0.560) 
0.513 (0.340-0.774) 
0.520 (0.180-1.50) 
0.534 (0.193-1.48) 
1.36 (0.806-2.30) 
6.35 (2.85-14.1) 
7.84 (2.32-26.5) 
12.0 (4.17-34.5) 
d i f f e r e n t f r o m f luspip 
Slope 
1.859 
2.008 
1.305 
2.075 
1.635 
1.414 
1.334 
1.692 
1.405 
2.523 
— 
2.013 
2.188 
1.865 
1.673 
5.057 
2.460 
1.924 
2.719 
4.590 
2.544 
erone ( 
S l o p e r a t i o ( l i m i t · ) 
1. 
1 . 0 8 ( 0 . 5 3 - 2 . 2 0 ) 
1 . 4 2 ( 0 . 9 0 - 2 . 2 5 ) 
1 . 1 2 ( 0 . 5 7 - 2 . 1 7 ) 
1 . 1 4 ( 0 . 6 3 - 2 . 0 5 ) 
1 .31 ( 0 . 8 2 - 2 . 1 1 ) 
1 . 3 9 ( 0 . 8 8 - 2 . 2 1 ) 
1 . 1 0 ( 0 . 6 4 - 1 . 9 0 ) 
1 . 3 2 ( 0 . 8 2 - 2 . 1 4 ) 
1 .Э6 ( 0 . 5 4 - 3 . 4 2 ) 
1.08 (0.57-2.05) 
1.18 (0.51-2.71) 
1.00 (0.53-1.88) 
1.11 (0.65-1.90) 
2.72 (0.73-10.1) 
1.32 (0.60-2.93) 
1.03 (0.33-2.00) 
1.46 (0.71-3.02) 
2.47 (0.61-10.0) 
1.37 (0.59-3.15) 
э ( . 0 5 ) . 
Potency ratio (limit·) 
1. 
1.02 (0.48-2.14) 
1.10 (0.62-1.96) 
1.10 (0.55-2.19) 
1.20 (0.57-2.52) 
1.57 (0.83-2.95) 
1.81 ( 1 . 0 0 - 3 . 2 8 ) * 
3.13 ( 1 . 6 3 - 5 . 9 9 ) * 
5.33 (2.84-9.99) » 
7.31 (3.34-16.0) * 
8.79 (4.48-17.3) · 
14.8 ( 6 . 6 7 - 3 3 . 0 ) · 
18.7 (9.25-37.7)« 
28.2 (14.8-53.7)» 
2 8 . 6 ( 8 . 8 8 - 9 2 . 0 ) » 
2 9 . 3 ( 9 . 4 5 - 9 1 . 1 ) » 
74.7 (36.3-154 ) · 
349. (136 -894) » 
431. (116-1606)* 
659. ( 2 0 5 - 2 1 1 8 ) · 
' 
32.4. Control base-line 
It appears from Fig. la-f, that there is an inverse relationship between 
base-line responding (response rates increase from SPC 1 to SPC 6) and 
neuroleptic-induced inhibition. That is: response inhibition is more 
pronounced at the low SPC's than at the high SPC's. This relationship 
was statistically substantiated by the Friedman two-way analysis of 
variance (see detailed description in Siegel, 1956, pp. 166-172). (Fig. 2). 
Basically, the test applied used the rank-order of the percentages 
inhibition obtained at the 6 SPC's with the 4 doses of the 20 neuroleptics. 
The analysis was made as follows: the percentage inhibition obtained 
with the 1st dose of a neuroleptic, at SPC 1, SPC 2 ... SPC 6, is given a 
rank-order (column); this is repeated for each of the 20 neuroleptics 
tested (rows). 
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Fig. 2: Friedman two-way analysis of variance carried out on the rank-
orders of the percentages of inhibition obtained with 4 doses of20 neuro-
lepticsat thebSPC's (see details in text). 
Σ Ranks 
120-, 
100 
80 
60 
40 
20 
0J 
6 SPC 
Friedman two-way analysis of variance 
l 5 ' Dose · 
2 n d Dose Δ 
3 , h D o s e Д 
4 t h Dose о 
Overall
 0 
effects u 
z ranks 
SPC 1 
44 
Э6 
43 
5Θ 
32 
2 
60 
61 
49 
74 5 
54 
3 
83 S 
68 
72 
57 5 
73 
66 
67 
62 
64 5 
65 
5 
91 
108 
111 
83 5 
107 
6 
96 S 
101 
104 
103 
110 
Χ
2 
27 81 
48 73 
54 44 
21 07 
62 99 
Ρ 
< 0 0 0 1 
< 0 001 
< 0 001 
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for example: 
3rd dose 
fluspiperone 
(% inhibition); 
( rank-order): 
spiperone 
(% inhibition): 
( rank-order): 
... 
thioridazine 
(% inhibition): 
( rank-order): 
SPC1 
-84.7 
1 
-81.6 
1 
-50.5 
1 
SPC 2 
-33.2 
2 
-51.9 
2 
-18.8 
4 
SPC3 
- 8.5 
6 
- 5.9 
5 
-27.9 
3 
SPC 4 
-28.3 
3 
-26.5 
3 
-48.2 
2 
SPC 5 
-19.5 
4 
- 8.1 
4 
- 9.6 
6 
SPC 6 
- 9.4 
5 
- 1.1 
6 
-15.9 
5 
Then, the sum of ranks is made and finally, Χι-2 is calculated according to 
the formula described by Siegel (1956, p. 168). The same is repeated for 
the 2nd, 3rd and 4th dose and for the sum of all doses. 
If there is no preference for one of the conditions (SPC-effect), then one 
finds a nearly equal sum of ranks; if not, one can expect a systematic 
effect. It was found that with each of the doses tested, there is a 
systematic relationship between SPC and percentage inhibition, i.e. high 
inhibition (low sum of ranks) for low SPC's and vice versa (ρ \ .002). 
32.5. Discussion 
All neuroleptics tested induced a dose-related inhibition of self-
stimulation. The dose-response curves are quite similar, but the 
neuroleptics differ largely with respect to potency. However, as 
described in section 6, neuroleptics differ largely with respect to their 
effects on DA and NA. 
Although self-stimulation is nearly completely suppressed by the highest 
dose of the neuroleptics tested, rats tend to self-stimulate at normal or 
higher rates than control animals during the first minutes of the session. 
Fig. 3 illustrates such an observation (similar observations were 
mentioned by Liebman and Butcher, 1974; Rolls et al., 1974b). This was 
recently confirmed by Fouriezos and Wise (1976) and discussed as 
follows. The temporal pattern of responding suggests that cessation of 
responding occurs in a similar way to extinction. If neuroleptics block the 
motor system, one would not expect the rats to start self-stimulating. 
The latter observation not only suggests that the ability to press a lever is 
intact, but also that the anticipation of brain-stimulation reward may be 
unaffected. The cues associated with self-stimulation (conditioned 
motivation, i.e. smell, sight of the lever, etc.) are still present and induce 
the rats to start lever-pressing. The lack of sustained responding is not 
related to drug-onset, because lever-pressing occurs whenever the rats 
are put in the self-stimulation cage after drug-injection (Fouriezos and 
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Fig. 3: Self-stimulation response rates of 6 rats obtained after the s.c. 
injection of saline fo-o) or haloperidol (0.08 mg/kg) (β-Φ) and during 
extinction ( — @) (no brain-stimulation available). 
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Wise, 1976). This observation rather suggests that the reinforcing value 
of brain-stimulation is lowered or eliminated after high doses, just as it is 
in extinction. 
A mechanism which could account for a lowering of the reinforcing 
value of the brain-stimulation is a drug-induced increase of the threshold 
for brain-stimulation. The latter was originally shown with chlor-
promazine by Stein (1962b). This is exactly the opposite of the effects 
obtained with CNS-stimulants (see previous chapter, section 3.2). 
Experiments along these lines, however, have not been carried out using 
other neuroleptics. Response inhibition was more pronounced at the low 
S PC's than at the high ones. Similar observations, using a different 
method, were described for pimozide by Liebman and Butcher (1973). 
These authors showed that pimozide (0.35 and 0.5 mg/kg, given ¡.p., 3 
hrs before the test) reduced self-stimulation for current intensities 
yielding 50 to 75 % of maximal rate. When the current was doubled, 
lever-pressing increased to base-line level. These findings are difficult to 
explain in terms of a performance effect, because one would expect an 
inhibition of the response rates, regardless of the particular SPC used. 
The differential inhibition suggests that the neuroleptic inhibitory 
property depends on the motivational strength of the stimulation. 
Within a given structure, different response rates are obtained by varying 
the SPC's and possibly reflect a different rewarding value. 
One could state that behaviour operating at a low motivational level is 
more susceptible to the neuroleptic-induced inhibition than behaviour 
maintained at a high motivational level. A low intensity or a low 
frequency stimulation is less reinforcing. Rats do not work continuously 
to obtain the reward, and the response rates are often erratic. 
Consequently, the expectancy is low and the habit strength less, than 
when rats work for higher intensities or frequencies of stimulation. In the 
latter case, the expectancy of reward is stronger. 
Neuroleptics do not interfere with self-stimulation by altering the general 
activity level, or by disturbing the motor function, but maybe by lowering 
the reinforcing value. Whether neuroleptics also affect reward is still an 
open question. 
Valenstein and Meyers (1974) developed a «rate-free» test of self-
stimulation, which does not require lever-pressing. In short, the 
apparatus used is a shuttle box with a tilt platform. Moving the animal to 
one part of the cage closes a microswitch which activates programming 
equipment, so that the rat automatically obtains brain-stimulation. The 
time spent in the «active part» of the cage gives an indication of «self-
stimulation». The programming is such that the rat has to move only a 
few times during an experimental session. 
In the rate-free situation used by Liebman and Butcher (1974) they also 
measured gross locomotor activity. An increase in motor activity does 
not necessarily increase the time of stimulation. The authors showed, 
conversely, that a decrease in activity does not necessarily result in a 
reduction of brain-stimulation. Apomorphine, for instance, increased 
self-stimulation, despite a decreased locomotor activity. Liebman and 
Butcher (1974) showed that pimozide (0.35 mg/kg and 0.5 mg/kg) 
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reduced self-stimulation as measured in this rate-free situation, with rats 
bearing electrodes in the substantia nigra and lateral hypothalamus. In 
the rate-free situation, rats have only to walk to a part of the cage and, 
therefore, the obtained inhibition cannot be due to motor deficits. 
Because this rate-free test probably constitutes a more valid measure of 
the rewarding value of the stimulation, the authors concluded that 
pimozide reduced self-stimulation by interfering with the reward. 
Although the experiments reported strongly support the consideration 
already stated above, that performance deficits are not a sufficient 
explanation of neuroleptic-induced inhibition, it is hard to accept that 
reward deficits account for the effects. Neuroleptics do not only inhibit 
positively motivated behaviour but negatively motivated behaviour as 
well. Doses almost identical to those inhibiting self-stimulation also 
inhibit Sidman shock-avoidance (see Table 2). 
An important consideration, however, is that the sensitivity to the 
inhibitory effects of the neuroleptics might depend on the operant itself. 
This will be dealt with in an experiment reported in the next section. 
4. LICK-EXPERIMENT 
The inhibition obtained with neuroleptics is clearly base-line-dependent 
(see previous section). Some experiments (see for instance Huston and 
Ornstein, 1976) showed that brain-stimulation persisted after lesioning 
the nigral system, but rats were unable to perform complex responses, 
requiring orientation in space, such as lever-pressing. By analogy, the 
neuroleptic-induced inhibition might depend on the operant used. We 
therefore compared, in these experiments, the effectiveness of 4 selected 
neuroleptics on brain-stimulation obtained after either pressing a lever or 
licking a steel ball. 
4.1. Methods 
Rats were trained to receive brain-stimulation either by licking a stainless 
steel ball or by pressing a lever, during the same session. Since the 
licking rate is very rapid, a fixed ratio reinforcement schedule 3:1 (FR 3) 
was applied during the licking period. Lever-pressing was carried out on 
a continuous reinforcement schedule (CRF). Half of the rats were 
required to lick for brain-stimulation for 15 min, followed by 15 min of 
lever-pressing (Group 1). Other rats were given the opposite sequence 
(Group 2). For each rat, the sequence remained the same during the 
whole experiment. The stimulation parameters of brain-stimulation were 
the same for licking as well as for lever-pressing (SPC 6). 
Rats were run in daily half hour sessions, 5 days a week. Stable 
performance (variation within 10 % of the mean over 3 days) for both 
licking and lever-pressing, was reached within 3 weeks. 
Groups of 6 rats were treated with 4 doses of a neuroleptic: pimozide, 
haloperidol, pipamperone or azaperone (Table 2, Fig. 4). Pimozide was 
injected s.c, 2 hrs before the session, while the other neuroleptics were 
given s.c, 1 hr before the session. There was an interval of at least 2 
sessions between each drug-treatment. 
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Fig. 4: Percentage response rates as compared with control for lever-
pressing (o — o) and licking (Φ —Φ) for brain-stimulation after4 doses ofthe 
neuroleptics indicated. Group 1 started the self-stimulation session with 
licking (15min), group2 started the session with lever-pressing (15 min). 
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Table 2: Total number of licks and lever-pressings for brain stimulation 
obtained after saline or drug-injection, with 3 rats which licked for 15 min 
followed by 15 min of lever-pressing (group 1), and with 3 rats which 
pressed a lever for 15 min, and than licked for 15min (group2). 
Drug 
О 
2 
о 
a 
л 
ы 
в. 
о J 
ъ 
vi 
ы 
Рч 
S 
E 
H 
S 
« 
< 
N 
< 
Dose 
(mg/kg) 
• aline 
0.04 
saline 
0.08 
ealinc 
0.16 
saline 
0.31 
sal ine 
0.01 
saline 
0.02 
saline 
0.04 
saline 
0.08 
saline 
0.63 
ealine 
1.25 
saline 
2 .50 
saline 
5.00 
saline 
0.08 
saline 
0.16 
saline 
0.31 
saline 
0.63 
Group 1 
Licks 
4035 
3966 
4370 
3608 
5023 
3188 
5170 
1 3 « 
3139 
3033 
31)1 
2748 
3207 
2242 
2896 
1043 
4487 
3520 
4389 
3822 
4866 
3391 
4410 
1901 
5142 
4141 
4687 
4260 
4811 
2818 
5071 
1792 
Lcvcr-
press . 
2878 
2818 
2845 
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The Wilcoxon matched-pairs signed-ranks test (one-tailed probability, 
ρ ( .05) was used as a test for significance of differences between drug-
and control-session. 
4.2. Results 
Table 2 depicts the total number of licks and lever-pressings during 
saline- and drug-session. Fig. 4 depicts the percentage response rates 
obtained after drug-treatment as compared with the median of the pre-
drug control response rates for each individual rat. 
Saline-treated rats: the licking response rates always exceeded the 
lever-pressing response rates in total, and for each individual rat, except 
for rat 3 during the haloperidol experiment. The licking-rate was higher in 
group 2 (which started the session with lever-pressing) than in group 1. 
The lever-pressing rate, on the other hand, was higher in group 1 than in 
group 2 (Table 2). The total number of licks was two times and two to 
three times the number of lever-pressings in group 1 and group 2 
respectively. 
Drug-treated rats: in general, a dose-related inhibition of licking for brain-
stimulation was found, while the inhibition of lever-pressing was only 
marked at the highest dose of the neuroleptics tested (Table 2), except 
for rat 3 in the haloperidol-experiment. The rats of group 2, which scored 
the highest number of licks, were more sensitive to the neuroleptic-
induced inhibition than the rats of group 1 (Table 2). 
The estimated EDtft-values of inhibition were: 
for pimozide 
for haloperidol 
for pipamperone 
for azaperone 
licking 
lever-pressing 
licking 
lever-pressing 
licking 
lever-pressing 
licking 
lever-pressing 
Group 1 
0.19 
> 0.31 
0.053 
> 0.08 
3.86 
> 5 
0.42 
> 0.63 
Group 2 
0.13 
) 0.31 
0.039 
>0.08 
1.92 
>5 
0.27 
)0.63 
In conclusion: the lick-response is more inhibited than lever-pressing; the 
group (2) which scored the highest number of licks was more sensitive to 
drug-effects; within the respective dose-range tested, all neuroleptics 
elicit similar effects. 
4.3. Discussion 
In the context of the rat's development, licking has been associated with 
different functions, such as licking at a tube to obtain water, licking as a 
cleaning habit and so on. Lever-pressing on the other hand, is a learned 
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response and is not part of the rat's natural repertoire but appears only in 
one situation, namely as a means of obtaining brain-stimulation. One 
could argue that the consummatory response must be more susceptible 
to the neuroleptic effects than a response lacking. However, Rolls et al. 
(1974b) showed that spiroperidol attenuated water-licking from a tube 
less than lever-pressing for self-stimulation. 
It was stated in 3.2.4. that high response rates were less susceptible to 
the inhibitory effects of neuroleptics. This was confirmed for lever-
pressing in this experiment. However, the licking rate was higher than 
the lever-pressing rate and yet was more sensitive to the inhibition. 
Further, the rats scoring the highest number of lick-responses (group 2) 
were inhibited at lower doses than the group (1) which scored fewer 
licks. Moreover, the 4 neuroleptics elicited rather similar effects, although 
they caused different behavioural effects at high dose levels: Haloperidol 
and pimozide causing catalepsy and pipamperone and azaperone 
causing sedation (see also section 6). 
The differential inhibition of licking and lever-pressing could be partially 
due to the schedule applied during the licking period (FR-3) and 
lever-pressing period (CRF). Licking was more sensitive than lever-
pressing in both groups, although group 1 licked far less than group 2; 
the numbers of stimulations received by group 2 for lever-pressing and 
for licking were almost equal. The differential sensitivity cannot, 
therefore, be sufficiently explained by the schedule differences. 
Apparently, another factor is responsible for the differential sensitivity to 
the inhibitory effect. Neuroleptics might for instance differentially affect 
the motor system involved in the reflexive lick-response and the motor 
system involved in lever-pressing. This remains speculative since there 
are no experiments dealing with differential influence on different motor 
systems. 
In conclusion: it appears that the neuroleptic-induced inhibition of 
self-stimulation depends on the operant used. However, it remains 
difficult to present a conclusive interpretation of the differential 
sensitivity. On the basis of the present experiments, it cannot be stated 
affirmatively whether the differential inhibition is a performance - or 
reinforcement - effect. 
5. IMPLANTATION SITE AND SPECIES DIFFERENCES 
5.1. Implantation site 
One of the structures which has been extensively explored in self 
stimulation is the lateral hypothalamic area. Our studies also deal with 
self-stimulation in the lateral hypothalamus. Obviously, one could ask 
whether the inhibitory properties of neuroleptics are related to, or rather 
independent of, the implantation site. 
Pimozide is a specific dopaminergic blocking agent (Andén et al., 1970). 
One would expect pimozide to reduce only partially or to fail to inhibit 
self-stimulation elicited in purely noradrenergic cell bodies such as the 
locus coeruleus, origin of the dorsal noradrenergic bundle. The under-
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lying assumption is that pimozide selectively disrupts a DA-mediated 
system. 
The experiments of Ritter and Stein (1973) apparently confirmed this 
hypothesis: 1 mg/kg of pimozide injected s.c. as an aqueous suspension, 
inhibited self-stimulation in the locus coeruleus (89.7 % of control) less 
than in the medial forebrain bundle (69.8 % of control). 
Liebman and Butcher (1974) also showed that 0.5 mg/kg of pimozide 
inhibited self-stimulation in the substantia nigra slightly more effectively 
than in the lateral hypothalamus. 
Site-dependent effects have been described for other neuroleptics. 
Rolls et al. (1974a) described a dose-related inhibition of self-stimulation 
by spiroperidol, in the nucleus accumbens, the septal region, the 
hippocampus, the anterior hypothalamus, the lateral hypothalamus and 
the ventral tegmental area. The inhibition was relative to base-line, but 
some regional differences were apparent. For example, the response 
rates obtained after 0.05 mg/kg of spiroperidol as compared to control, 
were approximately 40 %, 20 %, 0 %, 60 %, 50 % and 70 % for the 
respective structures just mentioned. 
Stark et al. (1969) described that chlorpromazine inhibited self-
stimulation in the septum, anterior and posterior hypothalamus and in 
the ventral tegmentum. The posterior hypothalamic self-stimulation was 
somewhat more affected by the lowest dose of chlorpromazine. 
Olds and Travis (1959) and Olds et al. (1957) described anatomical 
differences with respect to the inhibitory effects of chlorpromazine. They 
noted that chlorpromazine strongly inhibited self-stimulation in the 
ventral posterior hypothalamus, was less effective in the septal region 
and had a negligible effect in the anterior hypothalamic area. 
In contrast, Phillips et al. (1975) obtained a similar dose-related response 
inhibition with pimozide and Haloperidol in rats self-stimulating in the 
dorsal noradrenergic bundle and in the dopaminergic nucleus accum-
bens. Similarly, Liebman and Butcher (1973) found no difference 
between the effects of pimozide injected in rats self-stimulating in the 
lateral hypothalamus or in the mesencephalic central gray area. 
Moreover, the latter structure does not contain dopaminergic neurons 
(Ungerstedt, 1971a). 
Definitive conclusions cannot be derived from the reported experiments. 
Apparently, methodological problems are involved. Without being ex-
haustive, it is suggested that the following factors could be responsible 
for these discrepancies: the differential site-dependent effects found by 
some authors, might reflect the central distribution of the drug over a 
period of time; state-dependent effects might play a rôle and, more 
generally, the doses used, the injection route, etc. In the next section, 
species-related and site-dependent-related self-stimulation are described. 
52. Species 
52.1. Introduction 
For obvious reasons, rats were the subjects of choice for the pharma-
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cological self-stimulation experiments. Drug-results obtained in one 
species may not be generalized to other species without restrictions. A 
good example of species-related effects is the acute effects of narcotic 
analgesics. Morphine, or related drugs cause catatonia in rats (rigidity 
and loss of righting reflex), excitation in mice and sham-rage in cats. 
There are only two reports of drug-effects on self-stimulation in other 
species. Stark (1964) tested cholinergics, anticholinergics, serotonin-like 
and serotonin-antagonistic drugs in dogs. Horovitz et al. (1962) studied 
the effects of chlorpromazine in cats. They described that chlor-
promazine (2.5, 3.75 and 5.0 mg/kg) decreased self-stimulation in the 
lateral hypothalamus and equally in the caudate nucleus. In 2 out of 7 
cats, 0.5 and 1.0 mg/kg of chlorpromazine did not affect responding. 
The effects of different doses of pimozide, haloperidol and pipamperone 
on self-stimulation in dogs have been investigated (briefly reported in 
Wauquier, 1975). Dogs are extremely suitable for self-stimulation 
experiments because of their extensive behavioural repertoire. The aims 
of our studies were: to investigate whether neuroleptics inhibited 
self-stimulation in the same way as in rats, and whether neuroleptic-
induced inhibition depended on the brain-structure. 
522. Methods 
Seven beagle dogs were implanted with bipolar stainless steel electrodes 
in the anterior part of the basal forebrain, i.e. the nucleus accumbens and 
the lateral preoptic region; in the basolateral amygdala, the lateral 
hypothalamus and the substantia nigra. At least 3 electrodes out of 6 
implanted in each dog, sustained self-stimulation. Dogs were trained to 
lever-press for brain-stimulation during χ times 10-min periods (x being 
the number of positive electrodes). After training for at least 6 sessions, 
the dogs were treated with pipamperone (0.16, 0.31, 0.63, 1.25 and 
2.50 mg/kg) given s.c, 1 hr before the session; pimozide (0.04, 0.08, 0.16, 
0.31 and 0.63 mg/kg), given s.c. 4 hrs before the session, and haloperidol 
(0.04, 0.08, 0.16, 0.31 and 0.63 mg/kg) given s.c, 2 hrs before the 
session. The time-intervals were selected on the basis of pilot 
experiments in which different doses of these neuroleptics had been 
given to labradors, and self-stimulation measured for 10-min periods, 
1 hr, 2 hrs, 4 hrs and 6 hrs after injection. 
The histology of electrode placements was determined as follows: brains 
were embedded in celloidin and cut on a microtome at 100 microns. The 
slices containing the electrode tip were selected and stained by Weil's 
method. Photographs were made and brain structures outlined on 
transparent paper. Examples of electrode placements sustaining self-
stimulation are depicted in Fig. 5. 
52.3. Results 
The results of the pilot experiments are depicted in Fig. 6. As can be 
seen, the highest inhibition is obtained 4 to 6 hrs after pimozide-injection, 
2 to 4 hrs after the haloperidol-injection and 1 to 2 hrs after the 
pipamperone injection. 
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Fig. 5: Electrode placements of 2 dogs. D-Sh and LIM refer to the 
anterior position according the atlas of Dua-Sharma et al. (1970) and 
Lim et al. (7960) respective/y. Electrode El, E2 and E3: right side of the 
brain; E4, E5 and E6: left side of the brain. 
Dog left: 
position El and E4 in nucleus accumbens 
E2 and E5 in lateralpeoptic region 
E3 and E6 virtually outside amygdala 
(Self-stimulation in El, E2, E4andE5) 
Dog right: 
position El andE2 ventral to the caudate nucleus 
and between internal capsula and nucleus accumbens 
E4 and E5 in nucleus accumbens 
E3 in basolateral amygdala 
E6 in substan tia nigra 
(Self-stimulation in El, E2, E3, E4andE6) 
Abbreviations: 
NC - caudate nucleus, CC - corpus callosum, Spt - septum, CI - internal 
capsule. Ace - nucleus accumbens. Put - putamen, hx - fornix, CA -
anterior commissure. Pal - globus pallidus, APr - preoptic area, m -
media/, I - lateral, ChO - optic chiasm, TMT - tractus mammillo-
thalamicus, Pyr - lobus pyriformis, Hipp - hippocampus, CM - corpora 
mammillana, amygdala: NL - lateral nucleus, NB - basal nucleus 
(nomenclature after Lim), RH - rudimentum hippocampi, NO - optic 
nerve, Hab - habenu/a, CP - conico-pontine and CB - cortico-bulbar 
tracts, SN - substantia nigra, FMT - fasciculus mammillo-tegmentalis, 
SGC - substantia grísea centralis, Aq - aqueductus cerebri, £7 7 - tip 
of the electrode. 
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Drug-effects were obtained on 31 electrodes of 7 dogs. Fig. 7 depicts the 
response rates in relation to control rates after neuroleptic treatment. 
The number of electrodes tested is indicated. 
The three neuroleptics inhibited self-stimulation obtained in various brain-
structures of the dog. As compared with the inhibition of self-stimulation 
in rats, there are three important differences: the potency ratios between 
the neuroleptics, site-dependent effects and the fact that pimozide- or 
haloperidol-induced inhibition is associated with apparent behavioural 
changes. 
Firstly, pipamperone inhibits self-stimulation in dogs at doses 4 to 16 
times lower than those required in rats; the opposite holds for 
haloperidol, while pimozide is rather similarly active in rats. Further, 
smooth linear dose-related inhibition was not found at all electrode-sites 
tested. Atypical response curves as seen with pimozide in the nucleus 
accumbens, the lateral preoptic and substantia nigra, and with 
haloperidol in the lateral hypothalamus are particularly due to the effects 
of these neuroleptics on individual dogs. 
Secondly, different sensitivities to neuroleptic-induced inhibition, related 
to the brain-structure were apparent. With 0.31 mg/kg of pimozide, the 
numbers of lever-pressings as compared with that of the controls were 
47.8 %, 41.2 %, 11.1 % and 51.3 %, for the nucleus accumbens, the 
lateral preoptic, the substantia nigra and the lateral hyothalamus 
respectively. With 0.63 mg/kg of haloperidol, lever-pressing was 58.8 %, 
41.7 %, 21.2 % and 80.3 % as compared with control values for the 
nucleus accumbens, the lateral preoptic, the substantia nigra and lateral 
hypothalamus respectively. With 2.5 mg/kg of pipamperone, lever-
pressing was 43.3 %, 56.4 % and 8.75 % as compared with control 
values, for the nucleus accumbens, the lateral preoptic and basolateral 
amygdala respectively. 
Thirdly, behavioural changes accompanied the self-stimulation inhibition 
induced by pimozide and haloperidol. For instance, whilst neuroleptic-
treated dogs exhibited some opposition to being walked to the experi-
mental room, they walked back to their home cage without resistance. 
Further, the response pattern became irregular. Instead of an almost 
equal number of lever-pressings per minute, prolonged periods of non-
pressing occurred, while at other moments the dogs pressed the lever at 
an extremely fast rate. This occurred in 2 dogs in particular and resulted 
in a total amount of lever-pressings nearly equal to control rates. The 
latter is the reason for non-linear dose-related inhibition. During the 
periods of non-pressing, dogs often stereotypically scratched the floor 
with both forepaws. 
52.4. Conclusion 
In conclusion: self-stimulation in dogs is apparently sensitive to the 
suppressive effects of preferentially noradrenergic blocking agents 
(see 6). At the doses used, pipamperone only interferes with NA 
receptors (at least in rats, see Andén et al., 1970). The question of 
whether noradrenergic-mediated neurotransmission plays a primary rôle 
in self-stimulation in dogs merits further investigation. However, 
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Fig. 6: Self-stimulation response rates of 3dogs, as compared with control 
response rates, obtained in 10-min periods at different time-intervals (1,2, 
4and6hrs) after the s.c. injection of 5doses ofpimozide, haloperidoland 
pipamperone. Electrode positioned in the lateral preoptic region. 
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Fig. 7: Self-stimulation response rates in relation to control response rates 
(CRR = 700 %) after the injection of 5 doses of3 neuroleptics, obtained 
with 7 dogs, self-stimulating in different brain structures (details see text). 
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pipamperone also inhibits self-stimulation of the DA-nucleus accumbens, 
which might support the concepts of Franklin et al. (1976) and Stephens 
et al. (1976), that DA self-stimulation also requires transsynaptic 
activation of NA-structures. The mutual dependence of both amines 
would explain many of the controversies about a specific rôle for either 
one of these amines. As described in some reports on neuroleptic-
induced inhibition of self-stimulation in rats, the experiments with the 
dog also indicate that some brain sites are more sensitive than others. 
The pharmacokinetic distribution of drug may also explain the different 
sensitivities, because the order in which the electrodes were tested was 
different in the dogs. The results presented here again provide evidence 
that the neuroleptic-induced suppression is not in the first place a 
«response-effect». 
6. SELF-STIMULATION AND PSYCHOTROPIC ASSAYS (1) 
The previous section described the neuroleptic-induced inhibition on a 
quantitative basis. In spite of characteristics shared by all neuroleptics, 
these drugs are not a homogeneous group. The aim here is to describe 
the differentiation between the neuroleptics as based on different 
pharmacological tests. Further, appropriate methods make it possible to 
position the self-stimulation test with respect to other pharmacological 
experiments. 
6.1. Classification of neuroleptics 
Classifications of neuroleptics can be made on different bases such as 
chemical (e.g. Janssen, 1970, 1973), biochemical (e.g. Andén et al., 
1970), pharmacological (e.g. Janssen et al., 1965a) and clinical (e.g. 
Bobon et al. 1972). Herein we describe classifications of neuroleptics as 
based on pharmacological and clinical activity. 
6.1.1. Classification based on potency ratios 
Qualitative observations and comparative pharmacology of a large group 
of neuroleptics have been described extensively over the past years 
(Janssen, 1970, 1972; Janssen and Van Bever, 1975; Janssen et al., 
1965a, b, 1966,1967; Niemegeers, 1974). These allowed the construction 
of neuroleptic activity spectra as based on potency and ratios between 
potencies. 
Four main pharmacological tests (2) differentiate the neuroleptics: the 
induction of catalepsy (CA), palpebral ptosis (PP), the antagonism of 
amphetamine-induced stereotype behaviour (AM) and the antagonism 
of a lethal dose of norepinephrine (NE). The procedures used and criteria 
(1) This section has been written in collaboration with P.J. Lewi. 
(2) The serotonergic blocking effects as measured in the tryptamine-test will not be 
discussed here, but it should be mentioned that these tests add another dimension 
to the differentiation between neuroleptics. 
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applied to determine neuroleptic potency in these tests were described 
earlier (Niemegeers, 1974). The CA- and AM-test are indicative for 
predominant dopamine-blocking activity and the NE- and PP-test are 
indicative for a more pronounced noradrenergic blocking activity. 
High doses of incisive neuroleptics cause catalepsy. Muscle tonus in the 
cataleptic rats is normal. The same neuroleptics antagonize stereotyped 
behaviour induced by amphetamine. These neuroleptics have anti­
psychotic activity and often cause extrapyramidal side-effects in the 
clinic. 
High doses of sedative neuroleptics cause sedation and palpebral ptosis. 
These neuroleptics antagonize a lethal dose of norepinephrine. They 
have less, or are devoid of, antipsychotic activity. 
The EDso-values of the neuroleptics tested in self-stimulation, and in the 
CA-, PP-, AM- and NE-test are given in Table 3. The relative adrenolytic 
versus antipsychotic activity and the relative sedative versus neurologic 
Table 3: EDfjQ-values (mg/kg) after administration of various neuroleptics 
to brain self-stimulating (BS) rats, and after the following tests: ampheta­
mine-antagonism (AM), norepinephrine-antagonism (NE), catalepsy 
(CA), palpebral ptosis (PP), Sidman-shock avoidance (SA), ambulation 
(AMB) and rearing (REA). 
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effects, are indicated by the ratio of EDjjO-based activities. A low ratio of 
NE/AM and PP/CA, is found with alpha-adrenolytic neuroleptics, which 
preferentially bloc the noradrenergic receptors that cause sedation in 
rats, and autonomic side-effects in human subjects. A high ratio NE/AM 
and PP/CA is found with incisive neuroleptics, which preferentially block 
the dopaminergic receptors, that induce catalepsy in rats and cause 
extrapyramidal side-effects in man. The separation between incisive and 
sedative neuroleptics is evidently not an all-or-none phenomenon, but a 
continuum. 
The EDjjo-values of the neuroleptics tested in self-stimulation were 
correlated with the EDso-values obtained in the different tests mentioned 
(Janssen and Van Bever, 1975), i.e. CA, PP, NE and AM (Spearman 
rank-order correlation) (Fig. 8). 
Fig. 8: Correlation (Spearman rank-order correlation г^ between the 
EDpjQ-values of the inhibition on brain sel-f-stimulation (BS) and the 
EDijg-values of antagonism of amphetamine-induced stereotypies (AM), 
catalepsy (CA), norepinephrine-antagonism (NE) and palpebral ptosis 
(PP), obtained with various neuroleptics (n) (see Tab/e2). 
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Significant correlations were found between the self-stimulation in­
hibition and the induction of catalepsy (r = 0.736, ρ ( 0.01), antagonism 
of amphetamine (r = 0.925, ρ < 0.01) and induction of palpebral ptosis 
(r = 0.693, ρ < 0.01). The self-stimulation inhibition was not significantly 
correlated with the antagonism of norepinephrine lethality (r = 0.208, 
ρ > 0.05). 
It could be inferred that the dopaminergic receptor blocking activity is 
more specifically related to the self-stimulation inhibition than the norad­
renergic receptor blocking effects. Moreover, the doses of the sedative 
neuroleptics effectively inhibiting self-stimulation block noradrenergic as 
well as dopaminergic receptors (see e.g. Andén et al., 1970, Table 3). 
However, the correlations may also simply reflect the potency-relation-
ships. It is therefore, appropriate to apply a method which separates the 
potency of neuroleptics f rom their spectral information. 
6.1.2. Spectral map analysis 
A technique which separates the potency from the spectral information 
has been described by Lewi (1976a). In short, spectral map analysis is a 
mathemathical method, which extracts from the pharmacological data 
(such as EDso-values of neuroleptic activity in various tests), relevant 
dimensions which are related to the ratios between the assays. The 
compounds are projected on a (multi-dimensional) plane and the 
dominant axes drawn through this plane can be identified with the 
principal components. The percentage contribution to the total variance 
of the spectra are calculated. The spectral mapping in a plane thus 
provides two-dimensional information on the relative positions of the 
compounds. 
Fig. 9 shows the spectral maps (Lewi, 1975b, 1976b) of 24 neuroleptics 
according to 4 pharmacological assays in rats (Janssen and Van Bever, 
1975, see 6.1.1.) and with respect to 6 clinical observations (Bobon et al., 
1972). 
The pharmacological map shows the more incisive neuroleptics on the 
left, while more sedative compounds appear on the right. The incisive/ 
sedative ratio of the compounds can be estimated from the relative 
position of the projections of their images on the map upon the 
horizontal axis. This axis accounts for about 89 percent of the total 
information contained in the spectra. The second principal axis contri-
butes no more than 6 percent to the original information. 
The clinical map, on the other hand, shows a larger contribution of the 
minor principal axis, contributing 26 percent. This axis appears to be 
related to the antimanic/antiautistic differential score. It can be seen that 
the incisive/sedative classification derived from the horizontal axis of the 
clinical map agrees with the same classification based on the pharma-
cological assays in animals. The Spearman rank-order correlation 
between these two Lambert-type (Lambert and Revol, 1960) classifi-
cations is .79. 
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Fig. 9: Spectral map of various neuroleptics based on pharmacological 
assays (upper figure) and clinical observations (lower figure) (permission 
to reprint granted by North-Publishing Company). 
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62. Positioning of psychotropic assays 
This method (spectral map analysis) was applied to the neuroleptics 
tested in self-stimulation and enabled the demonstration of the inter-
relationship between the self-stimulation test and other pharmacological 
assays, such as the tests discussed in the previous section, as well as 
other tests of operant behaviour. The spectral map analysis was 
programmed and calculated on an interactive typewriter using APL, a 
computer language devised by Iverson (1962). The program listings are 
reported by Lewi (1975a). 
Spectral map analysis was carried out on 40 neuroleptics as tested in 
12 assays in rats. Two principal components were found, of which the 
horizontal one accounted for most of the information (73 %). This 
component reproduced the pharmacological classification described in 
the previous section, namely the bipolar incisive/sedative scale (Fig. 9). 
Many neuroleptics were tested in a variety of learned behavioural 
situations using different schedules in which responding was maintained 
by negative reinforcement: escape (Niemegeers et al., 1970b, 1972) and 
avoidance (Janssen and Niemegeers, 1961; Janssen et al., 1965a; 
Niemegeers, 1974; Niemegeers et al., 1969a, 1969b, 1970a, 1972). The 
EDsQ-values of the inhibition obtained with various neuroleptics on brain 
self-stimulation on the one hand, and various escape or avoidance 
situations on the other hand, are highly correlated (one example, Sidman 
shock-avoidance, is given in Table 2). In all these experiments (a) rats 
learned to press or to jump in order to escape, avoid or obtain reward, (b) 
well-trained rats and good performers were selected. The situations 
differed with respect to (a) acquisition rate, (b) training required before 
stable performance was achieved, (c) motivation (positive versus 
negative). 
The following operant behaviour assays are positioned on the map of 
neuroleptics (Fig. 10). Noise escape (effects on latency time and on 
number of responses), Sidman shock escape/avoidance, jumping box 
shock avoidance and intracranial self-stimulation. It is observed that all 
these operant behaviour assays are located on a line oriented from 
apomorphine and amphetamine inhibition towards unrestrained loco-
motor activity (rearing, ambulation), conditioned feeding (weight gain) 
and catalepsy. Furthermore, typical escape inhibition is associated most 
closely with the inhibition of apomorphine and amphetamine, while 
typical loss of avoidance is most correlated with conditioned and un-
restrained activities. Mixed escape/avoidance and intracranial self-
stimulation can be seen to occupy intermediate positions between these 
two extremes. As previously stated (6.1.1.), it appears that the neuro-
leptic effects on operant behaviour are more related to dopaminergic 
receptor blocking activity than to the noradrenergic receptor blocking 
effects. The neuroleptic-induced inhibition of operant behaviour is rather 
independent of the motivational sign, i.e. reward or aversion. 
The intermediate position of the self-stimulation shows the relationship 
with typical neuroleptic effects and with neurologic side-effects (motor 
impairment). Common to all these operant behavioural situations is that 
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they involve complex learned behaviour and involve the occurrence of a 
reinforcement process. It is suggested that neuroleptics interfere with 
integrative processes, i.e. interfere with the relationships between 
behaviour and its consequence. 
Fig. 10: Spectral map of various neuroleptics and various operant 
beha vi ou г assa у s. 
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7. STUDIES ON DRUG-INTERACTION 
Self-stimulation behaviour depends at least partly, on catecholaminergic 
and cholinergic interacting functions (Olds and Ito, 1973; Stein, 1968). 
Olds (1972a) showed that scopolamine (0.5 mg/kg) antagonized about 
60 % of the inhibition of self-stimulation induced by chlorpromazine 
(2.5 mg/kg). The aim of the following studies was to reveal the functional 
interaction between dopaminergic and cholinergic neurons. 
These studies have clinical relevance because of the treatment of 
Parkinson's disease with drugs which also antagonize the neuroleptic-
induced Parkinson-like symptoms; and further, because of the routine 
combined treatment of neuroleptics with antiparkinsonian agents in 
psychotic patients. 
In all the studies reported in this chapter, we used rats implanted with 
electrodes in the lateral hypothalamic region of the medial forebrain 
bundle. Rats were trained in 15-or 30-min daily sessions, using a stimulus 
parameter combination which elicited high response rates (SPC 6). At 
least two sessions separated each treatment. The test used to show 
significant differences between drug-session and control session was the 
Wilcoxon matched pairs signed-ranks test, two-tailed probability. The 
level of significance selected was p\< .05. Further details are reported in 
the different experiments. 
7.1. Literature on neuroleptic-anticholinergic interaction (1) 
Relatively few authors studied the interaction between the pharma-
cological effects of neuroleptics and anticholinergics. 
The effects studied were primarily concerned with changes in the extra-
pyramidal system, both at the behavioural level, e.g. catalepsy (Table 4); 
and at the biochemical level, e.g. counteraction of the increased levels of 
homovanillic acid in subcortical brain regions (Andén and Bédard, 1971; 
Bowers and Roth, 1972; Corrodi et al., 1972; O'Keeffe et al., 1970), and in-
creased rate of dopamine depletion after synthesis inhibition (Puri and Lai, 
1973; Puri et al., 1973). Partial blocking of the neuroleptic-induced inhibi-
tion of avoidance behaviour has been reported (Table 5). We recently 
reported on the antagonism of pimozide-induced inhibition of mouse-
jumping in amphetamine-dopa treated mice (Colpaert et al., 1975b). 
It follows that centrally acting anticholinergics are able to antagonize 
neuroleptic-induced effects. The doses required to antagonize catalepsy 
or inhibition of avoidance are much higher than those producing central 
or peripheral anticholinergic activity, as measured in the anti-pilocarpine 
test in rats (Janssen and Niemegeers, 1967) (Tables 4 and 5). 
Quantitative inter-drug comparisons are almost impossible to perform, 
because of the wide range in activity of the different compounds used, 
the variable doses, the different injection schedules and routes of 
administration. It will be shown in the experiments subsequently 
described that self-stimulation is a reliable means of studying neuroleptic-
antagonistic drug interaction. 
(1) Partially summarized in Wauquier et al., 1975. 
180 
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12. Reversal of the specific inhibition obtained with anticholiner-
gics 
It has been stated (see 6) that specific neuroleptics inhibit self-
stimulation by interference with the nigrostriatal system. The latter 
dopaminergic neurons interact with striatal cholinergic interneurons. 
Since DA-neural transmission appears to be involved in the neuroleptic-
induced inhibition of self-stimulation, one would expect anticholinergics 
to antagonize the inhibitory effects of specific DA-blocking neuroleptics. 
72.1. Differentiation f rom narcotic analgesics (1) 
Haloperidol and morphine have a number of similarities: they increase 
the turnover of striatal DA (Puri and Lai, 1974); they release prolactin 
(Dickerman et al., 1972); they inhibit the release of luteinizing hormone 
(Dobrin and Mares, 1974); they produce a state of immobility which can 
be reversed with apomorphine (Puri et al., 1973). They differ, however, in 
many respects: haloperidol lacks analgesic effects and tolerance (Lai and 
Puri, 1973) and neuroleptics cause catalepsy, while morphine-like drugs 
cause catatonia. 
The inhibition of self-stimulation obtained with 0.16 mg/kg of fentanyl or 
with 40 mg/kg of morphine could not be reversed by the centrally acting 
anticholinergic dexetimide (2.5 mg/kg) (Tables 6a, b). The associated 
catatonia was not reversed either. Naloxone on the other hand, reversed 
the self-stimulation inhibition and catatonia induced by the former drugs. 
These experiments showed that some actions induced by morphine-like 
agents are reversed by a specific antagonist. Since DA receptors appear 
to be involved in causing morphine- or neuroleptic-induced effects, one 
would expect different mechanisms of action (see also Broekkamp and 
van Rossum, 1975). 
122. Dose-related antagonism (2) 
As shown previously (see 3.2.) a dose of 0.08 mg/kg of haloperidol given 
S.C., 1 hr before the session, caused a nearly complete suppression of 
self-stimulation. Dexetimide, a centrally acting anticholinergic (Janssen 
and Niemegeers, 1967; Janssen et al., 1971), antagonized, in a 
dose-related manner the suppression of self-stimulation induced by 
haloperidol. 
Eight rats were trained to press a lever for brain-stimulation (SPC 6) in 
the lateral hypothalamus, during 2 daily 15-min sessions separated by a 
4-hr interval. After training they were injected s.c. with 0.08 mg/kg of 
haloperidol, 1 hr before the first daily session followed 30 min later with 
either 0.04, 0.16, 0.63 or 2.5 mg/kg of dexetimide s.c. Tables 6a and 6b 
show the results obtained. Dexetimide gradually reinstated self-stimula-
tion in a dose-related manner. Isopropamide, a peripherally acting 
anticholinergic drug, at a dose (10 mg/kg) 1000 times higher than those 
(1) This study was reported earlier (Wauquier et al., 1974). 
(2) This study was reported earlier (Wauquier et al., 1975). 
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Table 6a: Self-stimulation responses of individua/ rats, run twice daily, during pre-drug control sessions and after sub­
cutaneous administration of either 1 ml/kg of saline, 0 Овтд/kgofha/operido/, 0 Wmg/kg offentanyl, 1 hour, before the first 
session, or 2 5mgI kg of dexetimide, 1/2'hourbefore the first session. 
Self-stimulation r e s p o n s e s / ) 5 min 
Drug t r e a t m e n t 
Control 
Saline 
% change 
Control 
Haloperidol 
% change 
Control 
Fentanyl 
% change 
Control 
Dexetimide 
% change 
1 at sess ion 
Rats # 
1 
383 
424 
+ 10.7 
275 
2 
-99.3 
288 
0 
-100 
198 
360 
+81.8 
2 
461 
379 
-17.8 
346 
10 
-97.1 
513 
0 
-100 
441 
453 
+2.72 
3 
538 
502 
-6.69 
597 
133 
-77.7 
577 
0 
-100 
585 
487 
-16.8 
4 
627 
640 
+2.07 
64·; 
66 
-89 8 
609 
0 
-100 
705 
862 
+22.3 
5 
882 
879 
-0.34 
949 
202 
-78.7 
839 
0 
-100 
1062 
934 
-12.1 
6 
981 
1078 
+9.89 
1008 
117 
-88.4 
973 
0 
-100 
1325 
1178 
-11.1 
Median 
2nd sess ion. 4 h r s la ter 
Rats # 
1 
582.5 406 
571.0 400 
+0.865 -1.48 
621.0 
9 1 . 5 * 
- 89.1 
593.0 
0 * 
-100 
645.0 
674.5 
- 4.19 
261 
2 
-99.2 
317 
329 
+ 3.79 
182 
201 
+ 10.4 
2 
441 
189 
-57.1 
437 
175 
-60.0 
392 
736 
+87.8 
465 
517 
+11.2 
3 
540 
696 
+28.9 
567 
669 
+18.0 
544 
557 
+2.39 
593 
420 
-29.2 
4 
599 
572 
-4.51 
464 
277 
-40.3 
441 
502 
+ 13.8 
663 
911 
+37.4 
5 
900 
905 
+0.56 
935 
544 
-41.8 
1041 
890 
-14.5 
1065 
1126 
+ 5.73 
6 
1018 
1070 
+5.11 
1010 
938 
-7.13 
1039 
981 
-5.58 
1059 
737 
-30.4 
Median 
569.5 
634.0 
-0.460 
515.5 
410.5 
-41.05 
492.5 
646.5 
+ 3.09 
628.0 
627.0 
+8.065 
* Significant difference ( p < 05) between control- and drug ses s ion . 
Wilcoxon, matched-pa i r s signed-ranks test, two-tailed probability. 
Table 6b: Self-stimulation response of individual rats, run twice daily, during pre-drug control sessions and after sub­
cutaneous administration of 0.08 mg/kg of ha/operidol (Hal) orO. 16 mg/kg of fentanyl (Fen), 1 hour before the first session, 
followed 1/2 hour later, by either0.04, 0.16, 0.63 or 2.50 mg/kg ofdexetimide (DexJ. 
Self-slimuUuon r e i p o n e t · / ! Ь min 
Compound 
Control 
m i o p c n d o l 
Control 
Haloperidol (0.08) « Dexelimid« (0.04) 
% change 
Control 
Haloperidol (0. 0 ΐ ) • Dexetimide (0.16 
% change 
Control 
Haloperidol ( O . M ) » Deietunide (0.63) 
% change 
Control 
Haloperidol (0.08) • Deicetiimde (2.5) 
* change 
Control 
Fentanyl 
Control 
Fentanyl (0.16) t DeBelimide (2.5) 
% change 
l i t e e i M o n 
R a t # 
1 
275 
2 
191 
55 
-71.2 
242 
99 
-59.1 
263 
231 
- 1 2 . 2 
2OT 
241 
415.3 
288 
0 
319 
0 
-100 
2 
346 
1(1 
404 
-99 8 
397 
2 
-99.5 
420 
25 
- 9 4 . 0 
34 5 
1S4 
-46.7 
513 
0 
347 
0 
.100 
3 
597 
133 
634 
96 
- 8 4 . 9 
520 
344 
-33.8 
595 
366 
- 3 8 . 5 
196 
301 
- 2 4 . 0 
577 
0 
596 
0 
-100 
4 
645 
66 
676 
135 
- 8 0 . 0 
596 
137 
-77 0 
704 
586 
-16 8 
581 
511 
12 0 
609 
0 
628 
0 
100 
5 
949 
202 
993 
908 
-8 56 
881 
562 
-36.2 
987 
1029 
«4 26 
862 
875 
»1 51 
839 
0 
947 
0 
-100 
6 
1008 
117 
1030 
139 
-86.5 
992 
115 
-88 4 
1042 
806 
-22 6 
944 
978 
»3 60 
97 3 
0 
1263 
0 
-100 
Median 
621 0 
9 1 . 5 » 
655 0 
1 1 5 . 5 · 
-82 45 
558.0 
1 2 6 . 0 » 
-68.05 
649.5 
4 7 6 . 0 « 
- 19.7 
488.5 
406 0 $ 
- 5.25 
593.0 
0 * 
612.0 
0 . 
-100 
2nd aeaaion 4 h r · laier 
Hai ρ 
I 
261 
2 
185 
40 
-78 4 
227 
42 
-81.5 
136 
127 
-6 62 
151 
162 
47 28 
317 
329 
247 
27 
-89.1 
2 
4 37 
175 
403 
255 
- 3 6 . 7 
347 
373 
47.49 
315 
346 
49.84 
279 
286 
42.51 
392 
736 
3 37 
301 
-10 7 
3 
567 
669 
518 
381 
-26.4 
568 
336 
-40 8 
596 
502 
- 1 5 . 8 
501 
' 8 5 
• 16.8 
544 
557 
596 
737 
423 7 
4 
4 64 
277 
586 
633 
48 02 
565 
6 ) 5 
48.85 
680 
609 
-10.4 
570 
602 
45.61 
441 
502 
633 
739 
416.7 
5 
935 
544 
911 
696 
- 2 3 . 6 
903 
952 
45.43 
935 
427 
-54.3 
809 
842 
44.08 
1041 
890 
1026 
1135 
410 6 
6 
1010 
938 
1044 
1007 
•3.54 
988 
989 
40 10 
1003 
868 
-13.5 
1024 
934 
-8 79 
1039 
98! 
1034 
405 
-60 8 
Median 
515 5 
410 5 
552 0 
507 0 
- 25.0 
566 5 
494.0 
4 2.77 
638 0 
464 5 
-11 95 
535.5 
' 9 3 5 
4 4 85 
492 5 
646 5 
614 5 
571 0 
- 0.05 
Λ Significant difference (p < , 05) between control- and drug •«••ion. 
φ Significant difference (p< ,05) between halopendol· or fentanyMrtatment and combined treatment. 
WilcoMOQ matched-palra ligned-ranki teit, two-tailed probabili!" 
producing peripheral anticholinergic activity (Janssen and Niemegeers, 
1967), did not antagonize the haloperidol-induced inhibition. 
The reversal of the inhibition by dexetimide suggests that the 
haloperidol-effect was due to some altered relationship between 
dopaminergic and cholinergic activity in striatum (Klawans, 1973; 
Sigwald, 1971), either by cholinergic inhibition or dopaminergic 
stimulation. 
In the following studies, we selected the dose of 0.63 mg/kg of 
dexetimide, because this was the lowest dose to reverse more than 50 % 
of the haloperidol-induced inhibition. 
72.3. Antiparkinsonian drugs 
The reversal of the haloperidol-induced inhibition of self-stimulation was 
not an exclusive action of dexetimide. Benztropine (10 mg/kg) likewise 
antagonized the inhibition brought about by Haloperidol (Wauquier et al., 
1974). 
In another study we compared the antagonism of the penfluridol- and 
clopimozide-induced inhibition by three antiparkinsonian agents; dexe-
timide, benztropine and trihexyphenidyl. 
Seven rats were trained to self-stimulate for SPC 6 in daily 30-min 
sessions, 5 days a week, except for Monday when they were run twice, 
with a 4-hr interval between the sessions. A dose of the long-acting 
neuroleptics penfluridol (5 mg/kg) (Janssen et al., 1970) and clopimozide 
(1.25 mg/kg) (Janssen et al., 1975a) which, as described, suppressed 
self-stimulation virtually completely, was given orally 1 hr before the first 
session on Monday. During subsequent weeks rats were treated with the 
neuroleptic followed 4 hrs later, i.e. 1 hr before the second session on 
Monday, with either dexetimide (0.63 mg/kg), benztropine (10 mg/kg) or 
by trihexyphenidyl (10 mg/kg) s.c. Rats were only treated once per week. 
Tables 7a, b and Fig. 11 depict the results obtained. 
At the doses used, penfluridol and clopimozide significantly inhibited 
self-stimulation 4 hrs, 24 hrs and 48 hrs after injection. The inhibition was 
most pronounced 4 hrs after neuroleptic treatment and self-stimulation 
gradually recovered during the following 4 days. The three antiparkin-
sonian drugs, which by themselves did not significantly affect self-
stimulation, completely reversed the self-stimulation inhibition obtained 
4 hrs after neuroleptic treatment. Self-stimulation was completely 
normalized (not significantly different from controls) except for the 
combination of penfluridol with trihexyphenidyl. However, during the 
following days, self-stimulation rates did not differ from the rates 
obtained after neuroleptic treatment alone. 
This study showed that the self-stimulation inhibition induced by specific 
neuroleptics could be reversed by three different antiparkinsonian drugs 
at a time when maximum inhibition could be expected. 
Whether the anticholinergics were specific with respect to the reversal of 
the self-stimulation inhibition is still a matter of debate. 
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Fig. 11: Median self-stimulation response rates as a percentage of 
control values obtained with 7 rats, 1 hr, 4 hrs, 24 hrs, 48 hrs, 72 hrs and 
96 hrs after oral administration of 5 mg/kg of penfluridol (V (upper) or 
1.25 mg/kg of clopimozide (1) (lower) or, after combined treatment with 
either penfluridol or clopimozide, plus 0.63 mg/kg of dexetimide (2), 
10 mg/kg of benztropine (3) or Ю mg/kg of trihexyphenidyl (4). The latter 
antiparkinsonian drugs were given s. с 1 hr before the 4-hr session. 
PENFLURIDOL« ANTAGONISTS 
V. 120, 
100 
>0 
SO 
to. 
20. 
0 
·/. 120. 
100. 
80. 
60 
to. 
20] 
0 
сгШ 
1 2 3 « 
hf 1 
1 2 3 4 1 2 3 « 1 2 3 4 1 2 3 « 1 2 3 4 
« 24 « 72 96 
C L O P I M O Z I D E » A N T A G O N I S T S 
0 
1 2 3 4 
hr 1 
1 2 3 4 
4 
1 2 3 4 
34 
1 2 3 4 
48 
2 3 4 
72 
1 2 3 4 
96 
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Table 7a: Self-stimulation response rates of 7 rats run 1 hr, 4 hrs, 24 hrs, 
48 hrs, 72 hrs and 96 hrs after oral administration of water, penfluridol or 
the combination of penfluridol with either dexetimide, benztropine or tri­
hexyphenidyl given s.c. 3 hrs after penfluridol. 
Compound· 
Saline . e m o n i 
Penfluridol 
5 mg/kg or. 
Penfluridol 
5 mg/kg or. 
+ 
Dexet imide 
0 .63 mg/kg i . e . ( + 3 hr · ) 
Penfluridol 
5 mg/kg or. 
+ 
Benztropine 
10 mg/kg s . c . (+ 3 h r · ) 
Penfluridol 
5 mg/kg or. 
+ 
Trihexyphenidyl 
10 mg/kg i . e . ( + 3 h r · ) 
л Significant difference (P 
® Significant difference (P 
• igned-rank t e i t , two-ta 
Hr 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
Rat # 
1 
1390 
1465 
1416 
1400 
1449 
1433 
1377 
23 
182 
1265 
1310 
1458 
1539 
1200 
125 
597 
1204 
1373 
1534 
1265 
234 
1217 
1182 
1253 
1530 
1364 
203 
863 
996 
1288 
< 0.05) frc 
< 0.05) fro 
iled probab 
2 
1051 
1299 
1314 
1553 
1145 
1629 
1291 
5 
173 
78 
700 
736 
1039 
641 
67 
33 
630 
658 
390 
481 
153 
70 
72 
821 
913 
715 
97 
632 
1140 
1153 
m talir 
m pt.nf 
i l i ly). 
3 
2150 
1896 
2260 
2126 
2198 
2166 
2377 
971 
1389 
1680 
1982 
2440 
1832 
1927 
1400 
1125 
1727 
2276 
2292 
1800 
1333 
1495 
1721 
1964 
1262 
1774 
1566 
1558 
1800 
2064 
ur idol 
4 
1991 
2077 
1883 
2221 
1862 
2198 
2103 
no 
280 
1588 
2227 
2170 
2107 
1861 
251 
1729 
1133 
1986 
2147 
1047 
148 
1434 
1844 
2163 
2072 
1162 
509 
1398 
1984 
1971 
i o n · . 
t reatm 
5 
1085 
965 
974 
1092 
1225 
1225 
765 
52 
416 
767 
775 
907 
931 
1189 
221 
705 
970 
1099 
1148 
677 
171 
684 
851 
1140 
1029 
831 
147 
559 
815 
1145 
ent (Wi 
6 
787 
978 
839 
939 
1016 
916 
890 
11 
63 
407 
700 
962 
884 
1210 
184 
147 
796 
738 
962 
893 
197 
480 
928 
1104 
8 57 
1031 
115 
208 
74 
897 
Icoxon 
7 
859 
939 
1049 
1038 
1063 
1029 
1312 
64 
134 
148 
881 
971 
1086 
707 
54 
43 
15 
870 
1096 
1134 
95 
49 
308 
751 
1157 
613 
39 
72 
561 
764 
matche 
Median 
1085 
1299 
1314 
1400 
1225 
1433 
1312 
5 2 · 
182» 
7 6 7 * 
881 
971 
1086 
1200 ( ! ) 
184» 
5 9 7 * 
9 7 0 * 
1099» 
1148 
1047 ® 
1 7 1 . ^ 
6 8 4 * 
9 2 8 * 
1140 
1157 
1 0 3 1 * ® 
1 4 7 * 
632« 
9 9 6 * 
1 1 5 3 * 
J-pair· 
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Table 7b: Self-stimulation response rates of 7 rats run 1 hr, 4 hrs, 24 hrs, 
48 hrs, 72 hrs and 96 hrs after oral administration of water, clopimozide or 
the combination of clopimozide with either dexetimide, benztropine or 
trihexyphenidyl given s. с 3 hrs after clopimozide. 
Compounds 
S*Une sciBioni 
Clopimozide 
1.25 mg/kg or. 
Clopimozide 
1.25 mg/kg or. 
+ 
Dexetimide 
0.63 mg/kg т.е. (+ 3 h r · ) 
Clopimozide 
1.25 mg/kg or. 
Benztropine 
10 mg/kg i . e . ( + 3 h r · ) 
Clopimozide 
1 .25 mg/kg or. 
Trihexyphenidyl 
10 mg/Vg т.е. (+ 3 hr») 
H r 
1 
4 
24 
48 
72 
94 
1 
4 
24 
48 
72 
94 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
1 
4 
24 
48 
72 
96 
R » t # 
1 
1580 
1458 
1534 
1661 
1333 
1412 
1523 
42 
325 
128 
977 
1158 
1450 
1712 
414 
543 
1072 
1094 
1838 
1836 
233 
370 
1078 
1509 
1885 
1699 
518 
450 
1318 
1208 
2 
1611 
1727 
1494 
1052 
1274 
1383 
1779 
60 
504 
976 
1468 
1259 
1479 
1452 
785 
934 
1320 
1304 
2223 
1739 
577 
1330 
1713 
1981 
2573 
1795 
889 
671 
958 
1968 
3 
2071 
1951 
2021 
1885 
2021 
2021 
1925 
687 
1430 
1439 
1655 
1904 
2047 
1677 
1630 
1619 
1906 
1889 
1841 
1876 
1055 
1629 
2011 
1844 
1872 
1977 
1194 
1312 
952 
1826 
4 
2180 
1447 
1894 
2192 
2262 
2140 
2152 
101 
718 
1745 
2302 
2255 
1798 
1193 
779 
1734 
2200 
2158 
1849 
575 
411 
1613 
1968 
2125 
1930 
320 
637 
1684 
1823 
1970 
5 
1153 
1347 
1384 
1139 
1117 
1202 
967 
15 
313 
663 
972 
1205 
1249 
322 
204 
641 
1033 
1257 
1120 
273 
53 
691 
1301 
1499 
1445 
904 
71 
801 
1360 
1526 
6 
1032 
910 
1099 
1078 
1032 
924 
704 
0 
103 
694 
845 
877 
906 
1271 
99 
225 
865 
1197 
931 
1265 
99 
690 
910 
926 
986 
1235 
353 
457 
922 
950 
7 
1060 
793 
881 
1047 
1141 
1145 
1101 
115 
152 
69 
279 
765 
1274 
880 
330 
556 
503 
648 
1341 
1239 
238 
344 
1251 
1098 
1368 
1006 
286 
137 
773 
820 
Median 
1580 
1447 
1494 
1139 
1274 
1383 
1523 
60» 
325» 
694» 
977 
1205 
1450 
1271 ® 
414* 
641» 
1072» 
1257 
1838 
1265 ® 
238» 
6 9 1 * 
1301 
1509 
1872 
1235 ® 
518» 
671» 
958 
1526 
* Signifie Ant difference (P < 0.05) from filine » e · · ion«. 
® Significant difference (P< 0.05) from clopimoside treatment (Wilcoxon matched «pairs 
• igned-rank temt. two-tailed probability). 
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7.3. Differential antagonism 
In as much as DA-neural transmission is involved in the antagonism by 
antiparkinsonian drugs of neuroleptic-induced inhibition, one would 
expect anticholinergics to antagonize the inhibitory effects of specific 
DA-blocking neuroleptics, without affecting the inhibition brought about 
by NA-blocking neuroleptics. 
Further, different mechanisms could account for the reversal of the 
inhibition: anticholinergic activity, release of DA-uptake blocking activity 
and so forth. It was the aim of the following studies to elucidate the 
possible mechanism involved, by using various putative antagonists. 
7.3.1. Differential antagonism between the neuroleptics 
7.3.1.1. (1) Three different neuroleptics were selected: pimozide, 
haloperidol and pipamperone. Pimozide and haloperidol, are both 
specific DA-blocking neuroleptics; haloperidol, however, also blocks 
NA-receptors at high dose-levels. Pipamperone, on the contrary, blocks 
DA and NA receptors at approximately the same dose-levels (Andén et 
al., 1970) (see 6). Four doses of each neuroleptic were given, the second 
dose being approximately the EDsQ-value for inhibition, the fourth dose 
being 16 times higher. All rats were also given the combination of the 
neuroleptic and 0.63 mg/kg of dexetimide. Tables 8a, b, с and Fig. 12 
show the results obtained. 
Dexetimide completely reversed the self-stimulation inhibition induced 
by pimozide and self-stimulation was normalized to control levels. The 
haloperidol-induced inhibition was significantly antagonized at all dose-
levels, but self-stimulation was not normalized to control levels with the 
combination of dexetimide with 0.16 mg/kg and 0.63 mg/kg of 
haloperidol. The pipamperone-induced inhibition was not antagonized by 
dexetimide. 
The inhibition of self-stimulation induced by pimozide and haloperidol is 
probably due to the DA-blocking activity, whereas the pipamperone-
induced inhibition is related to the DA- and NA-blocking activity. It 
follows that dexetimide reversed the DA-blocking effect, whereas the 
NA-blocking effect would not be antagonized. The latter had to be 
evidenced further by using different neuroleptics, which preferentially 
block NA receptors. 
7.3.1.2. A group of rats was treated with various sedative neuroleptics 
(ratio NE/AM lower than 1, see 6.1.) and a combination of these 
neuroleptics with 0.63 mg/kg of dexetimide. The neuroleptics were: 
azaperone (2.5 mg/kg), chlorpromazine (2.5 mg/kg), chlorprotixene 
(2.5 mg/kg), clozapine (40 mg/kg), haloanisone (2.5 mg/kg), oxypertine 
(10 mg/kg), piperazetacine (0.63 mg/kg), promazine (40 mg/kg) and 
thioridazine (40 mg/kg). The dose of the neuroleptic was the first one of 
a geometrical series (0.04, 0.08,... 40 mg/kg of body weight) completely 
inhibiting self-stimulation (based on 3.2.2. and pilot experiments). 
(1) This study was reported earlier (Wauquier and Niemegeers, 1975). 
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Fig. 12: Self-stimulation in rats: median (8 rats) response rate expressed 
as a percentage of the preceding control (= 100 %) obtained after 
neuroleptic (&) and combined neuroleptic-anticholinergic treatment 
(Mi. (Permission to reprint granted by Arch. int. Pharmacodyn. Ther.i. 
Sentón 
063 001 
PIPAMPERONE 
«00 
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Table 8a: Self-stimulation response rates of 8 rats, run twice daily (4-hour 
interval), after subcutaneous administration of saline Π ml/kg) or 
different doses ofpimozide and the combination of pimozide, given2hrs, 
and dexetimide, given 1/2 hr before the first session. 
J 
m 
V 
>. 
Ï 
fa 
f 
• 
• 
V 
1 
« 
Compound· 
Sa l ine s e s i i o n i 
p r e c e d i n g 
p i m o z i d e doaea 
P i m o z i d e alone 
Sa l ine aeaaiona p r e c e -
ding p imoz ide doae + 
deKet imide 0. 63 m g / k g 
P i m o z i d e doaea 
* 
D e x e t i m i d e 0 . 6 3 m g / k g 
Sa l ine aeaaiona 
p reced ing 
p imoz ide doaea 
P i m o z i d e alone 
Sal ine aeaaiona p r e c e -
ding p imoz ide doac + 
d e x e t i m i d e 0 . 6 3 m g / k g 
P i m o z i d e doaea 
+ 
D e x e t i m i d e 0 . 6 3 m g / k g 
Doae 
m g / k g 
0 
0 
0 
0 
0 . 0 4 
0 16 
0 . 6 3 
2 . «0 
0 
0 
0 
0 
0 . 0 4 
0 . 1 6 
0 . 6 3 
2 . 5 0 
0 
0 
0 
0 
0 . 0 4 
0 . 1 6 
0 . 6 3 
2 . 5 0 
0 
0 
0 
0 
0 . 0 4 
0 . 1 6 
0 . 6 3 
2 . 5 0 
Rat # 
1 
1284 
1575 
1686 
1390 
1174 
612 
183 
18 
1433 
816 
1580 
991 
1470 
1574 
1837 
1334 
1495 
1412 
1547 
1459 
1382 
1275 
37 
12 
1505 
666 
1616 
1405 
1392 
979 
1067 
1279 
2 
1816 
1460 
1504 
1665 
1678 
79 
0 
0 
1750 
964 
1387 
1622 
1923 
900 
1426 
658 
1625 
1385 
1505 
1617 
1645 
539 
1 
1 
1820 
14 50 
1516 
1530 
1756 
1075 
901 
135 
1 
3 
433 
1347 
1439 
1461 
459 
849 
10 
3 
776 
1399 
1590 
1362 
14 34 
1824 
1509 
1334 
231 
1472 
1207 
1489 
612 
560 
0 
3 
784 
1413 
1680 
1518 
941 
7 58 
421 
79 
4 
1450 
1170 
2286 
1189 
1612 
1418 
261 
5 
1401 
1301 
22 68 
1390 
1985 
1915 
2154 
1868 
1341 
1317 
2282 
1070 
1514 
1698 
701 
0 
1701 
1317 
2471 
1483 
1427 
1361 
1738 
1831 
5 
1669 
1783 
1545 
1678 
968 
150 
33 
5 
1608 
1257 
894 
1326 
1464 
1655 
702 
1099 
17 30 
1707 
1520 
1616 
988 
151 
32 
15 
1628 
1506 
1184 
1287 
1311 
1424 
1110 
4 65 
6 
92 3 
1245 
1166 
1068 
1099 
887 
19 
33 
1056 
1136 
1002 
809 
1224 
1329 
98 6 
797 
967 
1148 
1199 
MOB 
1152 
888 
204 
7 
U l i 
1148 
986 
950 
829 
987 
919 
494 
7 
2607 
1953 
2630 
2641 
2729 
1117 
256 
41 
28 38 
1400 
2885 
2061 
3013 
1837 
1689 
1227 
2787 
1902 
2589 
2676 
2547 
1192 
151 
32 
3102 
1920 
2633 
2271 
2862 
1505 
1256 
402 
В 
696 
1322 
897 
8 0 9 
542 
1105 
34 
0 
598 
1202 
703 
569 
1149 
1475 
699 
421 
7 58 
1162 
702 
721 
597 
593 
2 
0 
559 
1203 
795 
549 
5 9 3 1 
1268 
274 
162 
M e d i a n 
1367 
1404 
1525 
1426 
1137 
8 6 8 (1) 
3 3 . 5 ( 2 ) 
5 (2) 
1417 
1230 
1484 
1344 
1 4 6 7 ( 1 ) 
1 6 1 5 ( 1 ) 
1468 
1163 
1418 
1399 
1513 
1474 
1267 
7 4 0 . 5 ( 1 ) 
3 4 . 5 (2) 
5 (2) 
1567 
1375 
1566 
1444 
1352 
1172 
9 9 3 (2) 
4 3 3 . 5 ( 1 ) 
(1) Significant difference between drug-ieaaion and preceding control aeaaion at the level 
of Ρ < .05 (Wilcoxon matched-paira aigned-rank teat, two-tailed probability). 
(2) P < . 0 1 
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Table 8b: Self-stimulation response rates of 8 rats, run twice daily (4-hour 
interval), after subcutaneous administration of saline (1 ml/kg) or 
different doses of haloperidol and the combination of haloperidol, given 
1 hr, and dexetimide, given 1/2 hr before the first session. 
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1 
С 
.2 
• 
tl 
• 
5 
• 
ь 
β 
• 
• 
1 
s υ 
IDS 
0 
( 2 ) 1 
Compound· 
Saline l e i i l o n · 
preceding 
haloperidol d o l e · 
Haloperidol alone 
Saline eeaa iom prece­
ding haloperidol dote + 
dexetimide 0 .63 mg/kg 
Haloperidol d o t t i 
4 
Dexetimide 0 .63 mg/kg 
Saline e e a i i o n i 
preceding 
haloperidol d o s e · 
Haloperidol alone 
Saline ee ia ione prece­
ding haloperidol do ie + 
dexetimide 0. 63 mg/kg 
Haloperidol doaea 
+ 
Dexetimide 0.63mg/kg 
igmficant difference betw 
f Ρ < .OS (Wilcoxon mate 
' < .01 
Dose 
mg/kg 
0 
0 
0 
0 
0.01 
0.04 
0.16 
0.63 
0 
0 
0 
0 
0.01 
0.04 
0.16 
0 .63 
0 
0 
0 
0 
0.01 
0.04 
0 .16 
0.63 
0 
0 
0 
0 
0.01 
0.04 
0.16 
0 .63 
een dru 
hed-pai 
Rat φ 
I 
8 6 3 
1 6 6 3 
1 4 1 3 
1 3 8 0 
631 
1 3 8 3 
S3 
0 
1361 
1 6 1 0 
1 3 3 3 
1 5 2 9 
1 4 9 4 
1 6 S 6 
981 
4 S 4 
1071 
use 
1 2 9 4 
1544 
541 
1 6 2 3 
2 7 4 
20 
1 3 3 8 
1434 
1 6 7 2 
1 5 1 9 
1 2 7 9 
1 6 4 0 
177 
1 0 1 5 
2 
8 7 8 
1 2 4 8 
1 5 7 6 
981 
6 0 6 
1 0 4 9 
14 
4 
1 5 6 2 
1 3 S 6 
1301 
1 2 9 2 
1417 
1 2 8 8 
4 3 1 
4 8 
1 0 7 4 
1094 
1 4 9 5 
1 3 2 9 
4 4 4 
1307 
1 2 7 6 
0 
1 3 0 2 
1237 
1 8 9 3 
1 4 4 0 
7 2 4 
3 5 9 
1 3 6 9 
4 9 
3 
9 1 2 
1 3 3 8 
S14 
1 4 4 3 
1 1 5 4 
1 7 9 
21 
1 
9 8 5 
1 5 4 6 
3 6 4 
1 4 2 1 
1 4 2 2 
1 8 2 4 
2 0 8 
6 4 
1 1 S 5 
1 5 0 9 
5 0 8 
1 3 4 7 
1 0 9 2 
1 1 4 8 
5 
12 
1 5 9 6 
1 1 4 7 
4 9 3 
1 6 8 2 
8 0 2 
1 0 8 0 
1 5 2 
4 0 5 
4 
1 1 6 2 
2 8 6 2 
1 5 7 0 
1 4 7 6 
1434 
164 
8 8 
0 
1 1 4 0 
2 3 4 8 
1 9 2 6 
1 3 4 5 
2 0 1 6 
2 5 9 8 
1 4 1 6 
1 4 2 
1217 
2 8 1 1 
1541 
1 2 9 2 
1307 
9 3 9 
16 
284 
1411 
2 3 4 4 
1677 
1194 
1 4 1 0 
2 1 2 3 
1 6 0 3 
127 
5 
1 7 8 0 
1731 
1821 
1 6 0 9 
1 9 1 3 
44 
17 
0 
1 8 1 3 
1 6 2 5 
1 9 5 6 
1 7 3 2 
2 1 2 3 
1 2 5 6 
1 4 3 8 
37 
1739 
1 5 5 5 
1854 
1464 
1 8 5 0 
50 
0 
2 
1 8 8 6 
1 6 2 9 
1 9 0 7 
1 5 0 7 
1 7 7 3 
14 2 9 
58 3 
334 
6 
1 3 3 0 
1 0 4 S 
9 2 3 
1 0 7 2 
1 2 2 5 
7 9 9 
1 5 3 
14 
1 3 3 2 
9 0 8 
6 7 4 
1 0 8 0 
1 6 8 0 
1 2 6 0 
7 52 
1 7 0 
1 4 0 4 
107 5 
7 7 4 
1 0 4 5 
1 3 6 8 
noe 
« 1 7 
β 
1 2 5 5 
9 2 2 
5 0 5 
1 0 9 9 
1 3 3 3 
9 5 3 
8 2 2 
52 
7 
1 9 7 1 
2 6 1 6 
2 5 2 8 
2 0 4 7 
2 0 9 3 
1 8 1 5 
94 
16 
1 9 8 3 
2 6 7 9 
2 8 4 2 
2 7 8 0 
1 8 6 0 
2 3 5 4 
2 4 8 1 
291 
2 2 8 7 
2 7 4 4 
2 5 9 0 
2 0 0 7 
2 2 2 6 
2 397 
5 4 0 
4 
1874 
2 5 2 6 
2 8 3 3 
27 52 
1 6 3 2 
24 9 3 
384 
7 38 
g - s e a i i o n and p r e c e d i n g c o n t r o l a e i a i o n 
ra a i g n e d - r a n k t e a t , t w o - t a i l e d p r o b a b i l 
8 
5 9 6 
9 6 S 
9 2 5 
eso 
4 5 9 
2 8 1 
0 
0 
6 4 2 
8 0 1 
8 9 6 
9 0 2 
1 4 6 1 
1 4 7 6 
1 3 3 
14 
5 8 9 
9 7 3 
7 8 8 
8 0 7 
651 
6 0 4 
2 
0 
67 5 
8 9 3 
7 9 5 
8 0 2 
2 9 7 
8 1 2 
211 
5 
a t th< 
i t y ) . 
M e d i a n 
1037 
1501 
1 4 9 2 
1 4 1 2 
1 1 9 0 
5 4 0 (2 ) 
37 (2) 
0 . 5 (2) 
1 3 4 7 
1 5 7 8 
1 3 1 7 
1 3 8 3 
1 5 8 7 
1 5 6 6 
8 6 6 . 5 ( 1 ) 
1 0 3 (2) 
1 1 8 6 
1 5 3 2 
1 3 9 5 
1 3 3 8 
1 2 0 0 
1 1 2 8 
1 4 5 (1) 
6 (2) 
1 3 7 5 
1 3 3 6 
1 6 7 5 
1 4 7 4 
1 3 0 6 (1) 
1 2 5 5 
4 8 3 . 5 ( 1 ) 
2 3 0 . 5(2) 
l e v e l 
Table 8c: Self-stimulation response rates of 8 rats, run twice daily (4-hour 
interval), after subcutaneous administration of saline (1 ml/kg) or 
different doses of pipamperone and the combination of pipamperone, 
given 1 hr, and dexetimide, given 1/2 hr before the first session. 
.1 
« 
ΐ 
m fa 
ξ 
• 
• 
• 
1 
s 
о 
и 
s, 
Compound· 
Saline шешщіопш 
preceding 
pipamperone d o t e · 
Pipamperone alone 
Saline aeas ion · prece­
ding pipamperone doae + 
dexetimide 0 .63 mg/kg 
Pipamperone doae· 
+ 
Dexetimide 0.63 mg/kg 
Saline aeaaion· 
preceding 
pipamperone doae· 
Pipamperone alone 
Saline aeaaion· prece­
ding pipamperone doae + 
dexetimide 0.63 mg/kg 
Pipamperone d o · · · 
+ 
Dexetimide 0.63 mg A g 
Doae 
mg/kg 
0 
0 
0 
0 
2 .50 
10.0 
4 0 . 0 
160 
0 
0 
0 
0 
2.50 
10.0 
4 0 . 0 
160 
0 
0 
0 
0 
2.SO 
10.0 
4 0 . 0 
i 60 
0 
0 
0 
0 
2.50 
10.0 
40 .0 
160 
Rat φ 
1 
579 
1522 
1779 
1589 
1010 
1256 
226 
23 
1687 
1319 
1653 
1367 
910 
83 
249 
0 
1331 
1477 
1967 
1588 
666 
1020 
223 
0 
1789 
1270 
1748 
1405 
1685 
1188 
400 
0 
2 
700 
1297 
1122 
1754 
1097 
687 
15 
18 
893 
1555 
1468 
1765 
779 
493 
95 
0 
993 
1437 
1486 
1461 
1266 
1062 
0 
0 
1050 
1736 
1324 
1750 
1187 
1097 
44 
0 
3 
1377 
518 
1338 
1147 
1255 
74 
0 
0 
1379 
479 
1505 
1646 
1086 
80 
1 
0 
1576 
559 
1431 
1268 
1191 
281 
4 32 
0 
1408 
488 
1533 
1637 
1583 
57 
1268 
0 
4 
1750 
1515 
1139 
1288 
1751 
1259 
6 
14 
1667 
1527 
1161 
1189 
1842 
1047 
177 
0 
1907 
1446 
1425 
1215 
1868 
1419 
296 
0 
1514 
1552 
1492 
1136 
1482 
1584 
1451 
0 
5 
1498 
1470 
1482 
722 
1087 
77 
3 
0 
1632 
1846 
1266 
989 
1231 
929 
16 
0 
1581 
1711 
154 3 
990 
1247 
1302 
2 
0 
1636 
1864 
1681 
894 
1408 
1394 
0 
0 
6 
958 
1076 
1291 
809 
931 
338 
29 
0 
1028 
1095 
1421 
892 
914 
504 
56 
0 
1006 
1167 
1250 
797 
810 
617 
323 
0 
1026 
1112 
1340 
826 
740 
579 
226 
0 
7 
603 
2850 
1599 
2093 
1094 
1880 
70 
0 
2651 
2936 
1828 
1973 
1571 
1837 
156 
0 
953 
2749 
1825 
2056 
973 
2290 
964 
0 
2 544 
2798 
2205 
1951 
2058 
2247 
371 
0 
8 
729 
598 
1167 
870 
793 
0 
0 
0 
529 
422 
921 
736 
1087 
91 
259 
0 
1312 
586 
1034 
897 
666 
320 
60 
0 
607 
461 
722 
773 
1313 
414 
401 
0 
Median 
843.5 
1384 
1315 
1218 
1091 
512.5(2) 
10.5 ( ί 
0 (2) 
1506 
1423 
1445 
1278 
1087 
4 98.5(2) 
125.5(2) 
0 (2) 
1322 
1442 
1459 
1242 
1082 
1041 (2) 
259.5(2) 
0 (2) 
1461 
1411 
1513 
1271 
1445 
1143(1) 
385.5(2) 
0 (2) 
(1) Significant difference betveen drug-teation and preceding control ae te ioo at the level 
of Ρ < .OS (WUcoKon matched-pftire algned-rftnk teet, two-tailed probability). 
(2) P < .01 
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The inhibition of self-stimulation induced by these neuroleptics was not 
reversed by dexetimide, except for thioridazine (see further 7.4). 
The self-stimulation inhibition is probably due to its NA-blocking and 
DA-blocking activity. Dexetimide could reverse the DA-blocking effect 
completely (as was shown for pimozide) but because of the NA-blocking 
effect, self-stimulation remained inhibited. 
7.32. Specificity of the antagonists 
Sedative neuroleptics could not be antagonized with the anticholinergic 
dexetimide, while specific neuroleptics were. Most anticholinergics, 
however, also inhibit the neuronal uptake of DA (e.g. Coyle and Snyder, 
1969). Dopamine-uptake blockers therefore, could be potential anta­
gonists of incisive neuroleptics. Further, amphetamine which releases 
DA and NA, could probably reverse to a certain extent the inhibition 
brought about by sedative neuroleptics, as well as, incisive neuroleptics. 
Firstly, different compounds which interact with DA- or NA-transmission 
were used as antagonists of the self-stimulation inhibition induced by 
pimozide. These were amphetamine (release of DA and NA), 
apomorphine and piribedil (DA receptor stimulating agents); cocaine and 
nomifensine (DA-uptake blocking agents); desipramine (NA-uptake 
blocking drug) and dexamisole (amine-uptake blocker, Vanhoutte and 
Van Nueten, 1975). 
Secondly, four sedative neuroleptics, i.e. chlorpromazine, pipamperone, 
clozapine and thioridazine were challenged with dexetimide (see 7.2), 
amphetamine and nomifensine. 
All experiments were carried out with rats self-stimulating for SPC 6 on 
daily half-hour sessions. Drug-treatment was randomized in each 
individual rat, but single treatment always preceded combined treatment. 
The results of the first experiment are given in Table 9. The antagonistic 
drugs, at the doses used, did not significantly affect self-stimulation, 
except for apomorphine, which caused a slight inhibition. The two 
DA-receptor stimulating drugs apomorphine and piribedil, did not 
antagonize the pimozide-induced inhibition; neither did desipramine. 
Amphetamine on the other hand, significantly antagonized the inhibition 
of self-stimulation but a large inter-individual variation was found. 
Cocaine, as well as nomifensine, significantly antagonized the inhibition 
of self-stimulation. With nomifensine, self-stimulation was completely 
normalized. 
The results of the second experiment are shown in Tables 10a, b, с and 
Fig. 13. The pimozide-induced inhibition was significantly antagonized 
with dexetimide, amphetamine and nomifensine. Self-stimulation rates 
were not normalized with amphetamine, whereas they were after 
dexetimide and nomifensine. 
Amphetamine and nomifensine completely normalized self-stimulation 
after chlorpromazine treatment. A very slight antagonism was found 
with dexetimide. Very little antagonism of the pipamperone-induced 
inhibition was found with dexetimide and amphetamine. The clozapine-
induced inhibition was slightly antagonized with amphetamine. 
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Table 9: Self-stimulation responses of individual rats, obtained during pre-drug sessions and after subcutaneous 
administration of either 1 ml/kg of saline or indicated compounds (left) or after 0.63 mg/kg of pimozide, 2 hrs before the 
session, followed 1 1/2 hr later by either nomifensine (2.5 mg/kg), cocaine (10 mg/kg), amphetamine (0.63 mg/kg), 
dexamisole (10 mg/kg), apomorphine (0.31 mg/kg), piribedil (10 mg/kg) or desipramine (10 mg/kg). 
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Table 10a: Self-stimulation responses of individual rats, obtained during 
pre-drug control sessions (C) and after administration of either pipam-
perone (40 mg/kg), clozapine (40 mglkg), thioridazine (40 mg/kg) or 
chlorpromazine (2.5 mg/kg), 7 hr before the session or these compounds 
followed 1/2 hr later by 0.63 mg/kg of dexetimide. All compounds were 
given subcutaneously, except clozapine, which was given orally. 
S c l f - e t l m u U t i o n r e a p o n i e i / 3 0 min ' 
Compound 
Pi pam perone 
+ Dexet imide 
% 
Clozapine 
% 
+ Dexet imide 
Thioridazine 
% 
+ Dexet imide 
Chlorpromazine 
i Dexet imide 
D o s e 
mg/kg 
4 0 
0 . 6 3 
4 0 
0 . 6 3 
40 
0 . 6 3 
2 . 5 
0 . 6 3 
С 
R 
C/R 
С 
R 
C/R 
С 
η 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
R » ' # 
1 
1779 
226 
12.7 
1653 
249 
15.1 
1504 
34 
2 . 2 6 
1470 
85 
5 .78 
1255 
19 
1.51 
1560 
1172 
75.1 
645 
1 
0 . 1 5 5 
694 
61 
8 . 7 9 
2 
1122 
15 
1.34 
1468 
95 
6.47 
938 
4 
0.426 
1251 
225 
1 8 . 0 
1550 
43 
2 .77 
1123 
912 
8 1 . 2 
2612 
33 
1.26 
2677 
359 
13.4 
3 
1338 
0 
0 
1505 
0 . 0 6 6 
1546 
0 
0 
1797 
0 
0 
726 
32 
4 .41 
1Z61 
1266 
100.4 
1613 
90 
5.58 
1549 
3 
0. 194 
4 
1139 
6 
0 . 5 2 7 
1161 
177 
1 5 . 2 
1255 
0 
0 
1110 
178 
1 6 . 0 
1164 
9 
0 . 7 7 3 
1314 
1548 
IIB 
598 
3 
0 . 5 0 2 
405 
2 
0 . 4 9 4 
5 
1482 
3 
0 202 
1266 
16 
1.26 
976 
0 
0 
1564 
0 
0 
2095 
24 7 
11 .8 
2206 
1790 
81.1 
1443 
104 
7.21 
1429 
20 
1.40 
6 
1291 
29 
2 . 2 5 
1421 
56 
3.94 
1267 
0 
0 
1092 
0 
0 
1062 
525 
4 9 . 4 
1100 
659 
59 9 
1470 
26 
1.77 
1476 
217 
14 7 
7 
1167 
0 
0 
921 
259 
2 8 . 1 
536 
0 
0 
433 
0 
0 
658 
271 
4 1 . 2 
788 
367 
46 6 
1501 
0 
0 
1066 
115 
10.8 
Median 
1291 
6 » 
0. 527 
1421 
95*3 
6.47 
1255 
0 * 
0 
1251 
Ο χ 
0 
1164 
43 * 
4 .41 
1261 
1 1 7 2 ® 
8 1 . I 
1470 
26 · 
1.26 
1429 
61 * 
8 79 
* Significant d i f ference (ρ < .05) between control- and drug »еввюп. 
® Significant d i f ference (p < .05) between neurolept ic-tr««tment and combined neuro lept ic-
dexet imide t r e a t m e n t . 
WilcoKon matched-pa i rs eigned-r^nta test, two-tai led probability. 
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Table 10b: Self-stimulation responses of individual rats, obtained during 
pre-drug control sessions (CÍ and after administration of either pipampe-
rorie (40 mg/kg), clozapine (40 mg/kg), thioridazine (40 mglkg) or 
chlorpromazine (2.5mg/kg), 1 hrbefore the session or these compounds 
followed 112 hr later by 0.63 mg/kg of amphetamine. All compounds 
were given subcutaneously, except clozapine, which was given orally. 
SeU-at lmuUtion r e a p o n i e t / 3 0 min 
Compound 
Pi pam perone 
% 
-f Amphetamine 
С laxa pine 
* 
+ Ampheumine 
Thioridazine 
* 
+ Amphetamine 
% 
ChlorproiTOzine 
% 
+ Amphetamine 
% 
Do· · 
mgAg 
40 
0 . 6 3 
40 
0 . 6 3 
40 
0 . 6 3 
40 
0 . 6 3 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
Rat # 
1 
1338 
0 
0 
1533 
3 
0 . 1 9 6 
1546 
0 
0 
1598 
1592 
9 9 . 6 
726 
32 
4.41 
'231 
1360 
110 
1470 
26 
1.77 
1176 
1549 
132 
2 
1291 
29 
2.25 
1140 
2 
0.175 
1267 
0 
0 
1193 
195 
16.3 
1062 
525 
49.4 
996 
1053 
106 
1501 
0 
0 
943 
924 
98.0 
3 
1779 
226 
12.7 
2207 
95 
4 . 3 0 
1841 
0 
0 
944 
951 
101 
1550 
43 
2.77 
909 
362 
39 8 
2612 
33 
1.26 
963 
871 
90.4 
4 
1139 
6 
0.527 
861 
25 
2 . 9 0 
997 
57 
5.72 
669 
148 
22.1 
1255 
19 
1.51 
584 
940 
161 
645 
1 
0 . 1 5 5 
1301 
720 
5 5 . 3 
5 
1482 
3 
0 . 2 0 2 
1849 
18 
0 . 9 7 3 
1156 
0 
0 
1240 
42 
3 .39 
2095 
247 
11.8 
1503 
1441 
9 5 . 9 
1613 
90 
5.58 
1332 
1374 
103 
6 
1338 
0 
0 
1384 
45 
3 .25 
928 
0 
0 
1416 
319 
22 5 
1164 
9 
0 .773 
1435 
1360 
94 8 
1443 
104 
7.21 
1219 
1856 
152 
7 
1122 
15 
1.34 
502 
46 
9 .16 
607 
0 
0 
583 
465 
79.8 
658 
271 
4 1 . 2 
510 
936 
184 
598 
3 
0.502 
610 
551 
9 0 . 3 
Median 
1338 
6 * 
0.527 
1384 
25 · 
2 .90 
1156 
0 * 
0 
1193 
3 1 9 ^ 
2 2 . 5 
1164 
43 a 
4.41 
996 
1 0 5 3 ® 
106 
1470 
2 6 * 
1.26 
Π 76 
9 2 4 ® 
9 8 . 0 
* Significant difference (ρ < . 0 5 ) between control- and drug «e••Ion. 
φ Significant difference ( P < . 0 5 ) between neuroleptic-treatment and combined neuroleptic 
amphetamine treatment, 
Wil сок on matched-pair · eigned-rmk· t e · ! , two-tailed probability. 
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Table 10c: Self-stimulation responses of individual rats, obtained during 
pre-drug control session (C) and after administration of either pimozide 
(0.63 mg/kg), 2 hrs before the session, or chlorpromazine (2.5 mg I kg), 
thioridazine (40 mg/kg), pipamperone or clozapine (40 mg/kg), 1 hr 
before the session, or these compounds followed by nomifensine 
(2.5 mg/kg), 1/2 hr before the session. All compounds were given sub-
cutaneously, except for clozapine which was given orally. 
Self-st imulation reeponeee/ îO min 
Compound 
Control 
% 
Nomi fen l ine 
% 
Pimozide 
% 
+ Nomifenfline 
% 
Chlorpromazine 
+ Nomifenfine 
7. 
Thioridazine 
+ Nomifensine 
Pi pampe ron« 
% 
+ Nomifensine 
% 
Clozapine 
% 
+ Nomifensine 
% 
Dose 
mg/kg 
г.S 
0.63 
2.5 
2 . 5 
2 . 5 
40 
2 . 5 
40 
2.5 
40 
2 . 5 
С 
c i/c
z 
R 
R/C 2 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
С 
R 
C/R 
R « # 
1 
1601 
1710 
107. 
1691 
98 9 
1564 
10 
0.639 
1617 
1944 
120 
1472 
26 
1.77 
1526 
1748 
115. 
1707 
32 
1.87 
1489 
1708 
115. 
1378 
0 
0 
1264 
0 
0 
1198 
0 
0 
1100 
0 
0 
2 
1386 
1236 
8 9 . 2 
2104 
170. 
1407 
44 
3 .13 
1484 
2166 
146 
1255 
33 
2 .63 
1226 
948 
7 7 . 3 
1359 
0 
0 
1683 
1383 
82 2 
1431 
13 
0.908 
1179 
28 
2 . 4 
846 
0 
0 
1327 
75 
5 7 
3 
2 528 
2645 
105. 
2798 
106. 
2677 
14 
0 .523 
2530 
2723 
108 
4 
8 57 
641 
74 .8 
784 
122. 
660 
109 
16 5 
381 
6) 
16 0 
733 
10 
1 36 
924 
776 
84 0 
555 
4 
0.721 
881 
956 
109. 
579 
0 
0 
795 
0 
0 
620 
9 
1 45 
779 
0 
0 
5 
1749 
1667 
95 3 
1439 
86 3 
1591 
35 
2.20 
1578 
2146 
136 
1552 
19 
1 22 
1655 
1828 
110 
1659 
76 
4.58 
1716 
1554 
90 6 
1829 
56 
3.06 
1608 
0 
0 
1621 
10 
D 617 
1771 
0 
0 
6 
1141 
1133 
99 3 
1131 
99 .8 
1330 
19 
1.43 
1346 
1334 
99 1 
1340 
г.1\ 
1401 
1571 
112 
1491 
42 
2 .82 
912 
857 
94 0 
1521 
28 
1 84 
4 3 3 
65 
5 7 
618 
0 
0 
661 
0 
0 
7 
1942 
1929 
9 9 . 3 
1918 
99 4 
1882 
0 
0 
1843 
1085 
58 9 
1885 
102 
5 41 
1839 
549 
22 9 
1876 
16 
0 853 
1891 
8 34 
44.1 
1493 
7 
0.469 
1516 
0 
0 
1601 
59 
3 69 
1853 
96 
5 2 
Median 
1601 
1667 
99 3 
1691 
99 .8 
1564 
1 9 * 
1.43 
1578 
1944® 
108 
1406 
28 5* 
2 04 
1463.5 
12 59 5 ® 
97 
1575 
24» 
1 36 
1586 
1169.5® 
9 2 . 3 
1462 
10» 
0.6885 
1221.5 
0 * 
0 
1022 
4 5 * 
11.3085 
1213 5 
0 » 
0 
* Significant difference ( p < .05) between control- ¿nd drug et-seion, 
® Significant difference ( p < ,05) between neuroleptic-treatment and combined neuroleptic-
nomifensine trentmeni. 
Wtlcoxon matched-pair» eigned-ranks test, two-taited probability. 
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Fig. 13: Self-stimulation in rats: median (7 rats) response rate expressed 
as a percentage of the preceding control (= 100 Ψο) obtained after the 
neuroleptics (Ш) pimozide (PIM), chlorpromazine (CHLOR), pipampe-
rone (PIP), clozapine (CLOZ) and thioridazine (THIO) and combined 
(Ш) neuroleptic treatment with dexetimide, amphetamine and nomifen­
sine. 
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Finally, the thioridazine-induced inhibition was equally antagonized to 
control levels with dexetimide, amphetamine and nomifensine. 
7.4. General discussion 
Dexetimide is considered to have reversed the specific neuroleptics 
because of its indirect action on DA, while amphetamine could reverse 
some neuroleptic effects, because of its releasing properties of DA and 
NA. According to the classification described in section 6 chlorpromazine 
and possibly also pipamperone, belong to the category of neuroleptics 
which are characterized by a low ratio of DA- to NA-receptor blocking 
activity (see also Andén et al., 1970). 
The results of the drug-antagonistic studies here, indicate that the 
presence or lack of antagonistic effects depends on the relative potency 
of the NA- versus DA-blocking activity achieved with the neuroleptics, 
but cannot be exclusively based on this ratio. Snyder et al. (1974) 
proposed that neuroleptics exerting antipsychotic activity but seemingly 
inducing fewer extrapyramidal effects, are compounds with inherent 
anticholinergic activity. One would expect anticholinergics to further 
enhance the anticholinergic activity and, thus, to completely antagonize 
the DA-blocking effect. This would explain why dexetimide quite 
effectively reversed the thioridazine-induced inhibition. However, the 
latter effect cannot be solely explained by a relatively high antagonistic 
potency at muscarinic receptor sites (Iversen, 1975), since clozapine was 
even more potent but was not reversed in our experiments. If the 
thioridazine NA-blocking effect is a more peripheral phenomenon, it 
could be assumed that the DA-blocking effect of thioridazine is 
responsible for the self-stimulation inhibition. Consequently, the in-
hibition could be antagonized with anticholinergics as well as with DA-
uptake blocking drugs. With the tests available central, as well as 
peripheral NA effects, are probably being measured. The two effects 
have not yet been separated. Further experiments are required to 
indicate whether a peripheral or a central N A receptor blocking activity is 
involved. 
The neuroleptic-antagonistic effect obviously does not depend on simple 
mechanisms. The results reported evidenced that anticholinergic as well 
as DA-uptake blocking activity are able to overcome the inhibition. 
DA-agonists have been used with variable success in the treatment of 
parkinsonism: both apomorphine (Cotzias et al., 1970,1972) and piribedil 
(Sweet et al., 1974; Vakil et al., 1973) affected tremor and rigidity. These 
two direct receptor stimulating agents were not able to antagonize the 
neuroleptic-induced self-stimulation inhibition. These results point to the 
difference between the receptor blocking activity and parkinsonism, the 
latter being due to a degeneration of the nigrostriatal DA pathway 
(Hornykiewicz, 1971) resulting in a lack of DA input to the striatum and a 
distorted balance between the transmitters operating in the caudate 
(Cools et al., 1975). One should not forget, however, that the action of 
apomorphine is far more complex than was originally supposed (Costali 
and Naylor, 1973 and see survey Colpaert et al., 1976c). 
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Desipramine, which is claimed to exert its antidepressant activity by 
blocking the uptake of NA, did not antagonize the pimozide-induced 
inhibition. 
Desipramine, at the doses used, also possesses α-adrenergic blocking 
activity which could further potentiate the inhibition (see chapter VI, 
section 3.6). It is interesting to note that dexamisole was able to 
antagonize the pimozide-induced inhibition. Dexamisole is, however, 
devoid of anticholinergic blocking activity (Van Nueten, 1972), but is 
described as having amine-blocking effects (Vanhoutte and Van Nueten, 
1975). The failure of this compound to cause antagonism in all rats 
probably reflects its less specific effects on DA. 
The results with nomifensine clearly indicate that the anticholinergic 
activity, in itself, is not a prerequisite for antagonism of specific DA 
inhibition. It is not known whether such a direct mechanism could also 
account, at least partially, for the dexetimide-reversal properties. This has 
to be elucidated by further biochemical studies. The antagonism of the 
neuroleptic self-stimulation inhibition may be more specific for DA-
uptake blockers than with the anticholinergics. As mentioned (see 7.1.), 
relatively high doses of the anticholinergics are required. 
The results of the interaction of pimozide with various antagonists favour 
the supposed connection between DA and ACh neurons. The 
interaction could be explained by an interference at the level of the 
inhibitory DA neurons. It has indeed been suggested that there may be 2 
different types of DA neurons, the second being excitatory and operating 
in the same way as the cholinergic striatal neurons (Cools, 1973). 
Neuroleptic treatment increased homovanillic acid (HVA) content in the 
striatum and in the limbic structures, an effect suggesting an increased 
DA turnover. Neuroleptics also increase the release of ACh and decrease 
its content in the striatum (Guyenet et al., 1975; McGeer et al., 1974; 
Stadler et al., 1973) but not in the limbic system (Andén, 1972; Bartholini 
et al., 1973; Lloyd et al., 1973) or other brain structures, such as the 
cortex and the hippocampus (Sethy and Van Woert, 1973). Furthermore, 
in the striatum but not in other brain structures, the neuroleptic-induced 
increase of HVA content is effectively antagonized by anticholinergics 
(Consolo et al., 1974; Stadler et al., 1973), whereas cholinergic drugs 
have been found to increase striatal HVA concentrations (Andén, 1974). 
Since complete antagonism of a DA-blocker with an anticholinergic is 
possible, the reported data might indicate that the inhibition of self-
stimulation is mainly due to an interference with DA sites in striatum. 
8. CONCLUSIONS 
A variety of neuroleptics belonging to various chemical classes and with 
widely different pharmacological profiles were tested on brain self-
stimulation. The neuroleptics were differentiated according to the effects 
obtained in pharmacological tests and on the basis of drug-interaction 
studies. The characteristics of the neuroleptic effects were described and 
will be discussed in the following section with the aim of formulating a 
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hypothesis on the impairment of self-stimulation and of operant 
behaviour in general (8.1.). Further, some clinical implications will be 
described (8.2.). 
8.1. Impairment of self-stimulation 
The neuroleptics described here inhibited self-stimulation in a dose-
dependent manner. They could be ranked according to a quantitative 
criterion, namely the EDpß-values of response inhibition from the most 
potent compound fluspiperone, to the least potent thioridazine. 
The self-stimulation inhibition could be interpreted in terms of an impact 
on the response required to obtain the reward or in terms of an alteration 
of the motivation. Neither of these is sufficient to explain the described 
experiments. An alternative interpretation is that neuroleptics interfere 
with the sensorimotor integrative function subserved by the basal 
ganglia. 
1. The fact that many types of behaviour are inhibited by neuroleptics 
might lead to the concept that the inhibition is due to an effect on motor 
performance. Effects on the motor function are to some degree causally 
related to the inhibition. The latter is suggested by the significant 
correlation found between self-stimulation inhibition and catalepsy. 
Further, the self-stimulation test is positioned between the catalepsy test 
and amphetamine-antagonism test (see 6.2.). 
There are a number of observations suggesting that the ability to perform 
is still present in neuroleptic-treated rats: they start pressing the lever 
when placed in the self-stimulation cage; they self-stimulate for high 
SPC's, whilst low base-line levels are inhibited; finally, they press the 
lever, but licking for the same brain-stimulation is inhibited. High doses 
of neuroleptics cause motor deficits (catalepsy or sedation) which might 
be related causally to the self-stimulation inhibition. However, the 
inhibition cannot be explained solely by an effect on performance ability. 
2. Self-stimulation inhibition could be explained in terms of a motiva-
tional deficit. However, the conditional motivation or anticipation of 
reward is not affected and the inhibition is, in contrast, independent of 
the motivational state. 
Firstly, the cues associated with reinforcing brain-stimulation, conditional 
motivation (Trowill, 1976) are unaffected. Neuroleptic-treated rats tend 
to lever-press during the first minutes of the self-stimulation session at 
equal or higher rates than control animals. Thereafter, though, respond-
ing declines. In fact the response curves very much resemble extinction 
curves. 
Secondly, the neuroleptic-induced inhibition of operant behaviour is 
independent of the nature of the motivational state. The performance of 
conditioned behaviour, whether the reinforcer is negative or positive, is 
equally well inhibited by neuroleptics. Therefore, it cannot be stated that 
neuroleptics specifically or exclusively alter the reward. 
Thirdly, the differential inhibition of different base-line rates of respond-
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ing can evidently not be related to drug-response effects. Inhibition is 
more easily obtained when behaviour operates at a low motivational level 
and vice versa. The differential effects could be interpreted in terms of an 
incentive model (Bolles, 1967) of brain self-stimulation (Gallistel, 1964; 
Trowill et al., 1969). Incentive motivation is conceived as a «response 
energized by anticipation of a stimulus and reinforced by its realization» 
(Seward et al., 1959, p. 294). According to this model, extinction and 
reinforcement are function of the characteristics of reward. Shifts from 
high to low reward cause negative contrast effects, shifts from low 
reward to high reward, cause positive contrast effects (Panksepp and 
Trowill, 1969,1970). 
In the experimental design we used (different SPC's given in a 
randomized order) high SPC's are more rewarding than the low SPC's. In 
the former case, the learned expectancy of reward is higher and habit 
strength stronger, because there has been more training (Trowill et al., 
1969). Therefore, high SPC's could be more resistant to drug-effects. At 
low SPC's, frustration of non-reward is less and extinction is readily 
established. 
Finally, neuroleptics could affect the perception of the reward con-
sequences. There is no evidence, however, that they interfere with the 
perception of the reward itself but rather with the association between a 
response and its consequence. 
3. It is alternatively emphasized that neuroleptics interfere at the level of 
sensorimotor integration. During the same experimental session licking 
for brain-stimulation was more inhibited than lever-pressing for the same 
reward. The difference in performance, determined by physiological 
characteristics of the response and partially by the different schedule 
applied, cannot account for the differential influence. Rats which made 
more lick responses were inhibited at lower doses than rats which 
performed at lower rates. Therefore, the difference in brain-stimulations 
received similarly fails to explain the differential influence. If neuroleptics 
inhibit self-stimulation by interfering with reward or the motor system, 
one would expect an equal inhibition regardless of the operant. The 
reward in both cases is the same; rats can apparently no longer associate 
the response and its consequence. 
4. There are a number of behavioural studies, pharmacological ex-
periments and lesioning experiments implicating the dopaminergic 
nigrostriatal system as a substrate of a stimulus-response association 
(see also Grossman, 1976). The dopaminergic nigrostriatal system is an 
indispensable link sustaining complex learned behaviour. This system is 
linked with the extrapyramidal structures which subserve integrative 
functions. The terminal structure, the caudate nucleus «forms a part of a 
system in which incoming signals are compared with previously 
established target values, i.e. links between two or more responses 
forming an integrated sequence of elements...» (Cools, 1973, p. 138). It is 
conceivable that the interference with these structures by neuroleptics is 
causally related to the inhibition. 
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It was shown in various experiments that aphagia and adipsia, earlier 
considered as a typical lateral hypothalamic syndrome (e.g. Anand and 
Brobeck, 1951; Teitelbaum and Epstein, 1962), were due to lesions of the 
nigrostriatal system (cell bodies or axons) (e.g. Ungerstedt, 1971b). In an 
experiment by Antelman and Szechtman (1975), tail-pinching was used 
to induce stimulus-bound behaviour. The particular response appeared 
to be determined by the stimulus-objects present in the environment 
(Valenstein, 1971). They described that consummatory behaviour was 
critically dependent on the dopaminergic nigrostriatal system. 
Lesioning of the nigrostriatal system not only caused deficits in consum-
matory responses, but resulted in a complex behavioural syndrome 
(Grossman, 1970; Grossman and Grossman, 1971). The impairment of 
learned behaviour (Kent and Grossman, 1973) depends on the extent of 
the transsections of fibres. Recovery and relearning occurred when 
lesions were smaller. With large lesions, reacquisition of lever-pressing 
for brain-stimulation proved impossible. Learning deficits were also 
shown after intraventricular injection of 6-hydroxy-dopamine (Mason 
and Iversen, 1974). However, it was not clear whether the depletion of 
dopamine or of noradrenaline was responsible for the observed effects. 
Acquisition and performance in positively or negatively reinforced 
situations are seriously affected by lesions of the substantia nigra, the 
nigrostriatal pathway and the caudate nucleus (e.g. Kirkby, 1970). See 
Cools (1973) for a survey on the literature implicating the caudate 
nucleus in highly complex behavioural performances. 
Electrical stimulation of the substantia nigra (Routtenberg and Holzman, 
1973), or lesioning of the caudate nucleus (Mikulas and Isaacson, 1965) 
also disrupted retention, which showed these structures to be involved in 
processed inputs. Routtenberg and Holzman (1973) suggested that the 
substantia nigra (zona compacta) might be physiologically active during 
learning. 
All these points suggest that the dopaminergic nigrostriatal system is 
highly involved in integrative processes during acquisition, learning, 
retention and performance of complex operant behaviour. In other words 
this system appears to be critically involved in the organisms' respons-
iveness to environmental stimuli (Antelman and Szechteman, 1975; 
Zigmond and Strieker, 1973). 
The experiments of Huston and Borbély (1973) and Huston and Ornstein 
(1976) clearly demonstrated that the dopaminergic nigrostriatal system is 
not critically involved in less complex behaviour. Learning in the thalamic 
preparation (i.e. rats with extensive lesions of the cortex hippocampus, 
septem and striatum) is, however, not adaptive since the response failed 
to become extinguished. 
Neuroleptics inhibit self-stimulation as well as other operant behaviours 
by virtue of the effect on the stimulus-response association. The degree 
to which this occurs depends on the complexity of the response and the 
complexity of the association. The substrate on which neuroleptics 
impinge is the dopaminergic nigrostriatal system. The latter system is 
linked up to a reinf orcing-reward substrate underlying complex behaviour 
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and forms a part of the structures subserving a sensorimotor integrative 
function. 
82. Clinical implications 
Experimental studies on the interaction of neuroleptics with other drugs 
are few. One of the reasons for this could be the difficulty in obtaining 
reliable and quantitative data. There is, however, an obvious need for 
such studies. Firstly, neuroleptic-induced parkinsonian-like effects could 
be of heuristic value for a better understanding of the treatment of 
parkinsonism. The drawback related to this model is the different 
aetiology: parkinsonism is mainly related to a degeneration of dopa-
minergic neurons, while the neuroleptic-induced effects are due to a 
postsynaptic receptor blockade. 
Secondly, psychotics are routinely given antiparkinsonian drugs in 
conjunction with neuroleptics, in order to alleviate extrapyramidal side-
effects (associated with high doses of neuroleptics). 
The self-stimulation inhibition and its antagonism or reversal showed 
that self-stimulation was a reliable tool providing quantitative data. 
Drugs effective in the treatment of parkinsonism reversed the self-
stimulation inhibition. It was shown that anticholinergic activity was not 
a prerequisite, but that drugs which block dopamine-uptake were also 
potent antagonists. Apomorphine, as well as piribedil, were ineffective as 
antagonists. Yet, both compounds have been used in the treatment of 
parkinsonism. Nomifensine, according to Costali et al. (1975), resembles 
apomorphine in that its stereotypic action was still present after 
disruption of presynaptic events. It was concluded that nomifensine 
could be used as a potential antiparkinsonian agent (preliminary clinical 
data confirmed this action, B. Costali, pers. communication). The 
antagonism of the neuroleptic-induced inhibition is not dependent upon 
its direct receptor activating properties. Rather, it is the ability of 
nomifensine to inhibit reuptake processes (Hunt et al., 1974) which 
accounts for its reversal properties. 
If self-stimulation inhibition reflects more the neuroleptic effect and not 
the neurological deficit caused by neuroleptics, one would expect the 
antagonists effectively reversing the inhibition to reverse therapeutic 
effects, too. This action is assumed to be localized at the level of the 
extrapyramidal structures. It was found that L-dopa treatment of 
parkinson-patients elicited psychotic side-effects (Goodwin, 1971), and 
L-dopa-treated schizophrenics were made worse without improvement 
of the extrapyramidal side-effects (Yaruyura-Tobias et al., 1970). 
Similarly, treatment with DA-receptor stimulants such as piribedil, 
caused a deterioration of psychiatric status (Angrist et al., 1975). 
Some clinical reports describe that antiparkinsonian drugs given in 
conjunction with neuroleptics induce a therapeutic reversal (Haase, 1972; 
Haase and Janssen, 1965; Singh and DiScipio, 1972; Singh and Kay, 
1974,1975; Singh and Smith, 1973a, b). Singh and Kay (1975) found that 
the counter-therapeutic effects were more extensive than originally 
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described (Singh and Smith, 1973). The counter-therapeutic reversal of 
the fundamental psychotic symptoms, was not due to some kind of toxic 
effect, but to an exacerbation of the disorder. 
Singh and Kay (1975) speculated that the counter-therapeutic effects are 
due to an interference with a periventricular cholinergic system, 
reciprocally interacting with the facilitatory catecholaminergic system, in 
limbic forebrain structures described by Stein (1968). 
It is conceivable that anticholinergic drugs influence striatal, limbic and 
cortical structures because in all these structures, Cholinesterase and 
acetylcholinesterase are present (Lewis and Shute, 1967; Shute and 
Lewis, 1967). This influence is of particular relevance when it can be 
shown that in these structures monoaminergic-containing systems 
produce effects contrary to those of the cholinergic system (Shute and 
Lewis, 1967). 
Many biochemical experiments substantiate the dopaminergic-choliner-
gic link in the caudate nucleus. Such a direct interaction in the limbic 
structures was, however, not evidenced (described in chapter 5). An 
interaction at the origin of the dopaminergic systems is not excluded and 
remains, therefore, a subject for further experimentation. Undoubtedly, 
anticholinergics influence the cholinergic neurons bypassing the dopa-
minergic links, whilst neuroleptics could affect dopamine functions in 
limbic structures, striatum and cortex. The different psychotic symptoms 
are probably also related to a dysfunctioning of various brain structures, 
which is at variance with the hypothesis of Snyder et al. (1974) that 
dopaminergic receptors of the mesolimbic system are the exclusive site 
for antipsychotic activity. Stevens (1973) pointed to the striking 
parallellism between the «limbic striatum» and the neostriatum. Dopa-
minergic cell bodies located in the ventral midbrain project to the 
neostriatum and the limbic striatum and further respectively to the 
globus pallidus and the substantia ¡nominata. Further, the cortex 
topographically projects into the caudate-putamen on the one hand and 
the limbic striatum on the other hand (Kemp and Powell, 1970). Both the 
neostriatum and the limbic striatum could act as central gating 
mechanisms for cortical output. It is thus quite feasible that both 
structures, when pathologically functioning, are substrates of psychosis. 
Stevens (1973, p. 187) wrote that «Although the circumstantial evidence 
for abnormal function in a limbic striatal gate in schizophrenia is 
heuristically attractive, direct anatomical evidence is sparse.» Anatomical 
evidence for an abnormal striatum was, however, already described in 
1955 by Mettler. The self-stimulation inhibition and its reversal probably 
reflects a part of the extensive counter-therapeutic effects found in the 
clinic. A failure of the cholinergic system in the striatum may be related 
to the social avoidance aspects described by Singh and Kay (1975). 
The practical consequence is that one should avoid the routine use of 
antiparkinsonian drugs together with neuroleptics. Because high doses 
of specific neuroleptics cause extrapyramidal side-effects, the degree of 
parkinsonism has been used as an index of efficacy. The fact that both 
phenomena are related to a striatal dopaminergic receptor blockade 
leads to this erroneous conclusion and was experimentally contradicted 
by Bishop et al. (1965). 
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Summary 
The aim of this thesis was to study the influence of psychopharma-
cological substances on self-stimulation behaviour in rats (and dogs). 
Chapter I introduces this study with a short historical description of the 
discovery of self-stimulation behaviour. The rewarding properties of 
electrical brain stimulation have been demonstrated in many species, 
including man and formed, together with the description of brain-
structures in which electrical stimulation elicited eversive behavioural 
reactions, a new approach to a hedonistic description of behaviour. The 
self-stimulation system is assumed to be the substrate of appetitive 
behaviour. The description of neurotransmitters mediating the self-
stimulation system has generated the catecholamine hypothesis. The 
pharmacological studies were then situated in a neurochemical frame. 
Chapter II describes the aims of this study. These were, in short to 
provide a thorough quantitative analysis of the influence of psychoactive 
drugs, belonging to various pharmacological and chemical classes, on 
self-stimulation behaviour. The qualitative interpretation is related to the 
question of whether drugs affect self stimulation behaviour specifically 
(for example on the reinforcing process) or rather unspecifically (for 
example changing general activity level). 
Chapter III gives a survey of the literature (period 1956, first publication, 
to 1974 + 1975) on the pharmacological influence of self-stimulation. 
Methods as well as results are described in tables. No comparative study 
has been made as this would be extremely difficult in view of the fact 
that the description of results is often inadequate and that there is a 
tremendous diversity in methodology. 
Chapter IV describes the general methods (subjects, surgery and 
materials) applied in this study. In addition, some critical aspects such as 
the type of electrode and the type of electrical stimulation, are 
considered. 
Chapter V. The interpretation of the effects of drugs is partly dependent 
on control values. This required a study of the electrical stimulation 
parameters, since these are some of the major factors determing the 
frequency of self-stimulation. One of the questions was whether the 
frequency of lever-pressing was determined by individual, parameters 
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(intensity, pulse frequency, etc.) or by the total electrical change 
contained in a stimulation. A significant, although poor correlation 
between total electrical charge and self-stimulation rate, was found; 
further, each parameter needed to exceed a threshold. Finally, it is 
possible to predict the frequency of self-stimulation at least within 
certain limits, by selecting a certain combination of stimulation para-
meters (SPC). 
Chapter VI. In a quantitative approach to behaviour, drug-effects are 
described as facilitatory or inhibitory depending on whether they 
increase or decrease self-stimulation. Therefore, a method (VI. 1) was 
applied in which different SPC's (based on Chapter V) were presented to 
the rats in a specific sequence during daily one hour experiments. This 
method made it possible to determine both increase and decrease of self-
stimulation, in the same rat during the same experiment. 
Because the frequency of lever-pressing is determined by various factors 
such as type of stimulator, SPC's and their sequence, subjects and time, 
an adequate analysis of the control values required an analysis of 
variance (VI.2.). The drugs effects had to be compared with the values 
for the preceding control session with the same rats, the same SPC's and 
during the same week of experiment, since the factors SPC, time, 
subjects and their interaction were found significant. These results 
further necessitated the use of a parameter-free test of significance. 
This section (VI.3) describes the effects of 18 psychoactive drugs of 
which 3 to 6 doses were given to groups of 3 to 6 rats, namely: 3 CNS-
stimulants (cocaine, amphetamine, apomorphine), 3 anticholinergics 
(dexetimide, benztropine, scopolamine), 3 minor tranquillizers (chlor-
diazepoxide, diazepam, nitrazepam), 3 narcotic analgesics (morphine, 
fentanyl, piritramide), 3 antidepressants (desipramine, amitriptyline, 
dexamisole) and 3 hypnosedatives (etomidate, methohexital, pentobarbi-
tal). 
Most drugs cause an increase as well as a decrease of self-stimulation. 
The effects are, however, dependent on the dose, injection time, control 
values and subjects. The depression of self-stimulation, for example by 
high doses of narcotic analgesics or CNS-stimulants, is an unspecific 
effect. The mechanism causing inhibition depends, however, on the 
particular drug. Inhibition can for instance, be due to the induction of 
muscle rigidity or to causing a competition between stereotype 
behaviour and adapted behaviour. 
The facilitation of self-stimulation might be due either to a sensitization 
of the self-stimulation substrate or to a reduction of threshold. Since this 
substrate is considered as a substrate of the «immediate reinforcement» 
of behaviour, it can be assumed that these effects are specific. Further, it 
appeared that the effects of different drugs could not be explained by a 
direct interference on the self-stimulation substrate, but rather by an 
interference on inhibitory systems (cholinergic and serotonergic) involv-
ed in the suppression of behaviour or induction of fear. In essence, a 
«balance-theory» is proposed. 
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Chapter VII describes a quantitative analysis of the influence of 20 neuro-
leptics, belonging to various chemical groups, tested according to the 
method described in Chapter VI. The object was to find out whether the 
inhibition of self-stimulation behaviour could be explained in terms of a 
blockade of the motor system or rather in terms of a motivational deficit. 
Because different neuroleptics are dopaminergic blocking agents, special 
attention has been given to the role of the nigrostriatal system. 
All neuroleptics inhibit self-stimulation in a dose-related way, but differ 
from one another in terms of potency. The inhibition can hardly be 
explained as being caused by a motoria! effect. Further, it appeared that 
strongly motivated behaviour is less susceptible to inhibition than weakly 
motivated behaviour. 
The response pattern seen after the administration of high doses of 
neuroleptics occurs in a way similar to that seen after applying an 
«extinction-procedure» (the elimination of the stimulation). The con-
ditioned anticipation appears to be present, but the lack of sustained 
responding points to a diminution or even an elimination of the 
reinforcing value of the electrical stimulation. This could be caused by an 
increase of the threshold or by changing the motivational value of the 
stimulation. 
In one of the experiments it appeared that another instrumental response 
used (in this case licking for stimulation) was more sensitive to the 
neuroleptic inhibition. This could mean that the complexity of the 
relation between response and stimulation is an important factor in the 
evaluation of the effects of a drug. 
Little is known about the influence of neuroleptics on self-stimulation 
behaviour in other species. In the dog, it appears that neuroleptics, which 
preferentially interfere with noradrenergic systems, are potent inhibitors 
even of self-stimulation obtained in dopaminergic structures. This could 
indicate an interaction between noradrenergic and dopaminergic 
systems. 
The classification of neuroleptics and their relation to pharmacological 
tests and behavioural tests was studied by a new method («spectral 
mapping»). The inhibition of self-stimulation caused by neuroleptics 
appeared to be more closely related to an interference on dopaminergic 
systems than to noradrenergic systems. 
The inhibition of self-stimulation caused by specific neuroleptics could 
be antagonized by anticholinergics and drugs which enhance dopaminer-
gic activity in a «physiological way». In addition, a distinction between 
sedative and incisive neuroleptics could be based on drug-interaction 
studies. Further, there are a number of possible clinical implications. 
The dopaminergic nigrostriatal system appears, apart from being a 
substrate of self-stimulation, to be critically involved in the respons-
iveness of the organism towards environmental stimuli and is incorporat-
ed at the end of processes which lead to overt behaviour. 
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Samenvatting 
Het doel van deze studie was na te gaan welke de invloed was van 
psychofarmaca op het zelfstimulatiegedrag van ratten (en honden). 
Hoofdstuk I leidt de studie in met een korte historische beschrijving van 
de ontdekking van het zelfstimulatiegedrag. De belonende waarde van 
elektrische hersenstimulatie werd in verschillende species, ook de mens, 
aangetoond en vormde tesamen met de beschrijving van hersenstruk-
turen waarin elektrische stimulatie aversieve gedragsreakties uitlokte, 
een vernieuwde aanzet tot een hedonistische beschrijving van het 
gedrag. 
Het zelfstimulatiesysteem zou het substraat van appetitief gedrag zijn. 
De beschrijving van de transmitters die het zelfstimulatiesysteem 
mediaren, heeft aanleiding gegeven tot de «catecholamine-hypothese». 
Meteen werden de farmakologische studies in een neurochemisch kader 
gesitueerd. 
Hoofdstuk II omschrijft de doelstellingen van deze studie. Kort samen-
gevat was het de bedoeling een grondige kwantitatieve analyze te maken 
van de invloed van psychofarmaca, behorende tot verschillende farma-
kologische en chemische klassen, op het zelfstimulatiegedrag. 
De kwalitatieve interpretatie heeft betrekking op de vraag of de stoffen op 
specifieke (b.v. op het versterkingsproces) dan wel een onspecifieke 
wijze (b.v. verandering van algemeen aktiviteitsniveau) het zelfstimulatie-
gedrag beïnvloeden. 
Hoofdstuk III geeft een zo volledig mogelijk overzicht van literatuur-
gegevens (periode 1956, eerste publikatie, tot 1974-1975) i.v.m. de 
farmakologische beïnvloeding van zelf stimulatie. Zowel methoden als 
resultaten werden getabelleerd. Een vergelijkende studie is niet voor-
handen en uitermate moeilijk omwille van soms gebrekkige resultaten-
beschrijving en de methodologische diversiteit. 
Hoofdstuk IV beschrijft de algemene methodiek (subjecten, implantatie 
en materiaal) van het onderzoek. Daarbij worden enkele kritische 
aspecten, zoals het type elektrode en het type elektrische stimulatie 
behandeld. 
Hoofdstuk V: Het beoordelen van de effekten van farmaca is gedeeltelijk 
afhankelijk van de kontrolewaarden. Dit vereist een studie van de 
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elektrische parameters van de stimulatie, gezien deze tot de determine-
rende faktoren voor de frekwentie van zelfstimulatie behoren. Eén van de 
vragen was of de individuele parameters (intensiteit, frekwentie van de 
pulsen, etc.) of, daarentegen, de totale elektrische lading bevat in de 
elektrische stimulatie, de frekwentie van het hefboomdrukken bepalen. 
Er werd een significante, doch lage correlatie gevonden tussen de totale 
elektrische lading en de frekwentie zelfstimulatie; verder diende iedere 
afzonderlijke parameter een drempelwaarde te overschrijden. Door de 
keuze van een bepaalde kombinatie van stimulatie-parameters (SPC) is 
het mogelijk de frekwentie van de zelfstimulatie althans binnen bepaalde 
grenzen, te voorspellen. 
Hoofdstuk VI. In een kwantitatieve benadering van het gedrag, worden 
de effekten van farmaca als faciliterend of inhiberend beschreven, naar-
gelang ze de frequentie van zelfstimulatie verhogen of verlagen. Daartoe 
werd een methode! VI. 1.) gebruikt waarbij verschillende SPC's (gebaseerd 
op hoofdstuk V) in een bepaalde volgorde aan ratten gepresenteerd 
werden gedurende dagelijkse experimenten van één uur. Deze methode 
liet toe zowel stijging als daling van de zelfstimulatie vast te stellen bij 
eenzelfde rat tijdens eenzelfde experiment. 
Gezien de frekwentie hefboomdrukken bepaald wordt door verschillende 
faktoren zoals type stimulator, SPC's en hun volgorde, subjecten en tijd, 
vereiste een adekwate analyse van de kontrole resultaten een variantie-
analyse (VI.2). Gezien de faktoren SPC, tijd en subjecten en hun 
¡nteraktie significant bevonden werden, diende de analyse van de 
effekten van farmaca beschreven te worden in vergelijking met de 
voorafgaande kontrolesessie bij dezelfde ratten, dezelfde SPC's en 
gedurende dezelfde week. Verder impliceerde dit het gebruik van een 
parametervrije signifikatietoets. 
In dit hoofdstuk (VI.3) worden de effekten van 18 psychofarmaca, waar-
van 3 tot 6 dosissen aan groepen van 3 tot 6 ratten gegeven werden, 
beschreven: met name 3 CNS-stimulantia (cocaïne, amphetamine, 
apomorphine), 3 anticholinergica (dexetimide, benztropine, scopolami-
ne), 3 minor tranquillizers (chlordiazepoxide, diazepam, nitrazepam), 3 
narcotisch analgetica (morphine, fentanyl, piritramide), 3 antidepressiva 
(desipramine, amitriptyline, dexamisole), 3 hypnosedativa (etomidate, 
methohexital, pentobarbital). De meeste stoffen veroorzaken zowel een 
stijging als een daling van de zelfstimulatie. De effekten zijn evenwel 
afhankelijk van dosis, injectietijd, kontrolewaarden en subjecten. 
De remming van de zelfstimulatie, veroorzaakt door bijvoorbeeld hoge 
doseringen van narcotisch analgetica of CNS-stimulantia, is een on-
specifiek effekt. Het mechanisme waardoor de remming veroorzaakt 
wordt, verschilt echter naargelang de soort stof. Inhibitie kan te wijten 
zijn aan bij voorbeeld, het induceren van spierrigiditeit en verlies van 
oprichtingsreflex of, door een kompetitie van stereotiep gedrag met 
aangepast gedrag. 
Facilitering van het zelfstimulatiegedrag kan o.m. te wijten zijn aan een 
sensitizering van het zelfstimulatiesubstraat of een verminderde drempel-
waarde. Gezien dit substraat beschouwd wordt als het substraat voor de 
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«onmiddellijke versterking» van het gedrag, kan aangenomen worden 
dat dergelijke effekten specifiek zijn. Verder bleek dat de effekten van 
verschillende farmaca niet noodzakelijk te verklaren zijn vanuit een recht-
streeks aangrijpen op het zelfstimulatiesubstraat maar veeleer vanuit het 
aangrijpen op inhiberende systemen (cholinerge en serotonerge) betrok-
ken in onderdrukking van het gedrag of het induceren van vrees. In 
essentie wordt een «balans»-theorie voorgestaan. 
Hoofdstuk VII beschrijft een kwantitatieve analyse van de invloed van 20 
neuroleptica behorende tot verscheiden chemische groepen, getest 
volgens dezelfde methode als beschreven in Hoofdstuk VI. De vraag 
werd gesteld of de inhibitie van het zelfstimulatiegedrag te verklaren is 
vanuit een motorische remming of veeleer vanuit een motivationeel 
deficiet. Omwille van het feit dat verschillende neuroleptica dopaminerg 
blokkerende stoffen zijn, werd vooral aandacht besteed aan de rol van 
het nigrostriataal systeem. 
Alle neuroleptica remmen de zelfstimulatie op een dosis-gerelateerde 
wijze, maar verschillen in de eerste plaats van elkaar in termen van 
potentie. De inhibitie kan moeilijk alleen vanuit een motorisch effekt ver-
klaard worden. Verder bleek dat sterk gemotiveerd gedrag moeilijker te 
onderdrukken valt dan zwak gemotiveerd gedrag. 
Het antwoordpatroon na toediening van vrij hoge doseringen verloopt op 
een wijze gelijkaardig aan deze die men aantreft bij het toepassen van 
een «extinctieprocedure» (het uitschakelen van de stimulatie). 
De gekonditioneerde anticipatie blijkt dus nog aanwezig te zijn, maar het 
gebrek aan doorzetting wijst op een vermindering op zelfs een uitschake-
ling van de versterkende waarde van de elektrische stimulatie. Dit zou 
kunnen het gevolg zijn van een drempelverhoging of door verandering 
van de motivationele waarde van de stimulatie. 
In één van de experimenten bleek dat het gebruik van een andere 
instrumentele respons (in dit geval likken voor stimulatie), gevoeliger te 
zijn aan de neuroleptische onderdrukking. Dit zou erop kunnen wijzen 
dat de complexiteit van de relatie tussen respons en stimulatie een 
belangrijke faktor is in de evaluatie van de effekten van farmaca. 
Weinig is bekend over de invloed van neuroleptica op het zelfstimulatie-
gedrag bij andere species. Bij de hond blijken neuroleptica die preferen-
tieel op noradrenerge systemen inwerken, potente inhibitoren zelfs op 
zelfstimulatie verkregen in dopaminerge strukturen. Dit kan wijzen op 
een interaktie tussen noradrenerge en dopaminerge systemen. 
De klassifikatie van de neuroleptica en de relatie tot farmakologische 
testen en gedragstesten werd met een nieuwe methode («spectral 
mapping») onderzocht. De inhibitie van zelfstimulatie door neuroleptica 
vertoonde een grotere relatie met de aangrijping op dopaminerge 
systemen dan op noradrenerge systemen. 
De inhibitie van zelfstimulatie door specifieke neuroleptica kon antago-
neerd worden door anticholinergica en stoffen die op een «fysiologische 
wijze» de dopaminerge aktiviteit verhogen. Tevens kon het onderscheid 
tussen sedatieve en incisieve neuroleptica op basis van interaktiestudies 
bepaald worden. Verder zijn er een aantal mogelijke klinische implicaties. 
252 
Het dopaminerg nigrostriataal systeem blijkt naast een substraat voor 
zelfstimulatie, kritisch betrokken te zijn in de responsiviteit van het 
organisme t.o.v. omgevingsstimuli en is ingeschakeld aan het einde van 
processen die leiden tot overt gedrag. 
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8. Het operationeel definiëren van psychologische concepten leidt veel-
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